CUMULATIVE SUPPLEMENT 9 SEPTEMBER 2015

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs

2015

Prepared By Office of Generic Drugs Office of Medical Products and Tobacco Center for Drug Evaluation and Research Food and Drug Administration

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Cumulative Supplement 9

September 2015

CONTENTS

PAGE

1.0 INTRODUCTION ...... iii 1.1 How to use the Cumulative Supplement ...... iii 1.2 Cumulative Supplement Content ...... iv 1.3 Applicant Name Changes ...... v 1.4 Levothyroxine Sodium ...... v 1.5 Availability of the Edition ...... vi 1.6 Report of Counts for the Prescription Drug Product List ...... vii 1.7 Cumulative Supplement Legend ...... viii

DRUG PRODUCT LISTS Prescription Drug Product List ...... 1-1 OTC Drug Product List ...... 2-1 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ...... 3-1 Orphan Product Designations and Approvals List ...... 4-1 Drug Products W hich Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ...... 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists ...... A-1 B. Patent and Exclusivity Terms ...... B-1

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 9 September 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

iii

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

• Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

• All product changes received and processed as of the date of publication. o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

• New Drug Application (NDA) approvals appear in the CS month they were approved.

iv

• Patent information, also updated daily in the EOB, is current to the date of publication.

• Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [email protected]. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff Office of Generic Drugs 7620 Standish Place Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME NEW APPLICANT NAME (FORMER ABBREVIATED NAME) (NEW ABBREVIATED NAME)

AGILA SPECIALTIES PRIVATE LTD MYLAN LABORORATORIES LTD (AGILA SPECLTS) (MYLAN LABS LTD)

EXCELLIUM PHARMACEUTICAL INC LEADING PHARMA LLC (EXCELLIUM) (LEADING PHARMA LLC)

MYLAN PHARMACEUTICALS INC MYLAN LABORATORIES LTD (MYLAN PHARMS INC) (MYLAN LABS LTD)

ONCO THERAPIES LTD MYLAN LABORATORIES LTD (ONCO THERAPIES LTD) (MYLAN LABS LTD)

REDKITT BENCKISER INDIVIOR INC PHARMACEUTICALS INC (RECKITT BENCKISER) (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

v

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name Applicant Potency TE Code Appl No Product No UNITHROID STEVENS J 0.025MG AB1 21210 001 LEVOTHYROXINE MYLAN 0.025MG AB1 76187 001 SODIUM LEVOXYL KING PHARMS 0.025MG AB1 21301 001 SYNTHROID ABBOTT 0.025MG AB1 21402 001 LEVO-T ALARA PHARM 0.025MG AB1 21342 001

SYNTHROID ABBOTT 0.025MG AB2 21402 001 LEVOTHYROXINE MYLAN 0.025MG AB2 76187 001 SODIUM LEVO-T ALARA PHARM 0.025MG AB2 21342 001 UNITHROID STEVENS J 0.025MG AB2 21210 001

LEVOXYL KUNG PHARMS 0.025MG AB3 21301 001 LEVO-T ALARA PHARM 0.025MG AB3 21342 001 UNITHROID STEVENS J 0.025MG AB3 21210 001 LEVOTHYROXINE MYLAN 0.025MG AB3 76187 001 SODIUM

LEVOTHROID LLOYD 0.025MG AB4 21116 001 LEVOTHYROXINE MYLAN 0.025MG AB4 76187 001 SODIUM

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent vi

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement. The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

vii

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED DEC 2014 MAR 2015 JUN 2015 SEPT 2015 DEC 2015

DRUG PRODUCTS LISTED 16150 16352 16543 16824 SINGLE SOURCE 2572 2608 2586 2613 (15.9%) (15.9%) (15.6%) (15.5%)

MULTISOURCE 13578 13744 13957 14211 (84.1%) (84.1%) (84.4%) (84.5%)

THERAPEUTICALLY 13443 13610 13832 14089 EQUIVALENT (83.2%) (83.2%) (83.6%) (83.7%)

NOT THERAPEUTICALLY 135 134 125 122 EQUIVALENT (0.8%) (0.8%) (0.8%) (0.7%)

1 EXCEPTIONS 77 75 75 75 (0.5%) (0.5%) (0.5%) (0.4%) NEW MOLECULAR ENTITIES APPROVED 13 22 12 37

NUMBER OF APPLICANTS 927 935 957 975

1 Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA New drug product approval usually in the supplement month. CAHN Applicant holder firm name has changed.

viii

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. CDFR Change. Dosage Form; Route of Administration. CFTG Change. A first time generic for the innovator product. A TE Code is added. CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status. CMS1 Change. Miscellaneous addition to list. CMS2 Change. Miscellaneous deletion from list. CPOT Change. Potency amount/unit. CRLD Change. Reference Listed Drug. CTEC Change. Therapeutic Equivalence Code. CTNA Change. Trade Name. DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ix

PRESCRIPTION DRUG PRODUCT LIST - 35TH EDITION RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL FIORICET @ ACTAVIS LABS UT INC 325MG;50MG;40MG A 088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL FIORICET W/ CODEINE AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N 020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE AA SUN PHARM INDS LTD 300MG;30MG A 085868 001 Apr CAHN AA 300MG;60MG A 087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN AA + MIKART 325MG;2.5MG A 040846 001 Jun 09, 2010 Feb CTEC @ SUN PHARM INDS LTD 325MG;10MG A 040826 001 Aug 16, 2007 Apr CAHN NORCO AA ACTAVIS LABS FL INC 325MG;2.5MG A 040148 004 Jul 07, 2014 Feb NEWA AA 325MG;5MG A 040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE CAPSULE, EXTENDED RELEASE;ORAL DIAMOX AB + TEVA BRANDED PHARM 500MG N 012945 001 Jun CAHN

ACETOHEXAMIDE TABLET;ORAL ACETOHEXAMIDE @ ANI PHARMS INC 250MG A 070869 001 Feb 09, 1987 Jul CAHN @ 500MG A 070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE INJECTABLE;INTRAVENOUS ACETYLCYSTEINE AP AKORN INC 6GM/30ML (200MG/ML) A 203173 001 Mar 24, 2015 Mar NEWA AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A 203624 001 Jun 19, 2015 Jun NEWA SOLUTION;INHALATION, ORAL ACETYLCYSTEINE >A> AN ALVOGEN INC 10% A 204674 001 Feb 11, 2014 Sep CAHN >A> AN 20% A 203853 001 Jun 21, 2012 Sep CAHN >D> AN INNOPHARMA LICENSING 10% A 204674 001 Feb 11, 2014 Sep CAHN >D> AN 20% A 203853 001 Jun 21, 2012 Sep CAHN

ACITRETIN CAPSULE;ORAL ACITRETIN AB MYLAN PHARMS INC 10MG A 202148 001 Sep 10, 2015 Aug NEWA AB 17.5MG A 203707 001 Sep 10, 2015 Aug NEWA AB 22.5MG A 203707 002 Sep 10, 2015 Aug NEWA AB 25MG A 202148 002 Sep 10, 2015 Aug NEWA AB SIGMAPHARM LABS LLC 10MG A 204633 001 May 22, 2015 May NEWA AB 17.5MG A 204633 002 May 22, 2015 May NEWA AB 22.5MG A 204633 003 May 22, 2015 May NEWA AB 25MG A 204633 004 May 22, 2015 May NEWA

ACLIDINIUM BROMIDE POWDER, METERED;INHALATION TUDORZA PRESSAIR + ASTRAZENECA PHARMS 0.375MG/INH N 202450 001 Jul 23, 2012 Apr CAHN + 0.4MG/INH N 202450 001 Jul 23, 2012 Aug CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -2

ACYCLOVIR TABLET;ORAL ACYCLOVIR AB SUN PHARM INDS LTD 400MG A 074980 001 Sep 30, 1998 Apr CAHN AB 800MG A 074980 002 Sep 30, 1998 Apr CAHN

ADAPALENE; BENZOYL PEROXIDE GEL;TOPICAL >A> ADAPALENE AND BENZOYL PEROXIDE >A> AB ACTAVIS MID ATLANTIC 0.1%;2.5% A 203790 001 Sep 30, 2015 Sep NEWA EPIDUO >D> + GALDERMA LABS LP 0.1%;2.5% N 022320 001 Dec 08, 2008 Sep CFTG >A> AB + 0.1%;2.5% N 022320 001 Dec 08, 2008 Sep CFTG EPIDUO FORTE + GALDERMA LABS 0.3%;2.5% N 207917 001 Jul 15, 2015 Aug CAHN + GALDERMA R AND D 0.3%;2.5% N 207917 001 Jul 15, 2015 Jul NEWA

ADENOSINE INJECTABLE;INJECTION ADENOSINE AP EUROHLTH INTL SARL 3MG/ML A 076500 001 Jun 16, 2004 Jun CAHN >A> @ 3MG/ML A 076501 001 Jun 16, 2004 Sep CAHN >D> @ HIKMA MAPLE 3MG/ML A 076501 001 Jun 16, 2004 Sep CAHN @ WOCKHARDT 3MG/ML A 090220 001 Jul 20, 2009 May DISC

ALBENDAZOLE TABLET, CHEWABLE;ORAL ALBENZA + AMEDRA PHARMS LLC 200MG N 207844 001 Jun 11, 2015 Jun NEWA

ALBUTEROL SULFATE POWDER, METERED;INHALATION PROAIR RESPICLICK + TEVA BRANDED PHARM EQ 0.090MG BASE/INH N 205636 001 Mar 31, 2015 Mar NEWA SYRUP;ORAL ALBUTEROL SULFATE AA G AND W LABS INC EQ 2MG BASE/5ML A 074454 001 Sep 25, 1995 Apr CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE AEROSOL, METERED;INHALATION COMBIVENT @ BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;0.018MG/INH N 020291 001 Oct 24, 1996 May DISC

ALFUZOSIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL ALFUZOSIN HYDROCHLORIDE @ WOCKHARDT LTD 10MG A 090221 001 Aug 10, 2012 Feb DISC UROXATRAL AB + CONCORDIA PHARMS INC 10MG N 021287 001 Jun 12, 2003 Jun CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET;ORAL TEKAMLO @ NOVARTIS EQ 150MG BASE;EQ 5MG BASE N 022545 001 Aug 26, 2010 May DISC @ EQ 150MG BASE;EQ 10MG BASE N 022545 002 Aug 26, 2010 May DISC @ EQ 300MG BASE;EQ 5MG BASE N 022545 003 Aug 26, 2010 May DISC @ EQ 300MG BASE;EQ 10MG BASE N 022545 004 Aug 26, 2010 May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE TABLET;ORAL AMTURNIDE @ NOVARTIS EQ 150MG BASE;EQ 5MG BASE;12.5MG N 200045 001 Dec 21, 2010 May DISC @ EQ 300MG BASE;EQ 5MG BASE;12.5MG N 200045 002 Dec 21, 2010 May DISC @ EQ 300MG BASE;EQ 5MG BASE;25MG N 200045 003 Dec 21, 2010 May DISC @ EQ 300MG BASE;EQ 10MG BASE;12.5MG N 200045 004 Dec 21, 2010 May DISC @ EQ 300MG BASE;EQ 10MG BASE;25MG N 200045 005 Dec 21, 2010 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -3

ALMOTRIPTAN MALATE TABLET;ORAL ALMOTRIPTAN MALATE AB TEVA PHARMS USA EQ 6.25MG BASE A 078027 001 Jul 07, 2015 Jun NEWA AB EQ 12.5MG BASE A 078027 002 Jul 07, 2015 Jun NEWA AXERT AB JANSSEN PHARMS EQ 6.25MG BASE N 021001 001 May 07, 2001 Jun CFTG AB + EQ 12.5MG BASE N 021001 002 May 07, 2001 Jun CFTG

ALOSETRON HYDROCHLORIDE TABLET;ORAL ALOSETRON HYDROCHLORIDE AB ROXANE EQ 0.5MG BASE A 200652 001 May 04, 2015 Apr NEWA AB EQ 1MG BASE A 200652 002 May 04, 2015 Apr NEWA LOTRONEX AB PROMETHEUS LABS EQ 0.5MG BASE N 021107 002 Dec 23, 2003 Apr CFTG AB + EQ 1MG BASE N 021107 001 Feb 09, 2000 Apr CFTG

ALPRAZOLAM TABLET;ORAL ALPRAZOLAM @ ANI PHARMS INC 0.25MG A 074085 001 Feb 16, 1994 Jul CAHN @ 0.5MG A 074085 002 Feb 16, 1994 Jul CAHN @ 1MG A 074085 003 Feb 16, 1994 Jul CAHN @ 2MG A 074085 004 Feb 26, 1996 Jul CAHN AB AUROBINDO PHARMA LTD 0.25MG A 203346 001 Jul 31, 2015 Jul NEWA AB 0.5MG A 203346 002 Jul 31, 2015 Jul NEWA AB 1MG A 203346 003 Jul 31, 2015 Jul NEWA AB 2MG A 203346 004 Jul 31, 2015 Jul NEWA AB NATCO PHARMA LTD 0.25MG A 200739 001 Apr 15, 2015 Mar NEWA AB 0.5MG A 200739 002 Apr 15, 2015 Mar NEWA AB 1MG A 200739 003 Apr 15, 2015 Mar NEWA AB 2MG A 200739 004 Apr 15, 2015 Mar NEWA TABLET, EXTENDED RELEASE;ORAL ALPRAZOLAM >A> AB HERITAGE PHARMS INC 0.5MG A 078489 001 Oct 17, 2008 Sep CAHN >A> AB 1MG A 078489 002 Oct 17, 2008 Sep CAHN >A> AB 2MG A 078489 003 Oct 17, 2008 Sep CAHN >A> AB 3MG A 078489 004 Oct 17, 2008 Sep CAHN >D> AB ZYDUS PHARMS USA INC 0.5MG A 078489 001 Oct 17, 2008 Sep CAHN >D> AB 1MG A 078489 002 Oct 17, 2008 Sep CAHN >D> AB 2MG A 078489 003 Oct 17, 2008 Sep CAHN >D> AB 3MG A 078489 004 Oct 17, 2008 Sep CAHN

AMANTADINE HYDROCHLORIDE CAPSULE;ORAL AMANTADINE HYDROCHLORIDE AB BANNER LIFE SCIENCES 100MG A 078720 001 May 29, 2008 Jan CAHN SYRUP;ORAL AMANTADINE HYDROCHLORIDE @ G AND W LABS INC 50MG/5ML A 072655 001 Oct 30, 1990 May CAHN

AMIKACIN SULFATE INJECTABLE;INJECTION AMIKACIN SULFATE @ IGI LABS INC EQ 50MG BASE/ML A 063167 001 Dec 14, 1995 Mar CAHN @ EQ 250MG BASE/ML A 063169 001 Dec 14, 1995 Mar CAHN

AMILORIDE HYDROCHLORIDE TABLET;ORAL AMILORIDE HYDROCHLORIDE AB ZYDUS PHARMS USA INC 5MG A 204180 001 Aug 07, 2015 Jul NEWA

AMINO ACIDS INJECTABLE;INJECTION BRANCHAMIN 4% IN PLASTIC CONTAINER @ BAXTER HLTHCARE 4% (4GM/100ML) N 018684 001 Sep 28, 1984 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -4

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER @ BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/ N 020177 001 Oct 23, 1995 Feb DISC 100ML;35MG/100ML

AMINOCAPROIC ACID SYRUP;ORAL AMINOCAPROIC ACID AA VERSAPHARM INC 1.25GM/5ML A 074759 001 Sep 02, 1998 May CAHN TABLET;ORAL AMINOCAPROIC AB VERSAPHARM INC 500MG A 075602 001 May 24, 2001 May CAHN

AMITRIPTYLINE HYDROCHLORIDE TABLET;ORAL AMITRIPTYLINE HYDROCHLORIDE @ ANI PHARMS INC 10MG A 084910 003 Aug CAHN @ 25MG A 085031 001 Aug CAHN @ 50MG A 085032 001 Aug CAHN @ 75MG A 085030 001 Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE TABLET;ORAL LIMBITROL @ HERITAGE PHARMS INC EQ 12.5MG BASE;5MG N 016949 001 Jul CAHN LIMBITROL DS @ HERITAGE PHARMS INC EQ 25MG BASE;10MG N 016949 002 Jul CAHN

AMLODIPINE BESYLATE TABLET;ORAL AMLODIPINE BESYLATE AB CHINA RESOURCES EQ 5MG BASE A 090752 001 Apr 15, 2011 Mar CAHN AB EQ 10MG BASE A 090752 002 Apr 15, 2011 Mar CAHN >D> AB MATRIX LABS LTD EQ 2.5MG BASE A 078224 001 Feb 27, 2008 Sep CAHN >D> AB EQ 5MG BASE A 078224 002 Feb 27, 2008 Sep CAHN >D> AB EQ 10MG BASE A 078224 003 Feb 27, 2008 Sep CAHN >A> AB MYLAN PHARMS INC EQ 2.5MG BASE A 078224 001 Feb 27, 2008 Sep CAHN >A> AB EQ 5MG BASE A 078224 002 Feb 27, 2008 Sep CAHN >A> AB EQ 10MG BASE A 078224 003 Feb 27, 2008 Sep CAHN AB SOVEREIGN PHARMS EQ 2.5MG BASE A 204900 001 Jul 23, 2015 Jul NEWA AB EQ 5MG BASE A 204900 002 Jul 23, 2015 Jul NEWA AB EQ 10MG BASE A 204900 003 Jul 23, 2015 Jul NEWA AB SUN PHARM INDS LTD EQ 2.5MG BASE A 077974 001 Jul 09, 2007 Apr CAHN AB EQ 5MG BASE A 077974 002 Jul 09, 2007 Apr CAHN AB EQ 10MG BASE A 077974 003 Jul 09, 2007 Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN TABLET;ORAL AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE AB LUPIN LTD 5MG;12.5MG;160MG A 200797 001 Jun 03, 2015 May NEWA AB 5MG;25MG;160MG A 200797 002 Jun 03, 2015 May NEWA AB 10MG;12.5MG;160MG A 200797 003 Jun 03, 2015 May NEWA AB 10MG;25MG;160MG A 200797 004 Jun 03, 2015 May NEWA AB 10MG;25MG;320MG A 200797 005 Jun 03, 2015 May NEWA AB PAR PHARM 5MG;12.5MG;160MG A 201087 001 Jun 01, 2015 May NEWA AB 5MG;25MG;160MG A 201087 002 Jun 01, 2015 May NEWA AB 10MG;12.5MG;160MG A 201087 003 Jun 01, 2015 May NEWA AB 10MG;25MG;160MG A 201087 004 Jun 01, 2015 May NEWA AB 10MG;25MG;320MG A 201087 005 Jun 01, 2015 May NEWA AB TEVA PHARMS 5MG;12.5MG;160MG A 200435 001 Sep 25, 2012 May CAIN AB 5MG;25MG;160MG A 200435 002 Sep 25, 2012 May CAIN AB 10MG;12.5MG;160MG A 200435 005 Sep 25, 2012 May CAIN AB 10MG;25MG;160MG A 200435 003 Sep 25, 2012 May CAIN AB 10MG;25MG;320MG A 200435 004 Sep 25, 2012 May CAIN >D> AB TORRENT PHARMS LTD 5MG;12.5MG;160MG A 201593 001 Jun 04, 2015 Sep CMS1 >A> AB 5MG;12.5MG;160MG A 201593 001 Jun 03, 2015 Sep CMS1 AB 5MG;12.5MG;160MG A 201593 001 Jun 04, 2015 May NEWA >D> AB 5MG;25MG;160MG A 201593 002 Jun 04, 2015 Sep CMS1 >A> AB 5MG;25MG;160MG A 201593 002 Jun 03, 2015 Sep CMS1 AB 5MG;25MG;160MG A 201593 002 Jun 04, 2015 May NEWA >D> AB 10MG;12.5MG;160MG A 201593 003 Jun 04, 2015 Sep CMS1 RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -5

TABLET;ORAL AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE >A> AB 10MG;12.5MG;160MG A 201593 003 Jun 03, 2015 Sep CMS1 AB 10MG;12.5MG;160MG A 201593 003 Jun 04, 2015 May NEWA >D> AB 10MG;25MG;160MG A 201593 004 Jun 04, 2015 Sep CMS1 >A> AB 10MG;25MG;160MG A 201593 004 Jun 03, 2015 Sep CMS1 AB 10MG;25MG;160MG A 201593 004 Jun 04, 2015 May NEWA >D> AB 10MG;25MG;320MG A 201593 005 Jun 04, 2015 Sep CMS1 >A> AB 10MG;25MG;320MG A 201593 005 Jun 03, 2015 Sep CMS1 AB 10MG;25MG;320MG A 201593 005 Jun 04, 2015 May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE TABLET;ORAL PRESTALIA SYMPLMED PHARMS LLC EQ 2.5MG BASE;3.5MG N 205003 001 Jan 21, 2015 Jan NEWA EQ 5MG BASE;7MG N 205003 002 Jan 21, 2015 Jan NEWA + EQ 10MG BASE;14MG N 205003 003 Jan 21, 2015 Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN TABLET;ORAL AMLODIPINE BESYLATE AND VALSARTAN AB ALEMBIC PHARMS LTD EQ 5MG BASE;160MG A 202713 001 Apr 03, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 202713 003 Apr 03, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 202713 002 Apr 03, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 202713 004 Apr 03, 2015 Mar NEWA AB LUPIN EQ 5MG BASE;160MG A 090245 001 Mar 30, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 090245 003 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 090245 002 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 090245 004 Mar 30, 2015 Mar NEWA AB MATRIX LABS LTD EQ 5MG BASE;160MG A 090483 001 Mar 30, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 090483 003 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 090483 002 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 090483 004 Mar 30, 2015 Mar NEWA AB MYLAN PHARMS INC EQ 5MG BASE;160MG A 090483 001 Mar 30, 2015 Apr CAHN AB EQ 5MG BASE;320MG A 090483 003 Mar 30, 2015 Apr CAHN AB EQ 10MG BASE;160MG A 090483 002 Mar 30, 2015 Apr CAHN AB EQ 10MG BASE;320MG A 090483 004 Mar 30, 2015 Apr CAHN AB NOVEL LABS INC EQ 5MG BASE;160MG A 202829 001 Mar 30, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 202829 003 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 202829 002 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 202829 004 Mar 30, 2015 Mar NEWA AB TEVA PHARMS USA EQ 5MG BASE;160MG A 091235 001 Mar 30, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 091235 003 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 091235 002 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 091235 004 Mar 30, 2015 Mar NEWA AB TORRENT PHARMS LTD EQ 5MG BASE;160MG A 202377 001 Mar 30, 2015 Mar NEWA AB EQ 5MG BASE;320MG A 202377 002 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;160MG A 202377 003 Mar 30, 2015 Mar NEWA AB EQ 10MG BASE;320MG A 202377 004 Mar 30, 2015 Mar NEWA

AMMONIA N-13 INJECTABLE;INTRAVENOUS AMMONIA N 13 AP BIOMEDCL RES FDN 48.75mCi-487.5mCi/13ML (3.75- A 204352 001 May 01, 2015 Apr NEWA 37.5mCi/ML) CENTRAL RADIOPHARM 3.75-260mCi/ML A 204539 001 Jun 23, 2015 Jun NEWA AP IBA MOLECULAR N AM 18.8mCi-188mCi/5ML (3.75- A 204667 001 Apr 22, 2015 Apr NEWA 37.5mCi/ML) NCM USA BRONX LLC 3.75-260mCi/mL A 204515 001 Feb 04, 2015 Jan NEWA PRECISION NUCLEAR 3.75-260mCi/ML A 204547 001 Aug 14, 2015 Aug NEWA AP SPECTRON MRC LLC 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A 204455 001 Apr 23, 2015 Apr NEWA

AMOXICILLIN CAPSULE;ORAL AMOXICILLIN AB SUN PHARM INDS LTD 250MG A 065016 001 Apr 08, 1999 Apr CAHN AB 500MG A 065016 002 Apr 08, 1999 Apr CAHN FOR SUSPENSION;ORAL AMOXICILLIN @ SUN PHARM INDS LTD 200MG/5ML A 065113 001 Nov 29, 2002 Apr CAHN @ 400MG/5ML A 065113 002 Nov 29, 2002 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -6

TABLET;ORAL AMOXICILLIN AB SUN PHARM INDS LTD 500MG A 065059 001 Nov 24, 2000 Apr CAHN AB 875MG A 065059 002 Nov 24, 2000 Apr CAHN TABLET, CHEWABLE;ORAL AMOXICILLIN AB SUN PHARM INDS LTD 125MG A 065021 001 Dec 23, 1999 Apr CAHN @ 200MG A 065060 001 Nov 29, 2000 Apr CAHN AB 250MG A 065021 002 Dec 23, 1999 Apr CAHN @ 400MG A 065060 002 Nov 29, 2000 Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM FOR SUSPENSION;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB SUN PHARM INDS LTD 200MG/5ML;EQ 28.5MG BASE/5ML A 065132 001 Mar 19, 2003 Apr CAHN AB 400MG/5ML;EQ 57MG BASE/5ML A 065132 002 Mar 19, 2003 Apr CAHN AB 600MG/5ML;EQ 42.9MG BASE/5ML A 065207 002 Jan 30, 2007 Apr CAHN TABLET;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM @ SUN PHARM INDS LTD 500MG;EQ 125MG BASE A 065109 001 Nov 04, 2002 Apr CAHN AB 875MG;EQ 125MG BASE A 065102 001 Sep 17, 2002 Apr CAHN TABLET, CHEWABLE;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE A 065161 001 Dec 03, 2003 Apr CAHN AB 400MG;EQ 57MG BASE A 065161 002 Dec 03, 2003 Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB COREPHARMA 1.875MG;1.875MG;1.875MG;1.875MG A 040444 005 Nov 03, 2014 May NEWA AB 3.125MG;3.125MG;3.125MG;3.125MG A 040444 006 Nov 03, 2014 May NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 040444 007 Nov 03, 2014 May NEWA

AMPHETAMINE SULFATE TABLET;ORAL EVEKEO ARBOR PHARMS LLC 5MG A 200166 001 Aug 09, 2012 Mar CTNA + 10MG A 200166 002 Aug 09, 2012 Mar CTNA

AMPICILLIN SODIUM INJECTABLE;INJECTION AMPICILLIN SODIUM AP HOSPIRA INC EQ 250MG BASE/VIAL A 202864 001 Sep 04, 2015 Aug NEWA AP EQ 500MG BASE/VIAL A 202864 002 Sep 04, 2015 Aug NEWA AP EQ 1GM BASE/VIAL A 202864 003 Sep 04, 2015 Aug NEWA AP EQ 2GM BASE/VIAL A 202864 004 Sep 04, 2015 Aug NEWA AP EQ 10GM BASE/VIAL A 202865 001 Sep 04, 2015 Aug NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID FOR SUSPENSION;ORAL PROBAMPACIN @ G AND W LABS INC EQ 3.5GM BASE/BOT;1GM/BOT A 061741 001 Apr CAHN

ANASTROZOLE TABLET;ORAL ANASTROZOLE @ KREMERS URBAN PHARMS 1MG A 091331 001 Jan 05, 2011 Mar CAHN

ARGATROBAN INJECTABLE;INJECTION ARGATROBAN AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML) N 201811 001 Mar 23, 2015 Apr CDFR AP + PFIZER 250MG/2.5ML (100MG/ML) N 020883 001 Jun 30, 2000 Aug CTNA INJECTABLE;IV (INFUSION) ARGATROBAN AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML) N 201811 001 Mar 23, 2015 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -7

ARIPIPRAZOLE SOLUTION;ORAL ARIPIPRAZOLE AA AMNEAL PHARMS 1MG/ML A 203906 001 Aug 14, 2015 Aug NEWA >A> AA APOTEX INC 1MG/ML A 204094 001 Sep 30, 2015 Sep NEWA AA SILARX PHARMS INC 1MG/ML A 204171 001 Aug 14, 2015 Aug NEWA TABLET;ORAL ABILIFY AB OTSUKA 2MG N 021436 006 Nov 15, 2002 Apr CFTG AB + 5MG N 021436 005 Nov 15, 2002 Apr CFTG AB + 10MG N 021436 001 Nov 15, 2002 Apr CFTG AB 15MG N 021436 002 Nov 15, 2002 Apr CFTG AB 20MG N 021436 003 Nov 15, 2002 Apr CFTG AB 30MG N 021436 004 Nov 15, 2002 Apr CFTG ARIPIPRAZOLE AB ALEMBIC PHARMS LTD 2MG A 202101 001 Apr 28, 2015 Apr NEWA AB 5MG A 202101 002 Apr 28, 2015 Apr NEWA AB 10MG A 202101 003 Apr 28, 2015 Apr NEWA AB 15MG A 202101 004 Apr 28, 2015 Apr NEWA AB 20MG A 202101 005 Apr 28, 2015 Apr NEWA AB 30MG A 202101 006 Apr 28, 2015 Apr NEWA AB APOTEX INC 2MG A 078583 001 Jul 24, 2015 Jul NEWA AB 5MG A 078583 002 Jul 24, 2015 Jul NEWA AB 10MG A 078583 003 Jul 24, 2015 Jul NEWA AB 15MG A 078583 004 Jul 24, 2015 Jul NEWA AB 20MG A 078583 005 Jul 24, 2015 Jul NEWA AB 30MG A 078583 006 Jul 24, 2015 Jul NEWA >A> AB AUROBINDO PHARMA LTD 2MG A 203908 001 Oct 08, 2015 Sep NEWA >A> AB 5MG A 203908 002 Oct 08, 2015 Sep NEWA >A> AB 10MG A 203908 003 Oct 08, 2015 Sep NEWA >A> AB 15MG A 203908 004 Oct 08, 2015 Sep NEWA >A> AB 20MG A 203908 005 Oct 08, 2015 Sep NEWA >A> AB 30MG A 203908 006 Oct 08, 2015 Sep NEWA AB HETERO LABS LTD V 2MG A 205064 001 Apr 28, 2015 Apr NEWA AB 5MG A 205064 002 Apr 28, 2015 Apr NEWA AB 10MG A 205064 003 Apr 28, 2015 Apr NEWA AB 15MG A 205064 004 Apr 28, 2015 Apr NEWA AB 20MG A 205064 005 Apr 28, 2015 Apr NEWA AB 30MG A 205064 006 Apr 28, 2015 Apr NEWA AB TEVA PHARMS USA 2MG A 078607 001 Apr 28, 2015 Apr NEWA AB 5MG A 078607 002 Apr 28, 2015 Apr NEWA AB 10MG A 078608 001 Apr 28, 2015 Apr NEWA AB 15MG A 078708 001 Apr 28, 2015 Apr NEWA AB 20MG A 078708 002 Apr 28, 2015 Apr NEWA AB 30MG A 078708 003 Apr 28, 2015 Apr NEWA AB TORRENT PHARMS LTD 2MG A 201519 001 Apr 28, 2015 Apr NEWA AB 10MG A 201519 003 Apr 28, 2015 Apr NEWA AB 5MG A 201519 002 Apr 28, 2015 Apr NEWA AB 15MG A 201519 004 Apr 28, 2015 Apr NEWA AB 20MG A 201519 005 Apr 28, 2015 Apr NEWA AB 30MG A 201519 006 Apr 28, 2015 Apr NEWA TABLET, ORALLY DISINTEGRATING;ORAL ABILIFY AB + OTSUKA 10MG N 021729 002 Jun 07, 2006 Apr CFTG AB 15MG N 021729 003 Jun 07, 2006 Apr CFTG ARIPIPRAZOLE AB ALEMBIC PHARMS LTD 10MG A 202102 001 Apr 28, 2015 Apr NEWA AB 15MG A 202102 002 Apr 28, 2015 Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E INJECTABLE;INJECTION M.V.I.-12 LYOPHILIZED @ IGI LABS INC 100MG/VIAL;0.06MG/VIAL;0.005MG/VIA N 018933 002 Aug 08, 1985 Jun CAHN L;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;4 0MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/V IAL;1MG/VIAL;10MG/VIAL RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -8

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE FOR SOLUTION;ORAL PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID @ NOVEL LABS INC 4.7GM;100GM;1.015GM;5.9GM;2.691GM; A 090145 001 Jan 25, 2012 Aug CTNA 7.5GM

ASENAPINE MALEATE TABLET;SUBLINGUAL SAPHRIS FOREST LABS LLC EQ 5MG BASE N 022117 001 Aug 13, 2009 Jun CAHN + EQ 10MG BASE N 022117 002 Aug 13, 2009 Jun CAHN

>A> ASPIRIN >A> CAPSULE, EXTENDED RELEASE;ORAL >A> DURLAZA >A> + NEW HAVEN PHARMS 162.5MG N 200671 001 Sep 04, 2015 Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINE CAPSULE;ORAL FIORINAL AA + ACTAVIS LABS UT INC 325MG;50MG;40MG N 017534 005 Apr 16, 1986 Jan CAHN TABLET;ORAL FIORINAL @ ACTAVIS LABS UT INC 325MG;50MG;40MG N 017534 003 Apr 16, 1986 Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL FIORINAL W/CODEINE AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N 019429 003 Oct 26, 1990 Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE CAPSULE;ORAL SYNALGOS-DC + SUN PHARM INDS 356.4MG;30MG;16MG N 011483 004 Sep 06, 1983 Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE TABLET;ORAL NORGESIC @ MEDICIS 385MG;30MG;25MG N 013416 003 Oct 27, 1982 Mar DISC NORGESIC FORTE @ MEDICIS 770MG;60MG;50MG N 013416 004 Oct 27, 1982 Mar DISC ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE SANDOZ 385MG;30MG;25MG A 074654 001 Dec 31, 1996 Mar CTEC + 770MG;60MG;50MG A 074654 002 Dec 31, 1996 Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ASPIRIN AA ACTAVIS LABS FL INC 325MG;4.8355MG A 090084 001 Mar 22, 2011 Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT TABLET;ORAL EVOTAZ + BRISTOL MYERS SQUIBB EQ 300MG BASE;150MG N 206353 001 Jan 29, 2015 Jan NEWA

ATENOLOL TABLET;ORAL ATENOLOL AB ALVOGEN IPCO SARL 25MG A 073646 001 Jul 31, 1992 Jul CAHN AB 50MG A 072303 001 Jul 15, 1988 Jul CAHN AB 100MG A 072304 001 Jul 15, 1988 Jul CAHN @ DAVA PHARMS INC 25MG A 074099 001 Apr 28, 1992 Jun DISC TENORMIN AB ALVOGEN IPCO SARL 25MG N 018240 004 Apr 09, 1990 Feb CAHN AB 50MG N 018240 001 Feb CAHN AB + 100MG N 018240 002 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -9

ATENOLOL; CHLORTHALIDONE TABLET;ORAL ATENOLOL AND CHLORTHALIDONE AB ALVOGEN IPCO SARL 50MG;25MG A 072301 001 May 31, 1990 Jul CAHN AB 100MG;25MG A 072302 001 May 31, 1990 Jul CAHN TENORETIC 100 AB + ALVOGEN IPCO SARL 100MG;25MG N 018760 001 Jun 08, 1984 Feb CAHN TENORETIC 50 AB ALVOGEN IPCO SARL 50MG;25MG N 018760 002 Jun 08, 1984 Feb CAHN

ATORVASTATIN CALCIUM TABLET;ORAL ATORVASTATIN CALCIUM AB KREMERS URBAN PHARMS EQ 10MG BASE A 091624 001 Apr 05, 2013 Mar CAHN AB EQ 20MG BASE A 091624 002 Apr 05, 2013 Mar CAHN AB EQ 40MG BASE A 091624 003 Apr 05, 2013 Mar CAHN AB EQ 80MG BASE A 091624 004 Apr 05, 2013 Mar CAHN AB SUN PHARM INDS LTD EQ 10MG BASE A 076477 001 Nov 30, 2011 Apr CAHN AB EQ 20MG BASE A 076477 002 Nov 30, 2011 Apr CAHN AB EQ 40MG BASE A 076477 003 Nov 30, 2011 Apr CAHN AB EQ 80MG BASE A 076477 004 Nov 30, 2011 Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE TABLET;ORAL LIPTRUZET @ MERCK SHARP DOHME EQ 10MG BASE;10MG N 200153 001 May 03, 2013 May DISC @ EQ 20MG BASE;10MG N 200153 002 May 03, 2013 May DISC @ EQ 40MG BASE;10MG N 200153 003 May 03, 2013 May DISC @ EQ 80MG BASE;10MG N 200153 004 May 03, 2013 May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE TABLET;ORAL ATOVAQUONE AND PROGUANIL HYDROCHLORIDE AB GLENMARK GENERICS 62.5MG;25MG A 091211 002 Apr 06, 2015 Mar NEWA

ATRACURIUM BESYLATE INJECTABLE;INJECTION ATRACURIUM BESYLATE AP AUROBINDO PHARMA LTD 10MG/ML A 206011 001 Apr 08, 2015 Mar NEWA ATRACURIUM BESYLATE PRESERVATIVE FREE AP AUROBINDO PHARMA LTD 10MG/ML A 206010 001 Apr 08, 2015 Mar NEWA

ATROPINE SULFATE SOLUTION/DROPS;OPHTHALMIC ATROPINE SULFATE + AKORN 1% N 206289 001 Jul 18, 2014 May CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE TABLET;ORAL MOTOFEN + SEBELA IRELAND LTD 0.025MG;1MG N 017744 002 Feb CAHN MOTOFEN HALF-STRENGTH @ SEBELA IRELAND LTD 0.025MG;0.5MG N 017744 001 Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE TABLET;ORAL DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE @ ANI PHARMS INC 0.025MG;2.5MG A 086727 001 Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME POWDER;IV (INFUSION) AVYCAZ + CEREXA INC EQ 0.5GM BASE;2GM/VIAL N 206494 001 Feb 25, 2015 Feb NEWA

AZELAIC ACID AEROSOL, FOAM;TOPICAL FINACEA + BAYER HLTHCARE 15% N 207071 001 Jul 29, 2015 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -10

AZELASTINE HYDROCHLORIDE SPRAY, METERED;NASAL AZELASTINE HYDROCHLORIDE AB BRECKENRIDGE PHARMS EQ 0.125MG BASE/SPRAY A 090176 001 Jul 28, 2015 Jul NEWA

AZITHROMYCIN FOR SUSPENSION;ORAL AZITHROMYCIN AB LUPIN LTD EQ 100MG BASE/5ML A 065488 001 May 15, 2015 May NEWA AB EQ 200MG BASE/5ML A 065488 002 May 15, 2015 May NEWA INJECTABLE;INJECTION AZITHROMYCIN AP AUROBINDO PHARMA LTD EQ 500MG BASE/VIAL A 203294 001 Jun 19, 2015 Jun NEWA TABLET;ORAL AZITHROMYCIN AB LUPIN LTD EQ 250MG BASE A 065398 001 May 15, 2015 May NEWA AB EQ 500MG BASE A 065399 001 May 15, 2015 May NEWA AB EQ 600MG BASE A 065400 001 May 15, 2015 May NEWA

BALSALAZIDE DISODIUM CAPSULE;ORAL COLAZAL AB + VALEANT PHARMS INTL 750MG N 020610 001 Jul 18, 2000 Jul CAHN TABLET;ORAL BALSALAZIDE DISODIUM AB PAR PHARM INC 1.1GM A 206336 001 Sep 08, 2015 Aug NEWA GIAZO AB + VALEANT PHARMS INTL 1.1GM N 022205 001 Feb 03, 2012 Aug CFTG + 1.1GM N 022205 001 Feb 03, 2012 Jul CAHN

BENAZEPRIL HYDROCHLORIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AB AMNEAL PHARMS LLC 5MG A 076820 001 Feb 03, 2006 Jan CAHN AB 10MG A 076820 002 Feb 03, 2006 Jan CAHN AB 20MG A 076820 003 Feb 03, 2006 Jan CAHN AB 40MG A 076820 004 Feb 03, 2006 Jan CAHN AB SUN PHARM INDS LTD 5MG A 076344 001 Feb 11, 2004 Apr CAHN AB 10MG A 076344 002 Feb 11, 2004 Apr CAHN AB 20MG A 076344 003 Feb 11, 2004 Apr CAHN AB 40MG A 076344 004 Feb 11, 2004 Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE AB SUN PHARM INDS LTD 5MG;6.25MG A 077483 001 Sep 08, 2005 Apr CAHN AB 10MG;12.5MG A 077483 002 Sep 08, 2005 Apr CAHN AB 20MG;12.5MG A 077483 003 Sep 08, 2005 Apr CAHN AB 20MG;25MG A 077483 004 Sep 08, 2005 Apr CAHN

BENZONATATE CAPSULE;ORAL BENZONATATE AA APOTEX INC 100MG A 091310 001 Jan 16, 2015 Jan NEWA AA 200MG A 091310 002 Jan 16, 2015 Jan NEWA AA BANNER LIFE SCIENCES 100MG A 081297 001 Jan 29, 1993 Jan CAHN AA 200MG A 081297 002 Oct 30, 2007 Jan CAHN AA CSPC NBP PHARM CO 200MG A 202765 001 Jul 31, 2015 Jul NEWA AA STRIDES ARCOLAB LTD 100MG A 091133 001 Jul 30, 2015 Jul NEWA AA 200MG A 091133 002 Jul 30, 2015 Jul NEWA AA STRIDES PHARMA 100MG A 091133 001 Jul 30, 2015 Aug CAHN AA 200MG A 091133 002 Jul 30, 2015 Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE GEL;TOPICAL ACANYA AB + DOW PHARM 2.5%;EQ 1.2% BASE N 050819 001 Oct 23, 2008 Jun CFTG CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE AB ACTAVIS LABS UT INC 2.5%;EQ 1.2% BASE A 205128 001 Jun 19, 2015 Jun NEWA >A> AB PERRIGO ISRAEL 5%;EQ 1% BASE A 202440 001 Sep 21, 2015 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -11

GEL;TOPICAL ONEXTON + DOW PHARM 3.75%;EQ 1.2% BASE N 050819 002 Nov 24, 2014 Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCIN GEL;TOPICAL ERYTHROMYCIN AND BENZOYL PEROXIDE >A> AB LYNE 5%;3% A 065385 001 Sep 18, 2015 Sep NEWA

BENZPHETAMINE HYDROCHLORIDE TABLET;ORAL BENZPHETAMINE HYDROCHLORIDE AA + KVK TECH 50MG A 090968 001 Jul 20, 2010 Jun CRLD DIDREX @ PHARMACIA AND UPJOHN 50MG N 012427 002 Jun DISC

BENZTROPINE MESYLATE TABLET;ORAL BENZTROPINE MESYLATE AA NUVO PHARM INC 0.5MG A 204713 001 Apr 14, 2015 Mar NEWA AA 1MG A 204713 002 Apr 14, 2015 Mar NEWA AA 2MG A 204713 003 Apr 14, 2015 Mar NEWA

BETAMETHASONE DIPROPIONATE LOTION;TOPICAL BETAMETHASONE DIPROPIONATE AB G AND W LABS INC EQ 0.05% BASE A 071467 001 Aug 10, 1987 Apr CAHN @ EQ 0.05% BASE A 071882 001 Jun 06, 1988 Apr CAHN

BETAMETHASONE VALERATE CREAM;TOPICAL BETA-VAL AB G AND W LABS INC EQ 0.1% BASE N 018642 001 Mar 24, 1983 Aug CAHN LOTION;TOPICAL BETA-VAL AB G AND W LABS INC EQ 0.1% BASE A 070072 001 Jun 27, 1985 Apr CAHN

BETHANECHOL CHLORIDE TABLET;ORAL BETHANECHOL CHLORIDE AA HERITAGE PHARMA 5MG A 091256 001 May 04, 2010 Mar CAHN AA 10MG A 091256 002 May 04, 2010 Mar CAHN AA 25MG A 091256 003 May 04, 2010 Mar CAHN AA 50MG A 091256 004 May 04, 2010 Mar CAHN AA LANNETT HOLDINGS INC 5MG A 040703 001 Mar 27, 2008 Feb CMFD AA 50MG A 040677 001 Mar 27, 2008 Feb CMFD DUVOID AA WELLSPRING PHARM 10MG A 086262 001 Jan CMFD AA 25MG A 086263 001 May CMFD AA 50MG A 085882 003 May CMFD

BEXAROTENE CAPSULE;ORAL BEXAROTENE AB BANNER LIFE SCIENCES 75MG A 203174 001 Aug 12, 2014 Jun CMFD @ 75MG A 203174 001 Aug 12, 2014 Jan CAHN TARGRETIN AB + VALEANT LUXEMBOURG 75MG N 021055 001 Dec 29, 1999 Jun CTEC

BICALUTAMIDE TABLET;ORAL BICALUTAMIDE AB APOTEX INC 50MG A 200274 001 May 21, 2015 May NEWA AB STASON PHARMS 50MG A 091011 001 Jun 10, 2015 May NEWA

BIMATOPROST SOLUTION/DROPS;OPHTHALMIC BIMATOPROST AT ALCON RES LTD 0.03% A 202565 001 May 05, 2015 Apr NEWA AT APOTEX INC 0.03% A 090449 001 Jul 20, 2015 Jul NEWA AT + LUPIN LTD 0.03% A 203991 001 Feb 20, 2015 Apr CTEC + 0.03% A 203991 001 Feb 20, 2015 Mar CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -12

SOLUTION/DROPS;OPHTHALMIC BIMATOPROST AT + 0.03% A 203991 001 Feb 20, 2015 Feb NEWA

BIPERIDEN HYDROCHLORIDE TABLET;ORAL AKINETON @ ABBVIE 2MG N 012003 001 Aug DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE CAPSULE;ORAL PYLERA + FOREST LABS LLC 140MG;125MG;125MG N 050786 001 Sep 28, 2006 Jul CAHN

BIVALIRUDIN INJECTABLE;INTRAVENOUS BIVALIRUDIN AP HOSPIRA INC 250MG/VIAL A 090811 001 Jul 14, 2015 Jun NEWA AP 250MG/VIAL A 090816 001 Jul 14, 2015 Jun NEWA

BOSUTINIB MONOHYDRATE TABLET;ORAL BOSULIF + WYETH PHARMS INC EQ 100MG BASE N 203341 001 Sep 04, 2012 Jun CRLD EQ 500MG BASE N 203341 002 Sep 04, 2012 Jun CRLD

BREXPIPRAZOLE TABLET;ORAL REXULTI OTSUKA PHARM CO LTD 0.25MG N 205422 001 Jul 10, 2015 Jul NEWA 0.5MG N 205422 002 Jul 10, 2015 Jul NEWA 1MG N 205422 003 Jul 10, 2015 Jul NEWA 2MG N 205422 004 Jul 10, 2015 Jul NEWA 3MG N 205422 005 Jul 10, 2015 Jul NEWA + 4MG N 205422 006 Jul 10, 2015 Jul NEWA

BROMFENAC SODIUM SOLUTION/DROPS;OPHTHALMIC >D> BROMDAY >D> AT2 + BAUSCH AND LOMB INC EQ 0.09% ACID N 021664 002 Oct 16, 2010 Sep DISC >A> @ EQ 0.09% ACID N 021664 002 Oct 16, 2010 Sep DISC AT2 + EQ 0.09% ACID N 021664 002 Oct 16, 2010 May CTEC BROMFENAC SODIUM AT2 APOTEX INC EQ 0.09% ACID A 202620 001 Jun 23, 2014 May CTEC AT1 + COASTAL PHARMS EQ 0.09% ACID A 201211 001 May 11, 2011 May CRLD AT2 HI-TECH PHARMACAL EQ 0.09% ACID A 203395 001 Jan 22, 2014 May CTEC AT1 PADDOCK LLC EQ 0.09% ACID A 201941 001 Feb 10, 2015 Jan NEWA

BUDESONIDE AEROSOL, FOAM;RECTAL UCERIS + VALEANT PHARMS INTL 2MG/ACTUATION N 205613 001 Oct 07, 2014 Apr CAHN SPRAY, METERED;NASAL BUDESONIDE APOTEX INC 0.032MG/INH A 078949 001 May 12, 2014 Mar CTEC TABLET, EXTENDED RELEASE;ORAL UCERIS + VALEANT PHARMS INTL 9MG N 203634 001 Jan 14, 2013 Aug CAHN

BUMETANIDE INJECTABLE;INJECTION BUMETANIDE AP EUROHLTH INTL SARL 0.25MG/ML A 079196 001 Apr 30, 2008 Jun CAHN

BUPRENORPHINE HYDROCHLORIDE INJECTABLE;INJECTION BUPRENORPHINE HYDROCHLORIDE AP PAR STERILE PRODUCTS EQ 0.3MG BASE/ML A 206586 001 Jul 28, 2015 Jul NEWA TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AB ACTAVIS ELIZABETH EQ 2MG BASE A 090819 001 Feb 19, 2015 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -13

TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AB EQ 8MG BASE A 090819 002 Feb 19, 2015 Feb NEWA AB MYLAN PHARMS INC EQ 2MG BASE A 201066 001 Mar 06, 2015 Feb NEWA AB EQ 8MG BASE A 201066 002 Mar 06, 2015 Feb NEWA AB SANDOZ INC EQ 2MG BASE A 090279 001 Jun 10, 2015 May NEWA AB EQ 8MG BASE A 090279 002 Jun 10, 2015 May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE >A> FILM;BUCCAL, SUBLINGUAL >A> SUBOXONE >A> INDIVIOR INC EQ 2MG BASE;EQ 0.5MG BASE N 022410 001 Aug 30, 2010 Sep CDFR >A> EQ 4MG BASE;EQ 1MG BASE N 022410 003 Aug 10, 2012 Sep CDFR >A> EQ 8MG BASE;EQ 2MG BASE N 022410 002 Aug 30, 2010 Sep CDFR >A> + EQ 12MG BASE;EQ 3MG BASE N 022410 004 Aug 10, 2012 Sep CDFR >D> FILM;SUBLINGUAL >D> SUBOXONE >D> INDIVIOR INC EQ 2MG BASE;EQ 0.5MG BASE N 022410 001 Aug 30, 2010 Sep CDFR >D> EQ 4MG BASE;EQ 1MG BASE N 022410 003 Aug 10, 2012 Sep CDFR >D> EQ 8MG BASE;EQ 2MG BASE N 022410 002 Aug 30, 2010 Sep CDFR >D> + EQ 12MG BASE;EQ 3MG BASE N 022410 004 Aug 10, 2012 Sep CDFR TABLET;SUBLINGUAL ZUBSOLV OREXO AB EQ 2.9MG BASE;EQ 0.71MG BASE N 204242 005 Jun 04, 2015 Jun NEWA

BUPROPION HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL APLENZIN VALEANT PHARMS NORTH 174MG N 022108 001 Apr 23, 2008 Feb CAHN 348MG N 022108 002 Apr 23, 2008 Feb CAHN + 522MG N 022108 003 Apr 23, 2008 Feb CAHN

BUPROPION HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE AB1 PRINSTON INC 100MG A 202304 001 May 26, 2015 May NEWA AB1 150MG A 202304 002 May 26, 2015 May NEWA AB1 200MG A 202304 003 May 26, 2015 May NEWA AB2 SANDOZ INC 150MG A 077475 001 Mar 12, 2008 Mar CAHN @ WOCKHARDT LTD 100MG A 201331 001 Aug 30, 2012 May DISC @ 150MG A 201331 002 Aug 30, 2012 May DISC @ 200MG A 201331 003 Aug 30, 2012 May DISC

BUSPIRONE HYDROCHLORIDE TABLET;ORAL BUSPIRONE HYDROCHLORIDE >A> AB EMCURE PHARMS USA 5MG A 204582 001 Sep 18, 2015 Sep NEWA >A> AB 10MG A 204582 002 Sep 18, 2015 Sep NEWA >A> AB 15MG A 204582 003 Sep 18, 2015 Sep NEWA >A> AB 30MG A 204582 004 Sep 18, 2015 Sep NEWA

BUTABARBITAL SODIUM ELIXIR;ORAL BUTISOL SODIUM @ MEDA PHARMS 30MG/5ML A 085380 001 Jul DISC TABLET;ORAL BUTISOL SODIUM @ MEDA PHARMS 50MG N 000793 003 May DISC

BUTOCONAZOLE NITRATE CREAM;VAGINAL BUTOCONAZOLE NITRATE @ ELAN PHARMA INTL LTD 2% N 019881 001 Feb 07, 1997 May CTNA GYNAZOLE-1 + PERRIGO ISRAEL 2% A 200923 001 May 18, 2012 Jun CTNA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -14

CAFFEINE CITRATE SOLUTION;INTRAVENOUS CAFFEINE CITRATE >A> AP AUROBINDO PHARMA LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 205013 001 Sep 22, 2015 Sep NEWA

CALCIPOTRIENE CREAM;TOPICAL CALCIPOTRIENE AB GLENMARK PHARMS LTD 0.005% A 205772 001 Jun 09, 2015 May NEWA

CALCITONIN SALMON INJECTABLE;INJECTION CALCITONIN-SALMON @ IGI LABS INC 200 IU/ML A 073690 001 Apr 14, 1995 Mar CAHN MIACALCIN @ MYLAN IRELAND LTD 100 IU/ML N 017808 001 Jul 03, 1986 Aug CAHN + 200 IU/ML N 017808 002 Mar 29, 1991 Aug CAHN SPRAY, METERED;NASAL MIACALCIN AB + MYLAN IRELAND LTD 200 IU/SPRAY N 020313 002 Aug 17, 1995 Aug CAHN

CALCITRIOL CAPSULE;ORAL CALCITRIOL AB BANNER LIFE SCIENCES 0.25MCG A 091174 001 May 24, 2013 Jan CAHN AB 0.5MCG A 091174 002 May 24, 2013 Jan CAHN AB STRIDES PHARMA 0.25MCG A 091356 001 Dec 12, 2014 Jan CAHN AB 0.5MCG A 091356 002 Dec 12, 2014 Jan CAHN INJECTABLE;INJECTION CALCIJEX @ ABBVIE 0.001MG/ML N 018874 001 Sep 25, 1986 Jun DISC @ 0.002MG/ML N 018874 002 Sep 25, 1986 Jun DISC CALCITRIOL @ AKORN 0.002MG/ML A 078066 002 Jan 29, 2008 Jun DISC @ FRESENIUS KABI USA 0.001MG/ML A 075836 001 Dec 31, 2002 Jun DISC @ 0.002MG/ML A 075836 002 Dec 31, 2002 Jun DISC @ FRESENIUS MEDCL 0.001MG/ML A 075766 001 Feb 20, 2003 Jun DISC @ 0.002MG/ML A 075766 002 Feb 20, 2003 Jun DISC @ LUITPOLD 0.001MG/ML A 075746 001 Sep 26, 2003 Jun DISC @ 0.002MG/ML A 075746 002 Sep 26, 2003 Jun DISC @ SAGENT PHARMS 0.001MG/ML A 077102 001 Feb 08, 2006 Jun DISC

CALCIUM ACETATE CAPSULE;ORAL CALCIUM ACETATE >A> AB HERITAGE PHARMS INC EQ 169MG CALCIUM A 202315 001 Jun 29, 2015 Sep CAHN AB LUPIN LTD EQ 169MG CALCIUM A 202127 001 Jul 09, 2015 Jun NEWA >D> AB ZYDUS PHARMS USA INC EQ 169MG CALCIUM A 202315 001 Jun 29, 2015 Sep CAHN AB EQ 169MG CALCIUM A 202315 001 Jun 29, 2015 Jun NEWA TABLET;ORAL CALCIUM ACETATE >A> AB HERITAGE PHARMS INC EQ 169MG CALCIUM A 202885 001 Jan 22, 2015 Sep CAHN >D> AB ZYDUS PHARMS USA INC EQ 169MG CALCIUM A 202885 001 Jan 22, 2015 Sep CAHN AB EQ 169MG CALCIUM A 202885 001 Jan 22, 2015 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE INJECTABLE;INJECTION PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 010 Oct 10, 2008 Jan CPOT L;3.05GM/1000ML;0.157GM/1000ML;2.2 1GM/1000ML;7.07GM/1000ML (5000ML)

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER @ GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 012 Oct 10, 2008 Jan CPOT 00ML;3.05GM/1000ML;0.157GM/1000ML; 2.21GM/1000ML;7.07GM/1000ML (5000ML) PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 011 Oct 10, 2008 Jan CPOT L;3.05GM/1000ML;0.314GM/1000ML;2.2 1GM/1000ML;7.07 RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -15

INJECTABLE;INJECTION PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER GM/1000ML (5000ML) PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 013 Oct 10, 2008 Jan CPOT 00ML;3.05GM/1000ML;0.314GM/1000ML; 2.21GM/1000ML;7.07GM/1000ML (5000ML) PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 006 Oct 25, 2006 Jan CPOT 00ML;3.05GM/1000ML;N/A/1000ML;3.09 GM/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 002 Oct 25, 2006 Jan CPOT L;2.03GM/1000ML;0.157GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS 5.15GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 003 Oct 25, 2006 Jan CPOT 00ML;2.03GM/1000ML;0.157GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML) PRISMASOL BGK 4/0 IN PLASTIC CONTAINER @ GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 005 Oct 25, 2006 Jan CPOT L;3.05GM/1000ML;0.314GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 015 Oct 10, 2008 Jan CPOT L;2.44GM/1000ML;0.314GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 004 Oct 25, 2006 Jan CPOT 00ML;3.05GM/1000ML;0.314GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML) PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER @ GAMBRO RENAL PRODS 5.15GM/1000ML;20GM/1000ML;5.4GM/10 N 021703 008 Oct 25, 2006 Jan CPOT 00ML;2.03GM/1000ML;0.314GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML) PRISMASOL BK 0/0 IN PLASTIC CONTAINER @ GAMBRO RENAL PRODS N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703 007 Oct 25, 2006 Jan CPOT ;3.05GM/1000ML;N/A/1000ML;3.09GM/1 000ML;6.46GM/1000ML (5000ML)

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703 014 Oct 10, 2008 Jan CPOT ;2.44GM/1000ML;N/A/1000ML;3.09GM/1 000ML;6.46GM/1000ML (5000ML)

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER + GAMBRO RENAL PRODS 5.15GM/1000ML;N/A/1000ML;5.4GM/100 N 021703 001 Oct 25, 2006 Jan CPOT 0ML;2.03GM/1000ML;N/A/1000ML;3.09G M/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER @ GAMBRO RENAL PRODS 3.68GM/1000ML;N/A/1000ML;5.4GM/100 N 021703 009 Oct 25, 2006 Jan CPOT 0ML;3.05GM/1000ML;0.314GM/1000ML;3 .09GM/1000ML;6.46GM/1000ML (5000ML)

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE INJECTABLE;INJECTION PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER + GAMBRO LUNDIA N/A/1000ML;N/A/1000ML;N/A/1000ML;3 N 207026 002 Jan 13, 2015 Jan NEWA .05GM/1000ML;0.314GM/1000ML;2.21GM /1000ML;6.95GM/1000ML;0.187GM/1000 ML (5000ML) PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER + GAMBRO LUNDIA 3.68GM/1000ML;N/A/1000ML;N/A/1000M N 207026 001 Jan 13, 2015 Jan NEWA L;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187 GM/1000ML (5000ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -16

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE SOLUTION;IRRIGATION NAVSTEL @ ALCON PHARMS LTD 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.18 N 022193 001 Jul 24, 2008 Jun DISC 4MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M L;0.42MG/ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER @ BAXTER HLTHCARE 37MG/100ML;5GM/100ML;30MG/100ML;11 N 017390 001 Mar DISC 9MG/100ML;161MG/100ML;94MG/100ML;1 38MG/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION PLASMA-LYTE R IN PLASTIC CONTAINER @ BAXTER HLTHCARE 36.8MG/100ML;30.5MG/100ML;74.6MG/1 N 017438 001 Mar DISC 00ML;640MG/100ML;496MG/100ML;89.6M G/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE INJECTABLE;INJECTION PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER + GAMBRO LUNDIA N/A/1000ML;3.05GM/1000ML;0.314GM/1 N 207026 002 Jan 13, 2015 Feb CAIN 000ML;2.21GM/1000ML;6.95GM/1000ML; 0.187GM/1000ML (5000ML) PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER + GAMBRO LUNDIA 3.68GM/1000ML;3.05GM/1000ML;0.314G N 207026 001 Jan 13, 2015 Feb CAIN M/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE SOLUTION;IRRIGATION LACTATED RINGER'S IN PLASTIC CONTAINER >D> AT + BAXTER HLTHCARE 20MG/100ML;30MG/100ML;600MG/100ML; N 019933 001 Aug 29, 1989 Sep DISC 310MG/100ML >A> @ 20MG/100ML;30MG/100ML;600MG/100ML; N 019933 001 Aug 29, 1989 Sep DISC 310MG/100ML

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE TABLET;ORAL CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE AB MACLEODS PHARMS LTD 16MG;12.5MG A 204100 001 Feb 27, 2015 Feb NEWA AB 32MG;12.5MG A 204100 002 Feb 27, 2015 Feb NEWA AB 32MG;25MG A 204100 003 Feb 27, 2015 Feb NEWA

CAPECITABINE TABLET;ORAL CAPECITABINE AB ACCORD HLTHCARE 150MG A 202593 001 Apr 23, 2015 Apr NEWA AB 500MG A 202593 002 Apr 23, 2015 Apr NEWA

CAPTOPRIL TABLET;ORAL CAPOTEN @ PAR PHARM 12.5MG N 018343 005 Jan 17, 1985 May DISC @ 25MG N 018343 002 May DISC @ 50MG N 018343 001 May DISC @ 100MG N 018343 003 May DISC CAPTOPRIL @ G AND W LABS INC 12.5MG A 074433 001 Feb 13, 1996 Jul CAHN @ 12.5MG A 074462 001 Feb 13, 1996 Apr CAHN @ 12.5MG A 074483 001 Feb 13, 1996 Jul CAHN @ 12.5MG A 074590 004 Aug 30, 1996 Apr CAHN @ 25MG A 074433 002 Feb 13, 1996 Jul CAHN @ 25MG A 074462 002 Feb 13, 1996 Apr CAHN @ 25MG A 074483 002 Feb 13, 1996 Jul CAHN @ 25MG A 074590 002 Aug 30, 1996 Apr CAHN @ 50MG A 074433 003 Feb 13, 1996 Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -17

TABLET;ORAL CAPTOPRIL @ 50MG A 074462 003 Feb 13, 1996 Apr CAHN @ 50MG A 074483 003 Feb 13, 1996 Jul CAHN @ 50MG A 074590 001 Aug 30, 1996 Apr CAHN @ 100MG A 074433 004 Feb 13, 1996 Jul CAHN @ 100MG A 074462 004 Feb 13, 1996 Apr CAHN @ 100MG A 074483 004 Feb 13, 1996 Jul CAHN @ 100MG A 074590 003 Aug 30, 1996 Apr CAHN AB + MYLAN 100MG A 074434 004 Feb 13, 1996 May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE TABLET;ORAL CAPTOPRIL AND HYDROCHLOROTHIAZIDE AB G AND W LABS INC 25MG;15MG A 074827 001 Dec 29, 1997 Apr CAHN AB 25MG;25MG A 074827 002 Dec 29, 1997 Apr CAHN AB 50MG;15MG A 074827 004 Dec 29, 1997 Apr CAHN AB 50MG;25MG A 074827 003 Dec 29, 1997 Apr CAHN

CARBAMAZEPINE CAPSULE, EXTENDED RELEASE;ORAL CARBAMAZEPINE AB MYLAN PHARMS INC 100MG A 076697 001 May 20, 2011 May CAHN AB 200MG A 076697 002 May 20, 2011 May CAHN AB 300MG A 076697 003 May 20, 2011 May CAHN

CARBIDOPA; LEVODOPA CAPSULE, EXTENDED RELEASE;ORAL RYTARY IMPAX LABS INC 23.75MG;95MG N 203312 001 Jan 07, 2015 Jan NEWA 36.25MG;145MG N 203312 002 Jan 07, 2015 Jan NEWA 48.75MG;195MG N 203312 003 Jan 07, 2015 Jan NEWA + 61.25MG;245MG N 203312 004 Jan 07, 2015 Jan NEWA SUSPENSION;ENTERAL DUOPA + ABBVIE INC 4.63MG/ML;20MG/ML N 203952 001 Jan 09, 2015 Jan NEWA

>A> CARIPRAZINE HYDROCHLORIDE >A> CAPSULE;ORAL >A> VRAYLAR >A> FOREST RES INST INC EQ 1.5MG BASE N 204370 001 Sep 17, 2015 Sep NEWA >A> EQ 3MG BASE N 204370 002 Sep 17, 2015 Sep NEWA >A> EQ 4.5MG BASE N 204370 003 Sep 17, 2015 Sep NEWA >A> + EQ 6MG BASE N 204370 004 Sep 17, 2015 Sep NEWA

CARISOPRODOL TABLET;ORAL CARISOPRODOL AB INDICUS PHARMA 250MG A 205126 001 Jul 08, 2015 Jun NEWA AA 350MG A 205126 002 Jul 08, 2015 Jun NEWA SOMA AB + MEDA PHARMS 250MG N 011792 004 Sep 13, 2007 Jun CTEC

CARVEDILOL TABLET;ORAL CARVEDILOL @ HIKMA 3.125MG A 077887 001 Sep 07, 2007 Jun DISC @ 6.25MG A 077887 002 Sep 07, 2007 Jun DISC @ 12.5MG A 077887 003 Sep 07, 2007 Jun DISC @ 25MG A 077887 004 Sep 07, 2007 Jun DISC AB SUN PHARM INDS LTD 3.125MG A 076989 001 Sep 05, 2007 Apr CAHN AB 6.25MG A 076989 002 Sep 05, 2007 Apr CAHN AB 12.5MG A 076989 003 Sep 05, 2007 Apr CAHN AB 25MG A 076989 004 Sep 05, 2007 Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE FOR SUSPENSION;ORAL CEFADROXIL SUN PHARM INDS LTD EQ 125MG BASE/5ML A 065115 001 Mar 26, 2003 Apr CAHN AB EQ 250MG BASE/5ML A 065115 002 Mar 26, 2003 Apr CAHN AB EQ 500MG BASE/5ML A 065115 003 Mar 26, 2003 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -18

CEFAZOLIN SODIUM INJECTABLE;INJECTION CEFAZOLIN SODIUM AP FACTA FARMA EQ 500MG BASE/VIAL A 063214 001 Dec 27, 1991 Jan CAHN AP EQ 1GM BASE/VIAL A 063207 001 Dec 27, 1991 Jan CAHN AP EQ 10GM BASE/VIAL A 063209 001 Dec 27, 1991 Jan CAHN AP + EQ 20GM BASE/VIAL A 063209 002 Apr 30, 1999 Jan CAHN SOLUTION;INTRAVENOUS CEFAZOLIN IN PLASTIC CONTAINER >A> BAXTER HLTHCARE EQ 2GM BASE/100ML (EQ 20MG N 207131 001 Aug 07, 2015 Sep CAHN BASE/ML) >D> CELERITY PHARMS EQ 2GM BASE/100ML (EQ 20MG N 207131 001 Aug 07, 2015 Sep CAHN BASE/ML) EQ 2GM BASE/100ML (EQ 20MG N 207131 001 Aug 07, 2015 Aug NEWA BASE/ML)

CEFIXIME FOR SUSPENSION;ORAL CEFIXIME AB AUROBINDO PHARMA LTD 100MG/5ML A 204835 001 Apr 14, 2015 Apr NEWA AB 200MG/5ML A 204835 002 Apr 14, 2015 Apr NEWA SUPRAX AB LUPIN PHARMS 100MG/5ML A 065129 001 Feb 23, 2004 Apr CFTG AB 200MG/5ML A 065355 001 Apr 10, 2007 Apr CFTG

CEFOTETAN DISODIUM INJECTABLE;INJECTION CEFOTAN @ IGI LABS INC EQ 1GM BASE/VIAL A 063293 001 Apr 29, 1993 May CAHN @ EQ 1GM BASE/VIAL N 050588 001 Dec 27, 1985 Mar CAHN @ EQ 2GM BASE/VIAL A 063293 002 Apr 29, 1993 May CAHN @ EQ 2GM BASE/VIAL N 050588 002 Dec 27, 1985 Mar CAHN @ EQ 10GM BASE/VIAL N 050588 003 Apr 25, 1988 Mar CAHN CEFOTAN IN PLASTIC CONTAINER @ IGI LABS INC EQ 20MG BASE/ML N 050694 002 Jul 30, 1993 Mar CAHN @ EQ 40MG BASE/ML N 050694 001 Jul 30, 1993 Mar CAHN

CEFPODOXIME PROXETIL FOR SUSPENSION;ORAL CEFPODOXIME PROXETIL AB SUN PHARM INDS LTD EQ 50MG BASE/5ML A 065082 001 May 31, 2002 Apr CAHN AB EQ 100MG BASE/5ML A 065082 002 May 31, 2002 Apr CAHN TABLET;ORAL CEFPODOXIME PROXETIL AB SUN PHARM INDS LTD EQ 100MG BASE A 065083 001 Aug 20, 2003 Apr CAHN AB EQ 200MG BASE A 065083 002 Aug 20, 2003 Apr CAHN

CEFTAZIDIME INJECTABLE;INJECTION FORTAZ AP + CONCORDIA PHARMS INC 500MG/VIAL N 050578 001 Jul 19, 1985 Jun CAHN AP + 1GM/VIAL N 050578 002 Jul 19, 1985 Jun CAHN AP + 2GM/VIAL N 050578 003 Jul 19, 1985 Jun CAHN AP + 6GM/VIAL N 050578 004 Jul 19, 1985 Jun CAHN

CEFTAZIDIME SODIUM INJECTABLE;INJECTION FORTAZ IN PLASTIC CONTAINER @ CONCORDIA PHARMS INC EQ 10MG BASE/ML N 050634 001 Apr 28, 1989 Jun CAHN + EQ 20MG BASE/ML N 050634 002 Apr 28, 1989 Jun CAHN + EQ 40MG BASE/ML N 050634 003 Apr 28, 1989 Jun CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM POWDER;IV (INFUSION) ZERBAXA + CUBIST PHARMS LLC EQ 1GM BASE/VIAL;EQ 0.5GM N 206829 001 Dec 19, 2014 Aug CAHN BASE/VIAL RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -19

CEFTRIAXONE SODIUM INJECTABLE;INJECTION CEFTRIAXONE AP FACTA FARMA EQ 10GM BASE/VIAL A 065269 001 Feb 28, 2007 Jan CAHN INJECTABLE;INTRAMUSCULAR, INTRAVENOUS CEFTRIAXONE @ FACTA FARMA EQ 1GM BASE/VIAL A 065268 001 Feb 28, 2007 Jan CAHN @ EQ 2GM BASE/VIAL A 065268 002 Feb 28, 2007 Jan CAHN @ FRESENIUS KABI USA EQ 250MG BASE/VIAL A 065245 001 Feb 15, 2006 Jul DISC

CEFUROXIME AXETIL FOR SUSPENSION;ORAL CEFUROXIME AXETIL AB SUN PHARM INDS LTD EQ 125MG BASE/5ML A 065323 001 Feb 05, 2008 Apr CAHN AB EQ 250MG BASE/5ML A 065323 002 Feb 05, 2008 Apr CAHN TABLET;ORAL CEFUROXIME AXETIL AB ANI PHARMS INC EQ 250MG BASE A 065190 001 Oct 18, 2004 Jul CAHN AB EQ 500MG BASE A 065190 002 Oct 18, 2004 Jul CAHN AB SUN PHARM INDS LTD EQ 125MG BASE A 065118 001 Apr 25, 2003 Apr CAHN AB EQ 250MG BASE A 065118 002 Apr 25, 2003 Apr CAHN AB EQ 500MG BASE A 065118 003 Apr 25, 2003 Apr CAHN

CEFUROXIME SODIUM INJECTABLE;INJECTION CEFUROXIME SODIUM AP FACTA FARMA EQ 1.5GM BASE/VIAL A 064125 002 May 30, 1997 Jan CAHN AP EQ 7.5GM BASE/VIAL A 064124 001 May 30, 1997 Jan CAHN ZINACEF AP + CONCORDIA PHARMS INC EQ 1.5GM BASE/VIAL N 050558 003 Oct 19, 1983 Jun CAHN AP + EQ 7.5GM BASE/VIAL N 050558 004 Oct 23, 1986 Jun CAHN ZINACEF IN PLASTIC CONTAINER @ CONCORDIA PHARMS INC EQ 15MG BASE/ML N 050643 001 Apr 28, 1989 Jun CAHN + EQ 30MG BASE/ML N 050643 002 Apr 28, 1989 Jun CAHN INJECTABLE;INTRAMUSCULAR, INTRAVENOUS CEFUROXIME SODIUM AB FACTA FARMA EQ 750MG BASE/VIAL A 064125 001 May 30, 1997 Jan CAHN ZINACEF AB + CONCORDIA PHARMS INC EQ 750MG BASE/VIAL N 050558 002 Oct 19, 1983 Jun CAHN

CELECOXIB CAPSULE;ORAL CELECOXIB AB ALEMBIC PHARMS LTD 50MG A 204519 001 Aug 21, 2015 Aug NEWA AB 100MG A 204519 002 Aug 21, 2015 Aug NEWA AB 200MG A 204519 003 Aug 21, 2015 Aug NEWA AB 400MG A 204519 004 Aug 21, 2015 Aug NEWA AB APOTEX INC 50MG A 204197 001 Jun 02, 2015 May NEWA AB 100MG A 204197 002 Jun 02, 2015 May NEWA AB 200MG A 204197 003 Jun 02, 2015 May NEWA >A> AB CIPLA LTD 50MG A 207446 001 Sep 23, 2015 Sep NEWA >A> AB 100MG A 207446 002 Sep 23, 2015 Sep NEWA >A> AB 200MG A 207446 003 Sep 23, 2015 Sep NEWA >A> AB 400MG A 207446 004 Sep 23, 2015 Sep NEWA AB LUPIN LTD 100MG A 202240 002 Jun 09, 2015 May NEWA AB 200MG A 202240 003 Jun 09, 2015 May NEWA AB 400MG A 202240 004 Jun 09, 2015 May NEWA AB MYLAN PHARMS INC 100MG A 078857 002 Feb 11, 2015 Jan NEWA AB 200MG A 078857 003 Feb 11, 2015 Jan NEWA AB 400MG A 078857 004 Feb 11, 2015 Jan NEWA AB WATSON LABS INC 50MG A 200562 001 Feb 11, 2015 Jan NEWA AB 100MG A 200562 002 Feb 11, 2015 Jan NEWA AB 200MG A 200562 003 Feb 11, 2015 Jan NEWA AB 400MG A 200562 004 Feb 11, 2015 Jan NEWA

CEPHALEXIN CAPSULE;ORAL CEPHALEXIN AB SUN PHARM INDS LTD EQ 250MG BASE A 065007 001 Sep 16, 1999 Apr CAHN AB EQ 500MG BASE A 065007 002 Sep 16, 1999 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -20

FOR SUSPENSION;ORAL CEPHALEXIN @ SUN PHARM INDS LTD EQ 125MG BASE/5ML A 065081 001 Jul 27, 2001 Apr CAHN @ EQ 250MG BASE/5ML A 065081 002 Jul 27, 2001 Apr CAHN

CETIRIZINE HYDROCHLORIDE SYRUP;ORAL ZYRTEC AA + J AND J CONSUMER INC 5MG/5ML N 020346 001 Sep 27, 1996 Aug CAHN

CHLOROTHIAZIDE SODIUM INJECTABLE;INJECTION CHLOROTHIAZIDE SODIUM AP SAGENT PHARMS EQ 500MG BASE/VIAL A 202462 001 May 29, 2015 May NEWA

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE TABLET, EXTENDED RELEASE;ORAL CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE SPRIASO LLC 8MG;54.3MG N 206323 001 Jun 22, 2015 Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE SOLUTION;ORAL HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE AA TRIS PHARMA INC 4MG/5ML;5MG/5ML A 206438 001 Jan 27, 2015 Jan NEWA VITUZ AA + CYPRESS PHARM 4MG/5ML;5MG/5ML N 204307 001 Feb 20, 2013 Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE SOLUTION;ORAL HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE AA COASTAL PHARMS 4MG/5ML;5MG/5ML;60MG/5ML A 205657 001 Aug 03, 2015 Jul NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX SUSPENSION, EXTENDED RELEASE;ORAL TUZISTRA XR + TRIS PHARMA INC EQ 2.8MG BASE/5ML;EQ 14.7MG N 207768 001 Apr 30, 2015 Apr NEWA BASE/5ML + VERNALIS R AND D LTD EQ 2.8MG BASE/5ML;EQ 14.7MG N 207768 001 Apr 30, 2015 Jun CAHN BASE/5ML

CHLORPROMAZINE HYDROCHLORIDE CONCENTRATE;ORAL CHLORPROMAZINE HYDROCHLORIDE INTENSOL @ CYCLE PHARMS LTD 30MG/ML A 088157 001 Apr 27, 1983 Jun CAHN @ 100MG/ML A 088158 001 Apr 27, 1983 Jun CAHN INJECTABLE;INJECTION CHLORPROMAZINE HYDROCHLORIDE + EUROHLTH INTL SARL 25MG/ML A 083329 001 Feb CAHN TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE @ CYCLE PHARMS LTD 10MG A 085331 001 Jun CAHN @ 25MG A 085331 002 Jun CAHN @ 50MG A 085331 003 Jun CAHN @ 100MG A 085331 004 Jun CAHN @ 200MG A 085331 005 Jun CAHN @ SANDOZ 10MG A 080439 001 May DISC @ 25MG A 080439 002 May DISC @ 50MG A 080439 003 May DISC @ 100MG A 080439 004 May DISC @ 200MG A 080439 005 May DISC

CHLORTHALIDONE TABLET;ORAL CHLORTHALIDONE @ G AND W LABS INC 50MG A 088651 001 May 30, 1985 Apr CAHN AB MUTUAL PHARM 50MG A 089286 001 Jul 21, 1986 Mar CMFD AB + MYLAN 50MG A 086831 001 Jun CTEC THALITONE @ CITRON PHARMA LLC 15MG N 019574 001 Dec 20, 1988 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -21

CHOLESTYRAMINE POWDER;ORAL CHOLESTYRAMINE @ ANI PHARMS INC EQ 4GM RESIN/PACKET A 074554 001 Oct 02, 1996 Aug CAHN @ EQ 4GM RESIN/SCOOPFUL A 074554 002 Oct 02, 1996 Aug CAHN

CHOLIC ACID CAPSULE;ORAL CHOLBAM ASKLEPION PHARMS LLC 50MG N 205750 001 Mar 17, 2015 Mar NEWA + 250MG N 205750 002 Mar 17, 2015 Mar NEWA RTRX 50MG N 205750 001 Mar 17, 2015 Apr CAHN + 250MG N 205750 002 Mar 17, 2015 Apr CAHN

CHOLINE FENOFIBRATE CAPSULE, DELAYED RELEASE;ORAL FENOFIBRIC ACID >A> AB ACTAVIS ELIZABETH EQ 45MG FENOFIBRIC ACID A 200920 001 Oct 07, 2015 Sep NEWA >A> AB EQ 135MG FENOFIBRIC ACID A 200920 002 Oct 07, 2015 Sep NEWA

CICLOPIROX SOLUTION;TOPICAL CICLOPIROX >D> @ APOTEX INC 8% A 078172 001 Sep 18, 2007 Sep CMFD >A> AT 8% A 078172 001 Sep 18, 2007 Sep CMFD

CIDOFOVIR INJECTABLE;INJECTION CIDOFOVIR AP + MYLAN INSTITUTIONAL EQ 75MG BASE/ML A 201276 001 Jun 27, 2012 May CRLD VISTIDE @ GILEAD SCIENCES INC EQ 75MG BASE/ML N 020638 001 Jun 26, 1996 May DISC

CIMETIDINE HYDROCHLORIDE SOLUTION;ORAL CIMETIDINE HYDROCHLORIDE @ G AND W LABS INC EQ 300MG BASE/5ML A 074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN INJECTABLE;INJECTION CIPROFLOXACIN AP CLARIS PHARMASERVICE 200MG/20ML (10MG/ML) A 078062 001 Apr 29, 2008 Apr CAHN AP 400MG/40ML (10MG/ML) A 078062 002 Apr 29, 2008 Apr CAHN CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER AP CLARIS PHARMASERVICE 200MG/100ML A 078024 001 Mar 18, 2008 Apr CAHN AP 400MG/200ML A 078024 002 Mar 18, 2008 Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE TABLET;ORAL CIPROFLOXACIN HYDROCHLORIDE AB SUN PHARM INDS LTD EQ 250MG BASE A 075747 001 Jun 09, 2004 Apr CAHN AB EQ 500MG BASE A 075747 002 Jun 09, 2004 Apr CAHN AB EQ 750MG BASE A 075747 003 Jun 09, 2004 Apr CAHN

CISATRACURIUM BESYLATE INJECTABLE;INJECTION CISATRACURIUM BESYLATE AP FRESENIUS KABI USA EQ 2MG BASE/ML A 203183 001 Feb 26, 2015 Feb NEWA CISATRACURIUM BESYLATE PRESERVATIVE FREE AP FRESENIUS KABI USA EQ 2MG BASE/ML A 203182 001 Feb 26, 2015 Feb NEWA AP EQ 10MG BASE/ML A 203182 002 Feb 26, 2015 Feb NEWA

CISPLATIN INJECTABLE;INJECTION CISPLATIN AP ACCORD HLTHCARE 1MG/ML A 206774 001 Aug 18, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -22

CITALOPRAM HYDROBROMIDE TABLET;ORAL CITALOPRAM HYDROBROMIDE AB G AND W LABS INC EQ 10MG BASE A 077048 001 Nov 16, 2004 Apr CAHN AB EQ 20MG BASE A 077048 002 Nov 16, 2004 Apr CAHN AB EQ 40MG BASE A 077048 003 Nov 16, 2004 Apr CAHN

CLARITHROMYCIN FOR SUSPENSION;ORAL CLARITHROMYCIN AB SUN PHARM INDS LTD 125MG/5ML A 065382 001 Aug 30, 2007 Apr CAHN AB 250MG/5ML A 065382 002 Aug 30, 2007 Apr CAHN TABLET;ORAL CLARITHROMYCIN >A> AB HEC PHARM USA INC 250MG A 203584 001 Sep 28, 2015 Sep NEWA >A> AB 500MG A 203584 002 Sep 28, 2015 Sep NEWA AB SUN PHARM INDS LTD 250MG A 065174 001 Sep 24, 2004 Apr CAHN AB 500MG A 065174 002 Sep 24, 2004 Apr CAHN TABLET, EXTENDED RELEASE;ORAL CLARITHROMYCIN AB LUPIN LTD 500MG A 202532 001 Sep 15, 2015 Aug NEWA AB + TEVA 500MG A 065154 001 May 18, 2005 Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM INJECTABLE;INJECTION TIMENTIN @ GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM A 062691 001 Dec 19, 1986 May DISC BASE/VIAL @ EQ 100MG BASE/VIAL;EQ 3GM N 050590 001 Apr 01, 1985 May DISC BASE/VIAL @ EQ 200MG BASE/VIAL;EQ 3GM N 050590 002 Apr 01, 1985 May DISC BASE/VIAL @ EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL N 050590 003 Aug 18, 1987 May DISC TIMENTIN IN PLASTIC CONTAINER @ GLAXOSMITHKLINE EQ 100MG BASE/100ML;EQ 3GM N 050658 001 Dec 15, 1989 May DISC BASE/100ML

CLEMASTINE FUMARATE TABLET;ORAL CLEMASTINE FUMARATE @ ANI PHARMS INC 1.34MG A 073282 001 Jan 31, 1992 Jul CAHN

CLINDAMYCIN HYDROCHLORIDE CAPSULE;ORAL CLINDAMYCIN HYDROCHLORIDE AB G AND W LABS INC EQ 150MG BASE A 063029 001 Sep 20, 1989 Apr CAHN AB EQ 300MG BASE A 063029 002 Aug 05, 2005 Apr CAHN AB SUN PHARM INDS LTD EQ 150MG BASE A 065061 001 Feb 02, 2001 Apr CAHN AB EQ 300MG BASE A 065061 002 Feb 02, 2001 Apr CAHN

CLINDAMYCIN PHOSPHATE INJECTABLE;INJECTION CLINDAMYCIN PHOSPHATE >A> AP ALVOGEN INC EQ 150MG BASE/ML A 062800 001 Jul 24, 1987 Sep CAHN >A> AP EQ 150MG BASE/ML A 062801 001 Jul 24, 1987 Sep CAHN >A> AP EQ 150MG BASE/ML A 062943 001 Sep 29, 1988 Sep CAHN >D> AP HOSPIRA EQ 150MG BASE/ML A 062800 001 Jul 24, 1987 Sep CAHN >D> AP EQ 150MG BASE/ML A 062801 001 Jul 24, 1987 Sep CAHN >D> AP EQ 150MG BASE/ML A 062943 001 Sep 29, 1988 Sep CAHN @ IGI LABS INC EQ 150MG BASE/ML A 062928 001 Feb 13, 1989 Mar CAHN SOLUTION;TOPICAL CLINDAMYCIN PHOSPHATE @ BOCA PHARMA LLC EQ 1% BASE A 062944 001 Jan 11, 1989 Jan CAHN AT VINTAGE PHARMS EQ 1% BASE A 203343 001 May 29, 2015 May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN GEL;TOPICAL CLINDAMYCIN PHOSPHATE AND TRETINOIN AB ACTAVIS MID ATLANTIC 1.2%;0.025% A 202564 001 Jun 12, 2015 Jun NEWA ZIANA AB + MEDICIS 1.2%;0.025% N 050802 001 Nov 07, 2006 Jun CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -23

CLOBETASOL PROPIONATE CREAM;TOPICAL CLOBETASOL PROPIONATE (EMOLLIENT) AB2 + FOUGERA PHARMS 0.05% A 075430 001 May 26, 1999 May CRLD CORMAX AB1 + HI TECH PHARMA 0.05% A 074220 001 May 16, 1997 Jun CRLD TEMOVATE @ FOUGERA PHARMS 0.05% N 019322 001 Dec 27, 1985 Jun DISC TEMOVATE E @ FOUGERA PHARMS 0.05% N 020340 001 Jun 17, 1994 May DISC GEL;TOPICAL CLOBETASOL PROPIONATE AB + FOUGERA PHARMS 0.05% A 075368 001 Feb 15, 2000 May CRLD TEMOVATE @ FOUGERA PHARMS 0.05% N 020337 001 Apr 29, 1994 May DISC OINTMENT;TOPICAL CLOBETASOL PROPIONATE AB G AND W LABS INC 0.05% A 074089 001 Feb 16, 1994 Feb CAHN SOLUTION;TOPICAL CLOBETASOL PROPIONATE AT G AND W LABS INC 0.05% A 074331 001 Dec 15, 1995 Mar CMFD

CLOMIPHENE CITRATE TABLET;ORAL SEROPHENE @ EMD SERONO 50MG N 018361 001 Mar 22, 1982 Jun DISC

CLONIDINE FILM, EXTENDED RELEASE;TRANSDERMAL CLONIDINE AB ACTAVIS LABS UT INC 0.1MG/24HR A 090873 001 May 06, 2014 Mar CAHN AB 0.2MG/24HR A 090873 002 May 06, 2014 Mar CAHN AB 0.3MG/24HR A 090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE TABLET;ORAL CLONIDINE HYDROCHLORIDE @ DAVA PHARMS INC 0.1MG A 071783 001 Apr 05, 1988 May DISC @ 0.2MG A 071784 001 Apr 05, 1988 May DISC @ 0.3MG A 071785 001 Apr 05, 1988 May DISC TABLET, EXTENDED RELEASE;ORAL CLONIDINE HYDROCHLORIDE AB2 ACTAVIS ELIZABETH 0.1MG A 202792 001 May 15, 2015 May NEWA AB1 0.1MG A 203320 001 May 15, 2015 May NEWA @ 0.2MG A 202792 002 May 15, 2015 Aug DISC AB2 0.2MG A 202792 002 May 15, 2015 May NEWA @ 0.2MG A 203320 002 May 15, 2015 Aug DISC AB1 0.2MG A 203320 002 May 15, 2015 May NEWA @ ANCHEN PHARMS 0.1MG A 202983 001 Apr 02, 2014 Aug DISC AB2 0.1MG A 202983 001 Apr 02, 2014 May CTEC @ 0.2MG A 202983 002 Apr 02, 2014 Aug DISC AB2 0.2MG A 202983 002 Apr 02, 2014 May CTEC CLONIDINE HYDROCHLORIDE AB1 ANCHEN PHARMS 0.1MG A 202984 001 Sep 30, 2013 May CTEC @ 0.2MG A 202984 002 Sep 30, 2013 Aug DISC AB1 0.2MG A 202984 002 Sep 30, 2013 May CTEC KAPVAY AB1 + CONCORDIA PHARMS INC 0.1MG N 022331 003 Sep 28, 2010 Aug CRLD AB1 0.1MG N 022331 003 Sep 28, 2010 Jun CRLD AB1 + 0.1MG N 022331 003 Sep 28, 2010 May CTEC @ 0.2MG N 022331 004 Sep 28, 2010 Aug DISC AB1 + 0.2MG N 022331 004 Sep 28, 2010 Jun CRLD AB1 0.2MG N 022331 004 Sep 28, 2010 May CTEC

CLORAZEPATE DIPOTASSIUM TABLET;ORAL CLORAZEPATE DIPOTASSIUM AB SUN PHARM INDS LTD 3.75MG A 076911 001 Sep 29, 2004 Apr CAHN AB 7.5MG A 076911 002 Sep 29, 2004 Apr CAHN AB 15MG A 076911 003 Sep 29, 2004 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -24

CLOZAPINE TABLET;ORAL CLOZAPINE >A> AB ACTAVIS LABS FL INC 25MG A 203807 001 Sep 17, 2015 Sep NEWA >A> AB 100MG A 203807 002 Sep 17, 2015 Sep NEWA CLOZARIL AB HERITAGE LIFE 25MG N 019758 001 Sep 26, 1989 Aug CAHN AB + 100MG N 019758 002 Sep 26, 1989 Aug CAHN TABLET, ORALLY DISINTEGRATING;ORAL CLOZAPINE AB MYLAN PHARMS INC 25MG A 201824 002 Sep 15, 2015 Aug NEWA AB 100MG A 201824 003 Sep 15, 2015 Aug NEWA FAZACLO ODT AB JAZZ PHARMS III 25MG N 021590 001 Feb 10, 2004 Aug CFTG AB + 100MG N 021590 002 Feb 10, 2004 Aug CFTG

COBICISTAT; DARUNAVIR ETHANOLATE TABLET;ORAL PREZCOBIX + JANSSEN PRODS 150MG;EQ 800MG BASE N 205395 001 Jan 29, 2015 Jan NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE AA AMNEAL PHARMS 10MG/5ML;5MG/5ML;6.25MG/5ML A 200963 001 Aug 26, 2015 Aug NEWA

CODEINE SULFATE SOLUTION;ORAL CODEINE SULFATE @ ROXANE 30MG/5ML N 202245 001 Jun 30, 2011 Jan DISC

COLCHICINE CAPSULE;ORAL MITIGARE HIKMA INTL PHARMS 0.6MG N 204820 001 Sep 26, 2014 Jan CAHN

COLCHICINE; PROBENECID TABLET;ORAL PROBENECID AND COLCHICINE @ ANI PHARMS INC 0.5MG;500MG A 083734 001 Aug CAHN

COLISTIMETHATE SODIUM INJECTABLE;INJECTION COLISTIMETHATE SODIUM AP XELLIA PHARMS APS EQ 150MG BASE/VIAL A 205356 001 May 29, 2015 May NEWA

CORTICOTROPIN INJECTABLE;INJECTION H.P. ACTHAR GEL @ MALLINCKRODT ARD 40 UNITS/ML N 008372 006 Aug CAHN + 80 UNITS/ML N 008372 008 Aug CAHN

CYANOCOBALAMIN INJECTABLE;INJECTION CYANOCOBALAMIN @ EUROHLTH INTL SARL 1MG/ML A 080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE TABLET;ORAL CYCLOBENZAPRINE HYDROCHLORIDE AB ORIT LABS LLC 5MG A 078218 002 Jun 19, 2015 Jun NEWA AB SUN PHARM INDS LTD 5MG A 078722 001 May 12, 2008 Apr CAHN AB 7.5MG A 078722 002 May 12, 2008 Apr CAHN AB 10MG A 078722 003 May 12, 2008 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -25

CYPROHEPTADINE HYDROCHLORIDE TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE >A> AA MIRROR PHARMS LLC 4MG A 205087 001 Sep 23, 2015 Sep NEWA

DABRAFENIB MESYLATE CAPSULE;ORAL TAFINLAR NOVARTIS PHARMS CORP EQ 50MG BASE N 202806 001 May 29, 2013 Mar CAHN + EQ 75MG BASE N 202806 002 May 29, 2013 Mar CAHN

DACLATASVIR DIHYDROCHLORIDE TABLET;ORAL DAKLINZA BRISTOL-MYERS SQUIBB EQ 30MG BASE N 206843 001 Jul 24, 2015 Jul NEWA + EQ 60MG BASE N 206843 002 Jul 24, 2015 Jul NEWA

DALTEPARIN SODIUM INJECTABLE;INJECTION FRAGMIN @ PFIZER INC 7,500 IU/0.75ML N 020287 008 Apr 04, 2002 Jun CAHN @ PHARMACIA AND UPJOHN 7,500 IU/0.75ML N 020287 008 Apr 04, 2002 Apr CAHN INJECTABLE;SUBCUTANEOUS FRAGMIN PFIZER INC 2,500IU/0.2ML (12,500IU/ML) N 020287 001 Dec 22, 1994 Jun CAHN 5,000IU/0.2ML (25,000IU/ML) N 020287 003 Mar 18, 1996 Jun CAHN 7,500IU/0.3ML (25,000IU/ML) N 020287 005 Apr 04, 2002 Jun CAHN @ 10,000IU/0.4ML (25,000IU/ML) N 020287 002 May 01, 2007 Jun CAHN 10,000IU/ML (10,000IU/ML) N 020287 004 Jan 30, 1998 Jun CAHN 12,500IU/0.5ML (25,000IU/ML) N 020287 009 May 01, 2007 Jun CAHN 15,000IU/0.6ML (25,000IU/ML) N 020287 010 May 01, 2007 Jun CAHN 18,000IU/0.72ML (25,000IU/ML) N 020287 011 May 01, 2007 Jun CAHN + 95,000IU/3.8ML (25,000IU/ML) N 020287 006 Apr 04, 2002 Jun CAHN @ 95,000IU/9.5ML (10,000IU/ML) N 020287 007 Apr 04, 2002 Jun CAHN PHARMACIA AND UPJOHN 2,500IU/0.2ML (12,500IU/ML) N 020287 001 Dec 22, 1994 Apr CAHN 5,000IU/0.2ML (25,000IU/ML) N 020287 003 Mar 18, 1996 Apr CAHN 7,500IU/0.3ML (25,000IU/ML) N 020287 005 Apr 04, 2002 Apr CAHN @ 10,000IU/0.4ML (25,000IU/ML) N 020287 002 May 01, 2007 Apr CAHN 10,000IU/ML (10,000IU/ML) N 020287 004 Jan 30, 1998 Apr CAHN 12,500IU/0.5ML (25,000IU/ML) N 020287 009 May 01, 2007 Apr CAHN 15,000IU/0.6ML (25,000IU/ML) N 020287 010 May 01, 2007 Apr CAHN 18,000IU/0.72ML (25,000IU/ML) N 020287 011 May 01, 2007 Apr CAHN + 95,000IU/3.8ML (25,000IU/ML) N 020287 006 Apr 04, 2002 Apr CAHN @ 95,000IU/9.5ML (10,000IU/ML) N 020287 007 Apr 04, 2002 Apr CAHN

DANTROLENE SODIUM CAPSULE;ORAL DANTROLENE SODIUM AB ELITE LABS INC 25MG A 076686 001 Oct 24, 2005 May CAHN AB 50MG A 076686 002 Oct 24, 2005 May CAHN AB 100MG A 076686 003 Oct 24, 2005 May CAHN

DARIFENACIN HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL DARIFENACIN HYDROBROMIDE AB ANCHEN PHARMS EQ 7.5MG BASE A 091190 001 Mar 13, 2015 Mar NEWA AB EQ 15MG BASE A 091190 002 Mar 13, 2015 Mar NEWA ENABLEX AB WARNER CHILCOTT LLC EQ 7.5MG BASE N 021513 001 Dec 22, 2004 Mar CFTG AB + EQ 15MG BASE N 021513 002 Dec 22, 2004 Mar CFTG

DASATINIB TABLET;ORAL SPRYCEL >D> BRISTOL MYERS SQUIBB 100MG N 021986 004 May 30, 2008 Sep CRLD >A> + 100MG N 021986 004 May 30, 2008 Sep CRLD >D> + 140MG N 021986 006 Oct 28, 2010 Sep CRLD >A> 140MG N 021986 006 Oct 28, 2010 Sep CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -26

DECITABINE INJECTABLE;INTRAVENOUS DACOGEN AP + OTSUKA PHARM CO LTD 50MG/VIAL N 021790 001 May 02, 2006 Jan CAHN

DEFERASIROX TABLET;ORAL JADENU NOVARTIS PHARMS CORP 90MG N 206910 001 Mar 30, 2015 Mar NEWA 180MG N 206910 002 Mar 30, 2015 Mar NEWA + 360MG N 206910 003 Mar 30, 2015 Mar NEWA

DEFERIPRONE >A> SOLUTION;ORAL >A> FERRIPROX >A> + APOPHARMA INC 100MG/ML N 208030 001 Sep 09, 2015 Sep NEWA

DEMECLOCYCLINE HYDROCHLORIDE TABLET;ORAL DEMECLOCYCLINE HYDROCHLORIDE AB EPIC PHARMA LLC 150MG A 065447 001 Aug 18, 2015 Aug NEWA AB 300MG A 065447 002 Aug 18, 2015 Aug NEWA

DEOXYCHOLIC ACID SOLUTION;SUBCUTANEOUS KYBELLA + KYTHERA BIOPHARMS 20MG/2ML (10MG/ML) N 206333 001 Apr 29, 2015 Apr NEWA

DESIPRAMINE HYDROCHLORIDE TABLET;ORAL DESIPRAMINE HYDROCHLORIDE >A> ANI PHARMS INC 25MG A 071803 002 Dec 08, 1987 Sep CMS1 >A> 50MG A 071803 003 Dec 08, 1987 Sep CMS1 >A> 75MG A 071803 004 Dec 08, 1987 Sep CMS1 >A> 150MG A 071803 005 May 29, 1997 Sep CMS1

DESIRUDIN RECOMBINANT INJECTABLE;SUBCUTANEOUS IPRIVASK + VALEANT PHARMS NORTH 15MG/VIAL N 021271 001 Apr 04, 2003 May CAHN

DESLORATADINE SOLUTION;ORAL CLARINEX AA + MERCK SHARP DOHME 0.5MG/ML N 021300 001 Sep 01, 2004 Jun CFTG DESLORATADINE AA TARO PHARM INDS 0.5MG/ML A 202592 001 Jun 30, 2015 Jun NEWA

DESMOPRESSIN ACETATE TABLET;ORAL DDAVP AB FERRING PHARMS INC 0.1MG N 019955 001 Sep 06, 1995 Jan CAHN AB + 0.2MG N 019955 002 Sep 06, 1995 Jan CAHN DESMOPRESSIN ACETATE AB GLENMARK PHARMS LTD 0.1MG A 201831 001 May 28, 2015 May NEWA AB 0.2MG A 201831 002 May 28, 2015 May NEWA

DESOGESTREL; ETHINYL ESTRADIOL TABLET;ORAL-28 BEKYREE AB LUPIN LTD 0.15MG,N/A;0.02MG,0.01MG A 202226 001 Aug 12, 2015 Jul NEWA CYCLESSA AB + ASPEN GLOBAL INC 0.1MG,0.125MG,0.15MG;0.025MG,0.025 N 021090 001 Dec 20, 2000 Aug CAHN MG,0.025MG ISIBLOOM AB SANDOZ INC 0.15MG;0.03MG A 202789 001 Aug 12, 2015 Jul NEWA KARIVA AB + BARR 0.15MG,N/A;0.02MG,0.01MG A 075863 001 Apr 05, 2002 Apr CTEC KIMIDESS AB VINTAGE PHARMS 0.15MG,N/A;0.02MG,0.01MG A 076681 001 Apr 30, 2015 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -27

DESONIDE CREAM;TOPICAL DESONIDE AB TEVA PHARMS 0.05% A 074027 001 Sep 28, 1992 May CMFD

DESOXIMETASONE CREAM;TOPICAL DESOXIMETASONE AB ACTAVIS MID ATLANTIC 0.25% A 205082 001 Sep 04, 2015 Aug NEWA AB VERSAPHARM INC 0.25% A 203234 001 Jun 12, 2015 Jun NEWA OINTMENT;TOPICAL DESOXIMETASONE AB PERRIGO NEW YORK 0.25% A 077770 001 Apr 20, 2015 Apr NEWA

DESVENLAFAXINE SUCCINATE TABLET, EXTENDED RELEASE;ORAL DESVENLAFAXINE SUCCINATE AB ALEMBIC PHARMS LTD EQ 50MG BASE A 204003 001 Jun 29, 2015 Jun NEWA AB EQ 100MG BASE A 204003 002 Jun 29, 2015 Jun NEWA AB LUPIN LTD EQ 50MG BASE A 204172 001 Jun 29, 2015 Jun NEWA AB EQ 100MG BASE A 204172 002 Jun 29, 2015 Jun NEWA AB MYLAN PHARMS INC EQ 50MG BASE A 204095 001 Jun 29, 2015 Jun NEWA AB EQ 100MG BASE A 204095 002 Jun 29, 2015 Jun NEWA AB SANDOZ INC EQ 50MG BASE A 204028 001 Jun 29, 2015 Jun NEWA AB EQ 100MG BASE A 204028 002 Jun 29, 2015 Jun NEWA PRISTIQ AB + WYETH PHARMS INC EQ 50MG BASE N 021992 001 Feb 29, 2008 Jun CFTG AB + EQ 100MG BASE N 021992 002 Feb 29, 2008 Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATE INJECTABLE;INJECTION DEXAMETHASONE SODIUM PHOSPHATE >A> AP BD RX EQ 4MG PHOSPHATE/ML A 203129 001 Sep 30, 2015 Sep NEWA @ EUROHLTH INTL SARL EQ 4MG PHOSPHATE/ML A 084282 001 Mar CAHN AP + EQ 10MG PHOSPHATE/ML A 087702 001 Sep 07, 1982 Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE OINTMENT;OPHTHALMIC MAXITROL AT + ALCON LABS INC 0.1%;EQ 3.5MG BASE/GM;10,000 N 050065 002 Mar CAHN UNITS/GM SUSPENSION/DROPS;OPHTHALMIC MAXITROL AT + ALCON LABS INC 0.1%;EQ 3.5MG BASE/ML;10,000 N 050023 002 Mar CAHN UNITS/ML

DEXMEDETOMIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEXMEDETOMIDINE HYDROCHLORIDE >A> AP FRESENIUS KABI USA EQ 200MCG BASE/2ML (EQ 100MCG A 201072 001 Sep 18, 2015 Sep NEWA BASE/ML) AP SUN PHARM INDS INC EQ 200MCG BASE/2ML (EQ 100MCG A 202126 001 Aug 20, 2015 Aug NEWA BASE/ML) PRECEDEX HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG N 021038 004 Nov 14, 2014 Jan NEWA BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE AB MYLAN PHARMS INC 5MG A 204266 001 Aug 25, 2015 Aug NEWA AB 10MG A 204266 002 Aug 25, 2015 Aug NEWA AB 15MG A 204266 003 Aug 25, 2015 Aug NEWA AB 40MG A 204266 007 Aug 25, 2015 Aug NEWA AB WATSON LABS INC 5MG A 079108 001 Aug 05, 2015 Jul NEWA AB 10MG A 079108 002 Aug 05, 2015 Jul NEWA TABLET;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE >A> AB SUN PHARM INDS LTD 2.5MG A 201231 001 Sep 24, 2015 Sep NEWA >A> AB 5MG A 201231 002 Sep 24, 2015 Sep NEWA >A> AB 10MG A 201231 003 Sep 24, 2015 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -28

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE INJECTABLE;INJECTION PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER @ BAXTER HLTHCARE 5GM/100ML;30MG/100ML;37MG/100ML;36 N 017451 001 Mar DISC 8MG/100ML;526MG/100ML;502MG/100ML

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM INJECTABLE;INJECTION MD-76R AP + LIEBEL-FLARSHEIM 66%;10% N 019292 001 Sep 29, 1989 Feb CAHN SOLUTION;ORAL, RECTAL MD-GASTROVIEW AA LIEBEL-FLARSHEIM 66%;10% A 087388 001 Jan CAHN

DICHLORPHENAMIDE TABLET;ORAL KEVEYIS TARO 50MG N 011366 002 Aug 07, 2015 Aug NEWA

DICLOFENAC SODIUM GEL;TOPICAL VOLTAREN + GLAXOSMITHKLINE CONS 1% N 022122 001 Oct 17, 2007 Aug CAHN SOLUTION;TOPICAL DICLOFENAC SODIUM AT IGI LABS INC 1.5% A 202769 001 Jul 08, 2015 Jun NEWA AT LUPIN LTD 1.5% A 204132 001 Aug 20, 2015 Aug NEWA

DIETHYLPROPION HYDROCHLORIDE TABLET;ORAL TENUATE AA + ACTAVIS LABS UT INC 25MG N 011722 002 Mar CAHN TABLET, EXTENDED RELEASE;ORAL TENUATE DOSPAN AB + ACTAVIS LABS UT INC 75MG N 012546 001 Mar CAHN

DIFLORASONE DIACETATE OINTMENT;TOPICAL DIFLORASONE DIACETATE AB VERSAPHARM INC 0.05% A 206572 001 Jul 24, 2015 Jul NEWA

DIFLUNISAL TABLET;ORAL DIFLUNISAL AB HERITAGE PHARMA 500MG A 202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN INJECTABLE;INJECTION DIGOXIN AP EUROHLTH INTL SARL 0.25MG/ML A 083391 001 Feb CAHN TABLET;ORAL DIGOXIN AB MYLAN PHARMS INC 0.125MG A 040282 001 Dec 23, 1999 Jan CTEC AB 0.25MG A 040282 002 Dec 23, 1999 Jan CTEC AB SUN PHARM INDS INC 0.125MG A 076363 001 Jan 31, 2003 Feb CMFD AB 0.25MG A 076363 002 Jan 31, 2003 Feb CMFD LANOXIN CONCORDIA PHARMS INC 0.0625MG N 020405 001 Sep 30, 1997 Apr CAHN AB 0.125MG N 020405 002 Sep 30, 1997 Apr CAHN 0.1875MG N 020405 003 Sep 30, 1997 Apr CAHN AB + 0.25MG N 020405 004 Sep 30, 1997 Apr CAHN @ 0.375MG N 020405 005 Sep 30, 1997 Apr CAHN @ 0.5MG N 020405 006 Sep 30, 1997 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -29

DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE AB2 + MYLAN 240MG A 075124 001 Mar 18, 1998 Feb CRLD TIAZAC AB4 VALEANT PHARMS NORTH 120MG N 020401 001 Sep 11, 1995 Feb CAHN AB4 180MG N 020401 002 Sep 11, 1995 Feb CAHN AB4 240MG N 020401 003 Sep 11, 1995 Feb CAHN AB4 300MG N 020401 004 Sep 11, 1995 Feb CAHN AB4 360MG N 020401 005 Sep 11, 1995 Feb CAHN AB4 + 420MG N 020401 006 Oct 16, 1998 Feb CAHN INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE AP EUROHLTH INTL SARL 5MG/ML A 078538 001 Dec 17, 2008 Jun CAHN

DIPHENHYDRAMINE HYDROCHLORIDE INJECTABLE;INJECTION DIPHENHYDRAMINE HYDROCHLORIDE AP + EUROHLTH INTL SARL 50MG/ML A 080817 002 Jun CAHN

DIPYRIDAMOLE INJECTABLE;INJECTION DIPYRIDAMOLE AP EUROHLTH INTL SARL 5MG/ML A 074521 001 Oct 18, 1996 Jun CAHN

DISULFIRAM TABLET;ORAL DISULFIRAM AB MYLAN PHARMS INC 250MG A 203916 001 Mar 04, 2015 Feb NEWA AB 500MG A 203916 002 Mar 04, 2015 Feb NEWA

DIVALPROEX SODIUM TABLET, EXTENDED RELEASE;ORAL DIVALPROEX SODIUM AB AMNEAL PHARMS EQ 250MG VALPROIC ACID A 203730 001 May 29, 2015 May NEWA AB EQ 500MG VALPROIC ACID A 203730 002 May 29, 2015 May NEWA @ G AND W LABS INC EQ 500MG VALPROIC ACID A 078700 001 Aug 03, 2009 Jul CAHN

DOBUTAMINE HYDROCHLORIDE INJECTABLE;INJECTION DOBUTAMINE HYDROCHLORIDE @ IGI LABS INC EQ 12.5MG BASE/ML A 074098 001 Feb 21, 1995 Mar CAHN

DOCETAXEL INJECTABLE;INJECTION DOCETAXEL AP TEVA PHARMS USA 20MG/ML (20MG/ML) A 203877 001 Sep 16, 2015 Aug NEWA AP 80MG/4ML (20MG/ML) A 203877 002 Sep 16, 2015 Aug NEWA

DONEPEZIL HYDROCHLORIDE TABLET;ORAL DONEPEZIL HYDROCHLORIDE AB HETERO LABS LTD V 5MG A 203034 001 Jan 30, 2015 Jan NEWA AB 10MG A 203034 002 Jan 30, 2015 Jan NEWA AB SUN PHARM INDS LTD 5MG A 076786 001 Nov 26, 2010 Apr CAHN AB 10MG A 076786 002 Nov 26, 2010 Apr CAHN AB 23MG A 204293 001 Jun 05, 2015 May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL NAMZARIC FOREST LABS LLC 10MG;14MG N 206439 001 Dec 23, 2014 Mar CAHN + 10MG;28MG N 206439 002 Dec 23, 2014 Mar CAHN

DOPAMINE HYDROCHLORIDE INJECTABLE;INJECTION DOPAMINE HYDROCHLORIDE @ IGI LABS INC 40MG/ML A 070087 001 Oct 23, 1985 Mar CAHN @ 40MG/ML N 018656 001 Jun 28, 1983 Mar CAHN @ 80MG/ML A 070089 001 Oct 23, 1985 Mar CAHN @ 80MG/ML A 070090 001 Oct 23, 1985 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -30

INJECTABLE;INJECTION DOPAMINE HYDROCHLORIDE @ 80MG/ML A 070091 001 Oct 23, 1985 Mar CAHN @ 160MG/ML A 070092 001 Oct 23, 1985 Mar CAHN @ 160MG/ML A 070093 001 Oct 23, 1985 Mar CAHN @ 160MG/ML A 070094 001 Oct 23, 1985 Mar CAHN

DOXAPRAM HYDROCHLORIDE INJECTABLE;INJECTION DOPRAM AP + EUROHLTH INTL SARL 20MG/ML N 014879 001 Jun CAHN

DOXEPIN HYDROCHLORIDE CAPSULE;ORAL DOXEPIN HYDROCHLORIDE AB + MYLAN PHARMS INC EQ 100MG BASE A 070791 005 May 13, 1986 Jan CRLD + PAR PHARM EQ 150MG BASE A 071669 001 Nov 09, 1987 Jan CRLD CREAM;TOPICAL ZONALON + DELCOR ASSET CORP 5% N 020126 001 Apr 01, 1994 Mar CAHN

DOXERCALCIFEROL INJECTABLE;INJECTION DOXERCALCIFEROL AP AKORN INC 4MCG/2ML (2MCG/ML) A 203929 001 May 07, 2015 Apr NEWA

DOXYCYCLINE CAPSULE;ORAL DOXYCYCLINE AB NOVEL LABS INC EQ 50MG BASE A 204446 001 May 28, 2015 May NEWA AB EQ 75MG BASE A 204446 002 May 28, 2015 May NEWA AB EQ 100MG BASE A 204446 003 May 28, 2015 May NEWA AB SUN PHARM INDS LTD EQ 50MG BASE A 065053 001 Nov 22, 2000 Apr CAHN AB EQ 75MG BASE A 065053 003 Sep 10, 2003 Apr CAHN AB EQ 100MG BASE A 065053 002 Nov 22, 2000 Apr CAHN TABLET;ORAL DOXYCYCLINE AB SUN PHARM INDS LTD EQ 50MG BASE A 065356 001 May 31, 2006 Apr CAHN AB EQ 75MG BASE A 065356 002 May 31, 2006 Apr CAHN AB EQ 100MG BASE A 065356 003 May 31, 2006 Apr CAHN

DOXYCYCLINE HYCLATE INJECTABLE;INJECTION DOXYCYCLINE @ EUROHLTH INTL SARL EQ 100MG BASE/VIAL A 062450 001 Oct 27, 1983 Jun CAHN @ EQ 200MG BASE/VIAL A 062450 002 Oct 27, 1983 Jun CAHN

DROPERIDOL INJECTABLE;INJECTION DROPERIDOL @ IGI LABS INC 2.5MG/ML A 072019 001 Oct 19, 1988 Mar CAHN @ 2.5MG/ML A 072020 001 Oct 19, 1988 Mar CAHN @ 2.5MG/ML A 072021 001 Oct 19, 1988 Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL TABLET;ORAL DROSPIRENONE AND ETHINYL ESTRADIOL AB GLENMARK PHARMS LTD 3MG;0.02MG A 204296 001 Aug 17, 2015 Aug NEWA

DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED REL PELLETS;ORAL DULOXETINE HYDROCHLORIDE AB ALKEM LABS LTD EQ 20MG BASE A 203197 001 Aug 26, 2015 Aug NEWA AB EQ 30MG BASE A 203197 002 Aug 26, 2015 Aug NEWA AB EQ 60MG BASE A 203197 003 Aug 26, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -31

ECONAZOLE NITRATE CREAM;TOPICAL ECONAZOLE NITRATE AB FOUGERA PHARMS 1% A 076075 001 Nov 26, 2002 Mar CRLD AB + PERRIGO NEW YORK 1% A 076479 001 Jun 23, 2004 Mar CRLD

EDOXABAN TOSYLATE TABLET;ORAL SAVAYSA DAIICHI SANKYO EQ 15MG BASE N 206316 001 Jan 08, 2015 Jan NEWA EQ 30MG BASE N 206316 002 Jan 08, 2015 Jan NEWA + EQ 60MG BASE N 206316 003 Jan 08, 2015 Jan NEWA

EDROPHONIUM CHLORIDE INJECTABLE;INJECTION ENLON + MYLAN INSTITUTIONAL 10MG/ML A 088873 001 Aug 06, 1985 Mar CRLD TENSILON @ IGI LABS INC 10MG/ML N 007959 001 Apr CAHN @ VALEANT PHARMS 10MG/ML N 007959 001 Mar DISC TENSILON PRESERVATIVE FREE @ IGI LABS INC 10MG/ML N 007959 002 Apr CAHN @ VALEANT PHARMS 10MG/ML N 007959 002 Mar DISC

ELTROMBOPAG OLAMINE FOR SUSPENSION;ORAL PROMACTA + NOVARTIS PHARMS CORP EQ 25MG ACID/PACKET N 207027 001 Aug 24, 2015 Aug NEWA TABLET;ORAL PROMACTA NOVARTIS PHARMS CORP EQ 12.5MG ACID N 022291 004 Oct 20, 2011 Mar CAHN EQ 25MG ACID N 022291 001 Nov 20, 2008 Mar CAHN EQ 50MG ACID N 022291 002 Nov 20, 2008 May CRLD + EQ 50MG ACID N 022291 002 Nov 20, 2008 Mar CAHN + EQ 75MG ACID N 022291 003 Sep 08, 2009 May CRLD EQ 75MG ACID N 022291 003 Sep 08, 2009 Mar CAHN + EQ 100MG ACID N 022291 005 Nov 16, 2012 May CRLD EQ 100MG ACID N 022291 005 Nov 16, 2012 Mar CAHN

ELUXADOLINE TABLET;ORAL VIBERZI FOREST TOSARA LTD 75MG N 206940 001 May 27, 2015 Jul CAHN + 100MG N 206940 002 May 27, 2015 Jul CAHN FURIEX PHARMS 75MG N 206940 001 May 27, 2015 May NEWA + 100MG N 206940 002 May 27, 2015 May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN TABLET;ORAL GLYXAMBI BOEHRINGER INGELHEIM 10MG;5MG N 206073 001 Jan 30, 2015 Jan NEWA + 25MG;5MG N 206073 002 Jan 30, 2015 Jan NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE TABLET;ORAL SYNJARDY BOEHRINGER INGELHEIM 5MG;500MG N 206111 001 Aug 26, 2015 Aug NEWA 5MG;1GM N 206111 002 Aug 26, 2015 Aug NEWA 12.5MG;500MG N 206111 003 Aug 26, 2015 Aug NEWA + 12.5MG;1GM N 206111 004 Aug 26, 2015 Aug NEWA

ENALAPRIL MALEATE TABLET;ORAL ENALAPRIL MALEATE AB SANDOZ INC 2.5MG A 075496 001 Aug 22, 2000 Mar CMFD AB 5MG A 075496 002 Aug 22, 2000 Mar CMFD AB 10MG A 075459 001 Aug 22, 2000 Mar CMFD AB 20MG A 075459 002 Aug 22, 2000 Mar CMFD @ SUN PHARM INDS LTD 2.5MG A 075556 001 Aug 22, 2000 Apr CAHN @ 5MG A 075556 002 Aug 22, 2000 Apr CAHN @ 10MG A 075556 003 Aug 22, 2000 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -32

TABLET;ORAL ENALAPRIL MALEATE @ 20MG A 075556 004 Aug 22, 2000 Apr CAHN VASOTEC AB VALEANT PHARMS NORTH 2.5MG N 018998 005 Jul 26, 1988 Apr CAHN AB 5MG N 018998 001 Dec 24, 1985 Apr CAHN AB 10MG N 018998 002 Dec 24, 1985 Apr CAHN AB + 20MG N 018998 003 Dec 24, 1985 Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE TABLET;ORAL ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE AB G AND W LABS INC 5MG;12.5MG A 075727 001 Sep 18, 2001 Apr CAHN AB 10MG;25MG A 075727 002 Sep 18, 2001 Apr CAHN

ENTACAPONE TABLET;ORAL ENTACAPONE AB AUROBINDO PHARMA LTD 200MG A 203437 001 Jun 19, 2015 Jun NEWA

ENTECAVIR TABLET;ORAL ENTECAVIR AB AUROBINDO PHARMA LTD 0.5MG A 206217 001 Aug 26, 2015 Aug NEWA AB 1MG A 206217 002 Aug 26, 2015 Aug NEWA AB HETERO LABS LTD V 0.5MG A 205740 001 Aug 21, 2015 Aug NEWA AB 1MG A 205740 002 Aug 21, 2015 Aug NEWA

EPINEPHRINE INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS ADRENALIN + PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML) N 204200 001 Dec 07, 2012 Jul CAIN INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS ADRENALIN + PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N 204640 001 Dec 18, 2013 Jul CAIN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE >A> @ EUROHLTH INTL SARL 0.01MG/ML;1% A 080406 001 Sep CAHN >A> @ 0.01MG/ML;2% A 080406 002 Sep CAHN >D> @ HIKMA MAPLE 0.01MG/ML;1% A 080406 001 Sep CAHN >D> @ 0.01MG/ML;2% A 080406 002 Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE TABLET;ORAL TEVETEN HCT @ ABBVIE 600MG;12.5MG N 021268 001 Nov 01, 2001 Jun DISC @ 600MG;25MG N 021268 002 Nov 01, 2001 Jun DISC

EPTIFIBATIDE INJECTABLE;INJECTION EPTIFIBATIDE AP TEVA PHARMS USA 2MG/ML A 090854 001 Jun 12, 2015 Jun NEWA AP 75MG/100ML A 091555 001 Jun 05, 2015 May NEWA INTEGRILIN AP + SCHERING 2MG/ML N 020718 001 May 18, 1998 Jun CTEC AP + 75MG/100ML N 020718 002 May 18, 1998 May CFTG

ERGOCALCIFEROL CAPSULE;ORAL VITAMIN D AA BANNER LIFE SCIENCES 50,000 IU A 080704 001 Jan CAHN

ERGOTAMINE TARTRATE TABLET;SUBLINGUAL ERGOSTAT @ WATSON LABS INC 2MG A 088337 001 Jun 08, 1984 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -33

ERLOTINIB HYDROCHLORIDE TABLET;ORAL ERLOTINIB HYDROCHLORIDE >D> AB MYLAN PHARMS INC EQ 25MG BASE A 091002 001 Jun 11, 2014 Sep DISC >A> @ EQ 25MG BASE A 091002 001 Jun 11, 2014 Sep DISC >D> AB EQ 100MG BASE A 091002 002 Jun 11, 2014 Sep DISC >A> @ EQ 100MG BASE A 091002 002 Jun 11, 2014 Sep DISC >D> AB EQ 150MG BASE A 091002 003 Jun 11, 2014 Sep DISC >A> @ EQ 150MG BASE A 091002 003 Jun 11, 2014 Sep DISC AB TEVA PHARMS USA EQ 100MG BASE A 091059 002 Aug 28, 2015 Aug NEWA AB EQ 150MG BASE A 091059 003 Aug 28, 2015 Aug NEWA TARCEVA >D> AB OSI PHARMS EQ 25MG BASE N 021743 001 Nov 18, 2004 Sep CTEC >A> EQ 25MG BASE N 021743 001 Nov 18, 2004 Sep CTEC

ERYTHROMYCIN ESTOLATE SUSPENSION;ORAL ERYTHROMYCIN ESTOLATE @ G AND W LABS INC EQ 125MG BASE/5ML A 062169 001 Oct 17, 1990 Apr CAHN @ EQ 250MG BASE/5ML A 062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE GRANULE;ORAL ERYTHROMYCIN ETHYLSUCCINATE @ ANI PHARMS INC EQ 200MG BASE/5ML A 062055 001 Jul CAHN

ESCITALOPRAM OXALATE SOLUTION;ORAL ESCITALOPRAM OXALATE AA ANTRIM PHARMS LLC EQ 5MG BASE/5ML A 203967 001 May 26, 2015 May NEWA TABLET;ORAL ESCITALOPRAM OXALATE AB MYLAN PHARMS INC EQ 5MG BASE A 077550 001 May 14, 2015 Apr NEWA AB EQ 10MG BASE A 077550 002 May 14, 2015 Apr NEWA AB EQ 20MG BASE A 077550 003 May 14, 2015 Apr NEWA AB PRINSTON INC EQ 5MG BASE A 078032 001 Aug 28, 2015 Aug NEWA AB EQ 10MG BASE A 078032 002 Aug 28, 2015 Aug NEWA AB EQ 20MG BASE A 078032 003 Aug 28, 2015 Aug NEWA

ESMOLOL HYDROCHLORIDE INJECTABLE;INJECTION ESMOLOL HYDROCHLORIDE AP AUROBINDO PHARMA LTD 10MG/ML A 205520 001 Jul 23, 2015 Jul NEWA AP LUITPOLD 10MG/ML A 201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM >A> AB DR REDDYS LABS LTD EQ 20MG BASE A 078279 001 Sep 25, 2015 Sep NEWA >A> AB EQ 40MG BASE A 078279 002 Sep 25, 2015 Sep NEWA >A> AB HETERO LABS LTD III EQ 20MG BASE A 202784 001 Sep 21, 2015 Sep NEWA >A> AB EQ 40MG BASE A 202784 002 Sep 21, 2015 Sep NEWA AB IVAX SUB TEVA PHARMS EQ 20MG BASE A 078003 001 Jan 26, 2015 Jan NEWA AB EQ 40MG BASE A 078003 002 Jan 26, 2015 Jan NEWA >D> AB MYLAN LABS LTD EQ 20MG BASE A 078936 001 Aug 02, 2015 Sep CAHN AB EQ 20MG BASE A 078936 001 Aug 02, 2015 Jul NEWA >D> AB EQ 40MG BASE A 078936 002 Aug 03, 2015 Sep CAHN AB EQ 40MG BASE A 078936 002 Aug 03, 2015 Jul NEWA >A> AB MYLAN PHARMS INC EQ 20MG BASE A 078936 001 Aug 02, 2015 Sep CAHN >A> AB EQ 40MG BASE A 078936 002 Aug 03, 2015 Sep CAHN NEXIUM AB ASTRAZENECA PHARMS EQ 20MG BASE N 021153 001 Feb 20, 2001 Jan CFTG AB + EQ 40MG BASE N 021153 002 Feb 20, 2001 Jan CFTG

ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS ESOMEPRAZOLE SODIUM >A> AP ACCORD HLTHCARE EQ 40MG BASE/VIAL A 205379 001 Sep 25, 2015 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -34

ESOMEPRAZOLE STRONTIUM CAPSULE, DELAYED RELEASE;ORAL ESOMEPRAZOLE STRONTIUM HANMI PHARM CO LTD 24.65MG N 202342 001 Aug 06, 2013 Aug CPOT + 49.3MG N 202342 002 Aug 06, 2013 Aug CPOT

ESTRADIOL FILM, EXTENDED RELEASE;TRANSDERMAL ALORA BX ACTAVIS LABS UT INC 0.025MG/24HR N 020655 004 Apr 05, 2002 Mar CAHN BX 0.05MG/24HR N 020655 001 Dec 20, 1996 Mar CAHN BX 0.075MG/24HR N 020655 002 Dec 20, 1996 Mar CAHN BX 0.1MG/24HR N 020655 003 Dec 20, 1996 Mar CAHN MINIVELLE NOVEN 0.025MG/24HR N 203752 005 Sep 23, 2014 Jan NEWA TABLET;VAGINAL ESTRADIOL @ AMNEAL PHARMS 10MCG A 205256 001 May 29, 2015 May DISC

ESZOPICLONE TABLET;ORAL ESZOPICLONE AB MACLEODS PHARMS LTD 1MG A 202929 001 Jan 30, 2015 Jan NEWA AB 2MG A 202929 002 Jan 30, 2015 Jan NEWA AB 3MG A 202929 003 Jan 30, 2015 Jan NEWA

ETHACRYNATE SODIUM INJECTABLE;INJECTION EDECRIN AP + ATON EQ 50MG BASE/VIAL N 016093 001 Jul CFTG ETHACRYNATE SODIUM AP PAR STERILE PRODUCTS EQ 50MG BASE/VIAL A 205473 001 Jul 29, 2015 Jul NEWA

ETHAMBUTOL HYDROCHLORIDE TABLET;ORAL ETHAMBUTOL HYDROCHLORIDE AB VERSAPHARM INC 100MG A 075095 001 Nov 30, 1999 Jan CMFD AB 400MG A 075095 002 Nov 30, 1999 Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL TABLET;ORAL ASHLYNA AB GLENMARK GENERICS 0.03MG,0.01MG;0.15MG,N/A A 203163 001 Feb 23, 2015 Feb NEWA LEVONORGESTREL AND ETHINYL ESTRADIOL AB GLENMARK GENERICS 0.02MG;0.09MG A 202791 001 Apr 09, 2015 Mar NEWA AB GLENMARK PHARMS LTD 0.03MG;0.15MG A 203164 001 Jun 12, 2015 Jun NEWA AB + WATSON LABS 0.02MG;0.09MG A 079218 001 Jun 06, 2011 Mar CTEC TABLET;ORAL-28 LEVORA 0.15/30-28 AB + WATSON LABS 0.03MG;0.15MG A 073594 001 Dec 13, 1993 Aug CRLD NORDETTE-28 @ TEVA BRANDED PHARM 0.03MG;0.15MG N 018782 001 Jul 21, 1982 Aug DISC VIENVA AB1 SANDOZ INC 0.02MG;0.1MG A 201088 001 May 21, 2015 May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE;TRANSDERMAL XULANE AB + MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A 200910 001 Apr 16, 2014 Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE TABLET;ORAL-21 BREVICON 21-DAY @ ACTAVIS LABS UT INC 0.035MG;0.5MG N 017566 001 Mar CAHN NORINYL 1+35 21-DAY AB ACTAVIS LABS UT INC 0.035MG;1MG N 017565 001 Feb CAHN TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N 018977 001 Apr 13, 1984 Feb CAHN 0.5MG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -35

TABLET;ORAL-28 BREVICON 28-DAY AB ACTAVIS LABS UT INC 0.035MG;0.5MG N 017743 001 Mar CAHN NORETHINDRONE AND ETHINYL ESTRADIOL AB FAMY CARE LTD 0.035MG;0.4MG A 200897 001 May 11, 2015 Apr NEWA AB + JAI PHARMA LTD 0.035MG;0.4MG A 200897 001 May 11, 2015 Jul CRLD + 0.05MG;1MG A 203006 001 Aug 05, 2013 Jul CTEC NORINYL 1+35 28-DAY AB ACTAVIS LABS UT INC 0.035MG;1MG N 017565 002 Feb CAHN OVCON-35 @ WARNER CHILCOTT LLC 0.035MG;0.4MG N 017716 001 Jul DISC TRI-NORINYL 28-DAY AB + ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N 018977 002 Apr 13, 1984 Feb CAHN 0.5MG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL FEMHRT AB WARNER CHILCOTT LLC 0.0025MG;0.5MG N 021065 001 Jan 14, 2005 Mar CTEC LARIN 24 FE AB NOVAST LABS LTD 0.02MG;1MG A 202994 001 Feb 18, 2015 Feb NEWA NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AB + BARR LABS INC 0.005MG;1MG A 076221 001 Nov 06, 2009 Mar CTEC AB GLENMARK GENERICS 0.0025MG;0.5MG A 203038 001 Apr 02, 2015 Mar NEWA AB 0.005MG;1MG A 203038 002 Apr 02, 2015 Mar NEWA NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB + AMNEAL PHARMS 0.02MG;1MG A 078267 001 Sep 01, 2009 Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE TABLET;ORAL-28 NORGESTIMATE AND ETHINYL ESTRADIOL AB JAI PHARMA LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A 202132 001 Sep 09, 2015 Aug NEWA 15MG,0.25MG AB OC PHARMA 0.035MG;0.035MG;0.035MG;0.18MG;0.2 A 200383 001 Apr 07, 2015 Mar NEWA 15MG;0.25MG AB 0.035MG;0.25MG A 200384 001 Apr 07, 2015 Mar NEWA TRI-LO-ESTARYLLA AB SANDOZ INC 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A 091232 001 Jun 29, 2015 Jun NEWA 15MG,0.25MG

ETHINYL ESTRADIOL; NORGESTREL TABLET;ORAL-28 LOW-OGESTREL-28 AB WATSON LABS 0.03MG;0.3MG A 075288 002 Jul 28, 1999 Feb CMFD

ETHOSUXIMIDE CAPSULE;ORAL ETHOSUXIMIDE AB BANNER LIFE SCIENCES 250MG A 040430 001 Oct 28, 2002 Jan CAHN >A> AB HERITAGE PHARMS INC 250MG A 200892 001 Sep 25, 2012 Sep CAHN >D> AB ZYDUS PHARMS USA INC 250MG A 200892 001 Sep 25, 2012 Sep CAHN

ETODOLAC TABLET;ORAL ETODOLAC >D> @ AAIPHARMA LLC 400MG A 074927 001 Oct 30, 1997 Sep CAHN >A> @ LEHIGH VALLEY 400MG A 074927 001 Oct 30, 1997 Sep CAHN

ETONOGESTREL IMPLANT;IMPLANTATION IMPLANON @ ORGANON USA INC 68MG/IMPLANT N 021529 001 Jul 17, 2006 Jun DISC

EZETIMIBE TABLET;ORAL EZETIMIBE @ GLENMARK PHARMS LTD 10MG A 078560 001 Jun 26, 2015 Jun DISC AB 10MG A 078560 001 Jun 26, 2015 Jun NEWA ZETIA + MSD INTL GMBH 10MG N 021445 001 Oct 25, 2002 Jun CTEC AB + 10MG N 021445 001 Oct 25, 2002 Jun CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -36

FAMOTIDINE INJECTABLE;INJECTION FAMOTIDINE AP + EUROHLTH INTL SARL 10MG/ML A 075488 001 Apr 16, 2001 Jun CAHN >A> @ 10MG/ML A 075799 001 Apr 30, 2002 Sep CAHN >D> @ HIKMA MAPLE 10MG/ML A 075799 001 Apr 30, 2002 Sep CAHN FAMOTIDINE PRESERVATIVE FREE AP + EUROHLTH INTL SARL 10MG/ML A 075486 001 Apr 16, 2001 Jun CAHN TABLET;ORAL PEPCID AB VALEANT PHARMS NORTH 20MG N 019462 001 Oct 15, 1986 Feb CAHN AB + 40MG N 019462 002 Oct 15, 1986 Feb CAHN

FELODIPINE TABLET, EXTENDED RELEASE;ORAL FELODIPINE AB ORCHID HLTHCARE 2.5MG A 203032 001 May 21, 2015 May NEWA AB 5MG A 203032 002 May 21, 2015 May NEWA AB 10MG A 203032 003 May 21, 2015 May NEWA AB SUN PHARM INDS LTD 2.5MG A 091200 001 Dec 13, 2013 Apr CAHN AB 5MG A 091200 002 Dec 13, 2013 Apr CAHN AB 10MG A 091200 003 Dec 13, 2013 Apr CAHN

FENOFIBRATE CAPSULE;ORAL FENOFIBRATE AB SUN PHARM INDS LTD 43MG A 201748 001 Oct 31, 2014 Apr CAHN AB 130MG A 201748 002 Oct 31, 2014 Apr CAHN TABLET;ORAL FENOFIBRATE AB LUPIN LTD 54MG A 204019 001 Aug 17, 2015 Aug NEWA AB 160MG A 204019 002 Aug 17, 2015 Aug NEWA AB SUN PHARM INDS LTD 54MG A 076635 001 Oct 31, 2005 Apr CAHN 107MG A 076635 002 Oct 31, 2005 Apr CAHN AB 160MG A 076635 003 Oct 31, 2005 Apr CAHN AB VALEANT PHARMS NORTH 48MG A 090715 001 Apr 05, 2012 Aug CAHN AB 145MG A 090715 002 Apr 05, 2012 Aug CAHN

FENOFIBRIC ACID TABLET;ORAL FIBRICOR TRIBUTE PHARMS INTL 35MG N 022418 001 Aug 14, 2009 Jun CAHN + 105MG N 022418 002 Aug 14, 2009 Jun CAHN

FENTANYL FILM, EXTENDED RELEASE;TRANSDERMAL FENTANYL-100 AB ACTAVIS LABS UT INC 100MCG/HR A 076709 004 Aug 20, 2007 Mar CAHN FENTANYL-12 AB MALLINCKRODT INC 12.5MCG/HR A 077154 005 Jun 11, 2015 Jun NEWA FENTANYL-25 AB ACTAVIS LABS UT INC 25MCG/HR A 076709 001 Aug 20, 2007 Mar CAHN FENTANYL-50 AB ACTAVIS LABS UT INC 50MCG/HR A 076709 002 Aug 20, 2007 Mar CAHN FENTANYL-75 AB ACTAVIS LABS UT INC 75MCG/HR A 076709 003 Aug 20, 2007 Mar CAHN

FENTANYL CITRATE FILM;BUCCAL ONSOLIS @ BIODELIVERY SCI INTL EQ 0.2MG BASE N 022266 001 Jul 16, 2009 Mar CAHN @ EQ 0.4MG BASE N 022266 002 Jul 16, 2009 Mar CAHN @ EQ 0.6MG BASE N 022266 003 Jul 16, 2009 Mar CAHN @ EQ 0.8MG BASE N 022266 004 Jul 16, 2009 Mar CAHN @ EQ 1.2MG BASE N 022266 005 Jul 16, 2009 Mar CAHN INJECTABLE;INJECTION FENTANYL CITRATE PRESERVATIVE FREE AP + EUROHLTH INTL SARL EQ 0.05MG BASE/ML N 019101 001 Jul 11, 1984 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -37

FENTANYL HYDROCHLORIDE SYSTEM;IONTOPHORESIS, TRANSDERMAL IONSYS @ THE MEDICINES CO 10.8MCG N 021338 001 May 22, 2006 Apr CAHN + EQ 40MCG BASE/ACTIVATION N 021338 001 May 22, 2006 Jun CMFD

FERRIC CITRATE TABLET;ORAL AURYXIA + KERYX BIOPHARMS EQ 210MG IRON N 205874 001 Sep 05, 2014 Jan CTNA

FERRIC PYROPHOSPHATE CITRATE SOLUTION;IV (INFUSION) TRIFERIC + ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N 206317 001 Jan 23, 2015 Jan NEWA

FIDAXOMICIN TABLET;ORAL DIFICID + CUBIST PHARMS LLC 200MG N 201699 001 May 27, 2011 Aug CAHN

FLECAINIDE ACETATE TABLET;ORAL FLECAINIDE ACETATE AB ANI PHARMS INC 50MG A 075882 001 Oct 28, 2002 Apr CAHN AB 100MG A 075882 002 Oct 28, 2002 Apr CAHN AB 150MG A 075882 003 Oct 28, 2002 Apr CAHN AB AUROBINDO PHARMA LTD 50MG A 202821 001 Jul 08, 2015 Jun NEWA AB 100MG A 202821 002 Jul 08, 2015 Jun NEWA AB 150MG A 202821 003 Jul 08, 2015 Jun NEWA AB SUN PHARM INDS LTD 50MG A 076421 001 Mar 28, 2003 Apr CAHN AB 100MG A 076421 002 Mar 28, 2003 Apr CAHN AB 150MG A 076421 003 Mar 28, 2003 Apr CAHN

FLIBANSERIN TABLET;ORAL ADDYI + SPROUT PHARMS 100MG N 022526 001 Aug 18, 2015 Aug NEWA

FLUCONAZOLE FOR SUSPENSION;ORAL FLUCONAZOLE AB SUN PHARM INDS LTD 50MG/5ML A 076332 001 Jul 29, 2004 Apr CAHN AB 200MG/5ML A 076332 002 Jul 29, 2004 Apr CAHN INJECTABLE;INJECTION FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A 077988 001 May 26, 2010 Apr CAHN AP 400MG/200ML (2MG/ML) A 077988 002 May 26, 2010 Apr CAHN FLUCONAZOLE IN SODIUM CHLORIDE 0.9% AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A 077947 001 May 26, 2010 Apr CAHN AP 400MG/200ML (2MG/ML) A 077947 002 May 26, 2010 Apr CAHN FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER CLARIS PHARMASERVICE 100MG/50ML (2MG/ML) A 077909 003 Apr 20, 2015 Apr NEWA 100MG/50ML (2MG/ML) A 077909 003 Apr 20, 2015 Apr CAHN AP 200MG/100ML (2MG/ML) A 077909 001 May 26, 2010 Apr CAHN AP 400MG/200ML (2MG/ML) A 077909 002 May 26, 2010 Apr CAHN TABLET;ORAL FLUCONAZOLE AB HARRIS PHARM 50MG A 078423 001 Mar 07, 2011 May CMFD AB 100MG A 078423 002 Mar 07, 2011 May CMFD AB 150MG A 078423 003 Mar 07, 2011 May CMFD AB 200MG A 078423 004 Mar 07, 2011 May CMFD

FLUDEOXYGLUCOSE F-18 INJECTABLE;INTRAVENOUS FLUDEOXYGLUCOSE F18 AP IBA MOLECULAR N AM 20-300mCi/ML A 203591 001 Aug 31, 2015 Aug NEWA AP METHODIST HOSP RES 20-300mCi/ML A 203904 001 Apr 23, 2015 Apr NEWA AP MIPS CRF 20-300mCi/ML A 204472 001 Sep 11, 2015 Aug NEWA PRECISION NUCLEAR 20-500mCi/ML A 204546 001 Apr 07, 2015 Mar NEWA QUEEN HAMAMATSU PET 10-100mCi/ML A 203771 001 Aug 31, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -38

INJECTABLE;INTRAVENOUS FLUDEOXYGLUCOSE F18 SPECTRON MRC LLC 4-500mCi/ML A 203911 001 Apr 22, 2015 Apr NEWA AP UNIV MICHIGAN 20-300mCi/ML A 204531 001 Jul 17, 2015 Jul NEWA

FLUMAZENIL INJECTABLE;INJECTION FLUMAZENIL @ CLARIS PHARMASERVICE 0.5MG/5ML (0.1MG/ML) A 076755 002 Oct 12, 2004 Apr CAHN @ 1MG/10ML (0.1MG/ML) A 076755 001 Oct 12, 2004 Apr CAHN AP EUROHLTH INTL SARL 0.5MG/5ML (0.1MG/ML) A 076787 002 Oct 12, 2004 Jun CAHN AP 1MG/10ML (0.1MG/ML) A 076787 001 Oct 12, 2004 Jun CAHN

FLUOCINOLONE ACETONIDE OIL;TOPICAL FLUOCINOLONE ACETONIDE AT VERSAPHARM INC 0.01% A 091514 001 Jun 25, 2015 Jun NEWA SOLUTION;TOPICAL FLUOCINOLONE ACETONIDE AT GAVIS PHARMS LLC 0.01% A 206422 001 Sep 02, 2015 Aug NEWA

FLUOCINONIDE GEL;TOPICAL FLUOCINONIDE AB G AND W LABS INC 0.05% A 072537 001 Feb 07, 1989 Apr CAHN

FLUOROURACIL CREAM;TOPICAL CARAC AB + VALEANT PHARMS NORTH 0.5% N 020985 001 Oct 27, 2000 Apr CFTG + 0.5% N 020985 001 Oct 27, 2000 Feb CAHN FLUOROURACIL AB SPEAR PHARMS INC 0.5% A 203122 001 Apr 20, 2015 Apr NEWA >A> TOLAK >A> + HILL DERMACEUTICALS 4% N 022259 001 Sep 18, 2015 Sep NEWA

FLUOXETINE HYDROCHLORIDE CAPSULE;ORAL FLUOXETINE HYDROCHLORIDE @ ANI PHARMS INC EQ 10MG BASE A 076287 001 May 20, 2008 Mar DISC @ EQ 20MG BASE A 076287 002 May 20, 2008 Mar DISC + MYLAN EQ 20MG BASE A 078045 002 Nov 17, 2008 Mar CRLD EQ 20MG BASE A 078045 002 Nov 17, 2008 Mar CTEC @ SANDOZ EQ 10MG BASE A 077469 001 Nov 17, 2008 Mar DISC @ EQ 20MG BASE A 077469 002 Nov 17, 2008 Mar DISC AB1 SCIEGEN PHARMS INC EQ 10MG BASE A 204597 001 Mar 16, 2015 Mar NEWA AB1 EQ 20MG BASE A 204597 002 Mar 16, 2015 Mar NEWA AB EQ 40MG BASE A 204597 003 Mar 16, 2015 Mar NEWA AB SUN PHARM INDS LTD EQ 40MG BASE A 076990 001 Dec 13, 2004 Apr CAHN

FLURANDRENOLIDE OINTMENT;TOPICAL CORDRAN + AQUA PHARMS 0.05% N 012806 001 Jun CRLD 0.05% N 012806 001 May CMFD TAPE;TOPICAL CORDRAN + ACTAVIS LABS UT INC 0.004MG/SQ CM N 016455 001 Mar CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE POWDER;INHALATION BREO ELLIPTA GLAXO GRP LTD 0.2MG/INH;EQ 0.025MG BASE/INH N 204275 002 Apr 30, 2015 Apr NEWA

FLUVASTATIN SODIUM TABLET, EXTENDED RELEASE;ORAL FLUVASTATIN SODIUM AB MYLAN PHARMS INC 80MG A 202458 001 Sep 11, 2015 Aug NEWA LESCOL XL AB + NOVARTIS 80MG N 021192 001 Oct 06, 2000 Aug CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -39

FLUVOXAMINE MALEATE TABLET;ORAL FLUVOXAMINE MALEATE AB ANI PHARMS INC 25MG A 075897 001 Jan 25, 2001 Jul CAHN @ 25MG A 075898 001 Mar 12, 2001 Jul CAHN AB 50MG A 075897 002 Jan 25, 2001 Jul CAHN @ 50MG A 075898 002 Mar 12, 2001 Jul CAHN AB 100MG A 075897 003 Jan 25, 2001 Jul CAHN @ 100MG A 075898 003 Mar 12, 2001 Jul CAHN

FOLIC ACID TABLET;ORAL FOLIC ACID AA AIPING PHARM INC 1MG A 091145 001 Jul 12, 2013 Aug CAHN AA NUVO PHARM INC 1MG A 204418 001 Jul 28, 2015 Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE TABLET;ORAL FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE AB SUN PHARM INDS LTD 10MG;12.5MG A 076739 001 Dec 17, 2004 Apr CAHN AB 20MG;12.5MG A 076739 002 Dec 17, 2004 Apr CAHN

FUROSEMIDE INJECTABLE;INJECTION FUROSEMIDE @ IGI LABS INC 10MG/ML A 070095 001 Sep 09, 1985 Mar CAHN @ 10MG/ML A 070096 001 Sep 09, 1985 Mar CAHN

GABAPENTIN CAPSULE;ORAL GABAPENTIN AB SUN PHARM INDS LTD 100MG A 076606 001 Oct 07, 2005 Apr CAHN AB 300MG A 076606 002 Oct 07, 2005 Apr CAHN AB 400MG A 076606 003 Oct 07, 2005 Apr CAHN TABLET;ORAL GABAPENTIN @ HIKMA PHARMS 600MG A 078782 001 Jul 21, 2011 Jun DISC @ 800MG A 078782 002 Jul 21, 2011 Jun DISC

GADOVERSETAMIDE INJECTABLE;INJECTION OPTIMARK + LIEBEL-FLARSHEIM 1654.5MG/5ML (330.9MG/ML) N 020937 001 Dec 08, 1999 Feb CAHN + 3309MG/10ML (330.9MG/ML) N 020937 002 Dec 08, 1999 Feb CAHN + 4963.5MG/15ML (330.9MG/ML) N 020937 003 Dec 08, 1999 Feb CAHN + 6618MG/20ML (330.9MG/ML) N 020937 004 Dec 08, 1999 Feb CAHN + 16.545GM/50ML (330.9MG/ML) N 020975 001 Dec 08, 1999 Feb CAHN OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM 3309MG/10ML (330.9MG/ML) N 020976 002 Dec 08, 1999 Feb CAHN + 4963.5MG/15ML (330.9MG/ML) N 020976 003 Dec 08, 1999 Feb CAHN + 6618MG/20ML (330.9MG/ML) N 020976 004 Dec 08, 1999 Feb CAHN + 9927MG/30ML (330.9MG/ML) N 020976 001 Dec 08, 1999 Feb CAHN

GEFITINIB TABLET;ORAL IRESSA + ASTRAZENECA PHARMS 250MG N 206995 001 Jul 13, 2015 Jul NEWA

GEMFIBROZIL TABLET;ORAL GEMFIBROZIL AB AUROBINDO PHARMA LTD 600MG A 202726 001 Sep 16, 2015 Aug NEWA

GEMIFLOXACIN MESYLATE TABLET;ORAL FACTIVE AB + LG LIFE SCIENCES EQ 320MG BASE N 021158 001 Apr 04, 2003 Jun CFTG GEMIFLOXACIN MESYLATE AB ORCHID HLTHCARE EQ 320MG BASE A 090466 001 Jun 15, 2015 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -40

GLATIRAMER ACETATE INJECTABLE;SUBCUTANEOUS COPAXONE AP + TEVA PHARMS USA 20MG/ML N 020622 002 Feb 12, 2002 Mar CFTG GLATOPA AP SANDOZ INC 20MG/ML A 090218 001 Apr 16, 2015 Mar NEWA

GLIMEPIRIDE TABLET;ORAL GLIMEPIRIDE @ HIKMA PHARMS 1MG A 078952 001 Aug 01, 2013 Apr DISC @ 2MG A 078952 002 Aug 01, 2013 Apr DISC @ 4MG A 078952 003 Aug 01, 2013 Apr DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE TABLET;ORAL AVANDARYL @ SB PHARMCO 1MG;4MG N 021700 001 Nov 23, 2005 Jun DISC @ 2MG;4MG N 021700 002 Nov 23, 2005 Jun DISC @ 2MG;8MG N 021700 004 Mar 30, 2007 Jun DISC @ 4MG;4MG N 021700 003 Nov 23, 2005 Jun DISC @ 4MG;8MG N 021700 005 Mar 30, 2007 Jun DISC

GLIPIZIDE TABLET;ORAL GLIPIZIDE @ ANI PHARMS INC 5MG A 074387 001 Mar 04, 1996 Aug CAHN @ 10MG A 074387 002 Mar 04, 1996 Aug CAHN TABLET, EXTENDED RELEASE;ORAL GLIPIZIDE AB MYLAN PHARMS INC 2.5MG A 202298 001 May 19, 2015 May NEWA AB 5MG A 202298 002 May 19, 2015 May NEWA AB 10MG A 202298 003 May 19, 2015 May NEWA

GLUCAGON HYDROCHLORIDE POWDER;INTRAMUSCULAR, INTRAVENOUS GLUCAGON + FRESENIUS KABI USA EQ 1MG BASE/VIAL N 201849 001 May 08, 2015 May NEWA

GLYBURIDE TABLET;ORAL DIABETA >D> BX SANOFI AVENTIS US 1.25MG N 017532 001 May 01, 1984 Sep CFTG >A> AB2 1.25MG N 017532 001 May 01, 1984 Sep CFTG >D> BX 2.5MG N 017532 002 May 01, 1984 Sep CFTG >A> AB2 2.5MG N 017532 002 May 01, 1984 Sep CFTG >D> BX + 5MG N 017532 003 May 01, 1984 Sep CFTG >A> AB2 + 5MG N 017532 003 May 01, 1984 Sep CFTG GLYBURIDE >D> AB AUROBINDO PHARMA 1.25MG A 077537 001 Oct 18, 2007 Sep CTEC >A> AB1 1.25MG A 077537 001 Oct 18, 2007 Sep CTEC >D> AB 2.5MG A 077537 002 Oct 18, 2007 Sep CTEC >A> AB1 2.5MG A 077537 002 Oct 18, 2007 Sep CTEC >D> AB 5MG A 077537 003 Oct 18, 2007 Sep CTEC >A> AB1 5MG A 077537 003 Oct 18, 2007 Sep CTEC >D> AB COREPHARMA 1.25MG A 076257 001 Jun 27, 2002 Sep CTEC >A> AB1 1.25MG A 076257 001 Jun 27, 2002 Sep CTEC >A> AB2 1.25MG A 206079 001 Sep 30, 2015 Sep NEWA >D> AB 2.5MG A 076257 002 Jun 27, 2002 Sep CTEC >A> AB1 2.5MG A 076257 002 Jun 27, 2002 Sep CTEC >A> AB2 2.5MG A 206079 002 Sep 30, 2015 Sep NEWA >D> AB 5MG A 076257 003 Jun 27, 2002 Sep CTEC >A> AB1 5MG A 076257 003 Jun 27, 2002 Sep CTEC >A> AB2 5MG A 206079 003 Sep 30, 2015 Sep NEWA >D> AB HERITAGE PHARMS INC 1.25MG A 090937 001 Feb 28, 2011 Sep CTEC >A> AB1 1.25MG A 090937 001 Feb 28, 2011 Sep CTEC >D> AB 2.5MG A 090937 002 Feb 28, 2011 Sep CTEC >A> AB1 2.5MG A 090937 002 Feb 28, 2011 Sep CTEC >D> AB 5MG A 090937 003 Feb 28, 2011 Sep CTEC >A> AB1 5MG A 090937 003 Feb 28, 2011 Sep CTEC >D> AB TEVA 1.25MG A 074388 001 Aug 29, 1995 Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -41

TABLET;ORAL GLYBURIDE >A> AB1 1.25MG A 074388 001 Aug 29, 1995 Sep CTEC >D> AB 2.5MG A 074388 002 Aug 29, 1995 Sep CTEC >A> AB1 2.5MG A 074388 002 Aug 29, 1995 Sep CTEC >D> AB + 5MG A 074388 003 Aug 29, 1995 Sep CTEC >A> AB1 + 5MG A 074388 003 Aug 29, 1995 Sep CTEC

GLYCEROL PHENYLBUTYRATE LIQUID;ORAL RAVICTI + HORIZON THERAPS INC 1.1GM/ML N 203284 001 Feb 01, 2013 May CAHN

GLYCOPYRROLATE INJECTABLE;INJECTION ROBINUL AP + EUROHLTH INTL SARL 0.2MG/ML N 017558 001 Jun CAHN TABLET;ORAL GLYCOPYRROLATE AA SUN PHARM INDS LTD 1MG A 040844 001 Aug 18, 2009 Apr CAHN AA 2MG A 040844 002 Aug 18, 2009 Apr CAHN

GRANISETRON HYDROCHLORIDE INJECTABLE;INJECTION GRANISETRON HYDROCHLORIDE AP BANNER LIFE SCIENCES EQ 0.1MG BASE/ML (EQ 0.1MG A 078863 001 Jun 30, 2008 Jan CAHN BASE/ML) AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 078880 001 Jun 30, 2008 Jan CAHN @ CLARIS PHARMASERVICE EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 078198 001 Jun 30, 2008 Apr CAHN @ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 078198 002 Jun 30, 2008 Apr CAHN AP EUROHLTH INTL SARL EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 077177 001 Dec 31, 2007 Jun CAHN GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE AP BANNER LIFE SCIENCES EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 078863 002 Jun 30, 2008 Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE SOLUTION;ORAL FLOWTUSS >D> MIKART INC 200MG/5ML;2.5MG/5ML N 022424 001 May 14, 2015 Sep CAHN 200MG/5ML;2.5MG/5ML N 022424 001 May 14, 2015 May NEWA >A> MISSION PHARMACAL CO 200MG/5ML;2.5MG/5ML N 022424 001 May 14, 2015 Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE SOLUTION;ORAL HYCOFENIX + MIKART INC 200MG/5ML;2.5MG/5ML;30MG/5ML N 022279 001 May 14, 2015 May NEWA

GUANFACINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL GUANFACINE HYDROCHLORIDE AB MYLAN PHARMS INC EQ 1MG BASE A 202578 001 Jun 02, 2015 May NEWA AB EQ 2MG BASE A 202578 002 Jun 02, 2015 May NEWA AB EQ 3MG BASE A 202578 003 Jun 02, 2015 May NEWA AB EQ 4MG BASE A 202578 004 Jun 02, 2015 May NEWA AB SANDOZ INC EQ 1MG BASE A 202568 001 Jun 03, 2015 May NEWA AB EQ 2MG BASE A 202568 002 Jun 03, 2015 May NEWA AB EQ 3MG BASE A 202568 003 Jun 03, 2015 May NEWA AB EQ 4MG BASE A 202568 004 Jun 03, 2015 May NEWA AB TEVA PHARMS USA EQ 1MG BASE A 201382 001 Jun 02, 2015 May NEWA AB EQ 2MG BASE A 201382 002 Jun 02, 2015 May NEWA AB EQ 3MG BASE A 201382 003 Jun 02, 2015 May NEWA AB EQ 4MG BASE A 201382 004 Jun 02, 2015 May NEWA AB TWI PHARMS INC EQ 1MG BASE A 201408 001 Jun 02, 2015 May NEWA AB EQ 2MG BASE A 201408 002 Jun 02, 2015 May NEWA AB EQ 3MG BASE A 201408 003 Jun 02, 2015 May NEWA AB EQ 4MG BASE A 201408 004 Jun 02, 2015 May NEWA

HALOPERIDOL TABLET;ORAL HALOPERIDOL @ CYCLE PHARMS LTD 0.5MG A 071128 001 Feb 17, 1987 May CAHN @ 1MG A 071129 001 Feb 17, 1987 Jun CAHN @ 5MG A 071131 001 Feb 17, 1987 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -42

TABLET;ORAL HALOPERIDOL @ 10MG A 071132 001 May 12, 1987 Jun CAHN @ 20MG A 071133 001 May 12, 1987 May CAHN @ ROXANE 2MG A 071130 001 Feb 17, 1987 Jun CAHN

HALOPERIDOL LACTATE CONCENTRATE;ORAL HALOPERIDOL INTENSOL @ CYCLE PHARMS LTD EQ 2MG BASE/ML A 072045 001 Apr 12, 1988 May CAHN INJECTABLE;INJECTION HALOPERIDOL @ CLARIS PHARMASERVICE EQ 5MG BASE/ML A 076791 001 Aug 25, 2004 Apr CAHN @ EQ 5MG BASE/ML A 076828 001 Aug 25, 2004 May CAHN

HEPARIN SODIUM INJECTABLE;INJECTION HEPARIN SODIUM @ EUROHLTH INTL SARL 1,000 UNITS/ML N 017007 001 Aug CAHN AP + 1,000 UNITS/ML N 017037 001 Jun CAHN @ 2,500 UNITS/ML N 017007 007 Aug CAHN @ 5,000 UNITS/ML N 017007 002 Aug CAHN @ 5,000 UNITS/0.5ML N 017007 010 Aug CAHN AP + 5,000 UNITS/ML N 017037 002 Jun CAHN @ 5,000 UNITS/0.5ML N 017037 013 Apr 07, 1986 Jun CAHN @ 7,500 UNITS/ML N 017007 003 Aug CAHN @ 10,000 UNITS/ML N 017007 004 Aug CAHN AP + 10,000 UNITS/ML N 017037 003 Jun CAHN @ 15,000 UNITS/ML N 017007 005 Aug CAHN @ 20,000 UNITS/ML N 017007 006 Aug CAHN

HYDRALAZINE HYDROCHLORIDE INJECTABLE;INJECTION HYDRALAZINE HYDROCHLORIDE AP + AKORN 20MG/ML A 040730 001 Apr 21, 2009 Feb CRLD AP LUITPOLD 20MG/ML A 040136 001 Jun 30, 1997 Feb CRLD AP X-GEN PHARMS INC 20MG/ML A 203110 001 Jun 29, 2015 Jun NEWA TABLET;ORAL HYDRALAZINE HYDROCHLORIDE >A> @ HERITAGE PHARMS INC 10MG A 040858 001 Feb 26, 2010 Sep CAHN >A> @ 25MG A 040858 002 Feb 26, 2010 Sep CAHN >A> @ 50MG A 040858 003 Feb 26, 2010 Sep CAHN >A> @ 100MG A 040858 004 Feb 26, 2010 Sep CAHN >D> @ ZYDUS PHARMS USA 10MG A 040858 001 Feb 26, 2010 Sep CAHN >D> @ 25MG A 040858 002 Feb 26, 2010 Sep CAHN >D> @ 50MG A 040858 003 Feb 26, 2010 Sep CAHN >D> @ 100MG A 040858 004 Feb 26, 2010 Sep CAHN

HYDROCHLOROTHIAZIDE CAPSULE;ORAL HYDROCHLOROTHIAZIDE @ SUN PHARM INDS INC 12.5MG A 090651 001 Apr 07, 2014 Aug DISC MICROZIDE AB + ACTAVIS LABS UT INC 12.5MG N 020504 001 Dec 27, 1996 Feb CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL TABLET;ORAL LISINOPRIL AND HYDROCHLOROTHIAZIDE AB SUN PHARM INDS LTD 12.5MG;10MG A 076007 001 Jul 01, 2002 Apr CAHN AB 12.5MG;20MG A 076007 002 Jul 01, 2002 Apr CAHN AB 25MG;20MG A 076007 003 Jul 01, 2002 Apr CAHN ZESTORETIC AB ALVOGEN IPCO SARL 12.5MG;10MG N 019888 003 Nov 18, 1993 Feb CAHN AB + 12.5MG;20MG N 019888 001 Sep 20, 1990 Feb CAHN AB + 25MG;20MG N 019888 002 Jul 20, 1989 Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL DUTOPROL CONCORDIA PHARMS INC 12.5MG;EQ 25MG TARTRATE N 021956 001 Aug 28, 2006 Jun CAHN 12.5MG;EQ 50MG TARTRATE N 021956 002 Aug 28, 2006 Jun CAHN + 12.5MG;EQ 100MG TARTRATE N 021956 003 Aug 28, 2006 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -43

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ ANI PHARMS INC 25MG;40MG A 070704 001 Oct 01, 1986 Jul CAHN AB 25MG;40MG A 072042 001 Mar 14, 1988 Aug CAHN @ 25MG;80MG A 070705 001 Oct 01, 1986 Jul CAHN AB 25MG;80MG A 072043 001 Mar 14, 1988 Aug CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET;ORAL QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE AB SUN PHARM INDS LTD 12.5MG;EQ 10MG BASE A 078211 001 Mar 04, 2009 Apr CAHN AB 12.5MG;EQ 20MG BASE A 078211 002 Mar 04, 2009 Apr CAHN AB 25MG;EQ 20MG BASE A 078211 003 Mar 04, 2009 Apr CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE CAPSULE;ORAL TRIAMTERENE AND HYDROCHLOROTHIAZIDE @ ANI PHARMS INC 25MG;37.5MG A 074970 001 Jan 06, 1998 Aug CAHN TABLET;ORAL TRIAMTERENE AND HYDROCHLOROTHIAZIDE AB ANI PHARMS INC 50MG;75MG A 073467 001 Jan 31, 1996 Aug CAHN

HYDROCODONE BITARTRATE CAPSULE, EXTENDED RELEASE;ORAL ZOHYDRO ER + FERRIMILL LTD 10MG N 202880 001 Oct 25, 2013 Apr CAHN 15MG N 202880 002 Oct 25, 2013 Apr CAHN 20MG N 202880 003 Oct 25, 2013 Apr CAHN 30MG N 202880 004 Oct 25, 2013 Apr CAHN 40MG N 202880 005 Oct 25, 2013 Apr CAHN 50MG N 202880 006 Oct 25, 2013 Apr CAHN + PERNIX IRELAND PAIN 10MG N 202880 001 Oct 25, 2013 Jun CAHN 15MG N 202880 002 Oct 25, 2013 Jun CAHN 20MG N 202880 003 Oct 25, 2013 Jun CAHN 30MG N 202880 004 Oct 25, 2013 Jun CAHN 40MG N 202880 005 Oct 25, 2013 Jun CAHN 50MG N 202880 006 Oct 25, 2013 Jun CAHN TABLET, EXTENDED RELEASE;ORAL HYSINGLA + PURDUE PHARMA LP 20MG N 206627 001 Nov 20, 2014 Mar CRLD

HYDROCORTISONE CREAM;TOPICAL HYDROCORTISONE AT RISING PHARMS INC 2.5% A 040879 001 Aug 20, 2010 Mar CAHN POWDER;FOR RX COMPOUNDING HYDRO-RX @ X GEN PHARMS 100% A 085982 001 Apr DISC TABLET;ORAL HYDROCORTISONE AB HIKMA INTL PHARMS 5MG A 083365 002 Feb 23, 2015 Feb NEWA AB 10MG A 083365 003 Feb 23, 2015 Feb NEWA AB 20MG A 083365 001 Feb CMFD

HYDROCORTISONE ACETATE POWDER;FOR RX COMPOUNDING HYDROCORTISONE ACETATE @ X GEN PHARMS 100% A 085981 001 Apr DISC

HYDROCORTISONE VALERATE CREAM;TOPICAL HYDROCORTISONE VALERATE @ G AND W LABS INC 0.2% A 074489 001 Aug 12, 1998 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -44

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE SUSPENSION/DROPS;OTIC CORTISPORIN AT + CITRON PHARMA LLC 1%;EQ 3.5MG BASE/ML;10,000 N 060613 001 Jun CMS2 UNITS/ML

HYDROMORPHONE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL HYDROMORPHONE HYDROCHLORIDE AB PADDOCK LLC 8MG A 204278 001 Apr 06, 2015 Mar NEWA AB 12MG A 204278 002 Apr 06, 2015 Mar NEWA AB 16MG A 204278 003 Apr 06, 2015 Mar NEWA

HYDROXOCOBALAMIN INJECTABLE;INJECTION CYANOKIT @ SERB SAS 2.5GM/VIAL (5GM/KIT) N 022041 002 Dec 15, 2006 Apr CAHN + 5GM/VIAL (5GM/KIT) N 022041 001 Apr 08, 2011 Apr CAHN

HYDROXYCHLOROQUINE SULFATE TABLET;ORAL PLAQUENIL AB + CONCORDIA PHARMS INC 200MG N 009768 001 Jun CAHN

HYDROXYPROGESTERONE CAPROATE INJECTABLE;INJECTION HYDROXYPROGESTERONE CAPROATE @ ACTAVIS LABS UT INC 125MG/ML N 017439 001 Mar CAHN @ 250MG/ML N 017439 002 Mar CAHN + MCGUFF 250MG/ML A 200271 001 Aug 24, 2015 Aug NEWA

HYDROXYZINE HYDROCHLORIDE TABLET;ORAL HYDROXYZINE HYDROCHLORIDE AB ELITE LABS INC 10MG A 040600 001 Dec 28, 2004 Jun CAHN AB 25MG A 040602 001 Dec 28, 2004 Jun CAHN AB 50MG A 040604 001 Dec 28, 2004 Jun CAHN AB HERITAGE PHARMA 10MG A 204279 001 Aug 20, 2014 Mar CAHN AB 25MG A 204279 002 Aug 20, 2014 Mar CAHN AB 50MG A 204279 003 Aug 20, 2014 Mar CAHN AB MIKAH PHARMA 10MG A 040600 001 Dec 28, 2004 Mar CMFD AB 25MG A 040602 001 Dec 28, 2004 Mar CMFD AB 50MG A 040604 001 Dec 28, 2004 Mar CMFD @ MUTUAL PHARM 10MG A 089381 001 May 19, 1986 Jul DISC @ 25MG A 089382 001 May 19, 1986 Jul DISC @ 50MG A 089383 001 May 19, 1986 Jul DISC @ WATSON LABS 10MG A 088348 001 Sep 15, 1983 Jul DISC @ 25MG A 088349 001 Sep 15, 1983 Jul DISC @ 50MG A 088350 001 Sep 15, 1983 Jul DISC

HYDROXYZINE PAMOATE CAPSULE;ORAL HYDROXYZINE PAMOATE AB HERITAGE PHARMA EQ 25MG HYDROCHLORIDE A 201507 001 Jun 03, 2013 Mar CAHN AB EQ 50MG HYDROCHLORIDE A 201507 002 Jun 03, 2013 Mar CAHN

IBANDRONATE SODIUM INJECTABLE;INTRAVENOUS IBANDRONATE SODIUM AP AUROBINDO PHARMA LTD EQ 3MG BASE/3ML A 205332 001 Aug 19, 2015 Aug NEWA

IBUPROFEN TABLET;ORAL IBUPROFEN AB GRANULES INDIA LTD 400MG A 091625 001 Sep 15, 2015 Aug NEWA AB 600MG A 091625 002 Sep 15, 2015 Aug NEWA AB 800MG A 091625 003 Sep 15, 2015 Aug NEWA @ VINTAGE PHARMS 300MG A 071230 001 Oct 22, 1986 Jul DISC @ 400MG A 071231 001 Oct 22, 1986 Jul DISC @ 600MG A 071232 001 Oct 22, 1986 Jul DISC @ 800MG A 072004 001 Nov 18, 1987 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -45

ILOPERIDONE TABLET;ORAL FANAPT + VANDA PHARMS INC 1MG N 022192 001 May 06, 2009 Jan CAHN 2MG N 022192 002 May 06, 2009 Jan CAHN 4MG N 022192 003 May 06, 2009 Jan CAHN 6MG N 022192 004 May 06, 2009 Jan CAHN 8MG N 022192 005 May 06, 2009 Jan CAHN 10MG N 022192 006 May 06, 2009 Jan CAHN 12MG N 022192 007 May 06, 2009 Jan CAHN

IMIQUIMOD CREAM;TOPICAL IMIQUIMOD AB G AND W LABS INC 5% A 200481 001 Apr 18, 2011 Apr CAHN

INDAPAMIDE TABLET;ORAL INDAPAMIDE AB ANI PHARMS INC 1.25MG A 074299 002 Apr 29, 1996 Jul CAHN @ 1.25MG A 074498 002 Feb 12, 1998 Jul CAHN AB 2.5MG A 074299 001 Jul 27, 1995 Jul CAHN @ 2.5MG A 074498 001 Oct 31, 1996 Jul CAHN

INDOMETHACIN CAPSULE, EXTENDED RELEASE;ORAL INDOMETHACIN >A> AB JUBILANT GENERICS 75MG A 202706 001 Oct 05, 2015 Sep NEWA

INGENOL MEBUTATE GEL;TOPICAL PICATO + LEO PHARMA AS 0.015% N 202833 001 Jan 23, 2012 May CRLD

>A> INSULIN DEGLUDEC >A> SOLUTION;SUBCUTANEOUS >A> RYZODEG 70/30 >A> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N 203313 001 Sep 25, 2015 Sep NEWA >A> TRESIBA >A> NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N 203314 001 Sep 25, 2015 Sep NEWA >A> + 600 UNITS/3ML (200 UNITS/ML) N 203314 002 Sep 25, 2015 Sep NEWA

INSULIN GLARGINE RECOMBINANT SOLUTION;SUBCUTANEOUS TOUJEO SOLOSTAR + SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N 206538 001 Feb 25, 2015 Feb NEWA

INSULIN LISPRO RECOMBINANT SOLUTION;SUBCUTANEOUS HUMALOG KWIKPEN + ELI LILLY AND CO 200 UNITS/ML N 205747 001 May 26, 2015 May NEWA

INSULIN RECOMBINANT HUMAN POWDER;INHALATION AFREZZA SANOFI AVENTIS 12 UNITS/INH N 022472 003 Apr 17, 2015 Apr NEWA

IOHEXOL FOR SOLUTION;ORAL ORALTAG INTERPHARMA PRAHA AS 9.7GM/BOT N 205383 001 Mar 26, 2015 Mar NEWA

IOPAMIDOL INJECTABLE;INJECTION IOPAMIDOL-250 @ FRESENIUS KABI USA 51% A 074679 001 Apr 02, 1997 Jan DISC IOPAMIDOL-300 @ FRESENIUS KABI USA 61% A 074679 002 Apr 02, 1997 Jan DISC IOPAMIDOL-370 @ FRESENIUS KABI USA 76% A 074679 003 Apr 02, 1997 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -46

INJECTABLE;INJECTION ISOVUE-200 + BRACCO 41% N 018735 006 Jul 07, 1987 Feb CTEC ISOVUE-250 + BRACCO 51% N 018735 007 Jul 06, 1992 Feb CTEC + 51% N 020327 002 Oct 12, 1994 Feb CTEC ISOVUE-300 + BRACCO 61% N 020327 003 Oct 12, 1994 Feb CTEC ISOVUE-370 + BRACCO 76% N 020327 004 Oct 12, 1994 Feb CTEC SCANLUX-300 AP MYLAN INSTITUTIONAL 61% A 090394 001 Jun 18, 2010 Aug CAHN SCANLUX-370 AP MYLAN INSTITUTIONAL 76% A 090394 002 Jun 18, 2010 Aug CAHN

IOTHALAMATE MEGLUMINE INJECTABLE;INJECTION CONRAY + LIEBEL-FLARSHEIM 60% N 013295 001 Feb CAHN CONRAY 30 + LIEBEL-FLARSHEIM 30% N 016983 001 Feb CAHN CONRAY 43 + LIEBEL-FLARSHEIM 43% N 013295 002 Feb CAHN SOLUTION;INTRAVESICAL CYSTO-CONRAY II LIEBEL-FLARSHEIM 17.2% N 017057 002 Feb CAHN

IOVERSOL INJECTABLE;INJECTION OPTIRAY 160 @ LIEBEL-FLARSHEIM 34% N 019710 003 Dec 30, 1988 Feb CAHN OPTIRAY 240 + LIEBEL-FLARSHEIM 51% N 019710 002 Dec 30, 1988 Feb CAHN @ 51% N 020923 001 May 28, 1998 Feb CAHN OPTIRAY 300 + LIEBEL-FLARSHEIM 64% N 019710 004 Jan 22, 1992 Feb CAHN + 64% N 020923 004 May 13, 1999 Feb CAHN OPTIRAY 320 + LIEBEL-FLARSHEIM 68% N 019710 001 Dec 30, 1988 Feb CAHN @ 68% N 020923 002 May 29, 1998 Feb CAHN OPTIRAY 350 + LIEBEL-FLARSHEIM 74% N 019710 005 Jan 22, 1992 Feb CAHN + 74% N 020923 003 May 28, 1998 Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM INJECTABLE;INJECTION HEXABRIX @ GUERBET 39.3%;19.6% N 018905 002 Jul 26, 1985 May DISC

IRBESARTAN TABLET;ORAL IRBESARTAN AB JUBILANT GENERICS 75MG A 203534 001 Feb 23, 2015 Feb NEWA AB 150MG A 203534 002 Feb 23, 2015 Feb NEWA AB 300MG A 203534 003 Feb 23, 2015 Feb NEWA

IRON DEXTRAN INJECTABLE;INJECTION INFED BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML N 017441 001 Mar CAHN

ISAVUCONAZONIUM SULFATE CAPSULE;ORAL CRESEMBA + ASTELLAS 186MG N 207500 001 Mar 06, 2015 Mar NEWA POWDER;IV (INFUSION) CRESEMBA + ASTELLAS 372MG N 207501 001 Mar 06, 2015 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -47

ISOSORBIDE DINITRATE TABLET;ORAL ISORDIL AB VALEANT PHARMS NORTH 5MG N 012093 007 Jul 29, 1988 Feb CAHN + 40MG N 012093 001 Jul 29, 1988 Feb CAHN

ISOTRETINOIN CAPSULE;ORAL ABSORICA RANBAXY 25MG N 021951 005 Aug 15, 2014 Feb NEWA 35MG N 021951 006 Aug 15, 2014 Feb NEWA MYORISAN AB DOUGLAS PHARMS 30MG A 076485 004 Aug 25, 2015 Aug NEWA SOTRET AB SUN PHARM INDS LTD 10MG A 076041 001 Dec 24, 2002 Apr CAHN AB 20MG A 076041 002 Dec 24, 2002 Apr CAHN AB 30MG A 076503 001 Jun 20, 2003 Apr CAHN AB 40MG A 076041 003 Dec 24, 2002 Apr CAHN ZENATANE AB DR REDDYS LABS LTD 30MG A 202099 004 Feb 23, 2015 Feb NEWA

ISRADIPINE CAPSULE;ORAL ISRADIPINE AB ELITE LABS INC 2.5MG A 077169 001 Apr 24, 2006 Mar CAHN AB 5MG A 077169 002 Apr 24, 2006 Mar CAHN

IVABRADINE HYDROCHLORIDE TABLET;ORAL CORLANOR AMGEN INC EQ 5MG BASE N 206143 001 Apr 15, 2015 Apr NEWA + EQ 7.5MG BASE N 206143 002 Apr 15, 2015 Apr NEWA

IVACAFTOR GRANULE;ORAL KALYDECO VERTEX PHARMS INC 50MG/PACKET N 207925 001 Mar 17, 2015 Mar NEWA + 75MG/PACKET N 207925 002 Mar 17, 2015 Mar NEWA

IVACAFTOR; LUMACAFTOR TABLET;ORAL ORKAMBI + VERTEX PHARMS INC 125MG;200MG N 206038 001 Jul 02, 2015 Jul NEWA

IXABEPILONE INJECTABLE;IV (INFUSION) IXEMPRA KIT + R-PHARM US LLC 15MG/VIAL N 022065 001 Oct 16, 2007 Jun CAHN + 45MG/VIAL N 022065 002 Oct 16, 2007 Jun CAHN

KANAMYCIN SULFATE INJECTABLE;INJECTION KANAMYCIN @ EUROHLTH INTL SARL EQ 75MG BASE/2ML A 062324 001 Jun CAHN @ EQ 500MG BASE/2ML A 062324 002 Jun CAHN @ EQ 1GM BASE/3ML A 062324 003 Jun CAHN

KETOROLAC TROMETHAMINE INJECTABLE;INJECTION KETOROLAC TROMETHAMINE >A> AP BD RX 15MG/ML A 203242 001 Oct 07, 2015 Sep NEWA >A> AP 30MG/ML A 203242 002 Oct 07, 2015 Sep NEWA @ CLARIS PHARMASERVICE 15MG/ML A 075631 002 Jun 29, 2001 Apr CAHN @ 30MG/ML A 075631 001 Jun 29, 2001 Apr CAHN @ EUROHLTH INTL SARL 15MG/ML A 075772 001 Jul 21, 2004 Jun CAHN @ 30MG/ML A 075772 002 Jul 21, 2004 Jun CAHN SPRAY, METERED;NASAL SPRIX + EGALET US INC 15.75MG/SPRAY N 022382 001 May 14, 2010 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -48

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION;IRRIGATION OMIDRIA + OMEROS EQ 4.24MG BASE/ML;EQ 12.4MG N 205388 001 May 30, 2014 Feb CPOT BASE/ML

LABETALOL HYDROCHLORIDE INJECTABLE;INJECTION LABETALOL HYDROCHLORIDE @ CLARIS PHARMASERVICE 5MG/ML A 076051 001 Jul 05, 2002 Apr CAHN TABLET;ORAL LABETALOL HYDROCHLORIDE AB MUTUAL PHARM 100MG A 075215 001 Jul 29, 1999 Jan CMFD AB 200MG A 075215 002 Jul 29, 1999 Jan CMFD AB 300MG A 075215 003 Jul 29, 1999 Jan CMFD

LACTULOSE SOLUTION;ORAL, RECTAL LACTULOSE AA BIO-PHARM INC 10GM/15ML A 203762 001 Mar 27, 2015 Mar NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM TABLET;ORAL DUTREBIS @ MERCK SHARP DOHME 150MG;EQ 300MG BASE N 206510 001 Feb 06, 2015 Aug DISC + 150MG;EQ 300MG BASE N 206510 001 Feb 06, 2015 Feb NEWA

LAMIVUDINE; ZIDOVUDINE TABLET;ORAL LAMIVUDINE AND ZIDOVUDINE AB HETERO LABS LTD III 150MG;300MG A 079124 001 Sep 17, 2015 Aug NEWA AB STRIDES ARCOLAB LTD 150MG;300MG A 079128 001 May 13, 2015 Apr NEWA AB STRIDES PHARMA 150MG;300MG A 079128 001 May 13, 2015 Aug CAHN

LAMOTRIGINE TABLET;ORAL LAMOTRIGINE @ HIKMA PHARMS 25MG A 078134 001 Apr 19, 2011 May DISC @ 100MG A 078134 002 Apr 19, 2011 May DISC @ 150MG A 078134 003 Apr 19, 2011 May DISC @ 200MG A 078134 004 Apr 19, 2011 May DISC

LAPATINIB DITOSYLATE TABLET;ORAL TYKERB + NOVARTIS PHARMS CORP EQ 250MG BASE N 022059 001 Mar 13, 2007 Mar CAHN

LENVATINIB MESYLATE CAPSULE;ORAL LENVIMA EISAI INC EQ 4MG BASE N 206947 001 Feb 13, 2015 Feb NEWA + EQ 10MG BASE N 206947 002 Feb 13, 2015 Feb NEWA

LEVETIRACETAM INJECTABLE;IV (INFUSION) LEVETIRACETAM AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A 090876 001 Aug 13, 2015 Jul NEWA SOLUTION;ORAL LEVETIRACETAM AA PHARM ASSOC 100MG/ML A 201157 001 Jun 04, 2015 May NEWA TABLET;ORAL SPRITAM APRECIA PHARMS CO 250MG N 207958 001 Jul 31, 2015 Jul NEWA 500MG N 207958 002 Jul 31, 2015 Jul NEWA 750MG N 207958 003 Jul 31, 2015 Jul NEWA 1GM N 207958 004 Jul 31, 2015 Jul NEWA TABLET, EXTENDED RELEASE;ORAL LEVETIRACETAM APOTEX INC 1GM A 202958 001 Feb 25, 2015 Feb NEWA AB DEXCEL PHARMA 500MG A 202167 001 Sep 04, 2015 Aug NEWA AB 750MG A 202167 002 Sep 04, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -49

TABLET, EXTENDED RELEASE;ORAL LEVETIRACETAM AB PHARMADAX INC 500MG A 201464 001 May 25, 2012 Aug CAHN AB 750MG A 201464 002 May 25, 2012 Aug CAHN AB PRINSTON INC 500MG A 203468 001 May 21, 2015 May NEWA AB 750MG A 203468 002 May 21, 2015 May NEWA

LEVOCARNITINE INJECTABLE;INJECTION LEVOCARNITINE @ TEVA PHARMS USA 200MG/ML A 075881 001 Mar 29, 2001 Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AB APOTEX INC 5MG A 203027 001 Feb 13, 2015 Feb NEWA AB SUN PHARM INDS LTD 5MG A 201653 001 Jun 26, 2015 Jun NEWA

LEVOFLOXACIN INJECTABLE;INJECTION LEVOFLOXACIN AP CLARIS PHARMASERVICE EQ 500MG/20ML (EQ 25MG/ML) A 091436 001 Jun 05, 2013 Apr CAHN AP HOSPIRA INC EQ 500MG/20ML (EQ 25MG/ML) A 078577 001 Aug 12, 2015 Jul NEWA AP EQ 750MG/30ML (EQ 25MG/ML) A 078577 002 Aug 12, 2015 Jul NEWA LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER AP CLARIS PHARMASERVICE EQ 250MG/50ML (EQ 5MG/ML) A 091397 001 Aug 08, 2013 Apr CAHN AP EQ 500MG/100ML (EQ 5MG/ML) A 091397 002 Aug 08, 2013 Apr CAHN AP EQ 750MG/150ML (EQ 5MG/ML) A 091397 003 Aug 08, 2013 Apr CAHN AP HOSPIRA INC EQ 250MG/50ML (EQ 5MG/ML) A 078579 001 Sep 03, 2015 Aug NEWA AP EQ 500MG/100ML (EQ 5MG/ML) A 078579 002 Sep 03, 2015 Aug NEWA AP EQ 750MG/150ML (EQ 5MG/ML) A 078579 003 Sep 03, 2015 Aug NEWA SOLUTION/DROPS;OPHTHALMIC LEVOFLOXACIN AT + NEXUS PHARMS 0.5% A 077700 001 Dec 20, 2010 Jul CRLD QUIXIN @ SANTEN 0.5% N 021199 001 Aug 18, 2000 Jul DISC TABLET;ORAL LEVOFLOXACIN AB JUBILANT GENERICS 250MG A 203613 001 Jun 19, 2015 Jun NEWA AB 500MG A 203613 002 Jun 19, 2015 Jun NEWA

LEVOLEUCOVORIN CALCIUM SOLUTION;IV (INFUSION) LEVOLEUCOVORIN CALCIUM SANDOZ EQ 250MG BASE/25ML (EQ 10MG A 203563 002 Mar 09, 2015 Feb NEWA BASE/ML) SANDOZ INC EQ 175MG BASE/17.5ML (EQ 10MG A 203563 001 Mar 09, 2015 Feb NEWA BASE/ML) + EQ 250MG BASE/25ML (EQ 10MG A 203563 002 Mar 09, 2015 Mar CRLD BASE/ML)

LEVONORGESTREL INTRAUTERINE DEVICE;INTRAUTERINE LILETTA MEDICINES360 52MG N 206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE TABLET;ORAL LEVORPHANOL TARTRATE + SENTYNL THERAPS INC 2MG A 074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE OINTMENT;TOPICAL LIDOCAINE AT AMNEAL PHARMS 5% A 206297 001 Aug 07, 2015 Jul NEWA >A> @ BELMORA LLC 5% A 080210 001 Sep CAHN >D> @ GRAHAM CHEM 5% A 080210 001 Sep CAHN PATCH;TOPICAL LIDOCAINE AB ACTAVIS LABS UT INC 5% A 200675 001 Aug 23, 2012 Mar CAHN AB MYLAN TECHNOLOGIES 5% A 202346 001 Aug 07, 2015 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -50

LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE @ EUROHLTH INTL SARL 1% A 080407 001 Mar CAHN @ 2% A 080407 002 Mar CAHN AP LUITPOLD 1% A 091564 001 Aug 14, 2015 Aug NEWA LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE @ EUROHLTH INTL SARL 1% A 084625 001 Feb CAHN @ 2% A 084625 002 Feb CAHN JELLY;TOPICAL ANESTACON @ BANNER LIFE SCIENCES 2% A 080429 001 Jan CAHN LIDOCAINE HYDROCHLORIDE @ G AND W LABS INC 2% A 081318 001 Apr 29, 1993 Apr CAHN

LIDOCAINE; PRILOCAINE CREAM;TOPICAL EMLA AB + ACTAVIS LABS UT INC 2.5%;2.5% N 019941 001 Dec 30, 1992 Feb CAHN

LINACLOTIDE CAPSULE;ORAL LINZESS FOREST LABS LLC 145MCG N 202811 001 Aug 30, 2012 Mar CAHN + 290MCG N 202811 002 Aug 30, 2012 Mar CAHN

LINCOMYCIN HYDROCHLORIDE INJECTABLE;INJECTION LINCOCIN AP + PHARMACIA AND UPJOHN EQ 300MG BASE/ML N 050317 001 May CFTG LINCOMYCIN AP X-GEN PHARMS INC EQ 300MG BASE/ML A 201746 001 Jun 04, 2015 May NEWA

LINEZOLID FOR SUSPENSION;ORAL LINEZOLID AB ROXANE 100MG/5ML A 200068 001 Jun 03, 2015 May NEWA ZYVOX AB + PHARMACIA AND UPJOHN 100MG/5ML N 021132 001 Apr 18, 2000 May CFTG SOLUTION;IV (INFUSION) LINEZOLID AP HOSPIRA INC 600MG/300ML (2MG/ML) A 205442 001 Jul 07, 2015 Jun NEWA AP SANDOZ INC 200MG/100ML (2MG/ML) A 200904 001 Jul 16, 2015 Jul NEWA AP 600MG/300ML (2MG/ML) A 200904 002 Jul 16, 2015 Jul NEWA AP TEVA PHARMS 600MG/300ML (2MG/ML) A 200222 001 Jun 27, 2012 May CDFR LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER + HOSPIRA INC 600MG/300ML (2MG/ML) N 206473 001 Jun 18, 2015 Jun NEWA ZYVOX AP PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML) N 021131 001 Apr 18, 2000 Jul CTEC 200MG/100ML (2MG/ML) N 021131 001 Apr 18, 2000 May CDFR 400MG/200ML (2MG/ML) N 021131 002 Apr 18, 2000 May NEWA AP + 600MG/300ML (2MG/ML) N 021131 003 Apr 18, 2000 May NEWA TABLET;ORAL LINEZOLID AB TEVA PHARMS USA 600MG A 078061 001 May 18, 2015 May NEWA ZYVOX AB + PHARMACIA AND UPJOHN 600MG N 021130 002 Apr 18, 2000 May CFTG

LISINOPRIL TABLET;ORAL LISINOPRIL AB SUN PHARM INDS LTD 2.5MG A 075944 001 Jul 01, 2002 Apr CAHN AB 5MG A 075944 002 Jul 01, 2002 Apr CAHN AB 10MG A 075944 003 Jul 01, 2002 Apr CAHN AB 20MG A 075944 004 Jul 01, 2002 Apr CAHN AB 30MG A 075944 006 Feb 11, 2003 Apr CAHN AB 40MG A 075944 005 Jul 01, 2002 Apr CAHN ZESTRIL AB ALVOGEN IPCO SARL 2.5MG N 019777 005 Apr 29, 1993 Feb CAHN AB 5MG N 019777 001 May 19, 1988 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -51

TABLET;ORAL ZESTRIL AB 10MG N 019777 002 May 19, 1988 Feb CAHN AB 20MG N 019777 003 May 19, 1988 Feb CAHN AB 30MG N 019777 006 Jan 20, 1999 Feb CAHN AB + 40MG N 019777 004 May 19, 1988 Feb CAHN

LITHIUM CARBONATE TABLET, EXTENDED RELEASE;ORAL LITHIUM CARBONATE AB ALEMBIC PHARMS LTD 300MG A 204445 001 Jun 10, 2015 May NEWA @ HIKMA INTL PHARMS 450MG A 076490 001 Jun 17, 2003 Feb DISC AB UNIQUE PHARM LABS 300MG A 204779 001 Jul 27, 2015 Jul NEWA

LOMITAPIDE MESYLATE CAPSULE;ORAL JUXTAPID AEGERION EQ 30MG BASE N 203858 004 Apr 23, 2015 Apr NEWA EQ 40MG BASE N 203858 005 Apr 23, 2015 Apr NEWA EQ 60MG BASE N 203858 006 Apr 23, 2015 Apr NEWA

LOMUSTINE CAPSULE;ORAL GLEOSTINE CORDEN PHARMA 5MG N 017588 004 Dec 19, 2014 Jan NEWA

LOPERAMIDE HYDROCHLORIDE CAPSULE;ORAL IMODIUM @ J AND J CONSUMER INC 2MG N 017690 001 Jul CAHN AB + 2MG N 017694 001 Jul CAHN

LOPINAVIR; RITONAVIR CAPSULE;ORAL KALETRA @ ABBVIE 133.3MG;33.3MG N 021226 001 Sep 15, 2000 Jun DISC

LORAZEPAM INJECTABLE;INJECTION ATIVAN AP + EUROHLTH INTL SARL 2MG/ML N 018140 001 Jun CAHN AP + 4MG/ML N 018140 002 Jun CAHN TABLET;ORAL LORAZEPAM AB SUN PHARM INDS LTD 0.5MG A 076045 001 Aug 29, 2001 Apr CAHN AB 1MG A 076045 002 Aug 29, 2001 Apr CAHN AB 2MG A 076045 003 Aug 29, 2001 Apr CAHN

LOSARTAN POTASSIUM TABLET;ORAL LOSARTAN POTASSIUM AB HETERO LABS LTD V 25MG A 203835 001 Aug 12, 2015 Jul NEWA AB 50MG A 203835 002 Aug 12, 2015 Jul NEWA AB 100MG A 203835 003 Aug 12, 2015 Jul NEWA AB WATSON LABS 25MG A 091129 001 Oct 06, 2010 Feb CMFD AB 50MG A 091129 002 Oct 06, 2010 Feb CMFD AB 100MG A 091129 003 Oct 06, 2010 Feb CMFD

LOVASTATIN TABLET, EXTENDED RELEASE;ORAL ALTOPREV @ COVIS PHARMA SARL 10MG N 021316 001 Jun 26, 2002 May CAHN 20MG N 021316 002 Jun 26, 2002 May CAHN 40MG N 021316 003 Jun 26, 2002 May CAHN + 60MG N 021316 004 Jun 26, 2002 May CAHN

LOXAPINE HYDROCHLORIDE CONCENTRATE;ORAL LOXITANE C @ ACTAVIS LABS UT INC EQ 25MG BASE/ML N 017658 001 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -52

INJECTABLE;INJECTION LOXITANE IM @ ACTAVIS LABS UT INC EQ 50MG BASE/ML N 018039 001 Mar CAHN

LOXAPINE SUCCINATE CAPSULE;ORAL LOXAPINE SUCCINATE AB ELITE LABS INC EQ 5MG BASE A 076868 001 Aug 04, 2005 May CAHN AB EQ 10MG BASE A 076868 002 Aug 04, 2005 May CAHN AB EQ 25MG BASE A 076868 003 Aug 04, 2005 May CAHN AB EQ 50MG BASE A 076868 004 Aug 04, 2005 May CAHN LOXITANE @ ACTAVIS LABS UT INC EQ 5MG BASE N 017525 001 Mar CAHN @ EQ 10MG BASE N 017525 002 Mar CAHN @ EQ 25MG BASE N 017525 003 Mar CAHN @ EQ 50MG BASE N 017525 004 Mar CAHN TABLET;ORAL LOXITANE @ ACTAVIS LABS UT INC EQ 10MG BASE N 017525 006 Mar CAHN @ EQ 25MG BASE N 017525 007 Mar CAHN @ EQ 50MG BASE N 017525 008 Mar CAHN

LUCINACTANT SUSPENSION;INTRATRACHEAL SURFAXIN @ DISCOVERY LABS 8.5ML N 021746 001 Mar 06, 2012 May DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION PLASMA-LYTE 56 IN PLASTIC CONTAINER @ BAXTER HLTHCARE 32MG/100ML;128MG/100ML;234MG/100ML N 019047 001 Jun 15, 1984 Mar DISC

MAGNESIUM SULFATE SOLUTION;INTRAMUSCULAR, INTRAVENOUS MAGNESIUM SULFATE AP EXELA PHARMA SCS LLC 5GM/10ML (500MG/ML) A 206039 001 Dec 18, 2014 Apr CDFR AP + FRESENIUS KABI USA 5GM/10ML (500MG/ML) N 019316 001 Sep 08, 1986 Apr CPOT AP + HOSPIRA 5GM/10ML (500MG/ML) A 075151 001 Apr 25, 2000 Apr CDFR HOSPIRA INC 10GM/20ML (500MG/ML) A 202411 001 May 14, 2015 Apr NEWA

MAGNESIUM SULFATE SOLUTION;INTRAMUSCULAR, INTRAVENOUS MAGNESIUM SULFATE + FRESENIUS KABI USA 1GM/2ML (500MG/ML) N 019316 002 Sep 08, 1986 Apr NEWA

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE SOLUTION;ORAL SUCLEAR @ BRAINTREE LABS 1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/ N 203595 001 Jan 18, 2013 Aug DISC A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0. 74GM,2.86GM,5.6GM

MANNITOL INJECTABLE;INJECTION MANNITOL 25% @ IGI LABS INC 12.5GM/50ML A 089239 001 May 06, 1987 Mar CAHN @ 12.5GM/50ML A 089240 001 May 06, 1987 Mar CAHN

MECLIZINE HYDROCHLORIDE TABLET;ORAL MECLIZINE HYDROCHLORIDE @ ANI PHARMS INC 12.5MG A 084975 001 Aug CAHN @ 25MG A 084657 001 Aug CAHN @ VINTAGE PHARMS 12.5MG A 040179 001 Jan 30, 1997 Jun DISC @ 25MG A 040179 002 Jan 30, 1997 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -53

MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL NAMENDA XR FOREST LABS LLC 7MG N 022525 001 Jun 21, 2010 Mar CAHN 14MG N 022525 002 Jun 21, 2010 Mar CAHN 21MG N 022525 003 Jun 21, 2010 Mar CAHN + 28MG N 022525 004 Jun 21, 2010 Mar CAHN SOLUTION;ORAL >A> MEMANTINE HYDROCHLORIDE >A> AA MACLEODS PHARMS LTD 2MG/ML A 202790 001 Oct 13, 2015 Sep NEWA >A> AA SILARX PHARMS INC 2MG/ML A 204033 001 Oct 13, 2015 Sep NEWA NAMENDA >D> + FOREST LABS LLC 2MG/ML N 021627 001 Apr 18, 2005 Sep CFTG >A> AA + 2MG/ML N 021627 001 Apr 18, 2005 Sep CFTG + 2MG/ML N 021627 001 Apr 18, 2005 Mar CAHN TABLET;ORAL MEMANTINE AB SUN PHARMA GLOBAL 5MG A 090058 001 May 05, 2010 Mar CMFD AB 10MG A 090058 002 May 05, 2010 Mar CMFD MEMANTINE HYDROCHLORIDE >A> AB ALEMBIC PHARMS LTD 5MG A 200891 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 200891 002 Oct 13, 2015 Sep NEWA AB AMNEAL PHARMS 5MG A 090041 001 Apr 10, 2015 Mar NEWA AB 10MG A 090041 002 Apr 10, 2015 Mar NEWA >A> AB AUROBINDO PHARMA LTD 5MG A 203175 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 203175 002 Oct 13, 2015 Sep NEWA AB DR REDDYS LABS LTD 5MG A 090048 001 Apr 14, 2010 Jun CMFD AB 10MG A 090048 002 Apr 14, 2010 Jun CMFD >A> AB JUBILANT GENERICS 5MG A 091585 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 091585 002 Oct 13, 2015 Sep NEWA AB LUPIN LTD 5MG A 090051 001 Apr 10, 2015 Mar NEWA AB 10MG A 090051 002 Apr 10, 2015 Mar NEWA >A> AB MACLEODS PHARMS LTD 5MG A 202840 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 202840 002 Oct 13, 2015 Sep NEWA AB MYLAN PHARMS INC 5MG A 079225 001 Jan 30, 2015 Jun CMFD @ 5MG A 079225 001 Jan 30, 2015 Mar DISC AB 5MG A 079225 001 Jan 30, 2015 Jan NEWA AB 10MG A 079225 002 Jan 30, 2015 Jun CMFD @ 10MG A 079225 002 Jan 30, 2015 Mar DISC AB 10MG A 079225 002 Jan 30, 2015 Jan NEWA AB TEVA PHARMS 5MG A 090052 001 Oct 25, 2011 May CMFD AB 10MG A 090052 002 Oct 25, 2011 May CMFD >A> AB TORRENT PHARMS LTD 5MG A 200155 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 200155 002 Oct 13, 2015 Sep NEWA >A> AB UNICHEM LABS LTD 5MG A 200022 001 Oct 13, 2015 Sep NEWA >A> AB 10MG A 200022 002 Oct 13, 2015 Sep NEWA AB UPSHER SMITH 5MG A 090043 001 Jul 31, 2015 Jul NEWA AB 10MG A 090043 002 Jul 31, 2015 Jul NEWA AB WOCKHARDT LTD 5MG A 090073 001 Sep 04, 2015 Aug NEWA AB 10MG A 090073 002 Sep 04, 2015 Aug NEWA NAMENDA AB FOREST LABS LLC 5MG N 021487 001 Oct 16, 2003 Mar CAHN AB + 10MG N 021487 002 Oct 16, 2003 Mar CAHN

MENOTROPINS (FSH;LH) INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS REPRONEX @ FERRING 75 IU/VIAL;75 IU/VIAL N 021047 001 Aug 27, 1999 May DISC

MEPERIDINE HYDROCHLORIDE INJECTABLE;INJECTION MEPERIDINE HYDROCHLORIDE AP EUROHLTH INTL SARL 25MG/ML A 080445 001 Feb CAHN AP 50MG/ML A 080445 002 Feb CAHN AP 75MG/ML A 080445 003 Feb CAHN AP 100MG/ML A 080445 004 Feb CAHN @ IGI LABS INC 25MG/ML A 089781 001 Mar 31, 1989 May CAHN @ 50MG/ML A 089782 001 Mar 31, 1989 Mar CAHN @ 50MG/ML A 089783 001 Mar 31, 1989 Mar CAHN @ 50MG/ML A 089784 001 Mar 31, 1989 Mar CAHN @ 75MG/ML A 089785 001 Mar 31, 1989 Mar CAHN @ 100MG/ML A 089786 001 Mar 31, 1989 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -54

INJECTABLE;INJECTION MEPERIDINE HYDROCHLORIDE @ 100MG/ML A 089787 001 Mar 31, 1989 Mar CAHN @ 100MG/ML A 089788 001 Mar 31, 1989 Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE INJECTABLE;INJECTION MEPERGAN @ EUROHLTH INTL SARL 25MG/ML;25MG/ML N 011730 001 Jun CAHN

MEROPENEM POWDER;IV (INFUSION) MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER B BRAUN MEDICAL INC 500MG/VIAL N 202106 001 Apr 30, 2015 Apr NEWA 1GM/VIAL N 202106 002 Apr 30, 2015 Apr NEWA

MESALAMINE CAPSULE, EXTENDED RELEASE;ORAL APRISO + VALEANT PHARMS INTL 375MG N 022301 001 Oct 31, 2008 Jul CAHN ENEMA;RECTAL MESALAMINE AB G AND W LABS INC 4GM/60ML A 076841 001 Sep 30, 2004 Aug CAHN SUPPOSITORY;RECTAL CANASA @ FOREST LABS LLC 500MG N 021252 001 Jan 05, 2001 Aug CAHN + 1GM N 021252 002 Nov 05, 2004 Aug CAHN

MESTRANOL; NORETHINDRONE TABLET;ORAL-20 NORINYL @ ACTAVIS LABS UT INC 0.1MG;2MG N 013625 004 Mar CAHN TABLET;ORAL-21 NORINYL 1+50 21-DAY @ ACTAVIS LABS UT INC 0.05MG;1MG N 013625 002 Mar CAHN TABLET;ORAL-28 NORINYL 1+50 28-DAY + ACTAVIS LABS UT INC 0.05MG;1MG N 016659 001 Mar CAHN

METAPROTERENOL SULFATE SOLUTION;INHALATION METAPROTERENOL SULFATE @ MYLAN SPECLT 0.4% A 071786 001 Aug 05, 1988 Apr DISC @ 0.6% A 070804 001 Aug 17, 1987 Apr DISC @ WOCKHARDT 0.4% A 075586 001 May 30, 2002 Apr DISC @ 0.6% A 075586 002 May 30, 2002 Apr DISC SYRUP;ORAL METAPROTERENOL SULFATE @ G AND W LABS INC 10MG/5ML A 072761 001 Feb 27, 1992 Apr CAHN @ 10MG/5ML A 073034 001 Aug 30, 1991 Apr CAHN

METAXALONE TABLET;ORAL METAXALONE COREPHARMA 400MG A 040486 001 Feb 27, 2015 Feb NEWA 640MG N 022503 001 Jun 01, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE SOLUTION;ORAL RIOMET + SUN PHARM INDS LTD 500MG/5ML N 021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE TABLET;ORAL PRANDIMET AB NOVO NORDISK INC 500MG;1MG N 022386 001 Jun 23, 2008 Jun CFTG AB + 500MG;2MG N 022386 002 Jun 23, 2008 Jun CFTG REPAGLINIDE AND METFORMIN HYDROCHLORIDE AB LUPIN LTD 500MG;1MG A 200624 001 Jul 15, 2015 Jun NEWA AB 500MG;2MG A 200624 002 Jul 15, 2015 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -55

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE TABLET;ORAL AVANDAMET @ SB PHARMCO 500MG;EQ 2MG BASE N 021410 002 Oct 10, 2002 May DISC @ 500MG;EQ 4MG BASE N 021410 003 Oct 10, 2002 May DISC @ 1GM;EQ 2MG BASE N 021410 004 Aug 25, 2003 May DISC @ 1GM;EQ 4MG BASE N 021410 005 Aug 25, 2003 May DISC ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE TEVA 500MG;EQ 2MG BASE A 077337 001 May 07, 2014 May CTEC 500MG;EQ 4MG BASE A 077337 002 May 07, 2014 May CTEC + 1GM;EQ 4MG BASE A 077337 004 May 07, 2014 May CRLD 1GM;EQ 2MG BASE A 077337 003 May 07, 2014 May CTEC

METHADONE HYDROCHLORIDE TABLET;ORAL METHADONE HYDROCHLORIDE AA AUROLIFE PHARMA LLC 5MG A 203502 001 Aug 31, 2015 Aug NEWA AA 10MG A 203502 002 Aug 31, 2015 Aug NEWA AA COREPHARMA 5MG A 090065 001 Aug 18, 2015 Aug NEWA AA 10MG A 090065 002 Aug 18, 2015 Aug NEWA

METHIMAZOLE TABLET;ORAL METHIMAZOLE AB HERITAGE PHARMA 5MG A 040734 001 Dec 14, 2007 Mar CAHN AB 10MG A 040734 002 Dec 14, 2007 Mar CAHN

METHOCARBAMOL SOLUTION;IM-IV ROBAXIN AP + EUROHLTH INTL SARL 1GM/10ML (100MG/ML) N 011790 001 Jun CAHN

METHOTREXATE SODIUM INJECTABLE;INJECTION METHOTREXATE PRESERVATIVE FREE AP FRESENIUS KABI USA EQ 25MG BASE/ML A 040265 001 Feb 26, 1999 May CMFD

METHOXSALEN CAPSULE;ORAL METHOXSALEN AB ACTAVIS INC 10MG A 202603 001 Jun 09, 2015 May NEWA

METHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL APTENSIO XR RHODES PHARMS 10MG N 205831 001 Apr 17, 2015 Apr NEWA 15MG N 205831 002 Apr 17, 2015 Apr NEWA 20MG N 205831 003 Apr 17, 2015 Apr NEWA 30MG N 205831 004 Apr 17, 2015 Apr NEWA 40MG N 205831 005 Apr 17, 2015 Apr NEWA 50MG N 205831 006 Apr 17, 2015 Apr NEWA + 60MG N 205831 007 Apr 17, 2015 Apr NEWA METHYLPHENIDATE HYDROCHLORIDE >A> AB2 MALLINCKRODT INC 10MG A 203583 001 Sep 29, 2015 Sep NEWA >A> AB2 20MG A 203583 002 Sep 29, 2015 Sep NEWA >A> AB2 30MG A 203583 003 Sep 29, 2015 Sep NEWA >A> AB2 40MG A 203583 004 Sep 29, 2015 Sep NEWA >A> AB2 50MG A 203583 005 Sep 29, 2015 Sep NEWA >A> AB2 60MG A 203583 006 Sep 29, 2015 Sep NEWA RITALIN LA AB1 NOVARTIS 40MG N 021284 003 Jun 05, 2002 Feb CRLD + 60MG N 021284 005 Oct 27, 2014 Feb CRLD SOLUTION;ORAL METHYLPHENIDATE HYDROCHLORIDE AA NOVEL LABS INC 5MG/5ML A 204602 001 Aug 14, 2015 Aug NEWA AA 10MG/5ML A 204602 002 Aug 14, 2015 Aug NEWA TABLET;ORAL METHYLPHENIDATE HYDROCHLORIDE >A> AB ASCENT PHARMS INC 5MG A 207416 001 Sep 22, 2015 Sep NEWA >A> AB 10MG A 207416 002 Sep 22, 2015 Sep NEWA >A> AB 20MG A 207416 003 Sep 22, 2015 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -56

TABLET, CHEWABLE;ORAL METHYLIN AB MALLINCKRODT 2.5MG N 021475 001 Apr 15, 2003 Feb CFTG AB 5MG N 021475 002 Apr 15, 2003 Feb CFTG AB + 10MG N 021475 003 Apr 15, 2003 Feb CFTG METHYLPHENIDATE HYDROCHLORIDE AB NOVEL LABS INC 2.5MG A 204115 001 Feb 25, 2015 Feb NEWA AB 5MG A 204115 002 Feb 25, 2015 Feb NEWA AB 10MG A 204115 003 Feb 25, 2015 Feb NEWA TABLET, EXTENDED RELEASE;ORAL METHYLIN ER AB MALLINCKRODT INC 10MG A 075629 001 May 09, 2000 May CTEC METHYLPHENIDATE HYDROCHLORIDE AB ABHAI 10MG A 207488 001 Jun 09, 2015 May NEWA AB 20MG A 207488 002 Jun 09, 2015 May NEWA

METHYLTESTOSTERONE CAPSULE;ORAL METHYLTESTOSTERONE >A> AB IMPAX LABS INC 10MG A 204851 001 Sep 21, 2015 Sep NEWA TESTRED >D> + VALEANT PHARM INTL 10MG A 083976 001 Sep CTEC >A> AB + 10MG A 083976 001 Sep CTEC

METOPROLOL TARTRATE INJECTABLE;INJECTION METOPROLOL TARTRATE AP CLARIS PHARMASERVICE 1MG/ML A 078950 001 Apr 29, 2013 Apr CAHN TABLET;ORAL METOPROLOL TARTRATE MYLAN 37.5MG A 076704 004 Mar 18, 2015 Mar NEWA 75MG A 076704 005 Mar 18, 2015 Mar NEWA

METRONIDAZOLE CREAM;TOPICAL NORITATE + VALEANT PHARMS NORTH 1% N 020743 001 Sep 26, 1997 Feb CAHN GEL;VAGINAL METRONIDAZOLE + ACTAVIS LABS UT INC 1.3% N 205223 001 Mar 24, 2014 Feb CAHN NUVESSA + ACTAVIS LABS UT INC 1.3% N 205223 001 Mar 24, 2014 Feb CTNA INJECTABLE;INJECTION METRONIDAZOLE @ EUROHLTH INTL SARL 500MG/100ML N 018907 001 Mar 30, 1984 Aug CAHN METRONIDAZOLE IN PLASTIC CONTAINER AP CLARIS PHARMASERVICE 500MG/100ML A 078084 001 Mar 31, 2008 Apr CAHN TABLET;ORAL METRONIDAZOLE >A> AB APPCO PHARMA LLC 250MG A 205245 001 Sep 23, 2015 Sep NEWA >A> AB 500MG A 205245 002 Sep 23, 2015 Sep NEWA AB AUROBINDO PHARMA LTD 250MG A 203974 001 May 29, 2015 May NEWA AB 500MG A 203974 002 May 29, 2015 May NEWA

MICONAZOLE TABLET;BUCCAL ORAVIG + DARA BIOSCIENCES 50MG N 022404 001 Apr 16, 2010 Apr CAHN

MIDAZOLAM HYDROCHLORIDE INJECTABLE;INJECTION MIDAZOLAM HYDROCHLORIDE @ CLARIS PHARMASERVICE EQ 1MG BASE/ML A 075637 001 Oct 31, 2000 Apr CAHN @ EQ 5MG BASE/ML A 075637 002 Oct 31, 2000 Apr CAHN AP EUROHLTH INTL SARL EQ 1MG BASE/ML A 075243 001 Jun 20, 2000 Jun CAHN AP EQ 5MG BASE/ML A 075243 002 Jun 20, 2000 Jun CAHN @ IGI LABS INC EQ 5MG BASE/ML A 075263 001 Jun 26, 2000 Apr CAHN @ WOCKHARDT EQ 1MG BASE/ML A 078141 001 May 30, 2008 Mar DISC @ EQ 1MG BASE/ML A 078511 001 Nov 10, 2008 Mar DISC @ EQ 5MG BASE/ML A 078141 002 May 30, 2008 Mar DISC @ EQ 5MG BASE/ML A 078511 002 Nov 10, 2008 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -57

SYRUP;ORAL MIDAZOLAM HYDROCHLORIDE AA SUN PHARM INDS LTD EQ 2MG BASE/ML A 076058 001 Mar 15, 2002 Apr CAHN

MIGLITOL TABLET;ORAL GLYSET AB PHARMACIA AND UPJOHN 25MG N 020682 001 Dec 18, 1996 Mar CTEC AA 25MG N 020682 001 Dec 18, 1996 Feb CFTG AB 50MG N 020682 002 Dec 18, 1996 Mar CTEC AA 50MG N 020682 002 Dec 18, 1996 Feb CFTG AB + 100MG N 020682 003 Dec 18, 1996 Mar CTEC AA + 100MG N 020682 003 Dec 18, 1996 Feb CFTG MIGLITOL AB ORIENT PHARMA CO LTD 25MG A 203965 001 Feb 24, 2015 Mar CTEC AA 25MG A 203965 001 Feb 24, 2015 Feb NEWA AB 50MG A 203965 002 Feb 24, 2015 Mar CTEC AA 50MG A 203965 002 Feb 24, 2015 Feb NEWA AB 100MG A 203965 003 Feb 24, 2015 Mar CTEC AA 100MG A 203965 003 Feb 24, 2015 Feb NEWA

MILRINONE LACTATE INJECTABLE;INJECTION MILRINONE LACTATE AP BEDFORD EQ 1MG BASE/ML A 075660 001 May 28, 2002 Jan CRLD AP EUROHLTH INTL SARL EQ 1MG BASE/ML A 075530 001 May 28, 2002 Jun CAHN >A> @ EQ 1MG BASE/ML A 075852 001 May 28, 2002 Sep CAHN AP + HIKMA FARMACEUTICA EQ 1MG BASE/ML A 077966 001 Dec 03, 2010 Jan CRLD >D> @ HIKMA MAPLE EQ 1MG BASE/ML A 075852 001 May 28, 2002 Sep CAHN

MINOCYCLINE HYDROCHLORIDE CAPSULE;ORAL MINOCYCLINE HYDROCHLORIDE AB SUN PHARM INDS LTD EQ 50MG BASE A 065062 001 Nov 30, 2000 Apr CAHN AB EQ 75MG BASE A 065062 002 Nov 30, 2000 Apr CAHN AB EQ 100MG BASE A 065062 003 Nov 30, 2000 Apr CAHN AB TORRENT PHARMA INC EQ 50MG BASE A 065062 001 Nov 30, 2000 Jun CAHN AB EQ 75MG BASE A 065062 002 Nov 30, 2000 Jun CAHN AB EQ 100MG BASE A 065062 003 Nov 30, 2000 Jun CAHN CAPSULE, EXTENDED RELEASE;ORAL XIMINO @ SUN PHARM INDS LTD EQ 45MG BASE N 201922 001 Jul 11, 2012 Apr CAHN @ EQ 67.5MG BASE N 201922 002 Jul 11, 2012 Apr CAHN @ EQ 90MG BASE N 201922 003 Jul 11, 2012 Apr CAHN @ EQ 112.5MG BASE N 201922 004 Jul 11, 2012 Apr CAHN @ EQ 135MG BASE N 201922 005 Jul 11, 2012 Apr CAHN TABLET;ORAL MINOCYCLINE HYDROCHLORIDE AB SUN PHARM INDS LTD EQ 50MG BASE A 065156 001 Jan 06, 2004 Apr CAHN AB EQ 75MG BASE A 065156 002 Jan 06, 2004 Apr CAHN AB EQ 100MG BASE A 065156 003 Jan 06, 2004 Apr CAHN AB TORRENT PHARMA INC EQ 50MG BASE A 065156 001 Jan 06, 2004 Jun CAHN AB EQ 75MG BASE A 065156 002 Jan 06, 2004 Jun CAHN AB EQ 100MG BASE A 065156 003 Jan 06, 2004 Jun CAHN TABLET, EXTENDED RELEASE;ORAL MINOCYCLINE HYDROCHLORIDE >D> AB SANDOZ EQ 135MG BASE A 090422 003 Aug 13, 2009 Sep CRLD >A> AB + EQ 135MG BASE A 090422 003 Aug 13, 2009 Sep CRLD AB SUN PHARM INDS LTD EQ 45MG BASE A 091118 001 Sep 25, 2014 Apr CAHN AB EQ 80MG BASE A 091118 004 Sep 25, 2014 Apr CAHN AB EQ 90MG BASE A 091118 005 Sep 25, 2014 Apr CAHN AB EQ 105MG BASE A 091118 006 Sep 25, 2014 Apr CAHN AB EQ 135MG BASE A 091118 008 Sep 25, 2014 Apr CAHN SOLODYN >D> + MEDICIS EQ 55MG BASE N 050808 008 Aug 27, 2010 Sep CRLD >A> EQ 55MG BASE N 050808 008 Aug 27, 2010 Sep CRLD >D> AB + EQ 80MG BASE N 050808 007 Aug 27, 2010 Sep CRLD >A> AB EQ 80MG BASE N 050808 007 Aug 27, 2010 Sep CRLD >D> AB EQ 115MG BASE N 050808 005 Jul 23, 2009 Sep CRLD >A> AB + EQ 115MG BASE N 050808 005 Jul 23, 2009 Sep CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -58

MIVACURIUM CHLORIDE SOLUTION;INTRAVENOUS MIVACRON ABBVIE EQ 10MG BASE/5ML (EQ 2MG BASE/ML) N 020098 004 Jan 22, 1992 Jan NEWA + EQ 20MG BASE/10ML (EQ 2MG BASE/ML) N 020098 005 Jan 22, 1992 Jan NEWA

MOLINDONE HYDROCHLORIDE TABLET;ORAL MOLINDONE HYDROCHLORIDE COREPHARMA 5MG A 090453 001 Mar 20, 2015 Mar NEWA 10MG A 090453 002 Mar 20, 2015 Mar NEWA + 25MG A 090453 003 Mar 20, 2015 Mar NEWA

MONTELUKAST SODIUM GRANULE;ORAL MONTELUKAST SODIUM AB AJANTA PHARMA LTD EQ 4MG BASE/PACKET A 203438 001 Jul 31, 2015 Jul NEWA TABLET;ORAL MONTELUKAST SODIUM AB AJANTA PHARMA LTD EQ 10MG BASE A 203432 001 Jul 31, 2015 Jul NEWA AB AMNEAL PHARMS EQ 10MG BASE A 204604 001 Sep 04, 2015 Aug NEWA AB KREMERS URBAN PHARMS EQ 10MG BASE A 201522 001 Aug 03, 2012 Mar CAHN >A> AB UNICHEM LABS LTD EQ 10MG BASE A 204290 001 Oct 08, 2015 Sep NEWA TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM AB AJANTA PHARMA LTD EQ 4MG BASE A 203328 001 Jul 31, 2015 Jul NEWA AB EQ 5MG BASE A 203328 002 Jul 31, 2015 Jul NEWA AB HETERO LABS LTD V EQ 4MG BASE A 204093 001 May 22, 2015 May NEWA AB EQ 5MG BASE A 204093 002 May 22, 2015 May NEWA AB JUBILANT GENERICS EQ 4MG BASE A 203795 001 Feb 27, 2015 Feb NEWA AB EQ 5MG BASE A 203795 002 Feb 27, 2015 Feb NEWA AB KREMERS URBAN PHARMS EQ 4MG BASE A 200405 001 Aug 03, 2012 Mar CAHN AB EQ 5MG BASE A 200405 002 Aug 03, 2012 Mar CAHN AB MACLEODS PHARMS LTD EQ 4MG BASE A 203582 001 Mar 12, 2015 Feb NEWA AB EQ 5MG BASE A 203582 002 Mar 12, 2015 Feb NEWA

MORPHINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL >D> AVINZA >D> AB2 KING PHARMS LLC 30MG N 021260 001 Mar 20, 2002 Sep DISC >A> @ 30MG N 021260 001 Mar 20, 2002 Sep DISC >D> AB2 45MG N 021260 005 Dec 18, 2008 Sep DISC >A> @ 45MG N 021260 005 Dec 18, 2008 Sep DISC >D> AB2 60MG N 021260 002 Mar 20, 2002 Sep DISC >A> @ 60MG N 021260 002 Mar 20, 2002 Sep DISC >D> AB2 75MG N 021260 006 Dec 18, 2008 Sep DISC >A> @ 75MG N 021260 006 Dec 18, 2008 Sep DISC >D> AB2 90MG N 021260 003 Mar 20, 2002 Sep DISC >A> @ 90MG N 021260 003 Mar 20, 2002 Sep DISC >D> AB2 + 120MG N 021260 004 Mar 20, 2002 Sep DISC >A> @ 120MG N 021260 004 Mar 20, 2002 Sep DISC KADIAN AB1 + ACTAVIS LABS UT INC 10MG N 020616 008 Apr 20, 2007 Mar CAHN AB1 20MG N 020616 001 Jul 03, 1996 Mar CAHN AB1 30MG N 020616 004 Mar 09, 2001 Mar CAHN AB1 40MG N 020616 009 Jul 09, 2012 May CTEC 40MG N 020616 009 Jul 09, 2012 Mar CAHN AB1 50MG N 020616 002 Jul 03, 1996 Mar CAHN AB1 60MG N 020616 005 Mar 09, 2001 Mar CAHN AB1 70MG N 020616 010 Jul 09, 2012 May CTEC 70MG N 020616 010 Jul 09, 2012 Mar CAHN AB1 80MG N 020616 006 Oct 27, 2006 Mar CAHN AB1 + 100MG N 020616 003 Jul 03, 1996 Mar CAHN 130MG N 020616 011 Jul 09, 2012 Mar CAHN 150MG N 020616 012 Jul 09, 2012 Mar CAHN AB1 + 200MG N 020616 007 Feb 27, 2007 Mar CAHN MORPHINE SULFATE >D> AB2 ACTAVIS ELIZABETH 30MG A 079040 001 Jan 16, 2013 Sep CTEC >A> 30MG A 079040 001 Jan 16, 2013 Sep CTEC >D> AB2 45MG A 079040 002 Jan 16, 2013 Sep CTEC >A> 45MG A 079040 002 Jan 16, 2013 Sep CTEC >D> AB2 60MG A 079040 003 Jan 16, 2013 Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -59

CAPSULE, EXTENDED RELEASE;ORAL MORPHINE SULFATE >A> 60MG A 079040 003 Jan 16, 2013 Sep CTEC >D> AB2 75MG A 079040 004 Jan 16, 2013 Sep CTEC >A> 75MG A 079040 004 Jan 16, 2013 Sep CTEC >D> AB2 90MG A 079040 005 Jan 16, 2013 Sep CTEC >A> 90MG A 079040 005 Jan 16, 2013 Sep CTEC >D> AB2 120MG A 079040 006 Jan 16, 2013 Sep CTEC >A> + 120MG A 079040 006 Jan 16, 2013 Sep CTEC AB1 TEVA PHARMS USA 40MG A 202718 007 Jun 03, 2015 May NEWA AB1 70MG A 202718 008 Jun 03, 2015 May NEWA INJECTABLE;INJECTION DURAMORPH PF AP + EUROHLTH INTL SARL 0.5MG/ML N 018565 001 Sep 18, 1984 Jun CAHN AP + 1MG/ML N 018565 002 Sep 18, 1984 Jun CAHN INFUMORPH + EUROHLTH INTL SARL 10MG/ML N 018565 003 Jul 19, 1991 Jun CAHN + 25MG/ML N 018565 004 Jul 19, 1991 Jun CAHN MORPHINE SULFATE AP EUROHLTH INTL SARL 4MG/ML A 205758 001 May 21, 2015 May NEWA AP 8MG/ML A 205758 002 May 21, 2015 May NEWA AP 10MG/ML A 205758 003 May 21, 2015 May NEWA AP + HOSPIRA INC 4MG/ML N 202515 002 Nov 14, 2011 May CFTG AP + 8MG/ML N 202515 003 Nov 14, 2011 May CFTG AP + 10MG/ML N 202515 004 Nov 14, 2011 May CFTG SOLUTION;ORAL MORPHINE SULFATE AA TRIS PHARMA INC 10MG/5ML A 203518 001 May 12, 2015 May NEWA AA 100MG/5ML A 203518 002 May 12, 2015 May NEWA TABLET, EXTENDED RELEASE;ORAL MORPHINE SULFATE AB ACTAVIS ELIZABETH 15MG A 203849 001 Apr 06, 2015 Mar NEWA AB 30MG A 203849 002 Apr 06, 2015 Mar NEWA AB 60MG A 203849 003 Apr 06, 2015 Mar NEWA AB 100MG A 203849 004 Apr 06, 2015 Mar NEWA AB 200MG A 203849 005 Apr 06, 2015 Mar NEWA AB SUN PHARM INDS LTD 15MG A 078761 001 May 11, 2012 Apr CAHN AB 30MG A 078761 002 May 11, 2012 Apr CAHN AB 60MG A 078761 003 May 11, 2012 Apr CAHN AB 100MG A 078761 004 May 11, 2012 Apr CAHN AB 200MG A 078761 005 May 11, 2012 Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE SOLUTION;IV (INFUSION) MOXIFLOXACIN HYDROCHLORIDE + FRESENIUS KABI USA EQ 400MG BASE/250ML (EQ 1.6MG N 205572 001 Apr 03, 2015 Apr NEWA BASE/ML) SOLUTION/DROPS;OPHTHALMIC MOXEZA AT2 + ALCON PHARMS LTD EQ 0.5% BASE N 022428 001 Nov 19, 2010 May CFTG MOXIFLOXACIN HYDROCHLORIDE AT1 LUPIN LTD EQ 0.5% BASE A 202867 001 Sep 04, 2014 May CTEC AT2 EQ 0.5% BASE A 204079 001 May 28, 2015 May NEWA AT1 WATSON LABS INC EQ 0.5% BASE A 202525 001 Mar 06, 2015 May CTEC AT EQ 0.5% BASE A 202525 001 Mar 06, 2015 Feb NEWA VIGAMOX AT1 + ALCON PHARMS LTD EQ 0.5% BASE N 021598 001 Apr 15, 2003 May CTEC TABLET;ORAL MOXIFLOXACIN HYDROCHLORIDE AB MYLAN PHARMS INC EQ 400MG BASE A 204635 001 Aug 31, 2015 Aug NEWA

NADOLOL TABLET;ORAL NADOLOL AB ORION CORP ORION 40MG A 201893 001 Sep 16, 2015 Aug NEWA AB 80MG A 201893 002 Sep 16, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -60

NALBUPHINE HYDROCHLORIDE INJECTABLE;INJECTION NALBUPHINE HYDROCHLORIDE @ IGI LABS INC 10MG/ML A 072070 001 Apr 10, 1989 Mar CAHN @ 10MG/ML A 072071 001 Apr 10, 1989 Mar CAHN @ 10MG/ML A 072072 001 Apr 10, 1989 Mar CAHN @ 20MG/ML A 072073 001 Apr 10, 1989 Mar CAHN @ 20MG/ML A 072074 001 Apr 10, 1989 Mar CAHN @ 20MG/ML A 072075 001 Apr 10, 1989 Mar CAHN

NALMEFENE HYDROCHLORIDE INJECTABLE;INJECTION REVEX @ EUROHLTH INTL SARL EQ 0.1MG BASE/ML N 020459 001 Apr 17, 1995 Jun CAHN @ EQ 1MG BASE/ML N 020459 002 Apr 17, 1995 Jun CAHN

NALOXONE HYDROCHLORIDE INJECTABLE;INJECTION NALOXONE @ EUROHLTH INTL SARL 0.4MG/ML A 070299 001 Sep 24, 1986 Mar CAHN NALOXONE HYDROCHLORIDE @ IGI LABS INC 0.02MG/ML A 072082 001 Apr 11, 1989 Mar CAHN @ 0.02MG/ML A 072083 001 Apr 11, 1989 Mar CAHN @ 0.02MG/ML A 072084 001 Apr 11, 1989 Mar CAHN @ 0.02MG/ML A 072085 001 Apr 11, 1989 Mar CAHN @ 0.4MG/ML A 072086 001 Apr 11, 1989 Mar CAHN @ 0.4MG/ML A 072087 001 Apr 11, 1989 Mar CAHN @ 0.4MG/ML A 072088 001 Apr 11, 1989 Mar CAHN @ 0.4MG/ML A 072089 001 Apr 11, 1989 Mar CAHN @ 0.4MG/ML A 072090 001 Apr 11, 1989 Mar CAHN @ 1MG/ML A 072091 001 Apr 11, 1989 Mar CAHN @ 1MG/ML A 072092 001 Apr 11, 1989 Mar CAHN @ 1MG/ML A 072093 001 Apr 11, 1989 Mar CAHN NARCAN AD APT@ ADAPT@ 0.02MG/ML N 016636 002 Aug CAHN @ 0.4MG/ML N 016636 001 Aug CAHN @ 1MG/ML N 016636 003 Jun 14, 1982 Aug CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE TABLET;ORAL NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE AB SUN PHARM INDS LTD EQ 0.5MG BASE;EQ 50MG BASE A 075523 001 Mar 17, 2000 Apr CAHN

NAPROXEN SUSPENSION;ORAL NAPROSYN AB + PEDIAPHARM INC 25MG/ML N 018965 001 Mar 23, 1987 Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE TABLET;ORAL TREXIMET PERNIX IRELAND LTD 60MG;EQ 10MG BASE N 021926 002 May 14, 2015 Jun NEWA

NEBIVOLOL HYDROCHLORIDE TABLET;ORAL NEBIVOLOL HYDROCHLORIDE @ ALKEM LABS LTD EQ 2.5MG BASE A 203741 001 Jun 24, 2015 Jun DISC EQ 2.5MG BASE A 203741 001 Jun 24, 2015 Jun NEWA @ EQ 5MG BASE A 203741 002 Jun 24, 2015 Jun DISC EQ 5MG BASE A 203741 002 Jun 24, 2015 Jun NEWA @ EQ 10MG BASE A 203741 003 Jun 24, 2015 Jun DISC EQ 10MG BASE A 203741 003 Jun 24, 2015 Jun NEWA @ EQ 20MG BASE A 203741 004 Jun 24, 2015 Jun DISC EQ 20MG BASE A 203741 004 Jun 24, 2015 Jun NEWA @ AMERIGEN PHARMS LTD EQ 2.5MG BASE A 203659 001 Apr 16, 2015 Apr DISC AB EQ 2.5MG BASE A 203659 001 Apr 16, 2015 Mar NEWA @ EQ 5MG BASE A 203659 002 Apr 16, 2015 Apr DISC AB EQ 5MG BASE A 203659 002 Apr 16, 2015 Mar NEWA @ EQ 10MG BASE A 203659 003 Apr 16, 2015 Apr DISC AB EQ 10MG BASE A 203659 003 Apr 16, 2015 Mar NEWA @ EQ 20MG BASE A 203659 004 Apr 16, 2015 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -61

TABLET;ORAL NEBIVOLOL HYDROCHLORIDE AB EQ 20MG BASE A 203659 004 Apr 16, 2015 Mar NEWA @ INDCHEMIE HEALTH EQ 2.5MG BASE A 203828 001 Jul 29, 2015 Jul DISC EQ 2.5MG BASE A 203828 001 Jul 29, 2015 Jul NEWA @ EQ 5MG BASE A 203828 002 Jul 29, 2015 Jul DISC EQ 5MG BASE A 203828 002 Jul 29, 2015 Jul NEWA @ EQ 10MG BASE A 203828 003 Jul 29, 2015 Jul DISC EQ 10MG BASE A 203828 003 Jul 29, 2015 Jul NEWA @ EQ 20MG BASE A 203828 004 Jul 29, 2015 Jul DISC EQ 20MG BASE A 203828 004 Jul 29, 2015 Jul NEWA

NEFAZODONE HYDROCHLORIDE TABLET;ORAL NEFAZODONE HYDROCHLORIDE @ IDT AUSTRALIA LTD 50MG A 076072 001 Sep 16, 2003 Apr CAHN @ 100MG A 076072 002 Sep 16, 2003 Apr CAHN @ 150MG A 076072 003 Sep 16, 2003 Apr CAHN @ 200MG A 076072 004 Sep 16, 2003 Apr CAHN @ 250MG A 076072 005 Sep 16, 2003 Apr CAHN AB SUN PHARM INDS LTD 50MG A 076409 001 Sep 16, 2003 Apr CAHN AB 100MG A 076409 002 Sep 16, 2003 Apr CAHN AB 150MG A 076409 003 Sep 16, 2003 Apr CAHN AB 200MG A 076409 004 Sep 16, 2003 Apr CAHN AB 250MG A 076409 005 Sep 16, 2003 Apr CAHN

NELARABINE INJECTABLE;IV (INFUSION) ARRANON + NOVARTIS PHARMS CORP 250MG/50ML (5MG/ML) N 021877 001 Oct 28, 2005 Mar CAHN

NEOSTIGMINE METHYLSULFATE SOLUTION;INTRAVENOUS NEOSTIGMINE METHYLSULFATE FRESENIUS KABI USA 5MG/10ML (0.5MG/ML) N 203629 001 Jan 08, 2015 Jan NEWA 10MG/10ML (1MG/ML) N 203629 002 Jan 08, 2015 Jan NEWA

NEVIRAPINE TABLET, EXTENDED RELEASE;ORAL NEVIRAPINE AB ALVOGEN PINE BROOK 400MG A 204621 001 Jul 10, 2015 Jun NEWA

NIACIN TABLET, EXTENDED RELEASE;ORAL NIACIN AB AMNEAL PHARMS 500MG A 203578 001 Jul 24, 2015 Jul NEWA AB 1GM A 203578 002 Jul 24, 2015 Jul NEWA

NIFEDIPINE CAPSULE;ORAL NIFEDIPINE AB HERITAGE PHARMA 10MG A 202644 001 Apr 25, 2013 Mar CAHN AB 20MG A 202644 002 Apr 25, 2013 Mar CAHN TABLET, EXTENDED RELEASE;ORAL NIFEDIPINE AB2 VALEANT PHARMS NORTH 30MG A 075289 002 Feb 06, 2001 Aug CAHN AB2 60MG A 075289 001 Sep 27, 2000 Aug CAHN

NILUTAMIDE TABLET;ORAL NILANDRON @ CONCORDIA PHARMS INC 50MG N 020169 001 Sep 19, 1996 Apr CAHN + 150MG N 020169 002 Apr 30, 1999 Apr CAHN

NIMODIPINE CAPSULE;ORAL NIMODIPINE AB + BANNER LIFE SCIENCES 30MG A 076740 001 Jan 17, 2008 Jan CAHN AB SOFGEN PHARMS 30MG A 201832 001 Jul 24, 2015 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -62

NINTEDANIB ESYLATE CAPSULE;ORAL OFEV BOEHRINGER INGELHEIM EQ 100MG BASE N 205832 001 Oct 15, 2014 Mar CAIN + EQ 150MG BASE N 205832 002 Oct 15, 2014 Mar CAIN

NITRIC OXIDE GAS;INHALATION INOMAX @ INO 100PPM N 020845 002 Dec 23, 1999 Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL MACRODANTIN AB ALVOGEN INC 25MG N 016620 003 Jun CTEC NITROFURANTOIN AB ACTAVIS LABS FL INC 25MG A 091095 001 Jun 18, 2015 Jun NEWA AB 50MG A 091095 002 Jun 18, 2015 Jun NEWA AB 100MG A 091095 003 Jun 18, 2015 Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) AB WATSON LABS INC 75MG;25MG A 202250 001 Jul 08, 2015 Jun NEWA

NORETHINDRONE TABLET;ORAL-28 NOR-QD AB1 + ACTAVIS LABS UT INC 0.35MG N 017060 001 Mar CAHN

NORGESTREL TABLET;ORAL OVRETTE @ LABORATOIRE HRA 0.075MG N 017031 001 Jun CAHN

NYSTATIN CREAM;TOPICAL NYSTATIN AT G AND W LABS INC 100,000 UNITS/GM A 061966 001 Jun CMFD SUSPENSION;ORAL NYSTATIN AA G AND W LABS INC 100,000 UNITS/ML A 062349 001 Jul 14, 1982 Apr CAHN @ 100,000 UNITS/ML A 062776 001 Dec 17, 1987 Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE CREAM;TOPICAL MYKACET AT G AND W LABS INC 100,000 UNITS/GM;0.1% A 062367 001 May 28, 1985 Mar CMFD OINTMENT;TOPICAL MYKACET AT G AND W LABS INC 100,000 UNITS/GM;0.1% A 062733 001 Mar 09, 1987 Mar CMFD

OFLOXACIN TABLET;ORAL OFLOXACIN AB LARKEN LABS 400MG A 076093 003 Sep 02, 2003 Jul CMFD

OLANZAPINE TABLET;ORAL OLANZAPINE AB IVAX PHARMS INC 20MG A 077301 001 Apr 29, 2015 Apr NEWA TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE AB MACLEODS PHARMS LTD 5MG A 203044 001 Feb 20, 2015 Feb NEWA AB 10MG A 203044 002 Feb 20, 2015 Feb NEWA AB 15MG A 203044 003 Feb 20, 2015 Feb NEWA AB 20MG A 203044 004 Feb 20, 2015 Feb NEWA AB ORCHID HLTHCARE 5MG A 202937 001 Mar 02, 2015 Feb NEWA AB 10MG A 202937 002 Mar 02, 2015 Feb NEWA AB 15MG A 202937 003 Mar 02, 2015 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -63

TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE AB 20MG A 202937 004 Mar 02, 2015 Feb NEWA

OLAPARIB CAPSULE;ORAL LYNPARZA ASTRAZENECA PHARMS 50MG N 206162 001 Dec 19, 2014 Jan CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE SPRAY, METERED;INHALATION STIOLTO RESPIMAT + BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH;EQ 0.0025MG N 206756 001 May 21, 2015 May NEWA BASE/INH

OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE AT BARR LABS INC EQ 0.2% BASE A 090848 001 Jul 13, 2015 Jun NEWA PATADAY AT + ALCON PHARMS LTD EQ 0.2% BASE N 021545 001 Dec 22, 2004 Jun CFTG PAZEO + ALCON RES LTD EQ 0.7% BASE N 206276 001 Jan 30, 2015 Jan NEWA

OMBITASVIR; PARITAPREVIR; RITONAVIR TABLET;ORAL TECHNIVIE + ABBVIE INC 12.5MG;75MG;50MG N 207931 001 Jul 24, 2015 Aug CMS1 + 12.5MG;75MG;50MG N 207931 001 Jul 25, 2015 Jul NEWA

OMEPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL OMEPRAZOLE AB AUROBINDO PHARMA USA 10MG A 203270 001 Aug 19, 2015 Aug NEWA AB 20MG A 203270 002 Aug 19, 2015 Aug NEWA AB 40MG A 203270 003 Aug 19, 2015 Aug NEWA AB LUPIN LTD 40MG A 202384 001 Aug 25, 2015 Aug NEWA

ONDANSETRON TABLET, ORALLY DISINTEGRATING;ORAL ONDANSETRON AB SUN PHARM INDS LTD 4MG A 078602 001 Feb 24, 2011 Apr CAHN AB 8MG A 078602 002 Feb 24, 2011 Apr CAHN ZOFRAN ODT AB NOVARTIS PHARMS CORP 4MG N 020781 001 Jan 27, 1999 Mar CAHN AB + 8MG N 020781 002 Jan 27, 1999 Mar CAHN

ONDANSETRON HYDROCHLORIDE INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE AP ACCORD HLTHCARE EQ 2MG BASE/ML A 206846 001 Jul 13, 2015 Jun NEWA AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A 078288 001 Feb 22, 2013 Apr CAHN AP EUROHLTH INTL SARL EQ 2MG BASE/ML A 077365 001 Dec 26, 2006 Jun CAHN ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A 078287 001 Feb 22, 2013 Apr CAHN AP EUROHLTH INTL SARL EQ 2MG BASE/ML A 077541 001 Dec 26, 2006 Jun CAHN @ TARO PHARMS IRELAND EQ 2MG BASE/ML A 078014 001 Mar 21, 2008 Jan DISC ZOFRAN AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N 020007 001 Jan 04, 1991 Mar CAHN ZOFRAN PRESERVATIVE FREE AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N 020007 003 Dec 10, 1993 Mar CAHN SOLUTION;ORAL ZOFRAN AA + NOVARTIS PHARMS CORP EQ 4MG BASE/5ML N 020605 001 Jan 24, 1997 Mar CAHN TABLET;ORAL ZOFRAN AB NOVARTIS PHARMS CORP EQ 4MG BASE N 020103 001 Dec 31, 1992 Mar CAHN AB EQ 8MG BASE N 020103 002 Dec 31, 1992 Mar CAHN AB + EQ 24MG BASE N 020103 003 Aug 27, 1999 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -64

ORPHENADRINE CITRATE INJECTABLE;INJECTION NORFLEX @ IGI LABS INC 30MG/ML N 013055 001 Apr CAHN @ MEDICIS 30MG/ML N 013055 001 Mar DISC ORPHENADRINE CITRATE AP + AKORN 30MG/ML A 040484 001 May 24, 2006 Mar CRLD

OXACILLIN SODIUM CAPSULE;ORAL OXACILLIN SODIUM @ ANI PHARMS INC EQ 250MG BASE A 062222 001 Aug CAHN @ EQ 500MG BASE A 062222 002 Aug CAHN

OXANDROLONE TABLET;ORAL OXANDRIN AB GEMINI LABS LLC 2.5MG N 013718 001 Aug CAHN AB + 10MG N 013718 002 Nov 05, 2001 Aug CAHN

OXCARBAZEPINE SUSPENSION;ORAL OXCARBAZEPINE AB SUN PHARM INDS LTD 300MG/5ML A 078734 001 Jun 26, 2009 Apr CAHN

OXYBUTYNIN FILM, EXTENDED RELEASE;TRANSDERMAL OXYTROL AB + ACTAVIS LABS UT INC 3.9MG/24HR N 021351 002 Feb 26, 2003 Mar CAHN GEL, METERED;TRANSDERMAL GELNIQUE 3% + ACTAVIS LABS UT INC 3% N 202513 001 Dec 07, 2011 Mar CAHN

OXYBUTYNIN CHLORIDE GEL;TRANSDERMAL GELNIQUE + ACTAVIS LABS UT INC 10%(100MG/PACKET) N 022204 001 Jan 27, 2009 Mar CAHN

OXYCODONE HYDROCHLORIDE CAPSULE;ORAL OXYCODONE HYDROCHLORIDE AB AVANTHI INC 5MG A 202773 001 Aug 17, 2015 Aug NEWA AB NOVEL LABS INC 5MG A 204752 001 Aug 24, 2015 Aug NEWA SOLUTION;ORAL OXYCODONE HYDROCHLORIDE AA ANI PHARMS INC 5MG/5ML A 204979 001 Jun 01, 2015 May NEWA AA NOVEL LABS INC 100MG/5ML A 204603 001 Apr 29, 2015 Apr NEWA AA WOCKHARDT BIO AG 5MG/5ML A 206456 001 Jun 16, 2015 Jun NEWA TABLET;ORAL OXAYDO ACURA PHARMS INC 5MG N 202080 001 Jun 17, 2011 Mar CTNA 7.5MG N 202080 002 Jun 17, 2011 Mar CTNA EGALET LTD 5MG N 202080 001 Jun 17, 2011 May CAHN 7.5MG N 202080 002 Jun 17, 2011 May CAHN EGALET US INC 5MG N 202080 001 Jun 17, 2011 Jul CAHN 7.5MG N 202080 002 Jun 17, 2011 Jul CAHN OXYCODONE HYDROCHLORIDE AB ACTAVIS ELIZABETH 5MG A 076636 003 Apr 07, 2015 Mar NEWA >A> AB EPIC PHARMA LLC 5MG A 202662 001 Sep 22, 2015 Sep NEWA >A> AB 10MG A 202662 002 Sep 22, 2015 Sep NEWA >A> AB 15MG A 202662 003 Sep 22, 2015 Sep NEWA >A> AB 30MG A 202662 004 Sep 22, 2015 Sep NEWA AB VINTAGE PHARMS 10MG A 077712 004 Apr 13, 2015 Mar NEWA AB 20MG A 077712 005 Apr 13, 2015 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -65

OXYMORPHONE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL OXYMORPHONE HYDROCHLORIDE AB SUN PHARM INDS LTD 5MG A 203506 001 Apr 24, 2015 Apr NEWA AB 7.5MG A 203506 002 Apr 24, 2015 Apr NEWA AB 10MG A 203506 003 Apr 24, 2015 Apr NEWA AB 15MG A 203506 004 Apr 24, 2015 Apr NEWA AB 20MG A 203506 005 Apr 24, 2015 Apr NEWA AB 30MG A 203506 006 Apr 24, 2015 Apr NEWA AB 40MG A 203506 007 Apr 24, 2015 Apr NEWA

OXYTOCIN INJECTABLE;INJECTION OXYTOCIN AP + EUROHLTH INTL SARL 10USP UNITS/ML (10USP UNITS/ML) N 018243 001 Feb CAHN AP + 100USP UNITS/10ML (10USP UNITS/ML) N 018243 002 Jan 10, 2007 Feb CAHN

PALBOCICLIB CAPSULE;ORAL IBRANCE PFIZER INC 75MG N 207103 001 Feb 03, 2015 Feb NEWA 100MG N 207103 002 Feb 03, 2015 Feb NEWA + 125MG N 207103 003 Feb 03, 2015 Feb NEWA

PALIPERIDONE TABLET, EXTENDED RELEASE;ORAL INVEGA AB JANSSEN PHARMS 1.5MG N 021999 006 Aug 26, 2008 Jul CFTG AB 3MG N 021999 001 Dec 19, 2006 Jul CFTG AB + 6MG N 021999 002 Dec 19, 2006 Jul CFTG AB 9MG N 021999 003 Dec 19, 2006 Jul CFTG PALIPERIDONE AB ACTAVIS LABS FL INC 1.5MG A 202645 001 Aug 03, 2015 Jul NEWA AB 3MG A 202645 002 Aug 03, 2015 Jul NEWA AB 6MG A 202645 003 Aug 03, 2015 Jul NEWA AB 9MG A 202645 004 Aug 03, 2015 Jul NEWA >A> AB MYLAN PHARMS INC 1.5MG A 203802 001 Sep 24, 2015 Sep NEWA >A> AB 3MG A 203802 002 Sep 24, 2015 Sep NEWA >A> AB 6MG A 203802 003 Sep 24, 2015 Sep NEWA >A> AB 9MG A 203802 004 Sep 24, 2015 Sep NEWA

PALIPERIDONE PALMITATE SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR INVEGA TRINZA JANSSEN PHARMS 273MG/0.875ML (273MG/0.875ML) N 207946 001 May 18, 2015 May NEWA 410MG/1.315ML (311.79MG/ML) N 207946 002 May 18, 2015 May NEWA 546MG/1.75ML (312MG/ML) N 207946 003 May 18, 2015 May NEWA + 819MG/2.625ML (312MG/ML) N 207946 004 May 18, 2015 May NEWA

PALONOSETRON HYDROCHLORIDE INJECTABLE;INTRAVENOUS ALOXI >D> + HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG N 021372 002 Feb 29, 2008 Sep CFTG BASE/ML) >A> AP + EQ 0.075MG BASE/1.5ML (EQ 0.05MG N 021372 002 Feb 29, 2008 Sep CFTG BASE/ML) >D> + EQ 0.25MG BASE/5ML (EQ 0.05MG N 021372 001 Jul 25, 2003 Sep CFTG BASE/ML) >A> AP + EQ 0.25MG BASE/5ML (EQ 0.05MG N 021372 001 Jul 25, 2003 Sep CFTG BASE/ML) >A> PALONOSETRON HYDROCHLORIDE >A> AP SANDOZ INC EQ 0.25MG BASE/5ML (EQ 0.05MG A 202521 001 Oct 13, 2015 Sep NEWA BASE/ML) >A> AP TEVA PHARMS USA EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 090713 002 Oct 13, 2015 Sep NEWA BASE/ML) >A> AP EQ 0.25MG BASE/5ML (EQ 0.05MG A 090713 001 Oct 13, 2015 Sep NEWA BASE/ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -66

PANCURONIUM BROMIDE INJECTABLE;INJECTION PANCURONIUM BROMIDE @ IGI LABS INC 1MG/ML A 072210 001 Mar 31, 1988 Mar CAHN @ 2MG/ML A 072211 001 Mar 31, 1988 Mar CAHN @ 2MG/ML A 072212 001 Mar 31, 1988 Mar CAHN @ 2MG/ML A 072213 001 Mar 31, 1988 Mar CAHN

PANOBINOSTAT CAPSULE;ORAL FARYDAK NOVARTIS PHARMS CORP 10MG N 205353 001 Feb 23, 2015 Feb NEWA 15MG N 205353 002 Feb 23, 2015 Feb NEWA + 20MG N 205353 003 Feb 23, 2015 Feb NEWA

PANOBINOSTAT LACTATE CAPSULE;ORAL FARYDAK NOVARTIS PHARMS CORP EQ 10MG BASE N 205353 001 Feb 23, 2015 Mar CAIN EQ 10MG BASE N 205353 001 Feb 23, 2015 Mar CPOT EQ 15MG BASE N 205353 002 Feb 23, 2015 Mar CAIN EQ 15MG BASE N 205353 002 Feb 23, 2015 Mar CPOT + EQ 20MG BASE N 205353 003 Feb 23, 2015 Mar CAIN + EQ 20MG BASE N 205353 003 Feb 23, 2015 Mar CPOT

PANTOPRAZOLE SODIUM INJECTABLE;IV (INFUSION) PANTOPRAZOLE SODIUM AP SANDOZ INC EQ 40MG BASE/VIAL A 090296 001 Jul 14, 2015 Jun NEWA TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM AB KREMERS URBAN PHARMS EQ 20MG BASE A 078281 001 Jan 20, 2011 Mar CAHN AB EQ 40MG BASE A 078281 002 Jan 20, 2011 Mar CAHN AB SUN PHARM INDS LTD EQ 20MG BASE A 200794 001 May 02, 2012 Apr CAHN AB EQ 40MG BASE A 200794 002 May 02, 2012 Apr CAHN

PARICALCITOL CAPSULE;ORAL PARICALCITOL AB BANNER LIFE SCIENCES 1MCG A 202539 001 Mar 27, 2014 Jan CAHN AB 2MCG A 202539 002 Mar 27, 2014 Jan CAHN AB 4MCG A 202539 003 Mar 27, 2014 Jan CAHN

PAZOPANIB HYDROCHLORIDE TABLET;ORAL VOTRIENT + NOVARTIS PHARMS CORP EQ 200MG BASE N 022465 001 Oct 19, 2009 Mar CAHN @ EQ 400MG BASE N 022465 002 Oct 19, 2009 Aug DISC EQ 400MG BASE N 022465 002 Oct 19, 2009 Mar CAHN

PENTOXIFYLLINE TABLET, EXTENDED RELEASE;ORAL PENTOXIFYLLINE AB VALEANT PHARMS 400MG A 075028 001 Jul 20, 1998 Feb CAHN

PHENDIMETRAZINE TARTRATE CAPSULE, EXTENDED RELEASE;ORAL BONTRIL @ VALEANT 105MG A 088021 001 Sep 21, 1982 Jan DISC PHENDIMETRAZINE TARTRATE + SANDOZ 105MG N 018074 001 Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE CAPSULE;ORAL DIBENZYLINE AB + CONCORDIA PHARMS INC 10MG N 008708 001 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -67

PHENTERMINE HYDROCHLORIDE CAPSULE;ORAL PHENTERMINE HYDROCHLORIDE AA MIKAH PHARMA LLC 37.5MG A 040228 001 Jun 19, 1997 Jun CMFD

PHENYLEPHRINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC PHENYLEPHRINE HYDROCHLORIDE >D> AKORN INC 2.5% N 207926 001 Jan 15, 2015 Sep CRLD >A> + 2.5% N 207926 001 Jan 15, 2015 Sep CRLD 2.5% N 207926 001 Jan 15, 2015 Jan NEWA >D> 10% N 207926 002 Jan 15, 2015 Sep CRLD >A> + 10% N 207926 002 Jan 15, 2015 Sep CRLD 10% N 207926 002 Jan 15, 2015 Jan NEWA >D> PARAGON BIOTECK 2.5% N 203510 001 Mar 21, 2013 Sep CRLD >A> + 2.5% N 203510 001 Mar 21, 2013 Sep CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETH VC PLAIN AA + G AND W LABS INC 5MG/5ML;6.25MG/5ML A 088761 001 Nov 08, 1984 Jul CAHN

PHENYTOIN SODIUM CAPSULE;ORAL EXTENDED PHENYTOIN SODIUM @ WOCKHARDT 30MG EXTENDED A 040759 001 Dec 18, 2007 Jun DISC @ WOCKHARDT USA 100MG EXTENDED A 040732 001 Jan 30, 2008 Jun DISC PHENYTOIN SODIUM AB AUROBINDO PHARMA LTD 100MG EXTENDED A 204309 001 Jun 10, 2015 May NEWA INJECTABLE;INJECTION PHENYTOIN SODIUM AP + EUROHLTH INTL SARL 50MG/ML A 084307 001 Feb CAHN

PHYTONADIONE INJECTABLE;INJECTION AQUAMEPHYTON @ IGI LABS INC 1MG/0.5ML N 012223 002 Apr CAHN @ 10MG/ML N 012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE GEL;OPHTHALMIC PILOPINE HS @ ALCON 4% N 018796 001 Oct 01, 1984 Aug DISC TABLET;ORAL PILOCARPINE HYDROCHLORIDE AB ELAN PHARMA INTL LTD 5MG A 076746 001 Nov 16, 2004 Mar CAHN

PIMOZIDE TABLET;ORAL ORAP >D> TEVA 1MG N 017473 003 Aug 27, 1997 Sep CFTG >A> AB 1MG N 017473 003 Aug 27, 1997 Sep CFTG >D> + 2MG N 017473 001 Jul 31, 1984 Sep CFTG >A> AB + 2MG N 017473 001 Jul 31, 1984 Sep CFTG >A> PIMOZIDE >A> AB PAR PHARM 1MG A 204521 001 Sep 28, 2015 Sep NEWA >A> AB 2MG A 204521 002 Sep 28, 2015 Sep NEWA

PINDOLOL TABLET;ORAL PINDOLOL @ G AND W LABS INC 5MG A 073661 001 Oct 31, 1993 Apr CAHN @ 5MG A 073687 001 Feb 26, 1993 Apr CAHN @ 5MG A 074123 001 Apr 17, 1997 Apr CAHN @ 10MG A 073661 002 Oct 31, 1993 Apr CAHN @ 10MG A 073687 002 Feb 26, 1993 Apr CAHN @ 10MG A 074123 002 Apr 17, 1997 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -68

PIRBUTEROL ACETATE AEROSOL, METERED;INHALATION MAXAIR @ MEDICIS EQ 0.2MG BASE/INH N 020014 001 Nov 30, 1992 Jan DISC

PIRFENIDONE CAPSULE;ORAL ESBRIET + GENENTECH INC 267MG N 022535 001 Oct 15, 2014 Feb CAHN

PIROXICAM CAPSULE;ORAL PIROXICAM AB MYLAN PHARMS INC 10MG A 074116 001 Jun 15, 1993 May CAHN AB 20MG A 074118 001 Jun 15, 1993 May CAHN

PODOFILOX GEL;TOPICAL CONDYLOX + ACTAVIS LABS UT INC 0.5% N 020529 001 Mar 13, 1997 Feb CAHN SOLUTION;TOPICAL CONDYLOX AT + ACTAVIS LABS UT INC 0.5% N 019795 001 Dec 13, 1990 Jan CAHN PODOFILOX AT BAUSCH AND LOMB INC 0.5% A 090184 001 Jul 21, 2010 May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE SOLUTION/DROPS;OPHTHALMIC TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE AT ALCON RES LTD 10,000 UNITS/ML;EQ 1MG BASE/ML A 064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE TABLET;ORAL ICLUSIG ARIAD EQ 30MG BASE N 203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL KLOR-CON AB UPSHER SMITH 8MEQ A 203106 001 Jul 10, 2015 Jun NEWA AB 10MEQ A 203106 002 Jul 10, 2015 Jun NEWA FOR SOLUTION;ORAL POTASSIUM CHLORIDE PHARMA RES SOFTWARE 20MEQ N 208019 001 Aug 19, 2015 Aug NEWA TABLET, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE AB1 ADARE PHARMS INC 20MEQ A 076368 001 Aug 18, 2004 Jul CAHN AB2 MYLAN PHARMS INC 8MEQ A 204662 001 Aug 21, 2014 Feb CPOT AB2 10MEQ A 204662 002 Aug 21, 2014 Feb CPOT

PRAMIPEXOLE DIHYDROCHLORIDE TABLET;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB GLENMARK GENERICS 0.75MG A 090781 006 Sep 11, 2015 Aug NEWA TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB DR REDDYS LABS LTD 0.375MG A 203354 001 Aug 07, 2015 Jul NEWA AB 0.75MG A 203354 002 Aug 07, 2015 Jul NEWA AB 1.5MG A 203354 003 Aug 07, 2015 Jul NEWA AB 3MG A 203354 004 Aug 07, 2015 Jul NEWA AB 4.5MG A 203354 005 Aug 07, 2015 Jul NEWA

PREDNICARBATE OINTMENT;TOPICAL DERMATOP AB + VALEANT PHARMS NORTH 0.1% N 019568 001 Sep 23, 1991 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -69

PREDNISONE TABLET;ORAL PREDNISONE @ HIKMA PHARMS 1MG A 040890 001 Nov 01, 2010 Aug DISC

PREGABALIN CAPSULE;ORAL LYRICA PF PRISM CV 25MG N 021446 001 Dec 30, 2004 Apr CTEC 50MG N 021446 002 Dec 30, 2004 Apr CTEC 75MG N 021446 003 Dec 30, 2004 Apr CTEC 100MG N 021446 004 Dec 30, 2004 Apr CTEC 150MG N 021446 005 Dec 30, 2004 Apr CTEC 200MG N 021446 006 Dec 30, 2004 Apr CTEC 225MG N 021446 007 Dec 30, 2004 Apr CTEC + 300MG N 021446 008 Dec 30, 2004 Apr CTEC

PROCAINAMIDE HYDROCHLORIDE CAPSULE;ORAL PROCAINAMIDE HYDROCHLORIDE @ IDT AUSTRALIA LTD 250MG A 089219 001 Jul 01, 1986 Jun CAHN @ 500MG A 089221 001 Jul 01, 1986 Jun CAHN TABLET, EXTENDED RELEASE;ORAL PROCAINAMIDE HYDROCHLORIDE @ IDT AUSTRALIA LTD 250MG A 089369 001 Aug 14, 1987 Jun CAHN @ 500MG A 089370 001 Jan 09, 1987 Jun CAHN @ 750MG A 089371 001 Aug 14, 1987 Jun CAHN

PROCHLORPERAZINE EDISYLATE INJECTABLE;INJECTION PROCHLORPERAZINE EDISYLATE AP + EUROHLTH INTL SARL EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Feb CAHN

PROGESTERONE CAPSULE;ORAL PROGESTERONE AB BANNER LIFE SCIENCES 100MG A 200900 001 Aug 16, 2013 Jan CAHN AB 200MG A 200900 002 Aug 16, 2013 Jan CAHN GEL;VAGINAL CRINONE ACTAVIS LABS UT INC 4% N 020701 001 Jul 31, 1997 Feb CAHN + 8% N 020701 002 Jul 31, 1997 Feb CAHN INJECTABLE;INJECTION PROGESTERONE AO + ACTAVIS LABS UT INC 50MG/ML N 017362 002 Mar CAHN

PROMETHAZINE HYDROCHLORIDE INJECTABLE;INJECTION PROMETHAZINE HYDROCHLORIDE AP + EUROHLTH INTL SARL 25MG/ML A 083312 001 Jun CAHN AP + 50MG/ML A 083312 002 Jun CAHN SUPPOSITORY;RECTAL PHENERGAN @ DELCOR ASSET CORP 12.5MG N 010926 002 Apr CAHN @ 25MG N 010926 001 Apr CAHN TABLET;ORAL PROMETHAZINE HYDROCHLORIDE AB HERITAGE PHARMA 12.5MG A 040673 001 Mar 05, 2008 Mar CAHN AB 25MG A 040673 002 Mar 05, 2008 Mar CAHN AB 50MG A 040673 003 Mar 05, 2008 Mar CAHN

PROPAFENONE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL PROPAFENONE HYDROCHLORIDE AB WATSON LABS INC 225MG A 202688 001 Aug 24, 2015 Aug NEWA AB 325MG A 202688 002 Aug 24, 2015 Aug NEWA AB 425MG A 202688 003 Aug 24, 2015 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -70

PYRIDOSTIGMINE BROMIDE TABLET;ORAL PYRIDOSTIGMINE BROMIDE @ ANI PHARMS INC 30MG A 040512 002 Jul 20, 2005 Aug CAHN @ 60MG A 040512 001 Oct 08, 2003 Aug CAHN AB ZYDUS PHARMS USA INC 60MG A 205650 001 Jun 22, 2015 Jun NEWA TABLET, EXTENDED RELEASE;ORAL MESTINON AB + VALEANT PHARMS LLC 180MG N 011665 001 Jun CFTG PYRIDOSTIGMINE BROMIDE AB ALVOGEN INC 180MG A 204737 001 Jun 26, 2015 Jun NEWA AB IMPAX LABS INC 180MG A 203184 001 Sep 15, 2015 Aug NEWA

PYRIMETHAMINE TABLET;ORAL DARAPRIM + TURING PHARMS AG 25MG N 008578 001 Aug CAHN

QUAZEPAM TABLET;ORAL DORAL @ SCIECURE PHARMA INC 15MG N 018708 001 Dec 27, 1985 Jun DISC

QUETIAPINE FUMARATE TABLET;ORAL SEROQUEL AB + ASTRAZENECA PHARMS EQ 25MG BASE N 020639 001 Sep 26, 1997 May CAHN AB EQ 50MG BASE N 020639 007 Oct 04, 2005 May CAHN AB EQ 100MG BASE N 020639 002 Sep 26, 1997 May CAHN @ EQ 150MG BASE N 020639 004 Dec 20, 1998 May CAHN AB EQ 200MG BASE N 020639 003 Sep 26, 1997 May CAHN AB + EQ 300MG BASE N 020639 005 Jul 26, 2000 May CAHN AB EQ 400MG BASE N 020639 006 Oct 04, 2005 May CAHN

QUINAPRIL HYDROCHLORIDE TABLET;ORAL QUINAPRIL HYDROCHLORIDE AB SUN PHARM INDS LTD EQ 5MG BASE A 076607 001 Dec 15, 2004 Apr CAHN AB EQ 10MG BASE A 076607 002 Dec 15, 2004 Apr CAHN AB EQ 20MG BASE A 076607 003 Dec 15, 2004 Apr CAHN AB EQ 40MG BASE A 076607 004 Dec 15, 2004 Apr CAHN

QUINIDINE GLUCONATE TABLET, EXTENDED RELEASE;ORAL QUINIDINE GLUCONATE @ CYCLE PHARMS LTD 324MG A 088431 001 Jan 06, 1984 Jun CAHN

QUINIDINE SULFATE TABLET;ORAL QUINIDINE SULFATE @ CYCLE PHARMS LTD 200MG A 083640 001 Jun CAHN @ 300MG A 085632 001 Jun CAHN TABLET, EXTENDED RELEASE;ORAL QUINIDINE SULFATE + G AND W LABS INC 300MG A 040045 001 Jun 30, 1994 Apr CAHN

QUININE SULFATE CAPSULE;ORAL QUININE SULFATE AB AMNEAL PHARMS 324MG A 203729 001 Jul 15, 2015 Jun NEWA AB LUPIN LTD 324MG A 203112 001 Apr 24, 2015 Apr NEWA AB RICONPHARMA LLC 324MG A 204372 001 Jul 22, 2015 Jul NEWA

RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL RABEPRAZOLE SODIUM AB AMNEAL PHARMS 20MG A 204179 001 Jul 31, 2015 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -71

RALOXIFENE HYDROCHLORIDE TABLET;ORAL RALOXIFENE HYDROCHLORIDE AB AUROBINDO PHARMA LTD 60MG A 204310 001 Aug 28, 2015 Aug NEWA AB WATSON LABS INC 60MG A 200825 001 Jan 21, 2015 Jan NEWA

RAMELTEON TABLET;ORAL RAMELTEON AB ACTAVIS LABS FL INC 8MG A 091610 001 Aug 19, 2015 Aug NEWA

RANITIDINE HYDROCHLORIDE INJECTABLE;INJECTION ZANTAC AP + CONCORDIA PHARMS INC EQ 25MG BASE/ML N 019090 001 Oct 19, 1984 Jun CAHN TABLET;ORAL RANITIDINE HYDROCHLORIDE @ SUN PHARM INDS LTD EQ 150MG BASE A 075439 001 Apr 19, 2000 Apr CAHN @ EQ 300MG BASE A 075439 002 Apr 19, 2000 Apr CAHN

REPAGLINIDE TABLET;ORAL REPAGLINIDE AB STANDARD CHEM PHARM 0.5MG A 091517 001 Apr 24, 2015 Apr NEWA AB 1MG A 091517 002 Apr 24, 2015 Apr NEWA AB 2MG A 091517 003 Apr 24, 2015 Apr NEWA

RIBAVIRIN CAPSULE;ORAL REBETOL @ MERCK SHARP DOHME 200MG N 020903 001 Jun 03, 1998 Jun DISC

RISEDRONATE SODIUM TABLET, DELAYED RELEASE;ORAL ATELVIA AB + WARNER CHILCOTT LLC 35MG N 022560 001 Oct 08, 2010 May CFTG RISEDRONATE SODIUM AB TEVA PHARMS USA 35MG A 203217 001 May 18, 2015 May NEWA

RISPERIDONE TABLET, ORALLY DISINTEGRATING;ORAL RISPERIDONE AB SUN PHARM INDS LTD 0.5MG A 077542 001 Aug 06, 2010 Apr CAHN AB 1MG A 077542 002 Aug 06, 2010 Apr CAHN AB 2MG A 077542 003 Aug 06, 2010 Apr CAHN AB 3MG A 078474 001 Aug 06, 2010 Apr CAHN AB 4MG A 078474 002 Aug 06, 2010 Apr CAHN

RIVAROXABAN TABLET;ORAL XARELTO JANSSEN PHARMS 10MG N 022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE FILM, EXTENDED RELEASE;TRANSDERMAL EXELON AB NOVARTIS 4.6MG/24HR N 022083 001 Jul 06, 2007 Aug CFTG AB + 9.5MG/24HR N 022083 002 Jul 06, 2007 Aug CFTG AB 13.3MG/24HR N 022083 005 Aug 31, 2012 Aug CFTG RIVASTIGMINE AB ALVOGEN INC 4.6MG/24HR A 204403 001 Sep 03, 2015 Aug NEWA AB 9.5MG/24HR A 204403 002 Sep 03, 2015 Aug NEWA AB 13.3MG/24HR A 204403 003 Aug 31, 2015 Aug NEWA AB ALVOGEN PINE BROOK 4.6MG/24HR A 204403 001 Sep 03, 2015 Aug CAHN AB 9.5MG/24HR A 204403 002 Sep 03, 2015 Aug CAHN AB 13.3MG/24HR A 204403 003 Aug 31, 2015 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -72

RIVASTIGMINE TARTRATE CAPSULE;ORAL RIVASTIGMINE TARTRATE AB ORCHID HLTHCARE EQ 1.5MG BASE A 090879 001 Jun 10, 2015 May NEWA AB EQ 3MG BASE A 090879 002 Jun 10, 2015 May NEWA AB EQ 4.5MG BASE A 090879 003 Jun 10, 2015 May NEWA AB EQ 6MG BASE A 090879 004 Jun 10, 2015 May NEWA

ROCURONIUM BROMIDE INJECTABLE;INJECTION ROCURONIUM BROMIDE AP SAGENT PHARMS 50MG/5ML (10MG/ML) A 091458 001 Jul 28, 2010 Aug CAHN AP 100MG/10ML (10MG/ML) A 091458 002 Jul 28, 2010 Aug CAHN

ROFLUMILAST TABLET;ORAL DALIRESP + ASTRAZENECA PHARMS 500MCG N 022522 001 Feb 28, 2011 Mar CAHN

>A> ROLAPITANT HYDROCHLORIDE >A> TABLET;ORAL >A> VARUBI >A> + TESARO INC EQ 90MG BASE N 206500 001 Sep 01, 2015 Sep NEWA

ROPINIROLE HYDROCHLORIDE TABLET;ORAL ROPINIROLE HYDROCHLORIDE AB G AND W LABS INC EQ 0.25MG BASE A 077460 001 May 05, 2008 Apr CAHN AB EQ 0.5MG BASE A 077460 002 May 05, 2008 Apr CAHN AB EQ 1MG BASE A 077460 003 May 05, 2008 Apr CAHN AB EQ 2MG BASE A 077460 004 May 05, 2008 Apr CAHN AB EQ 3MG BASE A 077460 005 May 05, 2008 Apr CAHN AB EQ 4MG BASE A 077460 006 May 05, 2008 Apr CAHN AB EQ 5MG BASE A 077460 007 May 19, 2008 Apr CAHN

SACUBITRIL; VALSARTAN TABLET;ORAL ENTRESTO NOVARTIS PHARMS CORP 24MG;26MG N 207620 001 Jul 07, 2015 Jul NEWA 49MG;51MG N 207620 002 Jul 07, 2015 Jul NEWA + 97MG;103MG N 207620 003 Jul 07, 2015 Jul NEWA

SCOPOLAMINE FILM, EXTENDED RELEASE;TRANSDERMAL SCOPOLAMINE AB PERRIGO PHARMS CO 1MG/72HR A 078830 001 Jan 30, 2015 Mar CAHN AB PERRIGO R AND D 1MG/72HR A 078830 001 Jan 30, 2015 Jan NEWA TRANSDERM SCOP AB + NOVARTIS 1MG/72HR N 017874 001 Jan CFTG

SELEGILINE HYDROCHLORIDE TABLET;ORAL SELEGILINE HYDROCHLORIDE @ G AND W LABS INC 5MG A 074537 001 Aug 02, 1996 Apr CAHN @ 5MG A 074744 001 Jan 27, 1997 Apr CAHN @ 5MG A 074756 001 Nov 25, 1998 Apr CAHN

SERTRALINE HYDROCHLORIDE TABLET;ORAL SERTRALINE HYDROCHLORIDE @ HIKMA PHARMS EQ 25MG BASE A 077864 001 Aug 10, 2009 May DISC @ EQ 50MG BASE A 077864 002 Aug 10, 2009 May DISC @ EQ 100MG BASE A 077864 003 Aug 10, 2009 May DISC AB SUN PHARM INDS LTD EQ 25MG BASE A 077977 001 Feb 06, 2007 Apr CAHN AB EQ 50MG BASE A 077977 002 Feb 06, 2007 Apr CAHN AB EQ 100MG BASE A 077977 003 Feb 06, 2007 Apr CAHN EQ 150MG BASE A 077977 004 Feb 06, 2007 Apr CAHN EQ 200MG BASE A 077977 005 Feb 06, 2007 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -73

SILDENAFIL CITRATE SOLUTION;INTRAVENOUS REVATIO AP + PFIZER EQ 10MG BASE/12.5ML (EQ 0.8MG N 022473 001 Nov 18, 2009 Mar CFTG BASE/ML) SILDENAFIL CITRATE AP AUROBINDO PHARMA LTD EQ 10MG BASE/12.5ML (EQ 0.8MG A 203988 001 Apr 01, 2015 Mar NEWA BASE/ML)

SILODOSIN CAPSULE;ORAL RAPAFLO + ACTAVIS LABS UT INC 4MG N 022206 001 Oct 08, 2008 Mar CAHN 8MG N 022206 002 Oct 08, 2008 Mar CAHN

SIMVASTATIN TABLET;ORAL SIMVASTATIN AB SUN PHARM INDS LTD 5MG A 076285 001 Dec 20, 2006 Apr CAHN AB 10MG A 076285 002 Dec 20, 2006 Apr CAHN AB 20MG A 076285 003 Dec 20, 2006 Apr CAHN AB 40MG A 076285 004 Dec 20, 2006 Apr CAHN AB 80MG A 076285 005 Jun 23, 2006 Apr CAHN

SODIUM CHLORIDE INJECTABLE;INJECTION SODIUM CHLORIDE 0.9% AP EUROHLTH INTL SARL 9MG/ML A 201850 001 Jan 20, 2012 Feb CAHN SODIUM CHLORIDE 0.9% EUROHLTH INTL SARL 9MG/ML A 201833 001 Sep 24, 2013 Feb CAHN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM 45MG/50ML (9MG/ML) N 021569 001 Jul 27, 2006 Feb CAHN 112.5MG/125ML (9MG/ML) N 021569 002 Jul 27, 2006 Feb CAHN + 405MG/50ML (9MG/ML) N 021569 001 Jul 27, 2006 Feb CPOT 1012.5MG/125ML (9MG/ML) N 021569 002 Jul 27, 2006 Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEX INJECTABLE;INJECTION SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE AB EUROHLTH INTL SARL 62.5MG/5ML A 078215 001 Mar 31, 2011 Jun CAHN

SODIUM FLUORIDE F-18 INJECTABLE;INTRAVENOUS SODIUM FLUORIDE F-18 >A> AP PETNAT SOLUTIONS IN 10-200mCi/ML A 203890 001 Sep 28, 2015 Sep NEWA AP CARDINAL HEALTH 414 10-200mCi/ML A 203780 001 Jul 30, 2015 Jul NEWA AP HOT SHOTS NM LLC 10-200mCi/ML A 204530 001 Jul 29, 2015 Jul NEWA AP IBA MOLECULAR N AM 10-200mCi/ML A 203592 001 Aug 18, 2015 Aug NEWA AP MIPS CRF 10-200mCi/ML A 204517 001 Jul 21, 2015 Jul NEWA AP PRECISION NUCLEAR 10-200mCi/ML A 204542 001 Feb 27, 2015 Feb NEWA AP SPECTRON MRC LLC 10-200mCi/ML A 203912 001 Apr 22, 2015 Apr NEWA AP UNIV UTAH CYCLOTRON 10-200mCi/ML A 204497 001 Apr 20, 2015 Apr NEWA

SODIUM IODIDE I-123 CAPSULE;ORAL SODIUM IODIDE I 123 AA + CARDINAL HEALTH 418 100uCi N 018671 001 May 27, 1982 Apr CAHN AA + 200uCi N 018671 002 May 27, 1982 Apr CAHN @ 400uCi N 018671 003 May 27, 1982 Apr CAHN

SODIUM LACTATE INJECTABLE;INJECTION >D> SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER >D> AP BAXTER HLTHCARE 1.87GM/100ML N 016692 001 Sep DISC >A> @ 1.87GM/100ML N 016692 001 Sep DISC SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER >D> AP B BRAUN 1.87GM/100ML N 020004 001 Apr 21, 1992 Sep CTEC >A> 1.87GM/100ML N 020004 001 Apr 21, 1992 Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -74

SODIUM POLYSTYRENE SULFONATE POWDER;ORAL, RECTAL KALEXATE KVK TECH 15GM/BOT A 040905 002 Apr 03, 2015 Mar NEWA KAYEXALATE AA + CONCORDIA PHARMS INC 453.6GM/BOT N 011287 001 Apr CAHN

SODIUM TETRADECYL SULFATE INJECTABLE;INJECTION SOTRADECOL + MYLAN INSTITUTIONAL 20MG/2ML (10MG/ML) A 040541 001 Nov 12, 2004 Jul CRLD

SOMATROPIN RECOMBINANT INJECTABLE;INJECTION NORDITROPIN FLEXPRO NOVO NORDISK INC 30MG/3ML N 021148 011 Jan 23, 2015 Jan NEWA NORDITROPIN NORDIFLEX @ NOVO NORDISK INC 30MG/3ML N 021148 007 Mar 10, 2009 Jul DISC 30MG/3ML N 021148 007 Mar 10, 2009 Mar CMFD @ 30MG/3ML N 021148 007 Mar 10, 2009 Jan DISC NUTROPIN @ GENENTECH 5MG/VIAL N 020168 001 Nov 17, 1993 Jun DISC @ 10MG/VIAL N 020168 002 Nov 17, 1993 Jun DISC BX + 10MG/VIAL N 020168 002 Nov 17, 1993 Mar CTEC NUTROPIN AQ @ GENENTECH 10MG/2ML (5MG/ML) N 020522 001 Dec 29, 1995 Jun DISC NUTROPIN AQ NUSPIN + GENENTECH 5MG/2ML (2.5MG/ML) N 020522 003 Jan 03, 2008 Jun CTNA + 10MG/2ML (5MG/ML) N 020522 005 Jan 03, 2008 Jun NEWA + 20MG/2ML (10MG/ML) N 020522 004 Jan 03, 2008 Jun CTNA NUTROPIN AQ PEN + GENENTECH 20MG/2ML (10MG/ML) N 020522 006 Jan 03, 2008 Jun NEWA ZOMACTON BX + FERRING 5MG/VIAL N 019774 002 Jan 04, 2002 Mar CTNA BX 10MG/VIAL N 019774 003 Mar 07, 2012 Apr CRLD BX + 10MG/VIAL N 019774 003 Mar 07, 2012 Mar NEWA

SONIDEGIB PHOSPHATE CAPSULE;ORAL ODOMZO + NOVARTIS PHARMS CORP EQ 200MG BASE N 205266 001 Jul 24, 2015 Jul NEWA

SOTALOL HYDROCHLORIDE SOLUTION;INTRAVENOUS SOTALOL HYDROCHLORIDE + ALTATHERA PHARMS LLC 150MG/10ML (15MG/ML) N 022306 001 Jul 02, 2009 Apr CAHN TABLET;ORAL BETAPACE AB1 COVIS PHARMA SARL 80MG N 019865 001 Oct 30, 1992 Mar CAHN AB1 120MG N 019865 005 Apr 20, 1994 Mar CAHN AB1 + 160MG N 019865 002 Oct 30, 1992 Mar CAHN AB1 240MG N 019865 003 Oct 30, 1992 Mar CAHN @ 320MG N 019865 004 Oct 30, 1992 Mar CAHN

STERILE WATER FOR INJECTION LIQUID;N/A STERILE WATER FOR INJECTION AP EUROHLTH INTL SARL 100% A 206369 001 Sep 02, 2015 Aug NEWA

SUCCINYLCHOLINE CHLORIDE INJECTABLE;INJECTION QUELICIN PRESERVATIVE FREE @ HOSPIRA 100MG/ML N 008845 004 Jun DISC

SUCRALFATE TABLET;ORAL SUCRALFATE AB MYLAN PHARMS INC 1GM A 074415 001 Jun 08, 1998 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -75

SUFENTANIL CITRATE INJECTABLE;INJECTION SUFENTANIL CITRATE AP EUROHLTH INTL SARL EQ 0.05MG BASE/ML A 074413 001 Dec 15, 1995 Jun CAHN

SULFACETAMIDE SODIUM LOTION;TOPICAL KLARON AB + VALEANT PHARMS NORTH 10% N 019931 001 Dec 23, 1996 Mar CAHN SOLUTION/DROPS;OPHTHALMIC SULFACETAMIDE SODIUM AT AKORN 10% A 040215 001 May 25, 1999 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM SUSPENSION;ORAL SULFAMETHOXAZOLE AND TRIMETHOPRIM @ ANI PHARMS INC 200MG/5ML;40MG/5ML A 070028 001 Jun 02, 1987 Jul CAHN

SULFANILAMIDE CREAM;VAGINAL SULFANILAMIDE @ G AND W LABS INC 15% A 088718 001 Sep 19, 1985 Apr CAHN

SULINDAC TABLET;ORAL SULINDAC @ ANI PHARMS INC 150MG A 072972 001 Feb 28, 1992 Aug CAHN @ 200MG A 072973 001 Feb 28, 1992 Aug CAHN

SUMATRIPTAN SUCCINATE TABLET;ORAL SUMATRIPTAN SUCCINATE >D> AB SANDOZ EQ 25MG BASE A 076976 001 Aug 10, 2009 Sep DISC >A> @ EQ 25MG BASE A 076976 001 Aug 10, 2009 Sep DISC >D> AB EQ 50MG BASE A 076976 002 Aug 10, 2009 Sep DISC >A> @ EQ 50MG BASE A 076976 002 Aug 10, 2009 Sep DISC >D> AB EQ 100MG BASE A 076976 003 Aug 10, 2009 Sep DISC >A> @ EQ 100MG BASE A 076976 003 Aug 10, 2009 Sep DISC AB SUN PHARM INDS LTD EQ 25MG BASE A 076554 001 Aug 10, 2009 Apr CAHN AB EQ 50MG BASE A 076554 002 Aug 10, 2009 Apr CAHN AB EQ 100MG BASE A 076572 001 Feb 09, 2009 Apr CAHN

TACROLIMUS TABLET, EXTENDED RELEASE;ORAL ENVARSUS XR VELOXIS PHARMS INC EQ 0.75MG BASE N 206406 001 Jul 10, 2015 Jul NEWA EQ 1MG BASE N 206406 002 Jul 10, 2015 Jul NEWA + EQ 4MG BASE N 206406 003 Jul 10, 2015 Jul NEWA

TAPENTADOL HYDROCHLORIDE SOLUTION;ORAL NUCYNTA + DEPOMED INC EQ 20MG BASE/ML N 203794 001 Oct 15, 2012 May CAHN TABLET;ORAL NUCYNTA DEPOMED INC EQ 50MG BASE N 022304 001 Nov 20, 2008 May CAHN EQ 75MG BASE N 022304 002 Nov 20, 2008 May CAHN + EQ 100MG BASE N 022304 003 Nov 20, 2008 May CAHN TABLET, EXTENDED RELEASE;ORAL NUCYNTA ER DEPOMED INC EQ 50MG BASE N 200533 001 Aug 25, 2011 May CAHN EQ 100MG BASE N 200533 002 Aug 25, 2011 May CAHN EQ 150MG BASE N 200533 003 Aug 25, 2011 May CAHN EQ 200MG BASE N 200533 004 Aug 25, 2011 May CAHN + EQ 250MG BASE N 200533 005 Aug 25, 2011 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -76

TEDIZOLID PHOSPHATE POWDER;IV (INFUSION) SIVEXTRO >D> + CUBIST PHARMS INC 200MG/VIAL N 205436 001 Jun 20, 2014 Sep CAHN >A> + CUBIST PHARMS LLC 200MG/VIAL N 205436 001 Jun 20, 2014 Sep CAHN TABLET;ORAL SIVEXTRO >D> + CUBIST PHARMS INC 200MG N 205435 001 Jun 20, 2014 Sep CAHN >A> + CUBIST PHARMS LLC 200MG N 205435 001 Jun 20, 2014 Sep CAHN

TELAPREVIR TABLET;ORAL INCIVEK @ VERTEX PHARMS 375MG N 201917 001 May 23, 2011 Jan DISC

TELMISARTAN TABLET;ORAL TELMISARTAN AB AMNEAL PHARMS 20MG A 204415 001 Sep 08, 2015 Aug NEWA AB 40MG A 204415 002 Sep 08, 2015 Aug NEWA AB 80MG A 204415 003 Sep 08, 2015 Aug NEWA AB AUROBINDO PHARMA LTD 20MG A 206511 001 Sep 03, 2015 Aug NEWA AB 40MG A 206511 002 Sep 03, 2015 Aug NEWA AB 80MG A 206511 003 Sep 03, 2015 Aug NEWA

TEMAZEPAM CAPSULE;ORAL TEMAZEPAM AB VINTAGE PHARMS 7.5MG A 201781 001 Jun 04, 2015 May NEWA AB 15MG A 201781 002 Jun 04, 2015 May NEWA AB 22.5MG A 201781 003 Jun 04, 2015 May NEWA AB 30MG A 201781 004 Jun 04, 2015 May NEWA

TEMOZOLOMIDE CAPSULE;ORAL TEMOZOLOMIDE AB AMNEAL PHARMS 5MG A 203691 001 May 08, 2015 Apr NEWA AB 20MG A 203691 002 May 08, 2015 Apr NEWA AB 100MG A 203691 003 May 08, 2015 Apr NEWA AB 140MG A 203691 004 May 08, 2015 Apr NEWA AB 180MG A 203691 005 May 08, 2015 Apr NEWA AB 250MG A 203691 006 May 08, 2015 Apr NEWA

TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL TENOFOVIR DISOPROXIL FUMARATE AB TEVA PHARMS USA 300MG A 091612 001 Mar 18, 2015 Mar NEWA VIREAD AB + GILEAD SCIENCES INC 300MG N 021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINE GEL;TOPICAL LAMISIL @ GLAXOSMITHKLINE CONS 1% N 020846 001 Apr 29, 1998 Aug CAHN

TERBINAFINE HYDROCHLORIDE SOLUTION;TOPICAL LAMISIL @ GLAXOSMITHKLINE CONS 1% N 020749 001 Oct 17, 1997 Aug CAHN TABLET;ORAL TERBINAFINE HYDROCHLORIDE @ WOCKHARDT EQ 250MG BASE A 078229 001 Jul 02, 2007 Feb DISC

TERCONAZOLE SUPPOSITORY;VAGINAL TERCONAZOLE >D> @ TARO 80MG A 077553 001 Mar 09, 2007 Sep CMFD >A> AB 80MG A 077553 001 Mar 09, 2007 Sep CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -77

TESTOSTERONE GEL;TRANSDERMAL ANDROGEL AB1 ABBVIE 25MG/2.5GM PACKET N 021015 001 Feb 28, 2000 Jan CTEC AB1 + 50MG/5GM PACKET N 021015 002 Feb 28, 2000 Jan CTEC TESTIM AB2 + AUXILIUM PHARMS 50MG/5GM PACKET N 021454 001 Oct 31, 2002 Jan CTEC TESTOSTERONE @ ACTAVIS LABS UT INC 1% (2.5GM/PACKET) A 076737 001 Jan 27, 2006 Mar CAHN @ 1% (5GM/PACKET) A 076737 002 Jan 27, 2006 Mar CAHN AB1 25MG/2.5GM PACKET A 076737 001 Jan 27, 2006 Jul CMFD AB1 50MG/5GM PACKET A 076737 002 Jan 27, 2006 Jul CMFD BX ANI PHARMS INC 25MG/2.5GM PACKET N 202763 001 Feb 14, 2012 May CAHN BX 50MG/5GM PACKET N 202763 002 Feb 14, 2012 May CAHN AB1 PAR PHARM 25MG/2.5GM PACKET A 076744 001 May 23, 2007 Aug CMFD AB1 50MG/5GM PACKET A 076744 002 May 23, 2007 Aug CMFD AB1 PERRIGO ISRAEL 25MG/2.5GM PACKET N 203098 002 Jan 31, 2013 Jan CTEC AB1 50MG/5GM PACKET N 203098 003 Jan 31, 2013 Jan CTEC VOGELXO AB2 UPSHER SMITH 50MG/5GM PACKET N 204399 002 Jun 04, 2014 Jan CTEC GEL, METERED;TRANSDERMAL ANDROGEL AB + ABBVIE 1.62% (20.25MG/1.25GM ACTUATION) N 022309 001 Apr 29, 2011 Jul CFTG FORTESTA AB + ENDO PHARMS 10MG/0.5GM ACTUATION N 021463 001 Dec 29, 2010 Jul CFTG TESTOSTERONE AB ACTAVIS LABS UT INC 10MG/0.5GM ACTUATION A 204571 001 Aug 05, 2015 Jul NEWA AB 12.5MG/1.25GM ACTUATION A 076737 003 Mar 09, 2015 Aug NEWA AB PERRIGO ISRAEL 1.62% (20.25MG/1.25GM ACTUATION) A 204268 001 Aug 04, 2015 Jul NEWA

TETRABENAZINE TABLET;ORAL TETRABENAZINE AB SUN PHARMA GLOBAL 12.5MG A 206129 001 Aug 17, 2015 Aug NEWA AB 25MG A 206129 002 Aug 17, 2015 Aug NEWA XENAZINE AB VALEANT PHARMS NORTH 12.5MG N 021894 001 Aug 15, 2008 Aug CFTG 12.5MG N 021894 001 Aug 15, 2008 Feb CAHN AB + 25MG N 021894 002 Aug 15, 2008 Aug CFTG + 25MG N 021894 002 Aug 15, 2008 Feb CAHN

TETRACYCLINE HYDROCHLORIDE CAPSULE;ORAL ACHROMYCIN V AB + HERITAGE PHARMS INC 500MG N 050278 001 Apr CRLD TETRACYCLINE HYDROCHLORIDE >A> @ CHARTWELL CIENCA 250MG A 062752 001 Aug 12, 1988 Sep CAHN >A> @ 500MG A 062752 002 Aug 12, 1988 Sep CAHN @ IVAX SUB TEVA PHARMS 250MG A 060704 001 Apr DISC @ 500MG A 060704 002 Apr DISC >D> @ LABS ATRAL 250MG A 062752 001 Aug 12, 1988 Sep CAHN >D> @ 500MG A 062752 002 Aug 12, 1988 Sep CAHN

THEOPHYLLINE TABLET;ORAL THEOLAIR @ MEDICIS 125MG A 086399 001 Mar DISC @ 250MG A 086399 002 Mar DISC TABLET, EXTENDED RELEASE;ORAL THEOPHYLLINE AB MYLAN PHARMS INC 400MG A 040595 001 Apr 21, 2006 May CAHN AB + 600MG A 040560 002 Apr 21, 2006 May CAHN

THIOTEPA INJECTABLE;INJECTION THIOTEPA + EUROHLTH INTL SARL 15MG/VIAL A 075547 001 Apr 02, 2001 May CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -78

TICAGRELOR TABLET;ORAL BRILINTA >A> ASTRAZENECA LP 60MG N 022433 002 Sep 03, 2015 Sep NEWA

TIGECYCLINE INJECTABLE;IV (INFUSION) TIGECYCLINE AP SANDOZ INC 50MG/VIAL A 091620 001 May 27, 2015 May NEWA TYGACIL AP + PF PRISM CV 50MG/VIAL N 021821 001 Jun 15, 2005 May CFTG

TIMOLOL MALEATE SOLUTION/DROPS;OPHTHALMIC ISTALOL AT2 + BAUSCH AND LOMB EQ 0.5% BASE N 021516 001 Jun 04, 2004 Apr CFTG TIMOLOL MALEATE AT1 AKORN EQ 0.5% BASE A 074466 001 Mar 25, 1997 Apr CTEC AT1 EQ 0.5% BASE A 074516 001 Mar 25, 1997 Apr CTEC AT1 ALCON RES LTD EQ 0.5% BASE A 074262 001 Apr 28, 1995 Apr CTEC AT2 APOTEX INC EQ 0.5% BASE A 204936 001 Apr 17, 2015 Apr NEWA AT1 BAUSCH AND LOMB EQ 0.5% BASE A 074776 001 Mar 25, 1997 Apr CTEC AT1 FDC LTD EQ 0.5% BASE A 077259 002 Apr 30, 2008 Apr CTEC AT1 HI TECH PHARMA EQ 0.5% BASE A 075163 001 Sep 10, 2002 Apr CTEC AT1 PACIFIC PHARMA EQ 0.5% BASE A 074747 001 Mar 25, 1997 Apr CTEC AT1 WOCKHARDT EQ 0.5% BASE A 078771 002 Sep 28, 2009 Apr CTEC TIMOPTIC AT1 + ATON EQ 0.5% BASE N 018086 002 Apr CTEC

TINIDAZOLE TABLET;ORAL TINIDAZOLE AB EDENBRIDGE PHARMS 250MG A 203808 001 Aug 04, 2015 Jul NEWA AB 500MG A 203808 002 Aug 04, 2015 Jul NEWA

TIOTROPIUM BROMIDE SPRAY, METERED;INHALATION SPIRIVA RESPIMAT >A> BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH N 021936 002 Sep 15, 2015 Sep NEWA

>A> TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE >A> TABLET;ORAL >A> LONSURF >A> TAIHO ONCOLOGY EQ 6.14MG BASE;15MG N 207981 001 Sep 22, 2015 Sep NEWA >A> + EQ 8.19MG BASE;20MG N 207981 002 Sep 22, 2015 Sep NEWA

TOBRAMYCIN SOLUTION;INHALATION KITABIS PAK AN PULMOFLOW INC 300MG/5ML N 205433 001 Dec 02, 2014 Feb CTEC TOBRAMYCIN AN AMNEAL PHARMS 300MG/5ML A 205501 001 Jul 13, 2015 Jun NEWA SOLUTION/DROPS;OPHTHALMIC TOBREX AT + ALCON LABS INC 0.3% N 050541 001 Mar CAHN

TOBRAMYCIN SULFATE INJECTABLE;INJECTION TOBRAMYCIN SULFATE @ IGI LABS INC EQ 10MG BASE/ML A 063119 001 Oct 31, 1994 Mar CAHN @ EQ 40MG BASE/ML A 063120 001 Oct 31, 1994 Mar CAHN @ EQ 40MG BASE/ML A 063121 001 Oct 31, 1994 Mar CAHN @ EQ 40MG BASE/ML A 063122 001 Oct 31, 1994 Mar CAHN TOBRAMYCIN SULFATE (PHARMACY BULK) + FRESENIUS KABI USA EQ 40MG BASE/ML A 065120 001 Nov 29, 2002 Jul CTEC AP + EQ 40MG BASE/ML A 065120 001 Nov 29, 2002 Jul CRLD @ HOSPIRA EQ 40MG BASE/ML A 063116 001 May 18, 1992 Jul DISC AP EQ 40MG BASE/ML A 063116 001 May 18, 1992 Jul CTNA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -79

TOLAZAMIDE TABLET;ORAL TOLAZAMIDE @ G AND W LABS INC 100MG N 018894 001 Nov 02, 1984 Apr CAHN @ 250MG N 018894 002 Nov 02, 1984 Apr CAHN @ 500MG N 018894 003 Nov 02, 1984 Apr CAHN

TOLCAPONE TABLET;ORAL TASMAR AB + VALEANT PHARMS LLC 100MG N 020697 001 Jan 29, 1998 Mar CFTG TOLCAPONE AB PAR PHARM INC 100MG A 204584 001 Mar 26, 2015 Mar NEWA

TOLMETIN SODIUM TABLET;ORAL TOLMETIN SODIUM @ G AND W LABS INC EQ 600MG BASE A 074399 001 Mar 28, 1996 May CAHN @ EQ 600MG BASE A 074729 001 Feb 27, 1997 Apr CAHN

TOLTERODINE TARTRATE CAPSULE, EXTENDED RELEASE;ORAL TOLTERODINE TARTRATE AB TORRENT PHARMS LTD 2MG A 203016 001 Aug 11, 2015 Jul NEWA AB 4MG A 203016 002 Aug 11, 2015 Jul NEWA TABLET;ORAL TOLTERODINE TARTRATE AB IVAX SUB TEVA PHARMS 1MG A 077006 001 Feb 23, 2015 Feb NEWA AB 2MG A 077006 002 Feb 23, 2015 Feb NEWA AB MACLEODS PHARMS LTD 1MG A 203409 001 Aug 31, 2015 Aug NEWA AB 2MG A 203409 002 Aug 31, 2015 Aug NEWA

TOPIRAMATE TABLET;ORAL TOPIRAMATE AB SUN PHARM INDS LTD 25MG A 076327 001 Mar 27, 2009 Apr CAHN AB 100MG A 076327 002 Mar 27, 2009 Apr CAHN AB 200MG A 076327 003 Mar 27, 2009 Apr CAHN @ WOCKHARDT USA 25MG A 090353 001 Sep 01, 2010 Apr DISC @ 50MG A 090353 002 Sep 01, 2010 Apr DISC @ 100MG A 090353 003 Sep 01, 2010 Apr DISC @ 200MG A 090353 004 Sep 01, 2010 Apr DISC TOPIRAMATE @ HIKMA PHARMS 25MG A 091185 001 Nov 25, 2013 May DISC @ 50MG A 091185 002 Nov 25, 2013 May DISC @ 100MG A 091185 003 Nov 25, 2013 May DISC @ 200MG A 091185 004 Nov 25, 2013 May DISC

TOPOTECAN HYDROCHLORIDE CAPSULE;ORAL HYCAMTIN NOVARTIS PHARMS CORP EQ 0.25MG BASE N 020981 001 Oct 11, 2007 Mar CAHN + EQ 1MG BASE N 020981 002 Oct 11, 2007 Mar CAHN INJECTABLE;INJECTION HYCAMTIN AP + NOVARTIS PHARMS CORP EQ 4MG BASE/VIAL N 020671 001 May 28, 1996 Mar CAHN TOPOTECAN HYDROCHLORIDE AP CHEM WERTH INC EQ 4MG BASE/VIAL A 201166 001 Aug 08, 2012 May CAHN

TORSEMIDE INJECTABLE;INJECTION TORSEMIDE @ EUROHLTH INTL SARL 20MG/2ML (10MG/ML) A 078007 001 Jun 11, 2008 Jan DISC @ 50MG/5ML (10MG/ML) A 078007 002 Jun 11, 2008 Jan DISC @ LUITPOLD 20MG/2ML (10MG/ML) A 090656 001 Apr 21, 2010 Jan DISC @ 50MG/5ML (10MG/ML) A 090656 002 Apr 21, 2010 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -80

TRAMADOL HYDROCHLORIDE TABLET;ORAL TRAMADOL HYDROCHLORIDE >A> AB MACLEODS PHARMS LTD 50MG A 205702 001 Sep 25, 2015 Sep NEWA

TRAMETINIB DIMETHYL SULFOXIDE TABLET;ORAL MEKINIST NOVARTIS PHARMS CORP EQ 0.5MG NON-SOLVATED PARENT N 204114 001 May 29, 2013 Mar CAHN EQ 1MG NON-SOLVATED PARENT N 204114 002 May 29, 2013 Mar CAHN + EQ 2MG NON-SOLVATED PARENT N 204114 003 May 29, 2013 Mar CAHN

TRANEXAMIC ACID INJECTABLE;INJECTION TRANEXAMIC ACID AP FRESENIUS KABI USA 100MG/ML A 091596 001 Mar 02, 2012 Apr CMFD TABLET;ORAL TRANEXAMIC ACID >A> AB MYLAN 650MG A 205133 001 Sep 21, 2015 Sep NEWA

TRANYLCYPROMINE SULFATE TABLET;ORAL PARNATE AB + CONCORDIA PHARMS INC EQ 10MG BASE N 012342 003 Aug 16, 1985 Jun CAHN

TRAVOPROST SOLUTION/DROPS;OPHTHALMIC IZBA @ ALCON LABS INC 0.003% N 204822 001 May 15, 2014 Jul DISC TRAVATAN Z AT + ALCON PHARMS LTD 0.004% N 021994 001 Sep 21, 2006 Jun CTEC TRAVOPROST AT APOTEX INC 0.004% A 203431 001 Jul 10, 2015 Jun NEWA

TRAZODONE HYDROCHLORIDE TABLET;ORAL DESYREL @ PRAGMA PHARMS LLC 50MG N 018207 001 May CAHN @ 100MG N 018207 002 May CAHN @ 150MG N 018207 003 Mar 25, 1985 May CAHN @ 300MG N 018207 004 Nov 07, 1988 May CAHN TABLET, EXTENDED RELEASE;ORAL OLEPTRO @ ANGELINI PHARMA 150MG N 022411 001 Feb 02, 2010 Mar DISC @ 300MG N 022411 002 Feb 02, 2010 Mar DISC

TRETINOIN CREAM;TOPICAL RENOVA + VALEANT PHARMS NORTH 0.02% N 021108 001 Aug 31, 2000 Apr CAHN AB2 + 0.05% N 019963 001 Dec 29, 1995 Apr CAHN RETIN-A AB + VALEANT PHARMS NORTH 0.1% N 017340 001 Apr CAHN GEL;TOPICAL ATRALIN AB + DOW PHARM 0.05% N 022070 001 Jul 26, 2007 Jul CTEC TRETINOIN AB SPEAR PHARMS INC 0.05% A 207955 001 Aug 13, 2015 Jul NEWA

TRIAMCINOLONE ACETONIDE CREAM;TOPICAL TRIAMCINOLONE ACETONIDE AT G AND W LABS 0.025% A 089797 001 May 31, 1991 Apr CMFD AT 0.1% A 089798 001 May 31, 1991 Apr CMFD TRIDERM AT CROWN LABS 0.025% A 088042 002 Mar 25, 2015 Mar NEWA AT 0.5% A 088042 003 Mar 25, 2015 Mar NEWA LOTION;TOPICAL TRIAMCINOLONE ACETONIDE AT G AND W LABS INC 0.1% A 089129 001 Aug 14, 1986 Mar CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -81

OINTMENT;TOPICAL KENALOG AT DELCOR ASSET CORP 0.025% N 011600 003 Mar CMFD AT 0.1% N 011600 001 Mar CMFD TRIAMCINOLONE ACETONIDE AT G AND W LABS 0.025% A 089795 001 Dec 23, 1988 Aug CMFD AT 0.1% A 089796 001 Dec 23, 1988 Aug CMFD SPRAY;TOPICAL KENALOG AT + RANBAXY 0.147MG/GM N 012104 001 Mar CFTG AT + SUN PHARM INDS LTD 0.147MG/GM N 012104 001 Aug CAHN TRIAMCINOLONE ACETONIDE AT PERRIGO UK FINCO 0.147MG/GM A 205782 001 Apr 13, 2015 Mar NEWA

TRIAMTERENE CAPSULE;ORAL DYRENIUM CONCORDIA PHARMS INC 50MG N 013174 001 Apr CAHN + 100MG N 013174 002 Apr CAHN

TRIMIPRAMINE MALEATE CAPSULE;ORAL SURMONTIL AB + ODYSSEY PHARMS EQ 50MG BASE N 016792 002 Jun CRLD AB EQ 100MG BASE N 016792 003 Sep 15, 1982 Jun CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE) CREAM;VAGINAL VAGILIA @ G AND W LABS INC 3.7%;2.86%;3.42% A 088821 001 Nov 09, 1987 Jul CAHN

TRIPTORELIN PAMOATE INJECTABLE;INTRAMUSCULAR TRELSTAR + ACTAVIS LABS UT INC EQ 3.75MG BASE/VIAL N 020715 001 Jun 15, 2000 Jan CAHN + EQ 11.25MG BASE/VIAL N 021288 001 Jun 29, 2001 Jan CAHN + EQ 22.5MG BASE/VIAL N 022437 001 Mar 10, 2010 Jan CAHN

TROSPIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL SANCTURA XR @ ALLERGAN 60MG N 022103 001 Aug 03, 2007 May DISC TROSPIUM CHLORIDE AB ACTAVIS LABS FL INC 60MG A 091289 001 Oct 12, 2012 Jun CRLD AB + 60MG A 091289 001 Oct 12, 2012 May CRLD AB SANDOZ INC 60MG A 091635 001 Apr 29, 2015 Apr NEWA TABLET;ORAL SANCTURA @ ALLERGAN 20MG N 021595 001 May 28, 2004 May DISC TROSPIUM CHLORIDE AB GLENMARK GENERICS 20MG A 091575 001 Aug 13, 2010 Jun CRLD AB + 20MG A 091575 001 Aug 13, 2010 May CRLD

UNOPROSTONE ISOPROPYL SOLUTION/DROPS;OPHTHALMIC RESCULA + R-TECH UENO LTD 0.15% N 021214 001 Aug 03, 2000 May CAHN + SUCAMPO PHARMA LLC 0.15% N 021214 001 Aug 03, 2000 Jan CAHN

>A> URIDINE TRIACETATE >A> GRANULE;ORAL >A> XURIDEN >A> + WELLSTAT THERAP 2GM/PACKET N 208169 001 Sep 04, 2015 Sep NEWA

URSODIOL CAPSULE;ORAL ACTIGALL @ ACTAVIS LABS UT INC 150MG N 019594 001 Dec 31, 1987 Mar CAHN AB + 300MG N 019594 002 Dec 31, 1987 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -82

VALACYCLOVIR HYDROCHLORIDE TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE AB HETERO LABS LTD V EQ 500MG BASE A 203047 001 Apr 08, 2015 Mar NEWA AB EQ 1GM BASE A 203047 002 Apr 08, 2015 Mar NEWA AB SUN PHARM INDS LTD EQ 500MG BASE A 076588 001 Jan 31, 2007 Apr CAHN AB EQ 1GM BASE A 076588 002 Jan 31, 2007 Apr CAHN

VALPROIC ACID CAPSULE;ORAL VALPROIC ACID AB BANNER LIFE SCIENCES 250MG A 073484 001 Jun 29, 1993 Jan CAHN CAPSULE, DELAYED RELEASE;ORAL STAVZOR @ BANNER LIFE SCIENCES 125MG N 022152 001 Jul 29, 2008 Jan CAHN @ 250MG N 022152 002 Jul 29, 2008 Jan CAHN @ 500MG N 022152 003 Jul 29, 2008 Jan CAHN

VALSARTAN TABLET;ORAL VALSARTAN AB PRINSTON INC 40MG A 204821 001 Jun 09, 2015 May NEWA AB 80MG A 204821 002 Jun 09, 2015 May NEWA AB 160MG A 204821 003 Jun 09, 2015 May NEWA AB 320MG A 204821 004 Jun 09, 2015 May NEWA

VANCOMYCIN HYDROCHLORIDE CAPSULE;ORAL VANCOMYCIN HYDROCHLORIDE AB LUPIN LTD EQ 125MG BASE A 090439 001 Jan 28, 2015 Jan NEWA AB EQ 250MG BASE A 090439 002 Jan 28, 2015 Jan NEWA INJECTABLE;INJECTION VANCOLED @ EUROHLTH INTL SARL EQ 500MG BASE/VIAL A 062682 001 Jul 22, 1986 Jun CAHN @ EQ 1GM BASE/VIAL A 062682 002 Mar 30, 1988 Jun CAHN @ EQ 2GM BASE/VIAL A 062682 003 May 11, 1988 Jun CAHN @ EQ 5GM BASE/VIAL A 062682 004 May 11, 1988 Jun CAHN @ EQ 10GM BASE/VIAL A 062682 005 May 11, 1988 Jun CAHN VANCOMYCIN HYDROCHLORIDE AP XELLIA PHARMS APS EQ 500MG BASE/VIAL A 091377 001 Sep 09, 2015 Aug NEWA AP EQ 1GM BASE/VIAL A 091377 002 Sep 09, 2015 Aug NEWA

VARDENAFIL HYDROCHLORIDE TABLET, ORALLY DISINTEGRATING;ORAL STAXYN AB + BAYER HLTHCARE 10MG N 200179 001 Jun 17, 2010 Apr CFTG VARDENAFIL HYDROCHLORIDE AB WATSON LABS INC 10MG A 203689 001 Apr 22, 2015 Apr NEWA

VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE AB VALEANT PHARMS NORTH EQ 37.5MG BASE A 090071 001 Apr 15, 2011 Feb CAHN AB EQ 75MG BASE A 090071 002 Apr 15, 2011 Feb CAHN AB EQ 150MG BASE A 090071 003 Apr 15, 2011 Feb CAHN TABLET;ORAL VENLAFAXINE HYDROCHLORIDE AB YAOPHARMA CO LTD EQ 25MG BASE A 202036 001 May 28, 2015 May NEWA AB EQ 37.5MG BASE A 202036 002 May 28, 2015 May NEWA AB EQ 50MG BASE A 202036 003 May 28, 2015 May NEWA AB EQ 75MG BASE A 202036 004 May 28, 2015 May NEWA AB EQ 100MG BASE A 202036 005 May 28, 2015 May NEWA

VERAPAMIL HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VERELAN AB RECRO GAINESVILLE 120MG N 019614 001 May 29, 1990 Apr CAHN AB 180MG N 019614 003 Jan 09, 1992 Apr CAHN AB 240MG N 019614 002 May 29, 1990 Apr CAHN + 360MG N 019614 004 May 10, 1996 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -83

CAPSULE, EXTENDED RELEASE;ORAL VERELAN PM AB RECRO GAINESVILLE 100MG N 020943 001 Nov 25, 1998 Apr CAHN AB 200MG N 020943 002 Nov 25, 1998 Apr CAHN AB + 300MG N 020943 003 Nov 25, 1998 Apr CAHN INJECTABLE;INJECTION CALAN @ EXELA PHARMA SCS LLC 2.5MG/ML N 018925 001 Mar 30, 1984 Aug CAHN ISOPTIN @ MT ADAMS 2.5MG/ML N 018485 001 Apr CAHN TABLET;ORAL ISOPTIN @ MT ADAMS 40MG N 018593 003 Nov 23, 1987 Apr CAHN @ 80MG N 018593 001 Mar 08, 1982 Apr CAHN @ 120MG N 018593 002 Mar 08, 1982 Apr CAHN

VERTEPORFIN INJECTABLE;INJECTION VISUDYNE + VALEANT LUXEMBOURG 15MG/VIAL N 021119 001 Apr 12, 2000 Mar CAHN

VILAZODONE HYDROCHLORIDE TABLET;ORAL VIIBRYD + FOREST LABS LLC 10MG N 022567 001 Jan 21, 2011 Mar CAHN 20MG N 022567 002 Jan 21, 2011 Mar CAHN 40MG N 022567 003 Jan 21, 2011 Mar CAHN

VINORELBINE TARTRATE INJECTABLE;INJECTION VINORELBINE TARTRATE >A> AP EUROHLTH INTL SARL EQ 10MG BASE/ML A 075992 001 Jun 10, 2003 Sep CAHN >D> AP HIKMA MAPLE EQ 10MG BASE/ML A 075992 001 Jun 10, 2003 Sep CAHN

VORICONAZOLE TABLET;ORAL VORICONAZOLE AB GLENMARK PHARMS LTD 50MG A 203503 001 Sep 02, 2015 Aug NEWA AB 200MG A 203503 002 Sep 02, 2015 Aug NEWA

ZAFIRLUKAST TABLET;ORAL ACCOLATE AB PAR PHARM INC 10MG N 020547 003 Sep 17, 1999 Feb CAHN AB + 20MG N 020547 001 Sep 26, 1996 Feb CAHN

ZOLEDRONIC ACID INJECTABLE;IV (INFUSION) ZOLEDRONIC ACID AP FRESENIUS KABI USA EQ 4MG BASE/5ML A 091516 001 Apr 23, 2015 Apr NEWA AP HOSPIRA INC EQ 4MG BASE/5ML A 090621 001 Mar 19, 2015 Mar NEWA AP MYLAN LABS LTD EQ 4MG BASE/5ML A 202650 001 Mar 04, 2013 Jul CAHN AP USV NORTH AMERICA EQ 4MG BASE/5ML A 202923 001 Sep 04, 2014 Mar CPOT

ZOLMITRIPTAN TABLET;ORAL ZOLMITRIPTAN >A> AB ALEMBIC PHARMS LTD 2.5MG A 204232 001 Sep 30, 2015 Sep NEWA >A> AB 5MG A 204232 002 Sep 30, 2015 Sep NEWA >A> AB MACLEODS PHARMS LTD 2.5MG A 203772 001 Sep 30, 2015 Sep NEWA >A> AB 5MG A 203772 002 Sep 30, 2015 Sep NEWA TABLET, ORALLY DISINTEGRATING;ORAL ZOLMITRIPTAN >A> AB JUBILANT GENERICS 2.5MG A 202956 001 Sep 17, 2015 Sep NEWA >A> AB 5MG A 202956 002 Sep 17, 2015 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 1 -84

ZOLPIDEM TARTRATE SPRAY, METERED;ORAL ZOLPIMIST >A> + AMHERST PHARMS LLC 5MG/SPRAY N 022196 001 Dec 19, 2008 Sep CAHN >D> + NOVADEL 5MG/SPRAY N 022196 001 Dec 19, 2008 Sep CAHN TABLET;ORAL ZOLPIDEM TARTRATE HI KMA@ HIKMA@ 5MG A 078129 001 Apr 30, 2008 Mar DISC @ 10MG A 078129 002 Apr 30, 2008 Mar DISC AB SUN PHARM INDS LTD 5MG A 078055 001 Apr 23, 2007 Apr CAHN AB 10MG A 078055 002 Apr 23, 2007 Apr CAHN TABLET;SUBLINGUAL INTERMEZZO AB PURDUE PHARMA 1.75MG N 022328 001 Nov 23, 2011 May CFTG AB + 3.5MG N 022328 002 Nov 23, 2011 May CFTG ZOLPIDEM TARTRATE AB NOVEL LABS INC 1.75MG A 204299 001 Jun 03, 2015 May NEWA AB 3.5MG A 204299 002 Jun 03, 2015 May NEWA

ZONISAMIDE CAPSULE;ORAL ZONISAMIDE AB BANNER LIFE SCIENCES 25MG A 077813 001 Aug 16, 2006 Jan CAHN AB 50MG A 077813 002 Aug 16, 2006 Jan CAHN AB 100MG A 077813 003 Aug 16, 2006 Jan CAHN OTC DRUG PRODUCT LIST - 35TH EDITION OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 2 -1

ACETAMINOPHEN SUPPOSITORY;RECTAL TYLENOL @ J AND J CONSUMER INC 120MG N 017756 002 Aug CAHN @ 650MG N 017756 001 Aug CAHN TABLET, EXTENDED RELEASE;ORAL ACETAMINOPHEN SUN PHARM INDS LTD 650MG A 078569 001 Dec 14, 2011 Apr CAHN @ 650MG A 090205 001 Nov 18, 2009 Apr CAHN TYLENOL + J AND J CONSUMER INC 650MG N 019872 001 Jun 08, 1994 Aug CAHN + 650MG N 019872 002 Jan 11, 2001 Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE LOTION;TOPICAL SHADE UVAGUARD + BAYER HEALTHCARE LLC 3%;7.5%;3% N 020045 001 Dec 07, 1992 Mar CAHN

BUDESONIDE SPRAY, METERED;NASAL RHINOCORT ALLERGY + ASTRAZENECA PHARMS 0.032MG/SPRAY N 020746 003 Mar 23, 2015 Mar NEWA

BUTENAFINE HYDROCHLORIDE CREAM;TOPICAL LOTRIMIN ULTRA + BAYER HEALTHCARE LLC 1% N 021307 001 Dec 07, 2001 Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE TABLET, CHEWABLE;ORAL PEPCID COMPLETE + J AND J CONSUMER INC 800MG;10MG;165MG N 020958 001 Oct 16, 2000 Aug CAHN

CETIRIZINE HYDROCHLORIDE CAPSULE;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY BANNER LIFE SCIENCES 5MG N 022429 001 Jul 23, 2009 Jan CAHN + 10MG N 022429 004 Jul 23, 2009 Jan CAHN CETIRIZINE HYDROCHLORIDE HIVES RELIEF BANNER LIFE SCIENCES 5MG N 022429 003 Jul 23, 2009 Jan CAHN + 10MG N 022429 002 Jul 23, 2009 Jan CAHN SYRUP;ORAL CHILDREN'S ZYRTEC ALLERGY + J AND J CONSUMER INC 5MG/5ML N 022155 002 Nov 16, 2007 Aug CAHN CHILDREN'S ZYRTEC HIVES RELIEF + J AND J CONSUMER INC 5MG/5ML N 022155 001 Nov 16, 2007 Aug CAHN TABLET;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY AUROBINDO PHARMA LTD 5MG A 090760 001 Aug 05, 2015 Jul NEWA 10MG A 090760 003 Aug 05, 2015 Jul NEWA SUN PHARM INDS LTD 5MG A 077498 001 Dec 27, 2007 Apr CAHN 10MG A 077498 002 Dec 27, 2007 Apr CAHN CETIRIZINE HYDROCHLORIDE HIVES SUN PHARM INDS LTD 5MG A 077498 003 Dec 27, 2007 Apr CAHN 10MG A 077498 004 Dec 27, 2007 Apr CAHN CETIRIZINE HYDROCHLORIDE HIVES RELIEF AUROBINDO PHARMA LTD 5MG A 090760 002 Aug 05, 2015 Jul NEWA 10MG A 090760 004 Aug 05, 2015 Jul NEWA ZYRTEC ALLERGY J AND J CONSUMER INC 5MG N 019835 003 Nov 16, 2007 Aug CAHN + 10MG N 019835 004 Nov 16, 2007 Aug CAHN ZYRTEC HIVES RELIEF J AND J CONSUMER INC 5MG N 019835 005 Nov 16, 2007 Aug CAHN + 10MG N 019835 006 Nov 16, 2007 Aug CAHN TABLET, CHEWABLE;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY JUBILANT GENERICS 5MG A 091116 001 Feb 19, 2015 Feb NEWA 10MG A 091116 002 Feb 19, 2015 Feb NEWA SANDOZ 5MG A 078692 001 Feb 14, 2008 Feb CTNA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 2 -2

TABLET, CHEWABLE;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY + 10MG A 078692 002 Feb 14, 2008 Feb CTNA CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF JUBILANT GENERICS 5MG A 091116 003 Feb 19, 2015 Feb NEWA 10MG A 091116 004 Feb 19, 2015 Feb NEWA CHILDREN'S ZYRTEC ALLERGY @ J AND J CONSUMER INC 5MG N 021621 003 Nov 16, 2007 Aug CAHN @ 10MG N 021621 004 Nov 16, 2007 Aug CAHN CHILDREN'S ZYRTEC HIVES RELIEF @ J AND J CONSUMER INC 5MG N 021621 005 Nov 16, 2007 Aug CAHN @ 10MG N 021621 006 Nov 16, 2007 Aug CAHN TABLET, ORALLY DISINTEGRATING;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY PAR PHARM INC 10MG A 205490 001 Sep 02, 2015 Aug NEWA ZYRTEC ALLERGY + J AND J CONSUMER INC 10MG N 022578 001 Sep 03, 2010 Aug CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL ZYRTEC-D 12 HOUR + J AND J CONSUMER INC 5MG;120MG N 021150 002 Nov 09, 2007 Aug CAHN

CHLORPHENIRAMINE MALEATE TABLET, EXTENDED RELEASE;ORAL CHLOR-TRIMETON @ BAYER HEALTHCARE LLC 8MG N 007638 001 Mar CAHN + 12MG N 007638 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE TABLET, EXTENDED RELEASE;ORAL CHLOR-TRIMETON + BAYER HEALTHCARE LLC 8MG;120MG N 018397 001 Mar CAHN

CLEMASTINE FUMARATE TABLET;ORAL CLEMASTINE FUMARATE @ ANI PHARMS INC 1.34MG A 073282 002 Dec 03, 1992 Jul CAHN

CLOTRIMAZOLE CREAM;VAGINAL GYNE-LOTRIMIN + BAYER HEALTHCARE LLC 1% N 018052 002 Nov 30, 1990 Mar CAHN GYNE-LOTRIMIN 3 + BAYER HEALTHCARE LLC 2% N 020574 001 Nov 24, 1998 Mar CAHN CREAM, TABLET;TOPICAL, VAGINAL GYNE-LOTRIMIN COMBINATION PACK + BAYER HEALTHCARE LLC 1%,100MG N 020289 002 Apr 26, 1993 Mar CAHN TABLET;VAGINAL GYNE-LOTRIMIN + BAYER HEALTHCARE LLC 100MG N 017717 002 Nov 30, 1990 Mar CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE ACTAVIS LABS FL INC 30MG;600MG A 091070 001 Aug 31, 2015 Aug NEWA 60MG;1.2GM A 091070 002 Aug 31, 2015 Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN CAPSULE;ORAL IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND A 090397 001 Nov 22, 2010 Jan CAHN POTASSIUM SALT

FAMOTIDINE TABLET;ORAL FAMOTIDINE SUN PHARM INDS LTD 10MG A 090283 001 Nov 17, 2009 Apr CAHN 20MG A 090283 002 Nov 17, 2009 Apr CAHN PEPCID AC J AND J CONSUMER INC 10MG N 020325 001 Apr 28, 1995 Jul CAHN OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 2 -3

TABLET;ORAL PEPCID AC + 20MG N 020325 002 Sep 23, 2003 Jul CAHN PEPCID AC J AND J CONSUMER INC 10MG N 020902 001 Aug 05, 1999 Aug CAHN TABLET, CHEWABLE;ORAL PEPCID AC @ J AND J CONSUMER INC 10MG N 020801 001 Sep 24, 1998 Aug CAHN + 20MG N 020801 002 Dec 17, 2007 Aug CAHN

FEXOFENADINE HYDROCHLORIDE TABLET;ORAL FEXOFENADINE HYDROCHLORIDE ALLERGY SCIEGEN PHARMS INC 60MG A 204507 002 Sep 16, 2015 Aug NEWA 180MG A 204507 003 Sep 16, 2015 Aug NEWA FEXOFENADINE HYDROCHLORIDE HIVES SCIEGEN PHARMS INC 60MG A 204507 004 Sep 16, 2015 Aug NEWA 180MG A 204507 005 Sep 16, 2015 Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE SUN PHARMA GLOBAL 60MG;120MG A 090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN ACTAVIS LABS FL INC 1.2GM A 091009 002 Sep 03, 2015 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE ACTAVIS LABS FL INC 600MG;60MG A 091071 001 May 27, 2015 May NEWA 1.2GM;120MG A 091071 002 May 27, 2015 May NEWA

IBUPROFEN CAPSULE;ORAL IBUPROFEN BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM A 078682 001 Mar 24, 2009 Jan CAHN SALT MIDOL LIQUID GELS + BANNER LIFE SCIENCES 200MG N 021472 001 Oct 18, 2002 Jan CAHN SUSPENSION;ORAL CHILDREN'S MOTRIN + J AND J CONSUMER INC 100MG/5ML N 020516 001 Jun 16, 1995 Aug CAHN SUSPENSION/DROPS;ORAL CHILDREN'S MOTRIN + J AND J CONSUMER INC 40MG/ML N 020603 001 Jun 10, 1996 Aug CAHN TABLET;ORAL IBUPROFEN @ ANI PHARMS INC 200MG A 072901 001 Dec 19, 1991 Aug CAHN @ 200MG A 072903 001 Dec 19, 1991 Aug CAHN JUNIOR STRENGTH MOTRIN J AND J CONSUMER INC 100MG N 020602 001 Jun 10, 1996 Aug CAHN MOTRIN IB + J AND J CONSUMER INC 200MG N 019012 003 Dec 17, 1990 Aug CAHN MOTRIN MIGRAINE PAIN + J AND J CONSUMER INC 200MG N 019012 004 Feb 25, 2000 Aug CAHN NUPRIN @ J AND J CONSUMER INC 200MG N 019012 001 May 18, 1984 Aug CAHN @ 200MG N 019012 002 Jul 29, 1987 Aug CAHN TABLET, CHEWABLE;ORAL CHILDREN'S MOTRIN J AND J CONSUMER INC 50MG N 020601 001 Nov 15, 1996 Aug CAHN JUNIOR STRENGTH MOTRIN + J AND J CONSUMER INC 100MG N 020601 003 Nov 15, 1996 Aug CAHN OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 2 -4

IBUPROFEN SODIUM TABLET;ORAL IBUPROFEN SODIUM PERRIGO R AND D EQ 200MG BASE A 206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE SUSPENSION;ORAL CHILDREN'S MOTRIN COLD + J AND J CONSUMER INC 100MG/5ML;15MG/5ML N 021128 001 Aug 01, 2000 Aug CAHN TABLET;ORAL SINE-AID IB J AND J CONSUMER INC 200MG;30MG N 019899 001 Dec 31, 1992 Aug CAHN

KETOTIFEN FUMARATE SOLUTION/DROPS;OPHTHALMIC ALAWAY BAUSCH AND LOMB EQ 0.035% BASE N 021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL TABLET;ORAL LEVONORGESTREL LOTUS PHARM CO LTD 1.5MG A 202246 001 Jun 05, 2015 May NEWA OC PHARMA 1.5MG A 202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE CAPSULE;ORAL LOPERAMIDE HYDROCHLORIDE BANNER LIFE SCIENCES 1MG N 021855 001 Aug 04, 2005 Jan CAHN + 2MG N 021855 002 Aug 04, 2005 Jan CAHN SOLUTION;ORAL IMODIUM A-D + J AND J CONSUMER INC 1MG/5ML N 019487 001 Mar 01, 1988 Aug CAHN SUSPENSION;ORAL IMODIUM A-D + J AND J CONSUMER INC 1MG/7.5ML N 019487 002 Jul 08, 2004 Aug CAHN TABLET;ORAL IMODIUM A-D + J AND J CONSUMER INC 2MG N 019860 001 Nov 22, 1989 Aug CAHN TABLET, CHEWABLE;ORAL IMODIUM A-D EZ CHEWS + J AND J CONSUMER INC 2MG N 020448 001 Jul 24, 1997 Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE TABLET;ORAL IMODIUM MULTI-SYMPTOM RELIEF + J AND J CONSUMER INC 2MG;125MG N 021140 001 Nov 30, 2000 Aug CAHN LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE SUN PHARM INDS LTD 2MG;125MG A 077500 001 Sep 06, 2006 Apr CAHN TABLET, CHEWABLE;ORAL IMODIUM MULTI-SYMPTOM RELIEF + J AND J CONSUMER INC 2MG;125MG N 020606 001 Jun 26, 1996 Aug CAHN

LORATADINE CAPSULE;ORAL CLARITIN + BAYER HEALTHCARE LLC 10MG N 021952 001 Jun 16, 2008 Mar CAHN SYRUP;ORAL CLARITIN + BAYER HEALTHCARE LLC 1MG/ML N 020641 002 Nov 27, 2002 Mar CAHN CLARITIN HIVES RELIEF @ BAYER HEALTHCARE LLC 1MG/ML N 020641 003 Nov 19, 2003 Mar CAHN LORATADINE TARO 1MG/ML A 201865 001 Jul 31, 2015 Jul NEWA TABLET;ORAL LORATADINE SUN PHARM INDS LTD 10MG A 076134 001 Aug 18, 2003 Apr CAHN TABLET, CHEWABLE;ORAL CHILDREN'S CLARITIN + BAYER HEALTHCARE LLC 5MG N 021891 001 Aug 23, 2006 Mar CAHN OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 2 -5

TABLET, ORALLY DISINTEGRATING;ORAL CLARITIN REDITABS + BAYER HEALTHCARE LLC 5MG N 021993 001 Dec 12, 2006 Mar CAHN LORATADINE REDIDOSE SUN PHARM INDS LTD 10MG A 077153 001 Apr 11, 2007 Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE TABLET, EXTENDED RELEASE;ORAL CLARITIN-D + BAYER HEALTHCARE LLC 5MG;120MG N 019670 002 Nov 27, 2002 Mar CAHN CLARITIN-D 24 HOUR + BAYER HEALTHCARE LLC 10MG;240MG N 020470 002 Nov 27, 2002 Mar CAHN LORATADINE AND PSEUDOEPHEDRINE SULFATE SUN PHARM INDS LTD 10MG;240MG A 076557 001 Sep 22, 2004 Apr CAHN

NAPROXEN SODIUM CAPSULE;ORAL NAPROXEN SODIUM + BANNER LIFE SCIENCES EQ 200MG BASE N 021920 001 Feb 17, 2006 Jan CAHN CATALENT EQ 200MG BASE A 202807 001 Feb 13, 2015 Feb NEWA OHM LABS INC EQ 200MG BASE A 202807 001 Feb 13, 2015 Jun CAHN TABLET;ORAL NAPROXEN SODIUM SUN PHARM INDS LTD EQ 200MG BASE A 091183 001 May 20, 2011 Apr CAHN

NICOTINE POLACRILEX GUM, CHEWING;BUCCAL NICOTINE POLACRILEX @ IVAX SUB TEVA PHARMS EQ 2MG BASE A 076880 001 Feb 18, 2009 Mar DISC @ EQ 4MG BASE A 077850 001 Feb 18, 2009 Mar DISC

OMEPRAZOLE MAGNESIUM TABLET, DELAYED RELEASE;ORAL OMEPRAZOLE MAGNESIUM PERRIGO R AND D EQ 20MG BASE A 204152 001 Jul 30, 2015 Jul NEWA

OMEPRAZOLE; SODIUM BICARBONATE CAPSULE;ORAL ZEGERID OTC + BAYER HEALTHCARE LLC 20MG;1.1GM N 022281 001 Dec 01, 2009 Mar CAHN FOR SUSPENSION;ORAL ZEGERID OTC + BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET N 022283 001 Jun 17, 2013 Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OCUCLEAR BAYER HEALTHCARE LLC 0.025% N 018471 001 May 30, 1986 Mar CAHN

POLYETHYLENE GLYCOL 3350 FOR SOLUTION;ORAL MIRALAX + BAYER HEALTHCARE LLC 17GM/SCOOPFUL N 022015 001 Oct 06, 2006 Mar CAHN POLYETHYLENE GLYCOL 3350 RARITAN PHARMS INC 17GM/SCOOPFUL A 202071 001 Dec 28, 2012 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL PSEUDOEPHEDRINE HYDROCHLORIDE SUN PHARM INDS LTD 120MG A 077442 001 Sep 28, 2005 Apr CAHN SUDAFED 24 HOUR + J AND J CONSUMER INC 240MG N 020021 002 Dec 15, 1992 Aug CAHN

RANITIDINE HYDROCHLORIDE TABLET;ORAL RANITIDINE HYDROCHLORIDE @ SUN PHARM INDS LTD EQ 75MG BASE A 075132 001 Jan 14, 2000 Apr CAHN @ WOCKHARDT EQ 75MG BASE A 078884 001 Jul 31, 2008 Jan DISC

3-1

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2015

NO SEPTEMBER 2015 APPROVALS

4-1

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at: http://www.fda.gov/orphan/designat/list.htm

5-1

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2015 ADDITIONS PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 35TH EDITION A - 1 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ABACAVIR SULFATE - ZIAGEN N 020977 001 D-147 Mar 23, 2018

ABACAVIR SULFATE - ZIAGEN N 020978 001 D-147 Mar 23, 2018

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ N 205551 001 6417191 Mar 28, 2016 DP U-1572 6417191*PED Sep 28, 2016

ABACAVIR SULFATE; LAMIVUDINE - EPZICOM N 021652 001 6417191 Mar 28, 2016 DP U-257 6417191*PED Sep 28, 2016

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR N 204031 001 8980319 Dec 21, 2030 DP 8992975 May 16, 2032 DP 9050335 May 16, 2032 DP

ACLIDINIUM BROMIDE - TUDORZA PRESSAIR N 202450 001 9056100 Jul 07, 2020 DP U-1263

ACYCLOVIR; HYDROCORTISONE - XERESE N 022436 001 7223387 Jul 24, 2021 DP U-1006 7223387 Jul 24, 2021 DP U-1484

ADAPALENE; BENZOYL PEROXIDE - EPIDUO N 022320 001 8936800 Dec 23, 2022 DP U-1078

ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE N 207917 001 8445543 Jul 12, 2027 U-1078 NP Jul 15, 2018 8703820 Mar 12, 2023 U-1078 8729127 Mar 12, 2023 U-1078 8785420 Dec 23, 2022 U-1078 8909305 Dec 23, 2022 U-1078 8936800 Dec 23, 2022 DP U-1078

ALBUTEROL SULFATE - PROAIR RESPICLICK N 205636 001 6446627 Dec 18, 2017 DP NP Mar 12, 2018 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT N 021747 001 8733341 Dec 16, 2029 DP 9027967 Mar 31, 2027 DP

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 001 8637079 Jun 04, 2029 DP

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 002 8637079 Jun 04, 2029 DP

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 003 8637079 Jun 04, 2029 DP A - 2 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 004 8637079 Jun 04, 2029 DP

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 005 8637079 Jun 04, 2029 DP

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 006 8637079 Jun 04, 2029 DP

ALVIMOPAN - ENTEREG N 021775 001 8946262 Feb 12, 2030 U-1655

AMOXICILLIN - MOXATAG N 050813 001 8778924 Dec 08, 2026 DS DP U-897

APIXABAN - ELIQUIS N 202155 001 6967208 Feb 03, 2023 DS DP U-1167 6967208 Feb 03, 2023 DS DP U-1200 6967208 Feb 03, 2023 DS DP U-1301 6967208 Feb 03, 2023 DS DP U-1302 6967208 Feb 03, 2023 DS DP U-1323 6967208 Feb 03, 2023 DS DP U-1501 6967208 Feb 03, 2023 DS DP U-1502 6967208 Feb 03, 2023 DS DP U-1729 6967208 Feb 03, 2023 DS DP U-1730

APIXABAN - ELIQUIS N 202155 002 6413980 Dec 22, 2019 DS DP U-1200 6413980 Dec 22, 2019 DS DP U-1301 6413980 Dec 22, 2019 DS DP U-1302 6967208 Feb 03, 2023 DS DP U-1200 6967208 Feb 03, 2023 DS DP U-1301 6967208 Feb 03, 2023 DS DP U-1302 6967208 Feb 03, 2023 DS DP U-1323

APREMILAST - OTEZLA N 205437 001 9018243 Mar 19, 2023 U-1505 9018243 Mar 19, 2023 U-1595

APREMILAST - OTEZLA N 205437 002 9018243 Mar 19, 2023 U-1505 9018243 Mar 19, 2023 U-1595

APREMILAST - OTEZLA N 205437 003 9018243 Mar 19, 2023 U-1505 9018243 Mar 19, 2023 U-1595

APREPITANT - EMEND N 021549 001 >A> 6096742 Jul 01, 2018 DS DP U-745 NPP Aug 28, 2018 >A> 6096742 Jul 01, 2018 DS DP U-1743 >A> 6096742 Jul 01, 2018 DS DP U-1744 >A> 8258132 Sep 26, 2027 DP U-901 >A> 8258132 Sep 26, 2027 DP U-1743

APREPITANT - EMEND N 021549 002 >A> 6096742 Jul 01, 2018 DS DP U-745 NPP Aug 28, 2018 >A> 6096742 Jul 01, 2018 DS DP U-1743 >A> 6096742 Jul 01, 2018 DS DP U-1744 >A> 8258132 Sep 26, 2027 DP U-901 >A> 8258132 Sep 26, 2027 DP U-1743 A - 3 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

APREPITANT - EMEND N 021549 003 >A> 6096742 Jul 01, 2018 DS DP U-745 NPP Aug 28, 2018 >A> 6096742 Jul 01, 2018 DS DP U-1743 >A> 6096742 Jul 01, 2018 DS DP U-1744 >A> 8258132 Sep 26, 2027 DP U-901 >A> 8258132 Sep 26, 2027 DP U-1743

ARIPIPRAZOLE - ABILIFY N 021436 001 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021436 002 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021436 003 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021436 004 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021436 005 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021436 006 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021713 001 5006528 Oct 20, 2014 DS DP U-543 ODE Dec 12, 2021 5006528 Oct 20, 2014 DS DP U-761 5006528*PED Apr 20, 2015 6977257 Apr 24, 2022 DP 6977257*PED Oct 24, 2022

ARIPIPRAZOLE - ABILIFY N 021729 002 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021729 003 9089567 Jan 28, 2022 U-543 ODE Dec 12, 2021 >A> 9125939 Jul 28, 2026 U-1749

ARIPIPRAZOLE - ABILIFY N 021729 004 ODE Dec 12, 2021

ARIPIPRAZOLE - ABILIFY N 021729 005 ODE Dec 12, 2021

ARIPIPRAZOLE - ABILIFY N 021866 001 5006528 Oct 20, 2014 DS DP U-543 ODE Dec 12, 2021 5006528 Oct 20, 2014 DS DP U-763 5006528*PED Apr 20, 2015

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 001 5006528 Oct 20, 2014 DS DP U-543 5006528 Oct 20, 2014 DS DP U-1632 5006528*PED Apr 20, 2015 8030313 Oct 19, 2024 U-543 A - 4 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 001 8030313 Oct 19, 2024 U-1632 8338427 Mar 15, 2025 DP U-543 8338427 Mar 15, 2025 DP U-1633 8338428 Aug 06, 2023 DP U-543 8338428 Aug 06, 2023 DP U-1633 8399469 Jun 29, 2025 DS 8759351 Aug 06, 2023 DP U-1530 8759351 Aug 06, 2023 DP U-1633 8993761 Sep 25, 2022 DS 9089567 Jan 28, 2022 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 002 5006528 Oct 20, 2014 DS DP U-543 5006528 Oct 20, 2014 DS DP U-1632 5006528*PED Apr 20, 2015 8030313 Oct 19, 2024 U-543 8030313 Oct 19, 2024 U-1632 8338427 Mar 15, 2025 DP U-543 8338427 Mar 15, 2025 DP U-1633 8338428 Aug 06, 2023 DP U-543 8338428 Aug 06, 2023 DP U-1633 8399469 Jun 29, 2025 DS 8759351 Aug 06, 2023 DP U-1530 8759351 Aug 06, 2023 DP U-1633 8993761 Sep 25, 2022 DS 9089567 Jan 28, 2022 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 003 5006528 Oct 20, 2014 DS DP U-543 5006528 Oct 20, 2014 DS DP U-1632 5006528*PED Apr 20, 2015 8030313 Oct 19, 2024 U-543 8030313 Oct 19, 2024 U-1632 8338427 Mar 15, 2025 DP U-543 8338427 Mar 15, 2025 DP U-1633 8338428 Aug 06, 2023 DP U-543 8338428 Aug 06, 2023 DP U-1633 8399469 Jun 29, 2025 DS 8759351 Aug 06, 2023 DP U-1530 8759351 Aug 06, 2023 DP U-1633 8993761 Sep 25, 2022 DS 9089567 Jan 28, 2022 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 004 5006528 Oct 20, 2014 DS DP U-543 5006528 Oct 20, 2014 DS DP U-1632 5006528*PED Apr 20, 2015 8030313 Oct 19, 2024 U-543 8030313 Oct 19, 2024 U-1632 8338427 Mar 15, 2025 DP U-543 8338427 Mar 15, 2025 DP U-1633 8338428 Aug 06, 2023 DP U-543 8338428 Aug 06, 2023 DP U-1633 8399469 Jun 29, 2025 DS 8759351 Aug 06, 2023 DP U-1530 8759351 Aug 06, 2023 DP U-1633 8993761 Sep 25, 2022 DS 9089567 Jan 28, 2022 U-543

ASENAPINE MALEATE - SAPHRIS N 022117 001 5763476 Jun 09, 2020 DP U-326 M-158 Mar 17, 2018 5763476*PED Dec 09, 2020 NPP Mar 17, 2018 7741358 Apr 06, 2026 DS DP U-1064 PED Sep 17, 2018 7741358*PED Oct 06, 2026 PED Sep 17, 2018 8022228 Apr 06, 2026 DS DP A - 5 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ASENAPINE MALEATE - SAPHRIS N 022117 001 8022228*PED Oct 06, 2026

ASENAPINE MALEATE - SAPHRIS N 022117 002 5763476 Jun 09, 2020 DP U-326 M-158 Mar 17, 2018 5763476*PED Dec 09, 2020 NPP Mar 17, 2018 7741358 Apr 06, 2026 DS DP U-1064 PED Sep 17, 2018 7741358*PED Oct 06, 2026 PED Sep 17, 2018 8022228 Apr 06, 2026 DS DP 8022228*PED Oct 06, 2026

ASPIRIN - ASPIRIN N 203697 001 9101637 Mar 23, 2022 U-1731 9101637 Mar 23, 2022 U-1732 9101637 Mar 23, 2022 U-1733

ATAZANAVIR SULFATE - REYATAZ N 021567 001 5849911 Jun 20, 2017 DS DP U-167 5849911*PED Dec 20, 2017 6087383 Dec 21, 2018 DS DP 6087383*PED Jun 21, 2019

ATAZANAVIR SULFATE - REYATAZ N 021567 002 5849911 Jun 20, 2017 DS DP U-167 5849911*PED Dec 20, 2017 6087383 Dec 21, 2018 DS DP 6087383*PED Jun 21, 2019

ATAZANAVIR SULFATE - REYATAZ N 021567 003 5849911 Jun 20, 2017 DS DP U-167 5849911*PED Dec 20, 2017 6087383 Dec 21, 2018 DS DP 6087383*PED Jun 21, 2019

ATAZANAVIR SULFATE - REYATAZ N 021567 004 5849911 Jun 20, 2017 DS DP U-167 5849911*PED Dec 20, 2017 6087383 Dec 21, 2018 DS DP 6087383*PED Jun 21, 2019

ATAZANAVIR SULFATE - REYATAZ N 206352 001 5849911 Jun 20, 2017 DS DP U-167 NP Jun 02, 2017 5849911*PED Dec 20, 2017 >A> NPP Sep 24, 2018 >A> 6087383 Dec 21, 2018 DS DP PED Dec 02, 2017 >A> 6087383*PED Jun 21, 2019 >A> PED Mar 24, 2019

ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ N 206353 001 5849911 Jun 20, 2017 DS DP U-167 5849911*PED Dec 20, 2017 6087383 Dec 21, 2018 DS DP 6087383*PED Jun 21, 2019 8148374 Sep 03, 2029 DS DP U-1279

AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ N 206494 001 7112592 Feb 24, 2022 DS DP U-282 7612087 Nov 12, 2026 DP 8178554 Jul 24, 2021 DS DP U-282 8471025 Aug 12, 2031 DS 8835455 Oct 08, 2030 DP 8969566 Jun 15, 2032 DS A - 6 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

AZELAIC ACID - FINACEA N 207071 001 6730288 Sep 08, 2019 DP NP Jul 29, 2018 7700076 Sep 18, 2027 DP 8435498 Mar 01, 2024 U-1727 8722021 Oct 24, 2023 DP 8900554 Oct 24, 2023 DP

AZELASTINE HYDROCHLORIDE - ASTEPRO N 022203 001 NPP Feb 20, 2018 NPP Feb 20, 2018

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA N 202236 001 8163723 Aug 29, 2023 U-77 NPP Feb 20, 2018 8163723 Aug 29, 2023 U-81 8163723 Aug 29, 2023 U-644 8163723 Aug 29, 2023 U-707 8163723 Aug 29, 2023 U-1667

AZILSARTAN KAMEDOXOMIL - EDARBI N 200796 001 9066936 Mar 26, 2028 DP

AZILSARTAN KAMEDOXOMIL - EDARBI N 200796 002 9066936 Mar 26, 2028 DP

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR N 202331 001 9066936 Mar 26, 2028 DP

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR N 202331 002 9066936 Mar 26, 2028 DP

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA N 050819 001 8895070 Jun 03, 2029 U-124 >A> 9078870 Jun 03, 2029 DP

BESIFLOXACIN HYDROCHLORIDE - BESIVANCE N 022308 001 8937062 Nov 13, 2029 U-80

BEXAROTENE - TARGRETIN N 021055 001 >A> M-164 Jul 29, 2018

BIMATOPROST - LUMIGAN N 022184 001 8933120 Mar 16, 2025 DP 8933127 Mar 16, 2025 DP

BIMATOPROST - LATISSE N 022369 001 7351404 May 25, 2024 U-939 Y 7388029 Jan 21, 2022 U-938 Y 8541466 Jan 31, 2021 U-1217 8986715 Jan 15, 2023 U-1217

BORTEZOMIB - VELCADE N 021602 001 5780454 May 03, 2017 DS DP D-141 Oct 08, 2017 5780454*PED Nov 03, 2017 D-142 Oct 08, 2017 6713446 Jan 25, 2022 DS DP I-695 Oct 08, 2017 6713446*PED Jul 25, 2022 M-139 Aug 08, 2017 6958319 Jan 25, 2022 DS DP >A> M-165 Sep 14, 2018 6958319*PED Jul 25, 2022 ODE Oct 08, 2021 PED Feb 08, 2018 PED Apr 08, 2018 PED Apr 08, 2018 PED Apr 08, 2018 >A> PED Mar 14, 2019 PED Apr 08, 2022 A - 7 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BORTEZOMIB - VELCADE N 021602 001 5780454 May 03, 2017 DS DP D-141 Oct 08, 2017 5780454*PED Nov 03, 2017 D-142 Oct 08, 2017 6713446 Jan 25, 2022 DS DP I-695 Oct 08, 2017 6713446*PED Jul 25, 2022 M-139 Aug 08, 2017 6958319 Jan 25, 2022 DS DP >A> M-165 Sep 14, 2018 6958319*PED Jul 25, 2022 ODE Oct 08, 2021 PED Feb 08, 2018 PED Apr 08, 2018 PED Apr 08, 2018 PED Apr 08, 2018 >A> PED Mar 14, 2019 PED Apr 08, 2022

BREXPIPRAZOLE - REXULTI N 205422 001 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BREXPIPRAZOLE - REXULTI N 205422 002 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BREXPIPRAZOLE - REXULTI N 205422 003 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BREXPIPRAZOLE - REXULTI N 205422 004 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BREXPIPRAZOLE - REXULTI N 205422 005 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BREXPIPRAZOLE - REXULTI N 205422 006 7888362 Feb 23, 2027 DS NCE Jul 10, 2020 8349840 Apr 12, 2026 DP U-1529 8618109 Apr 12, 2026 U-543

BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA N 204251 001 9044484 Oct 30, 2030 DP

BROMOCRIPTINE MESYLATE - CYCLOSET N 020866 001 8877708 Jun 07, 2030 DP U-1706

BUDESONIDE - UCERIS N 203634 001 9132093 Sep 07, 2031 DP

BUDESONIDE - UCERIS N 205613 001 5914122 Dec 19, 2015 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 001 8470361 May 22, 2030 DP U-1425 I-713 Aug 10, 2018 8940330 Sep 18, 2032 DP A - 8 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 002 8470361 May 22, 2030 DP U-1425 I-713 Aug 10, 2018 8940330 Sep 18, 2032 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 003 8470361 May 22, 2030 DP U-1425 I-713 Aug 10, 2018 8940330 Sep 18, 2032 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 004 8470361 May 22, 2030 DP U-1425 I-713 Aug 10, 2018 8940330 Sep 18, 2032 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 005 8454996 Sep 24, 2019 U-1421 I-713 Aug 10, 2018 8470361 May 22, 2030 DP U-1425 8658198 Dec 03, 2027 DP U-1494 8940330 Sep 18, 2032 DP

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE N 200063 001 8916195 Feb 02, 2030 U-1639 9107837 Jun 04, 2027 U-1639

CALCIUM ACETATE - PHOSLO GELCAPS N 021160 003 6875445 Jul 30, 2021 DP

CALCIUM ACETATE - PHOSLYRA N 022581 001 9089528 Jul 20, 2027 U-1469

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER N 207026 001 ODE Jan 13, 2022

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER N 207026 002 ODE Jan 13, 2022

CANGRELOR - KENGREAL N 204958 001 6114313 Dec 11, 2017 DP U-1715 NCE Jun 22, 2020 6130208 Jun 29, 2018 DP U-1715 8680052 Mar 09, 2033 U-1715 8759316 May 13, 2029 U-1715

CARBIDOPA; LEVODOPA - RYTARY N 203312 001 7094427 May 29, 2022 DP U-1645 NDF Jan 07, 2018 8377474 Dec 26, 2028 DP U-219 8377474 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-219 8454998 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-1646 8454998 Dec 26, 2028 DP U-1647 8454998 Dec 26, 2028 DP U-1649 8557283 Dec 26, 2028 DP U-219 8557283 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1720 9089608 Dec 26, 2028 DP

CARBIDOPA; LEVODOPA - RYTARY N 203312 002 7094427 May 29, 2022 DP U-1645 NDF Jan 07, 2018 8377474 Dec 26, 2028 DP U-219 8377474 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-219 8454998 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-1646 A - 9 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

CARBIDOPA; LEVODOPA - RYTARY N 203312 002 8454998 Dec 26, 2028 DP U-1647 8454998 Dec 26, 2028 DP U-1649 8557283 Dec 26, 2028 DP U-219 8557283 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1720 9089608 Dec 26, 2028 DP

CARBIDOPA; LEVODOPA - RYTARY N 203312 003 7094427 May 29, 2022 DP U-1645 NDF Jan 07, 2018 8377474 Dec 26, 2028 DP U-219 8377474 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-219 8454998 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-1646 8454998 Dec 26, 2028 DP U-1647 8454998 Dec 26, 2028 DP U-1649 8557283 Dec 26, 2028 DP U-219 8557283 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1720 9089608 Dec 26, 2028 DP

CARBIDOPA; LEVODOPA - RYTARY N 203312 004 7094427 May 29, 2022 DP U-1645 NDF Jan 07, 2018 8377474 Dec 26, 2028 DP U-219 8377474 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-219 8454998 Dec 26, 2028 DP U-1645 8454998 Dec 26, 2028 DP U-1646 8454998 Dec 26, 2028 DP U-1647 8454998 Dec 26, 2028 DP U-1649 8557283 Dec 26, 2028 DP U-219 8557283 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1645 9089607 Dec 26, 2028 DP U-1720 9089608 Dec 26, 2028 DP

CARBIDOPA; LEVODOPA - DUOPA N 203952 001 NP Jan 09, 2018 ODE Jan 09, 2022

CARFILZOMIB - KYPROLIS N 202714 001 I-712 Jul 24, 2018

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 001 >A> NCE Sep 17, 2020

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 002 >A> NCE Sep 17, 2020

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 003 >A> NCE Sep 17, 2020

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 004 >A> NCE Sep 17, 2020

CEFTAROLINE FOSAMIL - TEFLARO N 200327 001 6417175 Apr 11, 2022 DS DP U-1676 A - 10 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

CEFTAROLINE FOSAMIL - TEFLARO N 200327 002 6417175 Apr 11, 2022 DS DP U-1676

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA N 206829 001 8968753 Mar 14, 2034 U-1672 8968753 Mar 14, 2034 U-1673

CELECOXIB - CELECOXIB A 076898 002 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 076898 003 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 076898 004 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 078857 002 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 078857 003 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 078857 004 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 200562 002 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 200562 003 PC Jun 02, 2015

CELECOXIB - CELECOXIB A 200562 004 PC Jun 02, 2015

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE N 206323 001 6248363 Nov 23, 2019 DP U-1716 6383471 Apr 06, 2019 DP U-1716 9066942 Jan 03, 2032 U-1716

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR N 207768 001 8062667 Mar 29, 2029 DP 8790700 Mar 15, 2027 DP

CHOLIC ACID - CHOLBAM N 205750 001 ODE Mar 17, 2022

CHOLIC ACID - CHOLBAM N 205750 002 ODE Mar 17, 2022

CICLESONIDE - ALVESCO N 021658 002 8371292 Feb 01, 2028 U-1355

CICLESONIDE - ALVESCO N 021658 003 8371292 Feb 01, 2028 U-1355

CICLESONIDE - OMNARIS N 022004 001 8371292 Feb 01, 2028 U-1356 A - 11 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

CICLESONIDE - ZETONNA N 202129 001 8371292 Feb 01, 2028 U-1357

CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE A 090898 001 PC Jul 01, 2015

CLOBETASOL PROPIONATE - OLUX E N 022013 001 8962000 Aug 31, 2025 DP U-1410

COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX N 205395 001 5843946 Dec 01, 2015 DP U-1660 5843946*PED Jun 01, 2016 7470506 Jun 23, 2019 U-1660 7470506*PED Dec 23, 2019 7700645 Dec 26, 2026 DS DP 7700645*PED Jun 26, 2027 8148374 Sep 03, 2029 DS DP U-1660 8518987 Feb 16, 2024 DS DP 8518987*PED Aug 16, 2024 8597876 Jun 23, 2019 U-1660 8597876*PED Dec 23, 2019 RE42889 Oct 19, 2016 DP RE42889*PED Apr 19, 2017 RE43596 May 09, 2017 DS DP RE43596*PED Nov 09, 2017 RE43802 Oct 19, 2016 U-1660 RE43802*PED Apr 19, 2017

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD N 203100 001 8981103 Oct 26, 2026 DS DP I-704 Dec 17, 2017

COLCHICINE - MITIGARE N 204820 001 8927607 Aug 22, 2033 U-1020

CRIZOTINIB - XALKORI N 202570 001 7230098 Aug 26, 2025 DS >A> M-163 Sep 14, 2018

CRIZOTINIB - XALKORI N 202570 002 7230098 Aug 26, 2025 DS >A> M-163 Sep 14, 2018

CROFELEMER - FULYZAQ N 202292 001 8962680 Oct 31, 2031 U-1319

CYANOCOBALAMIN - NASCOBAL N 021642 001 7229636 Aug 01, 2024 DP U-817 7879349 Aug 01, 2024 DP U-1152 8003353 Aug 01, 2024 U-817 8940714 Feb 26, 2024 U-1152

CYSTEAMINE BITARTRATE - PROCYSBI N 203389 001 NPP Aug 14, 2018

CYSTEAMINE BITARTRATE - PROCYSBI N 203389 002 NPP Aug 14, 2018

DABRAFENIB MESYLATE - TAFINLAR N 202806 001 8703781 Oct 15, 2030 DS DP U-1713

DABRAFENIB MESYLATE - TAFINLAR N 202806 002 8703781 Oct 15, 2030 DS DP U-1713 A - 12 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DACLATASVIR DIHYDROCHLORIDE - DAKLINZA N 206843 001 8329159 Apr 13, 2028 DS NCE Jul 24, 2020 8629171 Jun 13, 2031 DS DP U-1724 8642025 Aug 11, 2027 DS DP U-1724 8642025 Aug 11, 2027 DS DP U-1725 8900566 Aug 08, 2027 U-1724 8900566 Aug 08, 2027 U-1725

DACLATASVIR DIHYDROCHLORIDE - DAKLINZA N 206843 002 8329159 Apr 13, 2028 DS NCE Jul 24, 2020 8629171 Jun 13, 2031 DS DP U-1724 8642025 Aug 11, 2027 DS DP U-1724 8642025 Aug 11, 2027 DS DP U-1725 8900566 Aug 08, 2027 U-1724 8900566 Aug 08, 2027 U-1725

DANTROLENE SODIUM - RYANODEX N 205579 001 ODE Jul 22, 2021

DAPAGLIFLOZIN PROPANEDIOL - FARXIGA N 202293 001 M-157 Mar 11, 2018

DAPAGLIFLOZIN PROPANEDIOL - FARXIGA N 202293 002 M-157 Mar 11, 2018

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED) N 206619 001 6037157 Jun 26, 2016 U-1635 6703403 Jun 26, 2016 U-1635 7148359 Jul 19, 2019 DP 7364752 Nov 10, 2020 DP 8188104 May 17, 2029 DS DP U-1636 8268349 Aug 25, 2024 DP 8399015 Aug 25, 2024 DP 8420596 Apr 10, 2031 DS DP 8466159 Sep 04, 2032 U-1637 8492386 Sep 04, 2032 U-1637 8501238 Sep 17, 2028 DS DP U-1636 8642538 Sep 10, 2029 DS DP U-1638 8680106 Sep 04, 2032 U-1637 8685984 Sep 04, 2032 U-1637 8686026 Jun 09, 2031 DP 8691938 Apr 13, 2032 DS DP 9006387 Jun 10, 2030 U-1687 9044480 Apr 10, 2031 U-1638

DEFERASIROX - EXJADE N 021882 001 ODE Jan 23, 2020

DEFERASIROX - EXJADE N 021882 002 ODE Jan 23, 2020

DEFERASIROX - EXJADE N 021882 003 ODE Jan 23, 2020

DEFERASIROX - JADENU N 206910 001 6465504 Apr 05, 2019 DS DP 6596750 Jun 24, 2017 DS U-735

DEFERASIROX - JADENU N 206910 002 6465504 Apr 05, 2019 DS DP 6596750 Jun 24, 2017 DS U-735 A - 13 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DEFERASIROX - JADENU N 206910 003 6465504 Apr 05, 2019 DS DP 6596750 Jun 24, 2017 DS U-735

DEFERIPRONE - FERRIPROX N 021825 001 >A> 7049328 Jun 28, 2021 U-735

DEFERIPRONE - FERRIPROX N 208030 001 >A> 7049328 Jun 28, 2021 U-735 >A> NCE Oct 14, 2016 >A> 8703156 Oct 29, 2029 DP U-735 >A> ODE Oct 14, 2016

DEOXYCHOLIC ACID - KYBELLA N 206333 001 7622130 Dec 10, 2027 U-1690 7754230 Dec 10, 2027 U-1690 8101593 Mar 02, 2030 DP 8242294 May 16, 2028 DS 8298556 Aug 03, 2025 U-1690 8367649 Mar 02, 2030 DP 8461140 Feb 21, 2028 DP 8546367 Feb 21, 2028 DP U-1690 8653058 Mar 02, 2030 DP 8846066 Feb 08, 2025 U-1690 8883770 Feb 21, 2028 DP

DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE A 200653 001 PC May 16, 2015

DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE A 200653 002 PC May 16, 2015

DESONIDE - VERDESO N 021978 001 8962000 Aug 31, 2025 DP U-1412

DESVENLAFAXINE SUCCINATE - PRISTIQ N 021992 003 6673838 Mar 01, 2022 DS U-860 6673838 Mar 01, 2022 DS U-1364 8269040 Jul 05, 2027 DS

DEXAMETHASONE - OZURDEX N 022315 001 8043628 Oct 20, 2020 U-1205 8088407 Oct 20, 2020 U-1205 9012437 Oct 20, 2020 U-1205

DEXLANSOPRAZOLE - DEXILANT N 022287 001 9011926 Feb 24, 2026 DP

DEXLANSOPRAZOLE - DEXILANT N 022287 002 8784885 Oct 15, 2023 DP U-1552 8784885 Oct 15, 2023 DP U-1553 8784885 Oct 15, 2023 DP U-1554 8784885*PED Apr 15, 2024 9011926 Feb 24, 2026 DP

DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX N 021038 004 6716867 Mar 31, 2019 U-1472 6716867*PED Oct 01, 2019 8242158 Jan 04, 2032 DP 8242158*PED Jul 04, 2032 8338470 Jan 04, 2032 DP 8338470*PED Jul 04, 2032 8455527 Jan 04, 2032 U-421 8455527*PED Jul 04, 2032 8648106 Jan 04, 2032 DP A - 14 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX N 021038 004 8648106*PED Jul 04, 2032

DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE A 078908 002 PC Aug 01, 2015

DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE A 078908 003 PC Dec 19, 2015

DICHLORPHENAMIDE - KEVEYIS N 011366 002 >A> ODE Aug 07, 2022

DICLOFENAC - ZORVOLEX N 204592 001 8999387 Apr 23, 2030 U-55 9017721 Apr 23, 2030 DP

DICLOFENAC - ZORVOLEX N 204592 002 8999387 Apr 23, 2030 U-55 9017721 Apr 23, 2030 DP

DICLOFENAC POTASSIUM - CAMBIA N 022165 001 8927604 Jun 16, 2026 U-436

DICLOFENAC SODIUM - DYLOJECT N 022396 001 6407079 Jun 18, 2019 DP 8946292 Mar 22, 2027 U-1659

DICLOFENAC SODIUM - PENNSAID N 204623 001 9066913 Oct 17, 2027 DP U-1488 9101591 Oct 17, 2027 DP U-1488 9132110 Oct 17, 2027 U-1488

DOLUTEGRAVIR SODIUM - TIVICAY N 204790 001 >A> M-166 Jul 30, 2018

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC N 206439 001 5061703 Apr 11, 2015 U-1641 5061703*PED Oct 11, 2015 8058291 Dec 05, 2029 U-1641 8168209 Nov 22, 2025 DP 8168209*PED May 22, 2026 8173708 Nov 22, 2025 U-1641 8173708*PED May 22, 2026 8283379 Nov 22, 2025 U-1641 8283379*PED May 22, 2026 8293794 Nov 22, 2025 DP

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC N 206439 002 5061703 Apr 11, 2015 U-1641 5061703*PED Oct 11, 2015 8039009 Mar 24, 2029 U-1641 8039009*PED Sep 24, 2029 8058291 Dec 05, 2029 U-1641 8168209 Nov 22, 2025 DP 8168209*PED May 22, 2026 8173708 Nov 22, 2025 U-1641 8173708*PED May 22, 2026 8283379 Nov 22, 2025 U-1641 8283379*PED May 22, 2026 8293794 Nov 22, 2025 DP 8329752 Nov 22, 2025 DP 8329752*PED May 22, 2026 8338485 Nov 22, 2025 DP A - 15 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC N 206439 002 8338486 Nov 22, 2025 U-1641 8362085 Nov 22, 2025 U-1641 8362085*PED May 22, 2026 8580858 Nov 22, 2025 U-1641 8598233 Nov 22, 2025 DP 8598233*PED May 22, 2026

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 001 9107898 May 01, 2028 DP U-620

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 002 9107898 May 01, 2028 DP U-620

DOXYCYCLINE HYCLATE - DOXTERIC N 050795 006 6958161 Dec 15, 2022 DP U-918 8715724 Feb 03, 2028 DP

DRONEDARONE HYDROCHLORIDE - MULTAQ N 022425 001 9107900 Apr 16, 2029 U-1726 9107900 Apr 16, 2029 U-1728

DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE A 090694 003 PC Jan 11, 2016

EDOXABAN TOSYLATE - SAVAYSA N 206316 001 7365205 Jun 12, 2023 DS NCE Jan 08, 2020

EDOXABAN TOSYLATE - SAVAYSA N 206316 002 7365205 Jun 12, 2023 DS NCE Jan 08, 2020

EDOXABAN TOSYLATE - SAVAYSA N 206316 003 7365205 Jun 12, 2023 DS NCE Jan 08, 2020

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA N 021937 001 9018192 Jun 13, 2026 U-750 9018192 Jun 13, 2026 U-1170

ELTROMBOPAG OLAMINE - PROMACTA N 022291 001 6280959 Oct 30, 2018 DS DP U-930 D-149 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1306 I-711 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1575 ODE Aug 26, 2021 6280959 Oct 30, 2018 DS DP U-1714 PED Dec 11, 2018 6280959*PED Apr 30, 2019 PED Dec 11, 2018 7160870 Nov 20, 2022 DS DP U-930 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1575 7160870 Nov 20, 2022 DS DP U-1714 7160870*PED May 20, 2023 7332481 May 24, 2021 U-930 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1575 7332481 May 24, 2021 U-1714 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP U-1714 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-930 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1575 7473686 May 24, 2021 DS DP U-1714 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-930 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 A - 16 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 001 7547719 Jul 13, 2025 DS DP U-1714 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-930 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1575 7790704 May 24, 2021 U-1714 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-930 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1575 7795293 May 21, 2023 U-1714 7795293*PED Nov 21, 2023 8052993 Aug 01, 2027 DP U-930 8052993 Aug 01, 2027 DP U-1306 8052993 Aug 01, 2027 DP U-1575 8052993 Aug 01, 2027 DP U-1714 8052993*PED Feb 01, 2028 8052994 Aug 01, 2027 DP U-1714 8052994*PED Feb 01, 2028 8062665 Aug 01, 2027 DP U-1714 8062665*PED Feb 01, 2028 8071129 Aug 01, 2027 DP U-1714 8071129*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-1619 8828430 Aug 01, 2027 DP U-1714 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 002 6280959 Oct 30, 2018 DS DP U-930 D-149 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1306 I-711 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1575 ODE Aug 26, 2021 6280959 Oct 30, 2018 DS DP U-1714 PED Dec 11, 2018 6280959*PED Apr 30, 2019 PED Dec 11, 2018 7160870 Nov 20, 2022 DS DP U-930 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1575 7160870 Nov 20, 2022 DS DP U-1714 7160870*PED May 20, 2023 7332481 May 24, 2021 U-930 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1575 7332481 May 24, 2021 U-1714 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP U-1714 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-930 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1575 7473686 May 24, 2021 DS DP U-1714 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-930 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-1714 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-930 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1575 7790704 May 24, 2021 U-1714 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-930 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1575 7795293 May 21, 2023 U-1714 7795293*PED Nov 21, 2023 A - 17 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 002 8052993 Aug 01, 2027 DP U-1714 8052993*PED Feb 01, 2028 8052994 Aug 01, 2027 DP U-930 8052994 Aug 01, 2027 DP U-1306 8052994 Aug 01, 2027 DP U-1575 8052994 Aug 01, 2027 DP U-1714 8052994*PED Feb 01, 2028 8062665 Aug 01, 2027 DP U-1714 8062665*PED Feb 01, 2028 8071129 Aug 01, 2027 DP U-1714 8071129*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-1619 8828430 Aug 01, 2027 DP U-1714 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 003 6280959 Oct 30, 2018 DS DP U-930 D-149 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1306 I-711 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1575 ODE Aug 26, 2021 6280959 Oct 30, 2018 DS DP U-1714 PED Dec 11, 2018 6280959*PED Apr 30, 2019 PED Dec 11, 2018 7160870 Nov 20, 2022 DS DP U-930 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1575 7160870 Nov 20, 2022 DS DP U-1714 7160870*PED May 20, 2023 7332481 May 24, 2021 U-930 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1575 7332481 May 24, 2021 U-1714 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP U-1714 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-930 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1575 7473686 May 24, 2021 DS DP U-1714 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-930 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-1714 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-930 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1575 7790704 May 24, 2021 U-1714 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-930 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1575 7795293 May 21, 2023 U-1714 7795293*PED Nov 21, 2023 8052993 Aug 01, 2027 DP U-1714 8052993*PED Feb 01, 2028 8052994 Aug 01, 2027 DP U-1714 8052994*PED Feb 01, 2028 8062665 Aug 01, 2027 DP U-714 8062665 Aug 01, 2027 DP U-930 8062665 Aug 01, 2027 DP U-1306 8062665 Aug 01, 2027 DP U-1575 8062665*PED Feb 01, 2028 8071129 Aug 01, 2027 DP U-1714 8071129*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 A - 18 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 003 8828430 Aug 01, 2027 DP U-1619 8828430 Aug 01, 2027 DP U-1714 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 004 6280959 Oct 30, 2018 DS DP U-930 D-149 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1306 I-711 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1575 ODE Aug 26, 2021 6280959 Oct 30, 2018 DS DP U-1714 PED Dec 11, 2018 6280959*PED Apr 30, 2019 PED Dec 11, 2018 7160870 Nov 20, 2022 DS DP U-930 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1575 7160870 Nov 20, 2022 DS DP U-1714 7160870*PED May 20, 2023 7332481 May 24, 2021 U-930 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1575 7332481 May 24, 2021 U-1714 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP U-1714 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-930 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1575 7473686 May 24, 2021 DS DP U-1714 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-930 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-1714 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-930 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1575 7790704 May 24, 2021 U-1714 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-930 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1575 7795293 May 21, 2023 U-1714 7795293*PED Nov 21, 2023 8052993 Aug 01, 2027 DP U-1714 8052993*PED Feb 01, 2028 8052994 Aug 01, 2027 DP U-1714 8052994*PED Feb 01, 2028 8062665 Aug 01, 2027 DP U-1714 8062665*PED Feb 01, 2028 8071129 Aug 01, 2027 DP U-930 8071129 Aug 01, 2027 DP U-1306 8071129 Aug 01, 2027 DP U-1575 8071129 Aug 01, 2027 DP U-1714 8071129*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-1619 8828430 Aug 01, 2027 DP U-1714 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 005 6280959 Oct 30, 2018 DS DP U-930 D-149 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1306 I-711 Jun 11, 2018 6280959 Oct 30, 2018 DS DP U-1575 ODE Aug 26, 2021 6280959 Oct 30, 2018 DS DP U-1714 PED Dec 11, 2018 6280959*PED Apr 30, 2019 PED Dec 11, 2018 7160870 Nov 20, 2022 DS DP U-930 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1306 A - 19 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 005 7160870 Nov 20, 2022 DS DP U-1575 7160870 Nov 20, 2022 DS DP U-1714 7160870*PED May 20, 2023 7332481 May 24, 2021 U-930 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1575 7332481 May 24, 2021 U-1714 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP U-1714 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-930 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1575 7473686 May 24, 2021 DS DP U-1714 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-930 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-930 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1575 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-930 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1575 7795293*PED Nov 21, 2023 8052995 Aug 01, 2027 DP U-1306 8052995 Aug 01, 2027 DP U-1575 8052995*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 207027 001 >A> 6280959 Oct 30, 2018 DS DP U-1736 D-149 Jun 11, 2018 >A> 7160870 Nov 20, 2022 DS DP U-1736 I-711 Jun 11, 2018 >A> 7332481 May 24, 2021 U-1736 ODE Nov 20, 2015 >A> 7452874 May 24, 2021 DS DP PED Dec 11, 2018 >A> 7473686 May 24, 2021 DS DP U-1736 PED Dec 11, 2018 >A> 7547719 Jul 13, 2025 DS DP U-1736 >A> 7790704 May 24, 2021 U-1736 >A> 7795293 May 24, 2023 U-1736

ELUXADOLINE - VIBERZI N 206940 001 7741356 Mar 25, 2028 DS DP NCE May 27, 2020 7786158 Mar 14, 2025 DS 8344011 Mar 14, 2025 U-1709 8609709 Mar 14, 2025 DS 8691860 Jul 07, 2028 DS U-1709 >A> 9115091 Jul 07, 2028 DS DP U-1738

ELUXADOLINE - VIBERZI N 206940 002 7741356 Mar 25, 2028 DS DP NCE May 27, 2020 7786158 Mar 14, 2025 DS 8344011 Mar 14, 2025 U-1709 8609709 Mar 14, 2025 DS 8691860 Jul 07, 2028 DS U-1709 >A> 9115091 Jul 07, 2028 DS DP U-1738

ELVITEGRAVIR - VITEKTA N 203093 001 8981103 Oct 26, 2026 DS DP

ELVITEGRAVIR - VITEKTA N 203093 002 8981103 Oct 26, 2026 DS DP A - 20 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

EMPAGLIFLOZIN - JARDIANCE N 204629 001 M-160 Jun 26, 2018 M-161 Jun 26, 2018

EMPAGLIFLOZIN - JARDIANCE N 204629 002 M-160 Jun 26, 2018 M-161 Jun 26, 2018

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 001 6303661 Apr 24, 2017 U-1651 NC Jan 30, 2018 6890898 Feb 02, 2019 U-1652 NCE May 02, 2016 7078381 Feb 02, 2019 U-1651 NCE Aug 01, 2019 7407955 Aug 12, 2023 DS DP 7459428 Feb 02, 2019 U-1651 7579449 Nov 05, 2025 DS 7713938 Apr 15, 2027 DS DP 8119648 Aug 12, 2023 U-1651 8178541 Aug 12, 2023 DP U-1653 8178541 Aug 12, 2023 DP U-1654 8551957 Oct 19, 2029 DP U-1651 8673927 May 04, 2027 DP U-1652 8846695 Jun 04, 2030 U-1652 8883805 Nov 26, 2025 DP

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 002 6303661 Apr 24, 2017 U-1651 NC Jan 30, 2018 6890898 Feb 02, 2019 U-1652 NCE May 02, 2016 7078381 Feb 02, 2019 U-1651 NCE Aug 01, 2019 7407955 Aug 12, 2023 DS DP 7459428 Feb 02, 2019 U-1651 7579449 Nov 05, 2025 DS 7713938 Apr 15, 2027 DS DP 8119648 Aug 12, 2023 U-1651 8178541 Aug 12, 2023 DP U-1653 8178541 Aug 12, 2023 DP U-1654 8551957 Oct 19, 2029 DP U-1651 8673927 May 04, 2024 DP U-1652 8846695 Jun 04, 2030 U-1652 8883805 Nov 26, 2025 DP

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 001 >A> 7579449 Nov 05, 2025 DS NCE Aug 01, 2019 >A> 7713938 Apr 15, 2027 DS DP NP Aug 26, 2018

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 002 >A> 7579449 Nov 05, 2025 DS NCE Aug 01, 2019 >A> 7713938 Apr 15, 2027 DS DP NP Aug 26, 2018

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 003 >A> 7579449 Nov 05, 2025 DS NCE Aug 01, 2019 >A> 7713938 Apr 15, 2027 DS DP NP Aug 26, 2018

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 004 >A> 7579449 Nov 05, 2025 DS NCE Aug 01, 2019 >A> 7713938 Apr 15, 2027 DS DP NP Aug 26, 2018

ENZALUTAMIDE - XTANDI N 203415 001 >A> 9126941 May 15, 2026 U-1588

EPINEPHRINE - AUVI-Q N 201739 001 8920377 Nov 23, 2024 DP 8926594 Mar 31, 2026 DP 9056170 Nov 23, 2024 DP A - 21 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

EPINEPHRINE - AUVI-Q N 201739 002 8920377 Nov 23, 2024 DP 8926594 Mar 31, 2026 DP 9056170 Nov 23, 2024 DP

EPINEPHRINE - ADRENALIN N 204640 001 9119876 Mar 13, 2035 DP

ERIBULIN MESYLATE - HALAVEN N 201532 001 6214865 Jul 20, 2023 DS

ERLOTINIB HYDROCHLORIDE - TARCEVA N 021743 001 5747498 Nov 08, 2018 DS DP U-659 I-671 May 14, 2016 5747498*PED May 08, 2019 PED Nov 14, 2016 6900221 Nov 09, 2020 DS DP U-659 6900221 Nov 09, 2020 DS DP U-875 6900221 Nov 09, 2020 DS DP U-1046 6900221 Nov 09, 2020 DS DP U-1403 6900221*PED May 09, 2021 7087613 Nov 09, 2020 U-659 7087613 Nov 09, 2020 U-1045 7087613 Nov 09, 2020 U-1403 7087613*PED May 09, 2021 RE41065 Nov 08, 2018 DS DP RE41065*PED May 08, 2019

ERLOTINIB HYDROCHLORIDE - TARCEVA N 021743 002 5747498 Nov 08, 2018 DS DP U-659 I-671 May 14, 2016 5747498*PED May 08, 2019 PED Nov 14, 2016 6900221 Nov 09, 2020 DS DP U-659 6900221 Nov 09, 2020 DS DP U-875 6900221 Nov 09, 2020 DS DP U-1046 6900221 Nov 09, 2020 DS DP U-1403 6900221*PED May 09, 2021 7087613 Nov 09, 2020 U-659 7087613 Nov 09, 2020 U-1045 7087613 Nov 09, 2020 U-1403 7087613*PED May 09, 2021 RE41065 Nov 08, 2018 DS DP RE41065*PED May 08, 2019

ERLOTINIB HYDROCHLORIDE - TARCEVA N 021743 003 5747498 Nov 08, 2018 DS DP U-659 I-671 May 14, 2016 5747498*PED May 08, 2019 PED Nov 14, 2016 6900221 Nov 09, 2020 DS DP U-659 6900221 Nov 09, 2020 DS DP U-875 6900221 Nov 09, 2020 DS DP U-1046 6900221 Nov 09, 2020 DS DP U-1403 6900221*PED May 09, 2021 7087613 Nov 09, 2020 U-659 7087613 Nov 09, 2020 U-1045 7087613 Nov 09, 2020 U-1403 7087613*PED May 09, 2021 RE41065 Nov 08, 2018 DS DP RE41065*PED May 08, 2019

ESLICARBAZEPINE ACETATE - APTIOM N 022416 001 >A> 5753646 Jun 27, 2016 DS DP U-1451 >A> D-150 Aug 27, 2018 >A> 5753646 Jun 27, 2016 DS DP U-1746 >A> I-715 Aug 27, 2018

ESLICARBAZEPINE ACETATE - APTIOM N 022416 002 >A> 5753646 Jun 27, 2016 DS DP U-1451 >A> D-150 Aug 27, 2018 >A> 5753646 Jun 27, 2016 DS DP U-1746 >A> I-715 Aug 27, 2018 A - 22 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ESLICARBAZEPINE ACETATE - APTIOM N 022416 003 >A> 5753646 Jun 27, 2016 DS DP U-1451 >A> D-150 Aug 27, 2018 >A> 5753646 Jun 27, 2016 DS DP U-1746 >A> I-715 Aug 27, 2018

ESLICARBAZEPINE ACETATE - APTIOM N 022416 004 >A> 5753646 Jun 27, 2016 DS DP U-1451 >A> D-150 Aug 27, 2018 >A> 5753646 Jun 27, 2016 DS DP U-1746 >A> I-715 Aug 27, 2018

ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR N 204655 001 5690960 Nov 25, 2014 DP U-1509 5690960*PED May 25, 2015 5714504 Feb 03, 2015 DP U-1509 5714504*PED Aug 03, 2015 5877192*PED Nov 27, 2014 5900424 May 04, 2016 DS U-1509 5900424*PED Nov 04, 2016 6369085 May 25, 2018 DS DP U-1509 6369085*PED Nov 25, 2018 6428810 Nov 03, 2019 DP U-1509 6428810*PED May 03, 2020 6875872*PED Nov 27, 2014 7411070 May 25, 2018 DS 7411070*PED Nov 25, 2018

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO N 022511 001 8945621 Oct 17, 2031 U-1661

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO N 022511 002 8945621 Oct 17, 2031 U-1661

ESTRADIOL - MINIVELLE N 203752 005 6841716 Apr 27, 2020 DP 8231906 Jul 04, 2030 DS DP

EVEROLIMUS - AFINITOR N 022334 001 8410131 Nov 01, 2025 DS DP U-1368 8410131*PED May 01, 2026 9006224 Jul 01, 2028 U-1681

EVEROLIMUS - AFINITOR N 022334 002 8410131 Nov 01, 2025 DS DP U-1368 8410131*PED May 01, 2026 9006224 Jul 01, 2028 U-1681

EVEROLIMUS - AFINITOR N 022334 003 8410131 Nov 01, 2025 DS DP U-1368 8410131*PED May 01, 2026 9006224 Jul 01, 2028 U-1681

EVEROLIMUS - AFINITOR N 022334 004 8410131 Nov 01, 2025 DS DP U-1368 8410131*PED May 01, 2026 9006224 Jul 01, 2028 U-1681

EXENATIDE SYNTHETIC - BYDUREON N 022200 001 >A> M-162 Sep 24, 2018

FEBUXOSTAT - ULORIC N 021856 001 9107912 Sep 08, 2031 U-1346 A - 23 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FEBUXOSTAT - ULORIC N 021856 002 9107912 Sep 08, 2031 U-1346

FENTANYL CITRATE - LAZANDA N 022569 001 9078814 Jan 08, 2024 DP

FENTANYL CITRATE - LAZANDA N 022569 002 9078814 Jan 08, 2024 DP

FENTANYL HYDROCHLORIDE - IONSYS N 021338 001 6169920 Jan 02, 2018 DP U-736 6181963 Nov 02, 2019 DP 8301238 Sep 30, 2031 DP 8428708 May 21, 2032 U-736 8428709 Jun 11, 2032 DP U-736 8781571 Mar 31, 2032 DP U-736 9095706 Jan 17, 2033 DP

FERRIC CITRATE - AURYXIA N 205874 001 8901349 Feb 18, 2024 U-1577 9050316 Feb 18, 2024 U-1577

FERRIC PYROPHOSPHATE CITRATE - TRIFERIC N 206317 001 6689275 Dec 31, 2016 U-1656 6779468 Dec 31, 2016 U-1656 7816404 Apr 17, 2029 DP U-1656

FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY N 201373 001 8933097 Aug 16, 2032 DP

FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES N 201373 002 8933097 Aug 16, 2032 DP

FINAFLOXACIN - XTORO N 206307 001 6133260 Apr 12, 2017 DS DP 6432948 Apr 12, 2017 DS DP 8536167 Aug 08, 2031 U-1679 9119859 Jul 02, 2030 U-1679

FLIBANSERIN - ADDYI N 022526 001 7151103 May 09, 2023 U-1734 NCE Aug 18, 2020 7420057 Aug 01, 2022 DS DP 8227471 May 09, 2023 U-1734

FLUOROURACIL - TOLAK N 022259 001 >A> NP Sep 18, 2018

FLUTEMETAMOL F-18 - VIZAMYL N 203137 001 8916131 Sep 16, 2028 DP

FLUTEMETAMOL F-18 - VIZAMYL N 203137 002 8916131 Sep 16, 2028 DP

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 001 6537983 Aug 03, 2021 DP U-1401 I-708 Apr 30, 2018 6537983 Aug 03, 2021 DP U-1691 6759398 Aug 03, 2021 DP U-1401 6759398 Aug 03, 2021 DP U-1691 7101866 Aug 03, 2021 DS DP U-1401 7101866 Aug 03, 2021 DS DP U-1691 7439393 Sep 11, 2022 DS DP U-1401 7439393 Sep 11, 2022 DS DP U-1691 A - 24 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 001 8511304 Jun 14, 2027 DP U-1424 8511304 Jun 14, 2027 DP U-1691 RE44874 Mar 23, 2023 DS DP U-1548 RE44874 Mar 23, 2023 DS DP U-1691

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 002 5873360 Feb 23, 2016 DP NP Apr 30, 2018 6537983 Aug 03, 2021 DP U-1691 6759398 Aug 03, 2021 DP U-1691 7101866 Aug 03, 2021 DS DP U-1691 7439393 Sep 11, 2022 DS DP U-1691 7629335 Aug 03, 2021 DP 7776895 Sep 11, 2022 DP 8113199 Oct 23, 2027 DP 8161968 Feb 05, 2028 DP 8511304 Jun 14, 2027 DP U-1691 8534281 Aug 10, 2029 DP 8746242 Oct 11, 2030 DP RE44874 Mar 23, 2023 DS DP U-1691

FLUTICASONE PROPIONATE - CUTIVATE N 021152 001 NPP Jan 16, 2018

GADOXETATE DISODIUM - EOVIST N 022090 001 M-155 Mar 27, 2018

GADOXETATE DISODIUM - EOVIST N 022090 002 M-155 Mar 27, 2018

GEFITINIB - IRESSA N 206995 001 5770599 May 05, 2017 DS DP U-1403 NP Jul 13, 2018 ODE Jul 13, 2022

GLATIRAMER ACETATE - COPAXONE N 020622 003 8969302 Aug 19, 2030 U-441 >A> 9155776 Aug 19, 2030 U-441

GLYCEROL PHENYLBUTYRATE - RAVICTI N 203284 001 9095559 Mar 09, 2032 U-1383

GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE A 200881 001 PC May 30, 2015

GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE A 200881 002 PC May 30, 2015

GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE A 200881 003 PC May 30, 2015

GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE A 200881 004 PC May 30, 2015

GUANFACINE HYDROCHLORIDE - INTUNIV N 022037 001 M-154 Mar 18, 2018

GUANFACINE HYDROCHLORIDE - INTUNIV N 022037 002 M-154 Mar 18, 2018

GUANFACINE HYDROCHLORIDE - INTUNIV N 022037 003 M-154 Mar 18, 2018 A - 25 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

GUANFACINE HYDROCHLORIDE - INTUNIV N 022037 004 M-154 Mar 18, 2018

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 001 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 002 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 003 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 004 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 005 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 006 >A> 9132096 Sep 12, 2034 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 001 9023401 Oct 30, 2021 DP 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 002 9023401 Oct 30, 2021 DP 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 003 9023401 Oct 30, 2021 DP 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 004 9023401 Oct 30, 2021 DP 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 005 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP A - 26 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

HYDROCODONE BITARTRATE - HYSINGLA N 206627 006 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

HYDROCODONE BITARTRATE - HYSINGLA N 206627 007 9056052 Oct 30, 2021 DP 9060940 Oct 30, 2021 U-1556 9084816 Aug 24, 2027 DP 9095614 Aug 24, 2027 U-1556 9095615 Aug 24, 2027 DP

IBRUTINIB - IMBRUVICA N 205552 001 8497277 Dec 28, 2026 U-1456 I-702 Jan 29, 2018 8497277 Dec 28, 2026 U-1491 ODE Jan 29, 2022 8497277 Dec 28, 2026 U-1650 8957079 Dec 28, 2026 DS DP 8999999 Jun 03, 2031 U-1683 8999999 Jun 03, 2031 U-1684 >A> 9125889 Jun 03, 2031 U-1745

IBUPROFEN - CALDOLOR N 022348 002 8871810 Sep 30, 2029 U-1599 9012508 Sep 14, 2030 U-981 >A> 9114068 Sep 30, 2029 U-1735

ICATIBANT ACETATE - FIRAZYR N 022150 001 5648333 Jul 15, 2019 DS DP U-1187

IDELALISIB - ZYDELIG N 205858 001 8138195 Apr 24, 2021 DS DP U-1549 8865730 Mar 05, 2033 DS DP U-1615 8980901 May 12, 2025 U-1678 RE44599 Jul 21, 2025 U-1558 RE44599 Jul 21, 2025 U-1615

IDELALISIB - ZYDELIG N 205858 002 8138195 Apr 24, 2021 DS DP U-1549 8865730 Mar 05, 2033 DS DP U-1615 8980901 May 12, 2025 U-1678 RE44599 Jul 21, 2025 U-1558 RE44599 Jul 21, 2025 U-1615

ILOPERIDONE - FANAPT N 022192 001 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 002 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674 A - 27 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ILOPERIDONE - FANAPT N 022192 002 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 003 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 004 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 005 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 006 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

ILOPERIDONE - FANAPT N 022192 007 8652776 Aug 31, 2030 U-1685 8999638 Oct 28, 2030 U-1674 9072742 Jan 16, 2031 U-1674 9074254 Dec 28, 2031 U-1674 9074255 Dec 17, 2030 U-1674 9074256 Feb 10, 2031 U-1674 >A> 9138432 Sep 30, 2025 U-1737 >A> 9157121 Apr 05, 2030 U-1674

INDACATEROL MALEATE - ARCAPTA NEOHALER N 022383 001 8658673 Jun 02, 2020 DS DP U-1168 A - 28 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

INDOMETHACIN - TIVORBEX N 204768 001 8992982 Apr 23, 2030 DP 9089471 Apr 23, 2030 U-55

INDOMETHACIN - TIVORBEX N 204768 002 8992982 Apr 23, 2030 DP 9089471 Apr 23, 2030 U-55

INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH N 020986 005 8920383 Jul 17, 2026 DP 9108002 Jan 20, 2026 DP 9132239 Feb 01, 2032 DP

INSULIN DEGLUDEC - RYZODEG 70/30 N 203313 001 >A> 5866538 Jun 20, 2017 DP >A> NCE Sep 25, 2020 >A> 6899699 Jan 02, 2022 DP >A> 7615532 May 25, 2025 DS DP >A> 7686786 Aug 03, 2026 DP >A> 8672898 Jan 02, 2022 DP >A> 8684969 Oct 20, 2025 DP >A> 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

INSULIN DEGLUDEC - TRESIBA N 203314 001 >A> 6899699 Jan 02, 2022 DP >A> NCE Sep 25, 2020 >A> 7615532 May 25, 2025 DS DP >A> 7686786 Aug 03, 2026 DP >A> 8672898 Jan 02, 2022 DP >A> 8684969 Oct 20, 2025 DP >A> 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

INSULIN DEGLUDEC - TRESIBA N 203314 002 >A> 6899699 Jan 02, 2022 DP >A> NCE Sep 25, 2020 >A> 7615532 May 25, 2025 DS DP >A> 7686786 Aug 03, 2026 DP >A> 8672898 Jan 02, 2022 DP >A> 8684969 Oct 20, 2025 DP >A> 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH N 021536 005 8920383 Jul 17, 2026 DP 9108002 Jan 20, 2026 DP 9132239 Feb 01, 2032 DP

INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR N 021081 002 8992486 Jun 05, 2024 DP 9011391 Mar 26, 2024 DP

INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR N 206538 001 7918833 Sep 23, 2027 DP NP Feb 25, 2018 7918833*PED Mar 23, 2028 8512297 Sep 15, 2024 DP 8556864 Mar 03, 2024 DP 8603044 Mar 02, 2024 DP 8679069 Apr 12, 2025 DP 8992486 Jun 05, 2024 DP 9011391 Mar 26, 2024 DP A - 29 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR N 021629 003 8992486 Jun 05, 2024 DP 9011391 Mar 26, 2024 DP

INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN N 205747 001 6034054 Jun 11, 2018 DP U-1707 6034054 Jun 11, 2018 DP U-1708 6551992 Jun 11, 2018 DP U-1707 6551992 Jun 11, 2018 DP U-1708 7291132 Aug 09, 2024 DP

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 001 8912193 Jun 12, 2029 DP U-1538

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 002 7943572 Aug 10, 2026 U-1539 8424518 Oct 17, 2031 DP 8623817 Sep 18, 2029 U-1537 8912193 Jun 12, 2029 DP U-1538

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 003 6444226 Jun 29, 2020 DP U-1534 NP Jun 27, 2017 6652885 Jun 29, 2020 U-1535 7305986 Jan 16, 2023 DP 7464706 Mar 02, 2023 DP 7648960 Jun 29, 2020 U-1535 7943178 Jun 29, 2020 DP U-1535 7943572 Aug 10, 2026 U-1539 8119593 Aug 11, 2029 U-1537 8146588 Apr 24, 2023 DP 8156936 Jan 16, 2023 DP 8215300 Nov 24, 2022 DP 8258095 Aug 11, 2029 U-1537 8389470 Jun 29, 2020 DP U-1697 8394414 May 15, 2015 DP U-1533 8424518 Oct 17, 2031 DP 8485180 Mar 25, 2030 DP 8499757 Feb 19, 2032 DP 8551528 Jun 11, 2030 DP 8623817 Sep 18, 2029 U-1537 8636001 Jul 12, 2032 DP 8729019 Jun 06, 2028 DP 8734845 Jun 11, 2030 DP 8778403 Jun 11, 2030 DP U-1538 8889099 Jun 29, 2020 DP U-1621 8912193 Jun 12, 2029 DP U-1538

IPRATROPIUM BROMIDE - ATROVENT HFA N 021527 001 8474447 Jan 17, 2030 DP

ISAVUCONAZONIUM SULFATE - CRESEMBA N 207500 001 6812238 Oct 31, 2020 DS NCE Mar 06, 2020 7459561 Oct 31, 2020 DS ODE Mar 06, 2022 GAIN Mar 06, 2025 GAIN Mar 06, 2027

ISAVUCONAZONIUM SULFATE - CRESEMBA N 207501 001 6812238 Oct 31, 2020 DS NCE Mar 06, 2020 7459561 Oct 31, 2020 DS ODE Mar 06, 2022 GAIN Mar 06, 2025 GAIN Mar 06, 2027 A - 30 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ISOTRETINOIN - ABSORICA N 021951 001 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

ISOTRETINOIN - ABSORICA N 021951 002 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

ISOTRETINOIN - ABSORICA N 021951 003 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

ISOTRETINOIN - ABSORICA N 021951 004 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

ISOTRETINOIN - ABSORICA N 021951 005 7435427 Sep 21, 2021 DP 8367102 Sep 21, 2021 U-1347 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

ISOTRETINOIN - ABSORICA N 021951 006 7435427 Sep 21, 2021 DP 8367102 Sep 21, 2021 U-1347 8952064 Sep 21, 2021 DP 9078925 Sep 21, 2021 DP >A> 9089534 Sep 21, 2021 DP

IVABRADINE HYDROCHLORIDE - CORLANOR N 206143 001 7361649 Apr 17, 2026 DS DP U-1694 NCE Apr 15, 2020 7361650 Apr 14, 2026 DS DP U-1694 7867996 Feb 22, 2026 DS DP U-1694 7879842 Feb 22, 2026 DS DP U-1694

IVABRADINE HYDROCHLORIDE - CORLANOR N 206143 002 7361649 Apr 17, 2026 DS DP U-1694 NCE Apr 15, 2020 7361650 Apr 14, 2026 DS DP U-1694 7867996 Feb 22, 2026 DS DP U-1694 7879842 Feb 22, 2026 DS DP U-1694

IVACAFTOR - KALYDECO N 203188 001 8354427 Jul 06, 2026 U-1311 I-705 Dec 30, 2017

IVACAFTOR - KALYDECO N 207925 001 7495103 May 20, 2027 DS DP 8324242 Apr 18, 2027 U-1311 8354427 Jul 06, 2026 U-1311 8410274 Dec 28, 2026 DP 8754224 Dec 28, 2026 DS DP 8883206 Feb 27, 2033 DP

IVACAFTOR - KALYDECO N 207925 002 7495103 May 20, 2027 DS DP 8324242 Apr 18, 2027 U-1311 8354427 Jul 06, 2026 U-1311 8410274 Dec 28, 2026 DP 8754224 Dec 28, 2026 DS DP 8883206 Feb 27, 2033 DP A - 31 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

IVACAFTOR - KALYDECO N 207925 002 7495103 May 20, 2027 DS DP 8324242 Apr 18, 2027 U-1311 8354427 Jul 06, 2026 U-1311 8410274 Dec 28, 2026 DP 8754224 Dec 28, 2026 DS DP 8883206 Feb 27, 2033 DP

IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 001 7495103 May 20, 2027 DS DP NCE Jul 02, 2020 8324242 Apr 18, 2027 U-1311 ODE Jul 02, 2022 8410274 Dec 28, 2026 DP 8507534 Sep 20, 2030 DS DP 8653103 Dec 04, 2028 DP 8716338 Nov 08, 2026 DP U-1718 8741933 Nov 08, 2026 U-1717 8754224 Dec 28, 2026 DS DP 8846718 Dec 04, 2028 U-1717 8993600 Dec 11, 2030 DP

IVERMECTIN - SOOLANTRA N 206255 001 5952372 Sep 18, 2018 U-1631 6133310 Apr 26, 2019 U-1631 7550440 Apr 22, 2024 DP U-1631 8080530 Apr 22, 2024 DP U-1631 8093219 Apr 22, 2024 DP U-1631 8415311 Apr 22, 2024 DP U-1631 8470788 Apr 22, 2024 DP U-1631 8815816 Apr 22, 2024 DP U-1631 9089587 Mar 13, 2034 U-1631

KETOROLAC TROMETHAMINE - ACULAR LS N 021528 001 8946281 May 28, 2024 U-1662

KETOROLAC TROMETHAMINE - ACUVAIL N 022427 001 8992952 Aug 05, 2024 DP

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA N 205388 001 9066856 Oct 23, 2033 DP

LAMIVUDINE - LAMIVUDINE A 203564 001 PC Sep 01, 2015

LAMIVUDINE - EPIVIR N 020564 001 5905082 May 18, 2016 DS DP D-147 Mar 23, 2018 5905082*PED Nov 18, 2016

LAMIVUDINE - EPIVIR N 020564 003 5905082 May 18, 2016 DS DP D-147 Mar 23, 2018 5905082*PED Nov 18, 2016

LAMIVUDINE - EPIVIR N 020596 001 5905082 May 18, 2016 DS DP D-147 Mar 23, 2018 6004968 Mar 20, 2018 DP U-248 6004968*PED Sep 20, 2018

LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS N 206510 001 7169780 Oct 03, 2023 DS DP 7217713 Oct 21, 2022 U-1663 7435734 Oct 21, 2022 U-1663 7754731 Mar 11, 2029 DS DP U-1663 7820660 Apr 25, 2023 DS A - 32 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LAMOTRIGINE - LAMOTRIGINE A 200828 001 PC Sep 28, 2015

LAMOTRIGINE - LAMOTRIGINE A 200828 002 PC Sep 28, 2015

LAMOTRIGINE - LAMOTRIGINE A 200828 003 PC Sep 28, 2015

LAMOTRIGINE - LAMOTRIGINE A 200828 004 PC Sep 28, 2015

LAMOTRIGINE - LAMICTAL N 020241 001 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL N 020241 002 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL N 020241 003 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL N 020241 004 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL N 020241 005 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL N 020241 006 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL CD N 020764 001 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL CD N 020764 002 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL CD N 020764 003 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL CD N 020764 004 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL ODT N 022251 001 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL ODT N 022251 002 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL ODT N 022251 003 M-159 May 18, 2018

LAMOTRIGINE - LAMICTAL ODT N 022251 004 M-159 May 18, 2018

LANTHANUM CARBONATE - FOSRENOL N 204734 001 8980327 Dec 01, 2030 DP

LANTHANUM CARBONATE - FOSRENOL N 204734 002 8980327 Dec 01, 2030 DP A - 33 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LAPATINIB DITOSYLATE - TYKERB N 022059 001 8821927 Sep 18, 2029 DS DP

LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 001 9085573 Mar 21, 2028 DS DP U-1470

LENALIDOMIDE - REVLIMID N 021880 001 9056120 Apr 11, 2023 U-1215 I-706 Feb 17, 2018 9101621 May 15, 2023 U-1216 ODE Feb 17, 2022 9101622 May 15, 2023 U-1216

LENALIDOMIDE - REVLIMID N 021880 002 9056120 Apr 11, 2023 U-1215 I-706 Feb 17, 2018 9101621 May 15, 2023 U-1216 ODE Feb 17, 2022 9101622 May 15, 2023 U-1216

LENALIDOMIDE - REVLIMID N 021880 003 9056120 Apr 11, 2023 U-1215 I-706 Feb 17, 2018 9101621 May 15, 2023 U-1216 ODE Feb 17, 2022 9101622 May 15, 2023 U-1216

LENALIDOMIDE - REVLIMID N 021880 004 9056120 Apr 11, 2023 U-1215 I-706 Feb 17, 2018 9101621 May 15, 2023 U-1216 ODE Feb 17, 2022 9101622 May 15, 2023 U-1216

LENALIDOMIDE - REVLIMID N 021880 005 9056120 Apr 11, 2023 U-1215 I-706 Feb 17, 2018 9101621 May 15, 2023 U-1216 ODE Feb 17, 2022 9101622 May 15, 2023 U-1216

LENALIDOMIDE - REVLIMID N 021880 006 5635517 Oct 04, 2019 DS U-1211 I-706 Feb 17, 2018 9056120 Apr 11, 2023 U-1215 ODE Feb 17, 2022 9101621 May 15, 2023 U-1216 9101622 May 15, 2023 U-1216

LENVATINIB MESYLATE - LENVIMA N 206947 001 7253286 Oct 19, 2021 DS DP NCE Feb 13, 2020 7612208 Sep 19, 2026 DS DP ODE Feb 13, 2022 9006256 Jul 27, 2027 U-1695

LENVATINIB MESYLATE - LENVIMA N 206947 002 7253286 Oct 19, 2021 DS DP NCE Feb 13, 2020 7612208 Sep 19, 2026 DS DP ODE Feb 13, 2022 9006256 Jul 27, 2027 U-1695

LEUPROLIDE ACETATE - LUPRON DEPOT N 020517 003 7429559 Jan 13, 2019 DP 8815801 Jun 28, 2022 DP 8921326 Feb 05, 2031 DP U-1666

LEVALBUTEROL HYDROCHLORIDE - XOPENEX N 020837 001 M-151 Jan 22, 2018

LEVALBUTEROL HYDROCHLORIDE - XOPENEX N 020837 002 M-151 Jan 22, 2018

LEVALBUTEROL HYDROCHLORIDE - XOPENEX N 020837 003 M-151 Jan 22, 2018 A - 34 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LEVALBUTEROL HYDROCHLORIDE - XOPENEX N 020837 004 M-151 Jan 22, 2018

LEVALBUTEROL TARTRATE - XOPENEX HFA N 021730 001 M-156 Mar 12, 2018

LEVETIRACETAM - SPRITAM N 207958 001 6471992 Feb 20, 2018 DP

LEVETIRACETAM - SPRITAM N 207958 002 6471992 Feb 20, 2018 DP

LEVETIRACETAM - SPRITAM N 207958 003 6471992 Feb 20, 2018 DP

LEVETIRACETAM - SPRITAM N 207958 004 6471992 Feb 20, 2018 DP

LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM A 203563 001 PC Oct 20, 2015

LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM A 203563 002 PC Oct 20, 2015

LEVONORGESTREL - LILETTA N 206229 001 NP Feb 26, 2018

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 202231 001 9006289 Oct 03, 2032 DP

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 202231 002 9006289 Oct 03, 2032 DP

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 202231 003 9006289 Oct 03, 2032 DP

LINACLOTIDE - LINZESS N 202811 001 8933030 Feb 17, 2031 DP

LINACLOTIDE - LINZESS N 202811 002 8933030 Feb 17, 2031 DP

LINAGLIPTIN - TRADJENTA N 201280 001 8673927 May 04, 2027 U-1503 8853156 Mar 05, 2031 U-1642

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 001 8673927 May 04, 2027 U-1503

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 002 8673927 May 04, 2027 U-1503

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 003 8673927 May 04, 2027 U-1503

LINEZOLID - LINEZOLID A 078061 001 PC Dec 19, 2015 A - 35 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LINEZOLID - LINEZOLID A 200222 001 PC Jul 04, 2015

LINEZOLID - ZYVOX N 021131 002 6559305 Jan 29, 2021 DS 6559305*PED Jul 29, 2021

LINEZOLID - ZYVOX N 021131 003 6559305 Jan 29, 2021 DS 6559305*PED Jul 29, 2021

LIRAGLUTIDE RECOMBINANT - VICTOZA N 022341 001 8846618 Jun 27, 2022 DP

LIRAGLUTIDE RECOMBINANT - SAXENDA N 206321 001 6268343 Aug 22, 2022 DS DP U-1255 6458924 Aug 22, 2017 DS DP U-1255 6899699 Jan 01, 2022 DP 7235627 Aug 22, 2017 DS DP 7686786 Aug 03, 2026 DP 8114833 Aug 13, 2025 DP 8672898 Jan 02, 2022 DP 8684969 Oct 20, 2025 DP 8846618 Jun 27, 2022 DP 8920383 Jul 17, 2026 DP >A> 9108002 Jan 26, 2026 DP >A> 9132239 Feb 01, 2032 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 001 >A> 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 >A> 7223735 Feb 24, 2023 DP >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 002 >A> 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 >A> 7223735 Feb 24, 2023 DP >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 003 >A> 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 >A> 7223735 Feb 24, 2023 DP >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 004 >A> 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 >A> 7105486 Feb 24, 2023 U-842 >A> 7223735 Feb 24, 2023 DP >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 A - 36 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 004 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 005 >A> 7105486 Feb 24, 2023 U-842 I-703 Jan 30, 2018 >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 006 >A> 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 >A> 7105486 Feb 24, 2023 U-842 >A> 7223735 Feb 24, 2023 DP >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP U-842 >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 007 >A> 7223735 Feb 24, 2023 DP I-703 Jan 30, 2018 >A> 7655630 Feb 24, 2023 DS >A> 7659253 Feb 24, 2023 DS DP U-727 >A> 7659254 Feb 24, 2023 U-1034 >A> 7662787 Feb 24, 2023 DS >A> 7662788 Feb 24, 2023 U-727 >A> 7671030 Feb 24, 2023 DP U-727 >A> 7671031 Feb 24, 2023 U-727 >A> 7674774 Feb 24, 2023 DP U-842 >A> 7678770 Feb 24, 2023 U-842 >A> 7678771 Feb 24, 2023 DP >A> 7687466 Feb 24, 2023 DP >A> 7687467 Feb 24, 2023 DP U-842 >A> 7700561 Feb 24, 2023 DP >A> 7713936 Feb 24, 2023 U-727 >A> 7718619 Feb 24, 2023 DP U-842

LOMITAPIDE MESYLATE - JUXTAPID N 203858 001 5712279 Feb 21, 2016 DS U-1317

LOMITAPIDE MESYLATE - JUXTAPID N 203858 002 5712279 Feb 21, 2016 DS U-1317

LOMITAPIDE MESYLATE - JUXTAPID N 203858 003 5712279 Feb 21, 2016 DS U-1317

LOMITAPIDE MESYLATE - JUXTAPID N 203858 004 5712279 Feb 21, 2016 DS U-1317 NCE Dec 21, 2017 6492365 Dec 10, 2019 U-1318 ODE Dec 21, 2019 7932268 Aug 19, 2027 U-1316 8618135 Mar 07, 2025 U-1316

LOMITAPIDE MESYLATE - JUXTAPID N 203858 005 5712279 Feb 21, 2016 DS U-1317 NCE Dec 21, 2017 6492365 Dec 10, 2019 U-1318 ODE Dec 21, 2019 7932268 Aug 19, 2027 U-1316 8618135 Mar 07, 2025 U-1316 A - 37 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LOMITAPIDE MESYLATE - JUXTAPID N 203858 005 5712279 Feb 21, 2016 DS U-1317 NCE Dec 21, 2017 6492365 Dec 10, 2019 U-1318 ODE Dec 21, 2019 7932268 Aug 19, 2027 U-1316 8618135 Mar 07, 2025 U-1316

LOMITAPIDE MESYLATE - JUXTAPID N 203858 006 5712279 Feb 21, 2016 DS U-1317 NCE Dec 21, 2017 6492365 Dec 10, 2019 U-1318 ODE Dec 21, 2019 7932268 Aug 19, 2027 U-1316 8618135 Mar 07, 2025 U-1316

LORATADINE - CLARITIN N 020641 002 6132758 Jun 01, 2018 DP

LORCASERIN HYDROCHLORIDE - BELVIQ N 022529 001 8946207 Jun 16, 2024 DP 8980881 Dec 20, 2025 U-1252 8980881 Dec 20, 2025 U-1253 8980881 Dec 20, 2025 U-1254 8980881 Dec 20, 2025 U-1255 8999970 Feb 07, 2033 U-1688 8999970 Feb 07, 2033 U-1689 8999970 Feb 07, 2033 U-1692

LOXAPINE - ADASUVE N 022549 001 8955512 Oct 26, 2021 DP 8991387 May 21, 2024 DP

LULICONAZOLE - LUZU N 204153 001 8980931 Apr 28, 2034 DP 9012484 Sep 06, 2033 DS DP U-540

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 001 RE45573 Jun 23, 2025 DS

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 002 RE45573 Jun 23, 2025 DS

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 003 RE45573 Jun 23, 2025 DS

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 004 RE45573 Jun 23, 2025 DS

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 005 RE45573 Jun 23, 2025 DS

MEGESTROL ACETATE - MEGACE ES N 021778 001 9040088 Apr 22, 2024 U-755 9101540 Apr 22, 2024 DP U-755 9101549 Apr 22, 2024 U-755 9107827 Apr 22, 2024 U-755

MESALAMINE - ASACOL HD N 021830 001 >A> 9089492 Nov 15, 2021 DP

MESALAMINE - APRISO N 022301 001 8940328 Apr 20, 2018 DP 8956647 Apr 20, 2018 DP A - 38 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET N 021842 001 9101660 Jan 22, 2027 DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET N 021842 002 9101660 Jan 22, 2027 DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR N 022024 001 9060941 Sep 19, 2023 DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR N 022024 002 9060941 Sep 19, 2023 DP

METHOTREXATE - OTREXUP N 204824 001 8945063 Mar 19, 2030 DP U-1442

METHOTREXATE - OTREXUP N 204824 002 8945063 Mar 19, 2030 DP U-1442

METHOTREXATE - OTREXUP N 204824 003 8945063 Mar 19, 2030 DP U-1442

METHOTREXATE - OTREXUP N 204824 004 8945063 Mar 19, 2030 DP U-1442

METHOTREXATE - OTREXUP N 204824 005 8945063 Mar 19, 2030 DP U-1442

METHYLPHENIDATE - DAYTRANA N 021514 001 9034370 Oct 07, 2025 DP

METHYLPHENIDATE - DAYTRANA N 021514 002 9034370 Oct 07, 2025 DP

METHYLPHENIDATE - DAYTRANA N 021514 003 9034370 Oct 07, 2025 DP

METHYLPHENIDATE - DAYTRANA N 021514 004 9034370 Oct 07, 2025 DP

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA N 021121 001 9000038 Jul 31, 2017 U-666 9000038 Jul 31, 2017 U-1693 9000038*PED Jan 31, 2018 9029416 Jul 31, 2017 DP U-666 >A> 9144549 Jul 31, 2017 U-1747 >A> 9144549 Jul 31, 2017 U-1748

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA N 021121 002 9000038 Jul 31, 2017 U-666 9000038 Jul 31, 2017 U-1693 9000038*PED Jan 31, 2018 9029416 Jul 31, 2017 DP U-666 >A> 9144549 Jul 31, 2017 U-1747 >A> 9144549 Jul 31, 2017 U-1748

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA N 021121 003 9000038 Jul 31, 2017 U-666 9000038 Jul 31, 2017 U-1693 9000038*PED Jan 31, 2018 9029416 Jul 31, 2017 DP U-666 >A> 9144549 Jul 31, 2017 U-1747 >A> 9144549 Jul 31, 2017 U-1748 A - 39 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA N 021121 003 9000038 Jul 31, 2017 U-666 9000038 Jul 31, 2017 U-1693 9000038*PED Jan 31, 2018 9029416 Jul 31, 2017 DP U-666 >A> 9144549 Jul 31, 2017 U-1747 >A> 9144549 Jul 31, 2017 U-1748

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA N 021121 004 9000038 Jul 31, 2017 U-666 9000038 Jul 31, 2017 U-1693 9000038*PED Jan 31, 2018 9029416 Jul 31, 2017 DP U-666 >A> 9144549 Jul 31, 2017 U-1747 >A> 9144549 Jul 31, 2017 U-1748

METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR N 202100 001 8956649 Feb 15, 2031 DP U-1665 9040083 Feb 15, 2031 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 001 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 002 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 003 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 004 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 005 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 006 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP A - 40 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 006 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 007 6419960 Dec 16, 2019 DP NP Apr 17, 2018 7083808 Dec 16, 2019 DP 7247318 Dec 16, 2019 DP 7438930 Dec 16, 2019 DP 8580310 Dec 16, 2019 DP 9066869 Dec 16, 2019 DP

METRONIDAZOLE - NUVESSA N 205223 001 7893097 Feb 19, 2028 DP 8658678 Jun 27, 2028 U-1682 8877792 Feb 02, 2028 DP 8946276 Jun 28, 2032 U-1664

MIFEPRISTONE - KORLYM N 202107 001 8921348 Aug 27, 2028 U-1643

MINOCYCLINE HYDROCHLORIDE - MINOCIN N 050444 001 9084802 May 12, 2031 U-282

MINOCYCLINE HYDROCHLORIDE - ARESTIN N 050781 001 7699609 Mar 29, 2022 DP

MINOXIDIL - WOMEN'S ROGAINE N 021812 002 6946120 Apr 20, 2019 DP U-702

MORPHINE SULFATE - MORPHINE SULFATE N 204223 001 9072781 Mar 12, 2034 DP

MORPHINE SULFATE - MORPHINE SULFATE N 204223 002 9072781 Mar 12, 2034 DP

MORPHINE SULFATE - MORPHINE SULFATE N 204223 003 9072781 Mar 12, 2034 DP

MORPHINE SULFATE - MORPHINE SULFATE N 204223 004 9072781 Mar 12, 2034 DP

MORPHINE SULFATE - MORPHINE SULFATE N 204223 005 9072781 Mar 12, 2034 DP

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 001 8623418 Nov 07, 2029 U-1640

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 002 8623418 Nov 07, 2029 U-1640

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 003 8623418 Nov 07, 2029 U-1640

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 004 8623418 Nov 07, 2029 U-1640

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 005 8623418 Nov 07, 2029 U-1640 A - 41 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA N 022321 006 8623418 Nov 07, 2029 U-1640

MOXIFLOXACIN HYDROCHLORIDE - MOXEZA N 022428 001 9114168 May 29, 2029 DP

NALOXEGOL OXALATE - MOVANTIK N 204760 001 7056500 Jun 29, 2024 DP U-1185 9012469 Apr 02, 2032 DS DP

NALOXEGOL OXALATE - MOVANTIK N 204760 002 7056500 Jun 29, 2024 DP U-1185 9012469 Apr 02, 2032 DS DP

NALOXONE HYDROCHLORIDE - EVZIO N 205787 001 8926594 Mar 31, 2026 DP 8939943 Feb 28, 2031 DP 9022022 Feb 28, 2031 DP 9056170 Nov 23, 2024 DP

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ N 205777 001 8969369 May 10, 2022 DP U-1556 9056051 May 10, 2022 DP U-1556 9073933 Mar 30, 2025 DS 9084729 May 10, 2022 DP U-1556

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ N 205777 002 8969369 May 10, 2022 DP U-1556 9056051 May 10, 2022 DP U-1556 9073933 Mar 30, 2025 DS 9084729 May 10, 2022 DP U-1556

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ N 205777 003 8969369 May 10, 2022 DP U-1556 9056051 May 10, 2022 DP U-1556 9073933 Mar 30, 2025 DS 9084729 May 10, 2022 DP U-1556

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET N 021926 001 6060499 Aug 14, 2017 DP U-867 6060499*PED Feb 14, 2018 6586458 Aug 14, 2017 DP U-867 6586458*PED Feb 14, 2018 7332183 Oct 02, 2025 DP U-867 7332183*PED Apr 02, 2026 8022095 Aug 14, 2017 DP U-867 8022095*PED Feb 14, 2018

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET N 021926 002 5872145 Aug 14, 2017 DP U-1719 NP May 14, 2018 5872145*PED Feb 14, 2018 PED Nov 14, 2018 6060499 Aug 14, 2017 DP U-1719 6060499*PED Feb 14, 2018 6586458 Aug 14, 2017 DP U-1719 6586458*PED Feb 14, 2018 7332183 Oct 02, 2025 DP U-1719 7332183*PED Apr 02, 2026

NEPAFENAC - ILEVRO N 203491 001 8921337 Mar 31, 2032 DP A - 42 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO N 205718 001 8951969 Nov 18, 2030 DP

NICOTINE - NICODERM CQ N 020165 004 8999379 Feb 13, 2020 U-1686

NICOTINE - NICODERM CQ N 020165 005 8999379 Feb 13, 2020 U-1686

NICOTINE - NICODERM CQ N 020165 006 8999379 Feb 13, 2020 U-1686

NICOTINE POLACRILEX - NICORETTE N 022360 001 8940772 Apr 30, 2029 DP

NICOTINE POLACRILEX - NICORETTE N 022360 002 8940772 Apr 30, 2029 DP

NINTEDANIB ESYLATE - OFEV N 205832 001 7989474 Apr 06, 2024 U-1677

NINTEDANIB ESYLATE - OFEV N 205832 002 7989474 Apr 06, 2024 U-1677

OLAPARIB - LYNPARZA N 206162 001 7151102 Apr 29, 2022 DS DP ODE Dec 19, 2021 7449464 Oct 11, 2024 DS DP 7981889 Oct 11, 2024 DS DP 8143241 Aug 12, 2027 U-1634 8247416 Sep 24, 2028 DS 8859562 Aug 04, 2031 U-1634 8912187 Mar 12, 2024 U-1634

OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT N 203108 001 8733341 Dec 16, 2029 DP 9027967 Mar 31, 2027 DP

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT N 206756 001 5964416 Oct 04, 2016 DP NC May 21, 2018 6149054 Dec 19, 2016 DP NCE Jul 31, 2019 6176442 Oct 04, 2016 DP 6453795 Dec 05, 2016 DP 6726124 Oct 04, 2016 DP 6846413 Aug 28, 2018 DP 6977042 Aug 28, 2018 DP 6988496 Feb 23, 2020 DP 7056916 Dec 07, 2023 DS DP 7104470 Oct 04, 2016 DP 7220742 May 12, 2025 DS DP U-1703 7246615 May 31, 2016 DP 7284474 Aug 26, 2024 DP 7396341 Oct 10, 2026 DP 7491719 Nov 10, 2023 DS DP 7727984 Nov 10, 2023 DS 7786111 Nov 10, 2023 DP 7802568 Feb 26, 2019 DP 7837235 Mar 13, 2028 DP 7896264 May 26, 2025 DP 7988001 Aug 04, 2021 DP 8034809 May 12, 2025 U-1702 8044046 Nov 10, 2023 U-1702 8733341 Dec 16, 2029 DP 9027967 Mar 31, 2027 DP RE39820 Jan 30, 2018 DS DP U-1702 A - 43 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT N 206756 001 5964416 Oct 04, 2016 DP NC May 21, 2018 6149054 Dec 19, 2016 DP NCE Jul 31, 2019 6176442 Oct 04, 2016 DP 6453795 Dec 05, 2016 DP 6726124 Oct 04, 2016 DP 6846413 Aug 28, 2018 DP 6977042 Aug 28, 2018 DP 6988496 Feb 23, 2020 DP 7056916 Dec 07, 2023 DS DP 7104470 Oct 04, 2016 DP 7220742 May 12, 2025 DS DP U-1703 7246615 May 31, 2016 DP 7284474 Aug 26, 2024 DP 7396341 Oct 10, 2026 DP 7491719 Nov 10, 2023 DS DP 7727984 Nov 10, 2023 DS 7786111 Nov 10, 2023 DP 7802568 Feb 26, 2019 DP 7837235 Mar 13, 2028 DP 7896264 May 26, 2025 DP 7988001 Aug 04, 2021 DP 8034809 May 12, 2025 U-1702 8044046 Nov 10, 2023 U-1702 8733341 Dec 16, 2029 DP 9027967 Mar 31, 2027 DP RE39820 Jan 30, 2018 DS DP U-1702

OLOPATADINE HYDROCHLORIDE - PAZEO N 206276 001 8791154 May 19, 2032 DP U-1680 NP Jan 30, 2018 PED Jul 30, 2018

OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE N 207931 001 6037157 Jun 26, 2016 U-1635 NCE Dec 19, 2019 6037157*PED Dec 26, 2016 NP Jul 24, 2018 6703403 Jun 26, 2016 U-1635 6703403*PED Dec 26, 2016 7148359 Jul 19, 2019 DP 7148359*PED Jan 19, 2020 7364752 Nov 10, 2020 DP 7364752*PED May 10, 2021 8268349 Aug 25, 2024 DP 8268349*PED Feb 25, 2025 8399015 Aug 25, 2024 DP 8399015*PED Feb 25, 2025 8420596 Apr 10, 2031 DS DP 8420596*PED Oct 10, 2031 8642538 Sep 10, 2029 DS DP U-1638 8686026 Jun 09, 2031 DP 8691938 Apr 13, 2032 DS DP 9006387 Jun 10, 2030 U-1687 9044480 Apr 10, 2031 U-1638

OMEGA-3-CARBOXYLIC ACIDS - EPANOVA N 205060 001 9012501 Feb 07, 2025 DP U-1511 9050308 Jan 04, 2033 U-1511 9050309 Jan 04, 2033 DS >A> 9132112 Feb 07, 2025 DP U-1511

OMEPRAZOLE - OMEPRAZOLE N 022032 001 9023391 Aug 16, 2025 DP

ONDANSETRON - ZUPLENZ N 022524 001 9095577 Jul 13, 2030 DP A - 44 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ONDANSETRON - ZUPLENZ N 022524 002 9095577 Jul 13, 2030 DP

OSPEMIFENE - OSPHENA N 203505 001 8642079 Jul 09, 2028 DP

OXCARBAZEPINE - OXTELLAR XR N 202810 001 9119791 Apr 13, 2027 U-1298

OXCARBAZEPINE - OXTELLAR XR N 202810 002 9119791 Apr 13, 2027 U-1298

OXCARBAZEPINE - OXTELLAR XR N 202810 003 9119791 Apr 13, 2027 U-1298

OXYBUTYNIN CHLORIDE - GELNIQUE N 022204 001 8920392 Mar 26, 2031 U-1644

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 001 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 002 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 003 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 004 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 005 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 006 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 007 9060976 Aug 06, 2022 DP M-153 Apr 16, 2016 9073933 Mar 30, 2025 DS NPP Aug 13, 2018

PACLITAXEL - ABRAXANE N 021660 001 9101543 Feb 21, 2026 U-1434

PALBOCICLIB - IBRANCE N 207103 001 6936612 Jan 22, 2023 DS DP NCE Feb 03, 2020 7208489 Jan 16, 2023 DS DP 7456168 Jan 16, 2023 U-1658

PALBOCICLIB - IBRANCE N 207103 002 6936612 Jan 22, 2023 DS DP NCE Feb 03, 2020 7208489 Jan 16, 2023 DS DP 7456168 Jan 16, 2023 U-1658 A - 45 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PALBOCICLIB - IBRANCE N 207103 003 6936612 Jan 22, 2023 DS DP NCE Feb 03, 2020 7208489 Jan 16, 2023 DS DP 7456168 Jan 16, 2023 U-1658

PALIPERIDONE PALMITATE - INVEGA TRINZA N 207946 001 6077843 May 12, 2017 DP U-543 NP May 18, 2018 6077843*PED Nov 12, 2017

PALIPERIDONE PALMITATE - INVEGA TRINZA N 207946 002 6077843 May 12, 2017 DP U-543 NP May 18, 2018 6077843*PED Nov 12, 2017

PALIPERIDONE PALMITATE - INVEGA TRINZA N 207946 003 6077843 May 12, 2017 DP U-543 NP May 18, 2018 6077843*PED Nov 12, 2017

PALIPERIDONE PALMITATE - INVEGA TRINZA N 207946 004 6077843 May 12, 2017 DP U-543 NP May 18, 2018 6077843*PED Nov 12, 2017

PALONOSETRON HYDROCHLORIDE - ALOXI N 021372 001 9066980 Jan 30, 2024 DP U-528 9125905 Jan 30, 2024 DP

PALONOSETRON HYDROCHLORIDE - ALOXI N 021372 002 9125905 Jan 30, 2024 DP

PANOBINOSTAT LACTATE - FARYDAK N 205353 001 6552065 Aug 31, 2021 DS DP NCE Feb 23, 2020 6833384 Sep 30, 2021 DS DP U-1669 ODE Feb 23, 2022 7067551 Aug 31, 2021 U-1669 7989494 Jan 17, 2028 DS DP 8883842 Jun 13, 2028 U-1669

PANOBINOSTAT LACTATE - FARYDAK N 205353 002 6552065 Aug 31, 2021 DS DP NCE Feb 23, 2020 6833384 Sep 30, 2021 DS DP U-1669 ODE Feb 23, 2022 7067551 Aug 31, 2021 U-1669 7989494 Jan 17, 2028 DS DP 8883842 Jun 13, 2028 U-1669

PANOBINOSTAT LACTATE - FARYDAK N 205353 003 6552065 Aug 31, 2021 DS DP NCE Feb 23, 2020 6833384 Sep 30, 2021 DS DP U-1669 ODE Feb 23, 2022 7067551 Aug 31, 2021 U-1669 7989494 Jan 17, 2028 DS DP 8883842 Jun 13, 2028 U-1669

PAROXETINE MESYLATE - BRISDELLE N 204516 001 8946251 Aug 04, 2026 DS DP U-904

PERAMPANEL - FYCOMPA N 202834 001 I-710 Jun 19, 2018

PERAMPANEL - FYCOMPA N 202834 002 I-710 Jun 19, 2018

PERAMPANEL - FYCOMPA N 202834 003 I-710 Jun 19, 2018 A - 46 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PERAMPANEL - FYCOMPA N 202834 004 I-710 Jun 19, 2018

PERAMPANEL - FYCOMPA N 202834 005 I-710 Jun 19, 2018

PERAMPANEL - FYCOMPA N 202834 006 I-710 Jun 19, 2018

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA N 022580 001 9011905 Jun 09, 2028 DP 9011906 Jun 09, 2028 U-1262

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA N 022580 002 9011905 Jun 09, 2028 DP 9011906 Jun 09, 2028 U-1262

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA N 022580 003 9011905 Jun 09, 2028 DP 9011906 Jun 09, 2028 U-1262

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA N 022580 004 9011905 Jun 09, 2028 DP 9011906 Jun 09, 2028 U-1262

PIRFENIDONE - ESBRIET N 022535 001 7696236 Dec 18, 2027 U-1601

POLIDOCANOL - VARITHENA N 205098 001 >A> RE40640 Oct 14, 2016 DS DP U-1462

POMALIDOMIDE - POMALYST N 204026 001 I-707 Apr 23, 2018

POMALIDOMIDE - POMALYST N 204026 002 I-707 Apr 23, 2018

POMALIDOMIDE - POMALYST N 204026 003 I-707 Apr 23, 2018

POMALIDOMIDE - POMALYST N 204026 004 I-707 Apr 23, 2018

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 001 9029533 Dec 22, 2026 U-836 9029533 Dec 22, 2026 U-1283 9029533 Dec 22, 2026 U-1699 9029533 Dec 22, 2026 U-1700 9029533 Dec 22, 2026 U-1701

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 002 9029533 Dec 22, 2026 U-836 9029533 Dec 22, 2026 U-1283 9029533 Dec 22, 2026 U-1699 9029533 Dec 22, 2026 U-1700 9029533 Dec 22, 2026 U-1701

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 003 9029533 Dec 22, 2026 U-836 9029533 Dec 22, 2026 U-1283 9029533 Dec 22, 2026 U-1699 9029533 Dec 22, 2026 U-1700 A - 47 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 003 9029533 Dec 22, 2026 U-1701

POSACONAZOLE - NOXAFIL N 205596 001 9023790 Jul 04, 2031 DP U-1698

PREDNISONE - RAYOS N 202020 001 9040085 Apr 23, 2024 U-1362

PREDNISONE - RAYOS N 202020 002 9040085 Apr 23, 2024 U-1362

PREDNISONE - RAYOS N 202020 003 9040085 Apr 23, 2024 U-1362

REGADENOSON - LEXISCAN N 022161 001 9045519 Jun 22, 2019 DP 9085601 Feb 02, 2027 DP

REGORAFENIB - STIVARGA N 203085 001 8637553 Feb 16, 2031 DS DP 8680124 Jun 02, 2030 U-1506

RIFAXIMIN - XIFAXAN N 022554 001 6861053 Aug 11, 2019 U-1707 I-709 May 27, 2018 6861053 Aug 11, 2019 U-1708 7452857 Aug 11, 2019 U-1707 7452857 Aug 11, 2019 U-1708 7605240 Aug 11, 2019 U-1707 7605240 Aug 11, 2019 U-1708 7718608 Aug 11, 2019 U-1707 7718608 Aug 11, 2019 U-1708 7915275 Feb 23, 2025 U-1707 7915275 Feb 23, 2025 U-1708 7935799 Aug 11, 2019 U-1707 7935799 Aug 11, 2019 U-1708 8193196 Sep 02, 2027 DS DP U-1707 8193196 Sep 02, 2027 DS DP U-1708 8309569 Jul 18, 2029 U-1707 8309569 Jul 18, 2029 U-1708 8741904 Feb 27, 2026 DS U-1526 8741904 Feb 27, 2026 DS U-1707 8741904 Feb 27, 2026 DS U-1708 8946252 Jul 24, 2029 U-1481 8969398 Oct 02, 2029 U-1481

RILPIVIRINE HYDROCHLORIDE - EDURANT N 202022 001 >A> 7125879 Apr 14, 2023 DS DP U-1153 NPP Aug 26, 2018 >A> 7125879 Apr 14, 2023 DS DP U-1307 >A> 7125879 Apr 14, 2023 DS DP U-1740

RISEDRONATE SODIUM - RISEDRONATE SODIUM A 077132 001 PC Nov 28, 2015

RISEDRONATE SODIUM - RISEDRONATE SODIUM A 077132 002 PC Nov 28, 2015

RISEDRONATE SODIUM - RISEDRONATE SODIUM A 077132 003 PC Nov 28, 2015 A - 48 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

RIVASTIGMINE - RIVASTIGMINE A 204403 003 PC Feb 29, 2016

ROFLUMILAST - DALIRESP N 022522 001 5712298 Jan 27, 2020 DS DP U-1115

ROLAPITANT HYDROCHLORIDE - VARUBI N 206500 001 >A> 7049230 Dec 08, 2023 DS DP U-1741 >A> NCE Sep 01, 2020 >A> 7563801 Apr 04, 2027 DP >A> 7981905 Apr 04, 2027 U-1741 >A> 7981905 Apr 04, 2027 U-1742 >A> 8178550 Apr 04, 2027 DS DP >A> 8361500 Oct 09, 2029 DP >A> 8404702 Oct 09, 2029 U-1741 >A> 8470842 Jan 18, 2029 U-1741 >A> 8796299 Dec 17, 2022 U-1741

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 001 9079912 Dec 12, 2026 U-1573 9079912 Dec 12, 2026 U-1721

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 002 9079912 Dec 12, 2026 U-1573 9079912 Dec 12, 2026 U-1721

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 003 9079912 Dec 12, 2026 U-1573 9079912 Dec 12, 2026 U-1721

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 004 9079912 Dec 12, 2026 U-1573 9079912 Dec 12, 2026 U-1721

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 005 9079912 Dec 12, 2026 U-1573 9079912 Dec 12, 2026 U-1721

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 001 7468390 Nov 27, 2023 DP NCE Jul 07, 2020 8101659 Jan 14, 2023 DP 8404744 Jan 14, 2023 DP 8796331 Jan 14, 2023 U-1723 8877938 May 27, 2027 DS DP

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 002 7468390 Nov 27, 2023 DP NCE Jul 07, 2020 8101659 Jan 14, 2023 DP 8404744 Jan 14, 2023 DP 8796331 Jan 14, 2023 U-1723 8877938 May 27, 2027 DS DP

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 003 7468390 Nov 27, 2023 DP NCE Jul 07, 2020 8101659 Jan 14, 2023 DP 8404744 Jan 14, 2023 DP 8796331 Jan 14, 2023 U-1723 8877938 May 27, 2027 DS DP

SIMEPREVIR SODIUM - OLYSIO N 205123 001 9040562 Jul 28, 2026 DS DP U-1467 A - 49 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SIROLIMUS - RAPAMUNE N 021083 001 ODE May 28, 2022

SIROLIMUS - RAPAMUNE N 021110 001 ODE May 28, 2022

SIROLIMUS - RAPAMUNE N 021110 002 ODE May 28, 2022

SIROLIMUS - RAPAMUNE N 021110 003 ODE May 28, 2022

SIROLIMUS - RAPAMUNE N 021110 004 ODE May 28, 2022

SODIUM OXYBATE - XYREM N 021196 001 8952062 Dec 22, 2019 U-1101 8952062 Dec 22, 2019 U-1102 9050302 Mar 15, 2033 U-1532

SOFOSBUVIR - SOVALDI N 204671 001 9085573 Mar 21, 2028 DS DP U-1470

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 008 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 009 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 010 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 011 5849700 Dec 15, 2015 U-1041 5849704 Dec 15, 2015 DS DP U-1041 6899699 Jan 02, 2022 DP 7686786 Aug 03, 2026 DP 8672898 Jan 02, 2022 DP 8684969 Oct 20, 2025 DP 8841252 Dec 26, 2017 DP 8920383 Jul 17, 2026 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP

SONIDEGIB PHOSPHATE - ODOMZO N 205266 001 8063043 Sep 15, 2029 DS DP NCE Jul 24, 2020 8178563 Feb 06, 2029 DS U-1722

SORAFENIB TOSYLATE - NEXAVAR N 021923 001 8124630 Jan 12, 2020 U-1459 8841330 Jan 12, 2020 U-1696

SPINOSAD - NATROBA N 022408 001 6063771 Jul 25, 2023 DP U-1670 M-152 Nov 30, 2017 A - 50 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SUMATRIPTAN SUCCINATE - ZECUITY N 202278 001 8983594 Nov 19, 2030 DP U-1328

TACROLIMUS - ENVARSUS XR N 206406 001 7994214 Aug 30, 2024 DP ODE Jul 10, 2022

TACROLIMUS - ENVARSUS XR N 206406 002 7994214 Aug 30, 2024 DP ODE Jul 10, 2022

TACROLIMUS - ENVARSUS XR N 206406 003 7994214 Aug 30, 2024 DP ODE Jul 10, 2022

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 001 >A> 8536130 Sep 22, 2028 U-1739

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 002 >A> 8536130 Sep 22, 2028 U-1739

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 003 >A> 8536130 Sep 22, 2028 U-1739

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 004 >A> 8536130 Sep 22, 2028 U-1739

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 005 >A> 8536130 Sep 22, 2028 U-1739

TASIMELTEON - HETLIOZ N 205677 001 9060995 Jan 25, 2033 U-1710

TEDUGLUTIDE RECOMBINANT - GATTEX KIT N 203441 001 5789379 Apr 14, 2016 DS DP U-1320 9060992 Nov 01, 2025 U-1320

TESTOSTERONE - ANDROGEL N 021015 001 9125816 Aug 30, 2020 U-490 >A> 9132089 Aug 30, 2020 U-490

TESTOSTERONE - ANDROGEL N 021015 002 9125816 Aug 30, 2020 U-490 >A> 9132089 Aug 30, 2020 U-490

TESTOSTERONE - ANDROGEL N 021015 003 9125816 Aug 30, 2020 U-490 >A> 9132089 Aug 30, 2020 U-490

TESTOSTERONE - ANDROGEL N 022309 001 9125816 Aug 30, 2020 U-1103 >A> 9132089 Aug 30, 2020 U-1103

TESTOSTERONE - ANDROGEL N 022309 002 9125816 Aug 30, 2020 U-1103 >A> 9132089 Aug 30, 2020 U-1103

TESTOSTERONE - ANDROGEL N 022309 003 9125816 Aug 30, 2020 U-1103 >A> 9132089 Aug 30, 2020 U-1103 A - 51 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TESTOSTERONE - AXIRON N 022504 001 8435944 Sep 27, 2027 U-1390 8993520 Jun 02, 2026 U-1390

TICAGRELOR - BRILINTA N 022433 001 >A> I-714 Sep 03, 2018

TICAGRELOR - BRILINTA N 022433 002 >A> 6251910 Jul 15, 2018 DS >A> NS Sep 03, 2018 >A> 6525060 Dec 02, 2019 DS DP U-1171 >A> 7250419 Dec 02, 2019 DS DP U-1171 >A> 7265124 Jul 09, 2021 DS DP U-1171 >A> 8425934 Apr 17, 2017 DP

TIGECYCLINE - TYGACIL N 021821 001 8975242 Oct 24, 2028 DP

TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT N 021936 001 8733341 Dec 16, 2029 DP 9027967 Mar 31, 2027 DP

TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT N 021936 002 >A> 5964416 Oct 04, 2016 DP >A> NP Sep 15, 2018 >A> 6149054 Dec 16, 2016 DP >A> 6176442 May 31, 2016 DP >A> 6453795 Dec 05, 2016 DP >A> 6726124 Oct 04, 2016 DP >A> 6846413 Aug 28, 2018 DP >A> 6977042 Aug 28, 2018 DP >A> 6988496 Feb 23, 2020 DP >A> 7104470 Oct 04, 2016 DP >A> 7246615 May 31, 2016 DP >A> 7284474 Aug 26, 2024 DP >A> 7396341 Oct 10, 2026 DP >A> 7802568 Feb 26, 2019 DP >A> 7837235 Mar 13, 2028 DP >A> 7896264 May 26, 2025 DP >A> 7988001 Aug 04, 2021 DP >A> 8733341 Dec 16, 2029 DP >A> 9027967 Mar 31, 2027 DP >A> RE39820 Jan 30, 2018 DS DP

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 001 >A> NCE Sep 22, 2020

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 002 >A> NCE Sep 22, 2020

TOPIRAMATE - TROKENDI XR N 201635 001 >A> 8298576 Apr 04, 2028 DP U-106 8992989 Nov 16, 2027 DP U-1675

TOPIRAMATE - TROKENDI XR N 201635 002 >A> 8298576 Apr 04, 2028 DP U-106 8992989 Nov 16, 2027 DP U-1675

TOPIRAMATE - TROKENDI XR N 201635 003 >A> 8298576 Apr 04, 2028 DP U-106 8992989 Nov 16, 2027 DP U-1675

TOPIRAMATE - TROKENDI XR N 201635 004 >A> 8298576 Apr 04, 2028 DP U-106 8992989 Nov 16, 2027 DP U-1675 A - 52 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TOPIRAMATE - TROKENDI XR N 201635 004 >A> 8298576 Apr 04, 2028 DP U-106 8992989 Nov 16, 2027 DP U-1675

TOPIRAMATE - QUDEXY XR N 205122 001 9101545 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 002 9101545 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 003 9101545 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 004 9101545 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 005 9101545 Mar 19, 2033 DP

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 001 8703781 Oct 15, 2030 DS DP U-1712

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 002 8703781 Oct 15, 2030 DS DP U-1712

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 8703781 Oct 15, 2030 DS DP U-1712

TRANEXAMIC ACID - LYSTEDA N 022430 001 8957113 Mar 04, 2025 DP U-1182 9060939 Mar 04, 2025 DP

TRAVOPROST - IZBA N 204822 001 8178582 Oct 10, 2029 DP >A> 9144561 Mar 13, 2029 DP

TRAZODONE HYDROCHLORIDE - DESYREL N 018207 001 8133893 Mar 13, 2029 DS DP

TRAZODONE HYDROCHLORIDE - DESYREL N 018207 002 8133893 Mar 13, 2029 DS DP

TRAZODONE HYDROCHLORIDE - DESYREL N 018207 003 8133893 Mar 13, 2029 DS DP

TRAZODONE HYDROCHLORIDE - DESYREL N 018207 004 8133893 Mar 13, 2029 DS DP

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 001 7417070 Jul 30, 2026 DS 9050311 May 24, 2024 DS DP

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 002 7417070 Jul 30, 2026 DS 9050311 May 24, 2024 DS DP

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 003 7417070 Jul 30, 2026 DS 9050311 May 24, 2024 DS DP A - 53 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 004 7417070 Jul 30, 2026 DS 9050311 May 24, 2024 DS DP

TRETINOIN - RETIN-A-MICRO N 020475 003 5955109 Sep 21, 2016 DP U-134

ULIPRISTAL ACETATE - ELLA N 022474 001 8962603 Jun 12, 2030 U-1657

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA N 203975 001 8511304 Jun 14, 2027 DP U-1476

URIDINE TRIACETATE - XURIDEN N 208169 001 >A> NCE Sep 04, 2020 >A> ODE Sep 04, 2022

VALGANCICLOVIR HYDROCHLORIDE - VALCYTE N 021304 001 D-148 Apr 23, 2018 NPP Apr 23, 2018

VALGANCICLOVIR HYDROCHLORIDE - VALCYTE N 022257 001 D-148 Apr 23, 2018 NPP Apr 23, 2018

VILAZODONE HYDROCHLORIDE - VIIBRYD N 022567 001 D-146 Mar 16, 2018

VILAZODONE HYDROCHLORIDE - VIIBRYD N 022567 002 D-146 Mar 16, 2018

VILAZODONE HYDROCHLORIDE - VIIBRYD N 022567 003 D-146 Mar 16, 2018

VORTIOXETINE HYDROBROMIDE - BRINTELLIX N 204447 001 8722684 Jun 30, 2031 DS DP 8969355 Jun 15, 2027 U-1668

VORTIOXETINE HYDROBROMIDE - BRINTELLIX N 204447 002 8722684 Jun 30, 2031 DS DP 8969355 Jun 15, 2027 U-1668

VORTIOXETINE HYDROBROMIDE - BRINTELLIX N 204447 003 8722684 Jun 30, 2031 DS DP 8969355 Jun 15, 2027 U-1668

VORTIOXETINE HYDROBROMIDE - BRINTELLIX N 204447 004 8722684 Jun 30, 2031 DS DP 8969355 Jun 15, 2027 U-1668

ZOLMITRIPTAN - ZOMIG N 021450 003 NPP Jun 12, 2018

ZOLMITRIPTAN - ZOMIG N 021450 004 NPP Jun 12, 2018

Footnote: 1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

B-1

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, APPROVED DRUG abbreviations and references have been developed.h Refer to the PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35 Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm